{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Tid-wrNW11pW"
      },
      "source": [
        "# Load Depenency"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 8,
      "metadata": {
        "id": "ACtufjx41sXQ"
      },
      "outputs": [],
      "source": [
        "#Cleaned up Crypto Example\n",
        "from os import system\n",
        "import pandas as pd\n",
        "import requests\n",
        "import datetime as dt\n",
        "# from pytrials.client import ClinicalTrials\n",
        "import json\n",
        "import ipywidgets as widgets\n",
        "import numpy as np\n",
        "np.random.seed(10031975)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 9,
      "metadata": {},
      "outputs": [],
      "source": [
        "from pytrials.utils import json_handler, csv_handler\n",
        "\n",
        "\n",
        "class ClinicalTrials:\n",
        "    \"\"\"ClinicalTrials API client\n",
        "\n",
        "    Provides functions to easily access the ClinicalTrials.gov API\n",
        "    (https://clinicaltrials.gov/api/)\n",
        "    in Python.\n",
        "\n",
        "    Attributes:\n",
        "        study_fields: List of all study fields you can use in your query.\n",
        "        api_info: Tuple containing the API version number and the last\n",
        "        time the database was updated.\n",
        "    \"\"\"\n",
        "\n",
        "    _BASE_URL = \"https://clinicaltrials.gov/api/\"\n",
        "    _INFO = \"info/\"\n",
        "    _QUERY = \"query/\"\n",
        "    _JSON = \"fmt=json\"\n",
        "    _CSV = \"fmt=csv\"\n",
        "\n",
        "    def __init__(self):\n",
        "        self.api_info = self.__api_info()\n",
        "\n",
        "    @property\n",
        "    def study_fields(self):\n",
        "        fields_list = json_handler(\n",
        "            f\"{self._BASE_URL}{self._INFO}study_fields_list?{self._JSON}\"\n",
        "        )\n",
        "        return fields_list[\"StudyFields\"][\"Fields\"]\n",
        "\n",
        "    def __api_info(self):\n",
        "        \"\"\"Returns information about the API\"\"\"\n",
        "        last_updated = json_handler(\n",
        "            f\"{self._BASE_URL}{self._INFO}data_vrs?{self._JSON}\"\n",
        "        )[\"DataVrs\"]\n",
        "        api_version = json_handler(f\"{self._BASE_URL}{self._INFO}api_vrs?{self._JSON}\")[\n",
        "            \"APIVrs\"\n",
        "        ]\n",
        "\n",
        "        return api_version, last_updated\n",
        "\n",
        "    def get_full_studies(self, search_expr, max_studies=50):\n",
        "        \"\"\"Returns all content for a maximum of 100 study records.\n",
        "\n",
        "        Retrieves information from the full studies endpoint, which gets all study fields.\n",
        "        This endpoint can only output JSON (Or not-supported XML) format and does not allow\n",
        "        requests for more than 100 studies at once.\n",
        "\n",
        "        Args:\n",
        "            search_expr (str): A string containing a search expression as specified by\n",
        "                `their documentation <https://clinicaltrials.gov/api/gui/ref/syntax#searchExpr>`_.\n",
        "            max_studies (int): An integer indicating the maximum number of studies to return.\n",
        "                Defaults to 50.\n",
        "\n",
        "        Returns:\n",
        "            dict: Object containing the information queried with the search expression.\n",
        "\n",
        "        Raises:\n",
        "            ValueError: The number of studies can only be between 1 and 100\n",
        "        \"\"\"\n",
        "        if max_studies > 100 or max_studies < 1:\n",
        "            raise ValueError(\"The number of studies can only be between 1 and 100\")\n",
        "\n",
        "        req = f\"full_studies?expr={search_expr}&max_rnk={max_studies}&{self._JSON}\"\n",
        "\n",
        "        full_studies = json_handler(f\"{self._BASE_URL}{self._QUERY}{req}\")\n",
        "\n",
        "        return full_studies\n",
        "\n",
        "    def get_study_fields(self, search_expr, fields, max_studies=50, min_rnk=1,fmt=\"csv\"):\n",
        "        \"\"\"Returns study content for specified fields\n",
        "\n",
        "        Retrieves information from the study fields endpoint, which acquires specified information\n",
        "        from a large (max 1000) studies. To see a list of all possible fields, check the class'\n",
        "        study_fields attribute.\n",
        "\n",
        "        Args:\n",
        "            search_expr (str): A string containing a search expression as specified by\n",
        "                `their documentation <https://clinicaltrials.gov/api/gui/ref/syntax#searchExpr>`_.\n",
        "            fields (list(str)): A list containing the desired information fields.\n",
        "            max_studies (int): An integer indicating the maximum number of studies to return.\n",
        "                Defaults to 50.\n",
        "            fmt (str): A string indicating the output format, csv or json. Defaults to csv.\n",
        "\n",
        "        Returns:\n",
        "            Either a dict, if fmt='json', or a list of records (e.g. a list of lists), if fmt='csv.\n",
        "            Both containing the maximum number of study fields queried using the specified search expression.\n",
        "\n",
        "        Raises:\n",
        "            ValueError: The number of studies can only be between 1 and 1000\n",
        "            ValueError: One of the fields is not valid! Check the study_fields attribute\n",
        "                for a list of valid ones.\n",
        "            ValueError: Format argument has to be either 'csv' or 'json'\n",
        "        \"\"\"\n",
        "        if max_studies > 1000 or max_studies < 1:\n",
        "            raise ValueError(\"The number of studies can only be between 1 and 1000\")\n",
        "        elif not set(fields).issubset(self.study_fields):\n",
        "            raise ValueError(\n",
        "                \"One of the fields is not valid! Check the study_fields attribute for a list of valid ones.\"\n",
        "            )\n",
        "        else:\n",
        "            concat_fields = \",\".join(fields)\n",
        "            # req = f\"study_fields?expr={search_expr}&max_rnk={max_studies}&fields={concat_fields}\"\n",
        "            req = f\"study_fields?expr={search_expr}&min_rnk={min_rnk}&max_rnk={max_studies+min_rnk-1}&fields={concat_fields}\"\n",
        "            if fmt == \"csv\":\n",
        "                url = f\"{self._BASE_URL}{self._QUERY}{req}&{self._CSV}\"\n",
        "                return csv_handler(url)\n",
        "\n",
        "            elif fmt == \"json\":\n",
        "                url = f\"{self._BASE_URL}{self._QUERY}{req}&{self._JSON}\"\n",
        "                return json_handler(url)\n",
        "\n",
        "            else:\n",
        "                raise ValueError(\"Format argument has to be either 'csv' or 'json'\")\n",
        "\n",
        "    def get_study_count(self, search_expr):\n",
        "        \"\"\"Returns study count for specified search expression\n",
        "\n",
        "        Retrieves the count of studies matching the text entered in search_expr.\n",
        "\n",
        "        Args:\n",
        "            search_expr (str): A string containing a search expression as specified by\n",
        "                `their documentation <https://clinicaltrials.gov/api/gui/ref/syntax#searchExpr>`_.\n",
        "\n",
        "        Returns:\n",
        "            An integer\n",
        "\n",
        "        Raises:\n",
        "            ValueError: The search expression cannot be blank.\n",
        "        \"\"\"\n",
        "        if not set(search_expr):\n",
        "            raise ValueError(\"The search expression cannot be blank.\")\n",
        "        else:\n",
        "            req = f\"study_fields?expr={search_expr}&max_rnk=1&fields=NCTId\"\n",
        "            url = f\"{self._BASE_URL}{self._QUERY}{req}&{self._JSON}\"\n",
        "            returned_data = json_handler(url)\n",
        "            study_count = returned_data[\"StudyFieldsResponse\"][\"NStudiesFound\"]\n",
        "            return study_count\n",
        "\n",
        "    def __repr__(self):\n",
        "        return f\"ClinicalTrials.gov client v{self.api_info[0]}, database last updated {self.api_info[1]}\""
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "0oKv5xQg2hgJ"
      },
      "source": [
        "# Load Data"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "https://clinicaltrials.gov/api/gui/ref/crosswalks"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "Disease 2 search for"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {},
      "outputs": [],
      "source": [
        "name=input()\n",
        "\n",
        "print(name)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "hit mesh some day"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "EnhcMRzm2zOQ",
        "outputId": "391e7565-dc90-41fc-c40e-ab2e3c4b7c9c"
      },
      "outputs": [],
      "source": [
        "# pd.DataFrame.from_records(ct_data[1:], columns=ct_data[0])"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "Pull ONE"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "h_DJC1iG4RSB"
      },
      "source": [
        "#Explore Data"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 10,
      "metadata": {},
      "outputs": [],
      "source": [
        "#change this out to NAME\n",
        "\n",
        "ct = ClinicalTrials()\n",
        "infodf= (ct.get_full_studies(search_expr=\"Parkinson\", max_studies=5 ))\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {},
      "outputs": [],
      "source": [
        "type(infodf)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {},
      "outputs": [],
      "source": [
        "number = print(infodf['FullStudiesResponse']['NStudiesFound'])"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 11,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "3656"
            ]
          },
          "execution_count": 11,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "ct.get_study_count(search_expr=\"Parkinson\")\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "'NStudiesFound': 3656,"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {},
      "outputs": [],
      "source": [
        "pd.read_json(infodf)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {},
      "outputs": [],
      "source": [
        "# df = pd.DataFrame([])\n",
        "# for i in range(5):\n",
        "#     data = dict(zip(np.random.choice(10, replace=False, size=5),\n",
        "#                     np.random.randint(10, size=5)))\n",
        "#     data = pd.DataFrame(data.items())\n",
        "#     data = data.transpose()\n",
        "#     data.columns = data.iloc[0]\n",
        "#     data = data.drop(data.index[[0]])\n",
        "#     df = df.append(data)\n",
        "# print('{}\\n'.format(df))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 27,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Empty DataFrame\n",
            "Columns: []\n",
            "Index: []\n",
            "[['Rank', 'NCTId'], ['1', 'NCT02370134'], ['2', 'NCT01662427'], ['3', 'NCT05245955'], ['4', 'NCT03152721'], ['5', 'NCT02016092'], ['6', 'NCT03888287'], ['7', 'NCT01877148'], ['8', 'NCT03111472'], ['9', 'NCT04994015'], ['10', 'NCT04023201'], ['11', 'NCT02975193'], ['12', 'NCT00037830'], ['13', 'NCT00256204'], ['14', 'NCT04032262'], ['15', 'NCT04648150'], ['16', 'NCT04903769'], ['17', 'NCT04176302'], ['18', 'NCT02283073'], ['19', 'NCT02917122'], ['20', 'NCT02012647'], ['21', 'NCT04057794'], ['22', 'NCT01835652'], ['23', 'NCT03830190'], ['24', 'NCT02038959'], ['25', 'NCT04729010'], ['26', 'NCT02896816'], ['27', 'NCT00282802'], ['28', 'NCT05164783'], ['29', 'NCT00880620'], ['30', 'NCT02763683'], ['31', 'NCT05084209'], ['32', 'NCT04876404'], ['33', 'NCT03337464'], ['34', 'NCT01747655'], ['35', 'NCT03848455'], ['36', 'NCT02265900'], ['37', 'NCT01301651'], ['38', 'NCT04553185'], ['39', 'NCT03384797'], ['40', 'NCT01955616'], ['41', 'NCT02474329'], ['42', 'NCT03241966'], ['43', 'NCT03466723'], ['44', 'NCT03105401'], ['45', 'NCT04485468'], ['46', 'NCT04797611'], ['47', 'NCT04933513'], ['48', 'NCT01428648'], ['49', 'NCT03578653'], ['50', 'NCT00976430'], ['51', 'NCT04496973'], ['52', 'NCT01532986'], ['53', 'NCT05065060'], ['54', 'NCT02168842'], ['55', 'NCT04455555'], ['56', 'NCT04414813'], ['57', 'NCT03459586'], ['58', 'NCT03857867'], ['59', 'NCT01007630'], ['60', 'NCT05066763'], ['61', 'NCT00212693'], ['62', 'NCT03633513'], ['63', 'NCT01280123'], ['64', 'NCT01351467'], ['65', 'NCT01573260'], ['66', 'NCT02937688'], ['67', 'NCT04919356'], ['68', 'NCT04327687'], ['69', 'NCT02847650'], ['70', 'NCT02045420'], ['71', 'NCT01684475'], ['72', 'NCT01782222'], ['73', 'NCT00040404'], ['74', 'NCT05204641'], ['75', 'NCT04728295'], ['76', 'NCT01757509'], ['77', 'NCT02864004'], ['78', 'NCT05205291'], ['79', 'NCT00862537'], ['80', 'NCT02701621'], ['81', 'NCT02760108'], ['82', 'NCT02360683'], ['83', 'NCT02881099'], ['84', 'NCT04101214'], ['85', 'NCT04996992'], ['86', 'NCT01113086'], ['87', 'NCT04997642'], ['88', 'NCT03336307'], ['89', 'NCT03141944'], ['90', 'NCT04735458'], ['91', 'NCT04101513'], ['92', 'NCT03808389'], ['93', 'NCT04228172'], ['94', 'NCT04453033'], ['95', 'NCT02476240'], ['96', 'NCT01839396'], ['97', 'NCT03366558'], ['98', 'NCT02246374'], ['99', 'NCT04116216'], ['100', 'NCT02217735']]\n",
            "[['Rank', 'NCTId'], ['101', 'NCT05209516'], ['102', 'NCT05107531'], ['103', 'NCT02588924'], ['104', 'NCT03792204'], ['105', 'NCT02406105'], ['106', 'NCT05175365'], ['107', 'NCT03587168'], ['108', 'NCT04726709'], ['109', 'NCT00823836'], ['110', 'NCT04694872'], ['111', 'NCT04579887'], ['112', 'NCT01360229'], ['113', 'NCT02034357'], ['114', 'NCT01646268'], ['115', 'NCT05231356'], ['116', 'NCT04284436'], ['117', 'NCT02680522'], ['118', 'NCT04291027'], ['119', 'NCT03944785'], ['120', 'NCT03137238'], ['121', 'NCT01268891'], ['122', 'NCT05001217'], ['123', 'NCT00740714'], ['124', 'NCT02738528'], ['125', 'NCT02419313'], ['126', 'NCT01479530'], ['127', 'NCT02104401'], ['128', 'NCT02227355'], ['129', 'NCT04084743'], ['130', 'NCT01727687'], ['131', 'NCT01564992'], ['132', 'NCT02073981'], ['133', 'NCT02578849'], ['134', 'NCT03793491'], ['135', 'NCT01996878'], ['136', 'NCT01275573'], ['137', 'NCT00974974'], ['138', 'NCT02168504'], ['139', 'NCT00315250'], ['140', 'NCT02756676'], ['141', 'NCT05225506'], ['142', 'NCT02175472'], ['143', 'NCT00219284'], ['144', 'NCT03129451'], ['145', 'NCT02315781'], ['146', 'NCT03536104'], ['147', 'NCT01022073'], ['148', 'NCT04180865'], ['149', 'NCT01629043'], ['150', 'NCT05329987'], ['151', 'NCT01878409'], ['152', 'NCT03866603'], ['153', 'NCT01580787'], ['154', 'NCT01506479'], ['155', 'NCT01330290'], ['156', 'NCT02438033'], ['157', 'NCT00391898'], ['158', 'NCT03589872'], ['159', 'NCT03432338'], ['160', 'NCT01049984'], ['161', 'NCT01380899'], ['162', 'NCT03974529'], ['163', 'NCT02855021'], ['164', 'NCT03103347'], ['165', 'NCT02243982'], ['166', 'NCT04042675'], ['167', 'NCT02012595'], ['168', 'NCT01904240'], ['169', 'NCT04821830'], ['170', 'NCT02134795'], ['171', 'NCT04668898'], ['172', 'NCT04687878'], ['173', 'NCT01151111'], ['174', 'NCT03865121'], ['175', 'NCT04048265'], ['176', 'NCT03211260'], ['177', 'NCT04569552'], ['178', 'NCT05011175'], ['179', 'NCT01750242'], ['180', 'NCT04837976'], ['181', 'NCT04955275'], ['182', 'NCT02902510'], ['183', 'NCT03565965'], ['184', 'NCT04618679'], ['185', 'NCT02937324'], ['186', 'NCT02225314'], ['187', 'NCT03329508'], ['188', 'NCT00528086'], ['189', 'NCT01246700'], ['190', 'NCT02719470'], ['191', 'NCT03697434'], ['192', 'NCT02144220'], ['193', 'NCT02103465'], ['194', 'NCT04389762'], ['195', 'NCT00841464'], ['196', 'NCT00873392'], ['197', 'NCT05043727'], ['198', 'NCT04346394'], ['199', 'NCT00517842'], ['200', 'NCT05120609']]\n",
            "[['Rank', 'NCTId'], ['201', 'NCT01504178'], ['202', 'NCT00217321'], ['203', 'NCT01100073'], ['204', 'NCT01628848'], ['205', 'NCT03232996'], ['206', 'NCT02933372'], ['207', 'NCT01052350'], ['208', 'NCT02904837'], ['209', 'NCT02728843'], ['210', 'NCT04232969'], ['211', 'NCT02051205'], ['212', 'NCT01462708'], ['213', 'NCT01032486'], ['214', 'NCT00476372'], ['215', 'NCT03972241'], ['216', 'NCT03568968'], ['217', 'NCT02969369'], ['218', 'NCT05348785'], ['219', 'NCT00519532'], ['220', 'NCT00558337'], ['221', 'NCT03921697'], ['222', 'NCT01227681'], ['223', 'NCT02228590'], ['224', 'NCT01080794'], ['225', 'NCT01283347'], ['226', 'NCT02509325'], ['227', 'NCT03859180'], ['228', 'NCT04963894'], ['229', 'NCT04174573'], ['230', 'NCT01738178'], ['231', 'NCT02452606'], ['232', 'NCT04472325'], ['233', 'NCT04527146'], ['234', 'NCT00361205'], ['235', 'NCT03037463'], ['236', 'NCT02893449'], ['237', 'NCT03350464'], ['238', 'NCT03131817'], ['239', 'NCT00282152'], ['240', 'NCT05230095'], ['241', 'NCT00833690'], ['242', 'NCT05340283'], ['243', 'NCT02909192'], ['244', 'NCT00625300'], ['245', 'NCT02894320'], ['246', 'NCT02239978'], ['247', 'NCT00196898'], ['248', 'NCT00115427'], ['249', 'NCT02510833'], ['250', 'NCT03100149'], ['251', 'NCT03454425'], ['252', 'NCT02236728'], ['253', 'NCT00869830'], ['254', 'NCT02038608'], ['255', 'NCT04194762'], ['256', 'NCT00180037'], ['257', 'NCT01748409'], ['258', 'NCT00312559'], ['259', 'NCT04408573'], ['260', 'NCT03521635'], ['261', 'NCT01928212'], ['262', 'NCT03845387'], ['263', 'NCT02615873'], ['264', 'NCT01723228'], ['265', 'NCT04214509'], ['266', 'NCT04658186'], ['267', 'NCT02516644'], ['268', 'NCT01336127'], ['269', 'NCT03779880'], ['270', 'NCT02837172'], ['271', 'NCT02258152'], ['272', 'NCT02816619'], ['273', 'NCT02894333'], ['274', 'NCT00350402'], ['275', 'NCT01628965'], ['276', 'NCT05150158'], ['277', 'NCT03406728'], ['278', 'NCT03582891'], ['279', 'NCT01792843'], ['280', 'NCT04228523'], ['281', 'NCT03235284'], ['282', 'NCT03968133'], ['283', 'NCT00591344'], ['284', 'NCT04877015'], ['285', 'NCT03212014'], ['286', 'NCT00329056'], ['287', 'NCT00250393'], ['288', 'NCT02415062'], ['289', 'NCT03562494'], ['290', 'NCT04097080'], ['291', 'NCT01211587'], ['292', 'NCT04189042'], ['293', 'NCT00367900'], ['294', 'NCT04706065'], ['295', 'NCT04782518'], ['296', 'NCT00762814'], ['297', 'NCT01174758'], ['298', 'NCT03129425'], ['299', 'NCT05166655'], ['300', 'NCT04054960']]\n",
            "[['Rank', 'NCTId'], ['301', 'NCT01798563'], ['302', 'NCT03421899'], ['303', 'NCT04524182'], ['304', 'NCT00053625'], ['305', 'NCT01142739'], ['306', 'NCT05127057'], ['307', 'NCT03947216'], ['308', 'NCT02424708'], ['309', 'NCT03342339'], ['310', 'NCT04154072'], ['311', 'NCT04450550'], ['312', 'NCT02753621'], ['313', 'NCT03811613'], ['314', 'NCT03639064'], ['315', 'NCT01096186'], ['316', 'NCT00617019'], ['317', 'NCT02488395'], ['318', 'NCT01076712'], ['319', 'NCT04223193'], ['320', 'NCT00449865'], ['321', 'NCT04665869'], ['322', 'NCT03205488'], ['323', 'NCT01221948'], ['324', 'NCT02289729'], ['325', 'NCT05119803'], ['326', 'NCT05094219'], ['327', 'NCT05347407'], ['328', 'NCT03808961'], ['329', 'NCT03550183'], ['330', 'NCT04381065'], ['331', 'NCT02933476'], ['332', 'NCT04730466'], ['333', 'NCT01106976'], ['334', 'NCT03981913'], ['335', 'NCT03128450'], ['336', 'NCT02403765'], ['337', 'NCT04976959'], ['338', 'NCT05154552'], ['339', 'NCT04422353'], ['340', 'NCT00556764'], ['341', 'NCT03958175'], ['342', 'NCT00099268'], ['343', 'NCT02923297'], ['344', 'NCT04884646'], ['345', 'NCT04440033'], ['346', 'NCT01989013'], ['347', 'NCT01470859'], ['348', 'NCT00234676'], ['349', 'NCT03823638'], ['350', 'NCT03189459'], ['351', 'NCT04724109'], ['352', 'NCT03301272'], ['353', 'NCT04466839'], ['354', 'NCT02337725'], ['355', 'NCT03473522'], ['356', 'NCT04110106'], ['357', 'NCT02797496'], ['358', 'NCT01364545'], ['359', 'NCT01932684'], ['360', 'NCT00455507'], ['361', 'NCT03369587'], ['362', 'NCT03905954'], ['363', 'NCT02953665'], ['364', 'NCT02610634'], ['365', 'NCT05320523'], ['366', 'NCT00129181'], ['367', 'NCT02248207'], ['368', 'NCT03700684'], ['369', 'NCT00586079'], ['370', 'NCT01178047'], ['371', 'NCT02769039'], ['372', 'NCT04152655'], ['373', 'NCT00438607'], ['374', 'NCT05235880'], ['375', 'NCT00748488'], ['376', 'NCT02799381'], ['377', 'NCT03288155'], ['378', 'NCT00360009'], ['379', 'NCT02515136'], ['380', 'NCT02764125'], ['381', 'NCT00272688'], ['382', 'NCT04591236'], ['383', 'NCT04653584'], ['384', 'NCT05349539'], ['385', 'NCT00199407'], ['386', 'NCT02495649'], ['387', 'NCT01646255'], ['388', 'NCT02164162'], ['389', 'NCT01970813'], ['390', 'NCT03953222'], ['391', 'NCT02536976'], ['392', 'NCT04769973'], ['393', 'NCT01140841'], ['394', 'NCT03971617'], ['395', 'NCT01018264'], ['396', 'NCT02703844'], ['397', 'NCT02231294'], ['398', 'NCT02859805'], ['399', 'NCT00199355'], ['400', 'NCT01423565']]\n",
            "[['Rank', 'NCTId'], ['401', 'NCT01987557'], ['402', 'NCT02547506'], ['403', 'NCT02306863'], ['404', 'NCT03582137'], ['405', 'NCT00642356'], ['406', 'NCT00623103'], ['407', 'NCT03104049'], ['408', 'NCT03213379'], ['409', 'NCT03960931'], ['410', 'NCT00134784'], ['411', 'NCT00160576'], ['412', 'NCT01968031'], ['413', 'NCT02318927'], ['414', 'NCT03662009'], ['415', 'NCT02731170'], ['416', 'NCT00623363'], ['417', 'NCT01149811'], ['418', 'NCT04101968'], ['419', 'NCT04783129'], ['420', 'NCT02641054'], ['421', 'NCT01388556'], ['422', 'NCT01010802'], ['423', 'NCT01521117'], ['424', 'NCT04002596'], ['425', 'NCT04536857'], ['426', 'NCT04090385'], ['427', 'NCT02231073'], ['428', 'NCT05253040'], ['429', 'NCT03837548'], ['430', 'NCT00104585'], ['431', 'NCT03528460'], ['432', 'NCT01300819'], ['433', 'NCT00387075'], ['434', 'NCT01981577'], ['435', 'NCT00001640'], ['436', 'NCT03133611'], ['437', 'NCT03000569'], ['438', 'NCT01860118'], ['439', 'NCT01227655'], ['440', 'NCT03463330'], ['441', 'NCT02687542'], ['442', 'NCT04731246'], ['443', 'NCT04904068'], ['444', 'NCT03175107'], ['445', 'NCT01544738'], ['446', 'NCT02814201'], ['447', 'NCT00117195'], ['448', 'NCT04590612'], ['449', 'NCT01061567'], ['450', 'NCT01792193'], ['451', 'NCT04349865'], ['452', 'NCT01867827'], ['453', 'NCT00491062'], ['454', 'NCT01167608'], ['455', 'NCT03415984'], ['456', 'NCT01005030'], ['457', 'NCT01336088'], ['458', 'NCT03263793'], ['459', 'NCT04569981'], ['460', 'NCT03473834'], ['461', 'NCT03984305'], ['462', 'NCT01971242'], ['463', 'NCT01766258'], ['464', 'NCT02469090'], ['465', 'NCT00228150'], ['466', 'NCT03573232'], ['467', 'NCT01723904'], ['468', 'NCT02107638'], ['469', 'NCT01636297'], ['470', 'NCT00456794'], ['471', 'NCT04986020'], ['472', 'NCT04620980'], ['473', 'NCT04652843'], ['474', 'NCT01014858'], ['475', 'NCT01973543'], ['476', 'NCT04249245'], ['477', 'NCT03716674'], ['478', 'NCT03866044'], ['479', 'NCT04982887'], ['480', 'NCT04046276'], ['481', 'NCT00806468'], ['482', 'NCT03827551'], ['483', 'NCT01052831'], ['484', 'NCT04651153'], ['485', 'NCT04303338'], ['486', 'NCT03769896'], ['487', 'NCT04493697'], ['488', 'NCT02930512'], ['489', 'NCT00044590'], ['490', 'NCT01870518'], ['491', 'NCT01803945'], ['492', 'NCT05286736'], ['493', 'NCT04837313'], ['494', 'NCT00914134'], ['495', 'NCT02616120'], ['496', 'NCT03937284'], ['497', 'NCT04308135'], ['498', 'NCT01646333'], ['499', 'NCT00477672'], ['500', 'NCT00522379']]\n",
            "[['Rank', 'NCTId'], ['501', 'NCT03146130'], ['502', 'NCT05268887'], ['503', 'NCT00940914'], ['504', 'NCT01237210'], ['505', 'NCT02240030'], ['506', 'NCT01558479'], ['507', 'NCT03049033'], ['508', 'NCT01060878'], ['509', 'NCT02007785'], ['510', 'NCT01568073'], ['511', 'NCT05179187'], ['512', 'NCT03103919'], ['513', 'NCT00890669'], ['514', 'NCT04428983'], ['515', 'NCT05106504'], ['516', 'NCT04634331'], ['517', 'NCT02655315'], ['518', 'NCT04333511'], ['519', 'NCT02072642'], ['520', 'NCT02125383'], ['521', 'NCT01536769'], ['522', 'NCT02657655'], ['523', 'NCT00443872'], ['524', 'NCT02263885'], ['525', 'NCT02939534'], ['526', 'NCT03185481'], ['527', 'NCT01898390'], ['528', 'NCT02611713'], ['529', 'NCT04380142'], ['530', 'NCT01968460'], ['531', 'NCT03645538'], ['532', 'NCT05134506'], ['533', 'NCT01696812'], ['534', 'NCT00957918'], ['535', 'NCT00736671'], ['536', 'NCT05106985'], ['537', 'NCT04260581'], ['538', 'NCT05146921'], ['539', 'NCT03476668'], ['540', 'NCT02267785'], ['541', 'NCT01523301'], ['542', 'NCT02939391'], ['543', 'NCT01177319'], ['544', 'NCT05008094'], ['545', 'NCT00321854'], ['546', 'NCT02745171'], ['547', 'NCT00153972'], ['548', 'NCT04778852'], ['549', 'NCT01556165'], ['550', 'NCT02388204'], ['551', 'NCT04638777'], ['552', 'NCT01650610'], ['553', 'NCT00105508'], ['554', 'NCT04715984'], ['555', 'NCT04054856'], ['556', 'NCT04273672'], ['557', 'NCT05320250'], ['558', 'NCT01715727'], ['559', 'NCT01496599'], ['560', 'NCT03743467'], ['561', 'NCT05180747'], ['562', 'NCT02305147'], ['563', 'NCT03407378'], ['564', 'NCT02005029'], ['565', 'NCT01525641'], ['566', 'NCT02869945'], ['567', 'NCT02034318'], ['568', 'NCT01968473'], ['569', 'NCT02138682'], ['570', 'NCT01650623'], ['571', 'NCT02006121'], ['572', 'NCT00909545'], ['573', 'NCT05034094'], ['574', 'NCT03781167'], ['575', 'NCT00802178'], ['576', 'NCT01100762'], ['577', 'NCT04568447'], ['578', 'NCT03837314'], ['579', 'NCT04675398'], ['580', 'NCT01010074'], ['581', 'NCT03531086'], ['582', 'NCT01485172'], ['583', 'NCT04164043'], ['584', 'NCT04361188'], ['585', 'NCT04811066'], ['586', 'NCT03156647'], ['587', 'NCT02382198'], ['588', 'NCT01003535'], ['589', 'NCT04991831'], ['590', 'NCT03053752'], ['591', 'NCT03060239'], ['592', 'NCT03808675'], ['593', 'NCT01168596'], ['594', 'NCT03043768'], ['595', 'NCT04119596'], ['596', 'NCT00466167'], ['597', 'NCT04277247'], ['598', 'NCT03306329'], ['599', 'NCT03022357'], ['600', 'NCT03580486']]\n",
            "[['Rank', 'NCTId'], ['601', 'NCT04467632'], ['602', 'NCT03353688'], ['603', 'NCT04491383'], ['604', 'NCT01191944'], ['605', 'NCT04434898'], ['606', 'NCT03329833'], ['607', 'NCT03582163'], ['608', 'NCT02683330'], ['609', 'NCT02250690'], ['610', 'NCT02125032'], ['611', 'NCT01939717'], ['612', 'NCT03964272'], ['613', 'NCT00640952'], ['614', 'NCT02647372'], ['615', 'NCT00442780'], ['616', 'NCT02728947'], ['617', 'NCT02231255'], ['618', 'NCT01960842'], ['619', 'NCT02668835'], ['620', 'NCT00199420'], ['621', 'NCT04259827'], ['622', 'NCT02438124'], ['623', 'NCT02347254'], ['624', 'NCT02709148'], ['625', 'NCT04082663'], ['626', 'NCT04956770'], ['627', 'NCT03970239'], ['628', 'NCT00434304'], ['629', 'NCT02023034'], ['630', 'NCT00737217'], ['631', 'NCT00004731'], ['632', 'NCT04777331'], ['633', 'NCT02231645'], ['634', 'NCT04157621'], ['635', 'NCT00917280'], ['636', 'NCT03909828'], ['637', 'NCT01141023'], ['638', 'NCT04127695'], ['639', 'NCT03187301'], ['640', 'NCT04182399'], ['641', 'NCT04048291'], ['642', 'NCT02702232'], ['643', 'NCT02941822'], ['644', 'NCT02688465'], ['645', 'NCT01794195'], ['646', 'NCT04237025'], ['647', 'NCT01272687'], ['648', 'NCT01620164'], ['649', 'NCT01628926'], ['650', 'NCT04934592'], ['651', 'NCT01163344'], ['652', 'NCT00029809'], ['653', 'NCT00105521'], ['654', 'NCT04297800'], ['655', 'NCT00907972'], ['656', 'NCT01652534'], ['657', 'NCT01519856'], ['658', 'NCT01028586'], ['659', 'NCT02824367'], ['660', 'NCT04389138'], ['661', 'NCT00642889'], ['662', 'NCT04340492'], ['663', 'NCT00229736'], ['664', 'NCT01749917'], ['665', 'NCT02940912'], ['666', 'NCT03552068'], ['667', 'NCT02593812'], ['668', 'NCT04566341'], ['669', 'NCT00668551'], ['670', 'NCT03319485'], ['671', 'NCT00518791'], ['672', 'NCT02401308'], ['673', 'NCT03381898'], ['674', 'NCT01338662'], ['675', 'NCT04580849'], ['676', 'NCT03318523'], ['677', 'NCT02548897'], ['678', 'NCT03621046'], ['679', 'NCT04044547'], ['680', 'NCT01120392'], ['681', 'NCT00641186'], ['682', 'NCT01016470'], ['683', 'NCT00858546'], ['684', 'NCT03413384'], ['685', 'NCT03675932'], ['686', 'NCT02783014'], ['687', 'NCT04369430'], ['688', 'NCT02561715'], ['689', 'NCT01738191'], ['690', 'NCT03314597'], ['691', 'NCT02098642'], ['692', 'NCT03440112'], ['693', 'NCT01399905'], ['694', 'NCT05047796'], ['695', 'NCT03034538'], ['696', 'NCT00643045'], ['697', 'NCT00912808'], ['698', 'NCT01892176'], ['699', 'NCT01502995'], ['700', 'NCT05083260']]\n",
            "[['Rank', 'NCTId'], ['701', 'NCT05142085'], ['702', 'NCT01556100'], ['703', 'NCT00474058'], ['704', 'NCT00397696'], ['705', 'NCT03104725'], ['706', 'NCT03095690'], ['707', 'NCT01014663'], ['708', 'NCT01865877'], ['709', 'NCT04038866'], ['710', 'NCT04181918'], ['711', 'NCT03230331'], ['712', 'NCT04650932'], ['713', 'NCT04293159'], ['714', 'NCT00865579'], ['715', 'NCT02731677'], ['716', 'NCT00943748'], ['717', 'NCT05131880'], ['718', 'NCT03193489'], ['719', 'NCT00610103'], ['720', 'NCT01634243'], ['721', 'NCT03061513'], ['722', 'NCT03416452'], ['723', 'NCT00853879'], ['724', 'NCT00058838'], ['725', 'NCT00036218'], ['726', 'NCT03703570'], ['727', 'NCT04547712'], ['728', 'NCT03720418'], ['729', 'NCT01467960'], ['730', 'NCT03938922'], ['731', 'NCT01446614'], ['732', 'NCT00646204'], ['733', 'NCT02055274'], ['734', 'NCT02627885'], ['735', 'NCT05312632'], ['736', 'NCT04354298'], ['737', 'NCT03854747'], ['738', 'NCT04918342'], ['739', 'NCT00086073'], ['740', 'NCT04796246'], ['741', 'NCT01971008'], ['742', 'NCT04884412'], ['743', 'NCT02447146'], ['744', 'NCT00637260'], ['745', 'NCT01754129'], ['746', 'NCT03433950'], ['747', 'NCT00505843'], ['748', 'NCT01809613'], ['749', 'NCT04888364'], ['750', 'NCT04379778'], ['751', 'NCT01539837'], ['752', 'NCT02906020'], ['753', 'NCT03214926'], ['754', 'NCT03439943'], ['755', 'NCT02249715'], ['756', 'NCT02617017'], ['757', 'NCT05184608'], ['758', 'NCT03799614'], ['759', 'NCT03130595'], ['760', 'NCT04201093'], ['761', 'NCT04879134'], ['762', 'NCT04558879'], ['763', 'NCT00468078'], ['764', 'NCT01294800'], ['765', 'NCT01038310'], ['766', 'NCT01429909'], ['767', 'NCT00537485'], ['768', 'NCT03998462'], ['769', 'NCT01155466'], ['770', 'NCT04692116'], ['771', 'NCT00381472'], ['772', 'NCT01039090'], ['773', 'NCT00143026'], ['774', 'NCT03244813'], ['775', 'NCT03383497'], ['776', 'NCT04651699'], ['777', 'NCT04228887'], ['778', 'NCT00082342'], ['779', 'NCT05036473'], ['780', 'NCT02265315'], ['781', 'NCT01536821'], ['782', 'NCT03152292'], ['783', 'NCT04157933'], ['784', 'NCT00875316'], ['785', 'NCT00918177'], ['786', 'NCT01491022'], ['787', 'NCT00857532'], ['788', 'NCT04829006'], ['789', 'NCT04978597'], ['790', 'NCT02875041'], ['791', 'NCT05152394'], ['792', 'NCT04267341'], ['793', 'NCT00242008'], ['794', 'NCT00220272'], ['795', 'NCT02642393'], ['796', 'NCT03773796'], ['797', 'NCT04387773'], ['798', 'NCT00237263'], ['799', 'NCT01998204'], ['800', 'NCT01528592']]\n",
            "[['Rank', 'NCTId'], ['801', 'NCT00582673'], ['802', 'NCT04810897'], ['803', 'NCT04887467'], ['804', 'NCT03368170'], ['805', 'NCT02443779'], ['806', 'NCT03938974'], ['807', 'NCT04266782'], ['808', 'NCT04652583'], ['809', 'NCT02599753'], ['810', 'NCT05233943'], ['811', 'NCT03083132'], ['812', 'NCT00024622'], ['813', 'NCT03686462'], ['814', 'NCT02605161'], ['815', 'NCT04196647'], ['816', 'NCT01351168'], ['817', 'NCT01367782'], ['818', 'NCT02533921'], ['819', 'NCT00462254'], ['820', 'NCT04948684'], ['821', 'NCT00550238'], ['822', 'NCT01102582'], ['823', 'NCT04867551'], ['824', 'NCT03774225'], ['825', 'NCT00330694'], ['826', 'NCT00244387'], ['827', 'NCT04983290'], ['828', 'NCT03212885'], ['829', 'NCT03741959'], ['830', 'NCT02460796'], ['831', 'NCT04512599'], ['832', 'NCT01453803'], ['833', 'NCT01446939'], ['834', 'NCT03443752'], ['835', 'NCT03652870'], ['836', 'NCT05094011'], ['837', 'NCT04953637'], ['838', 'NCT01563913'], ['839', 'NCT04945876'], ['840', 'NCT01662791'], ['841', 'NCT02468804'], ['842', 'NCT02453386'], ['843', 'NCT04863118'], ['844', 'NCT03555292'], ['845', 'NCT00611481'], ['846', 'NCT02039024'], ['847', 'NCT05344365'], ['848', 'NCT00766948'], ['849', 'NCT00477802'], ['850', 'NCT00957203'], ['851', 'NCT02611167'], ['852', 'NCT03313973'], ['853', 'NCT03648671'], ['854', 'NCT04622657'], ['855', 'NCT00558025'], ['856', 'NCT04062526'], ['857', 'NCT04720365'], ['858', 'NCT01036139'], ['859', 'NCT01606670'], ['860', 'NCT02438215'], ['861', 'NCT01089283'], ['862', 'NCT04377945'], ['863', 'NCT02538315'], ['864', 'NCT03860649'], ['865', 'NCT04787549'], ['866', 'NCT02190851'], ['867', 'NCT04212637'], ['868', 'NCT04051151'], ['869', 'NCT03204526'], ['870', 'NCT04379050'], ['871', 'NCT03879551'], ['872', 'NCT01174004'], ['873', 'NCT02763891'], ['874', 'NCT04598828'], ['875', 'NCT04218526'], ['876', 'NCT01734733'], ['877', 'NCT01744496'], ['878', 'NCT03119636'], ['879', 'NCT03409120'], ['880', 'NCT02248181'], ['881', 'NCT02701803'], ['882', 'NCT04165278'], ['883', 'NCT04799470'], ['884', 'NCT04415775'], ['885', 'NCT00753519'], ['886', 'NCT01824056'], ['887', 'NCT04428931'], ['888', 'NCT01489982'], ['889', 'NCT04267107'], ['890', 'NCT04915209'], ['891', 'NCT01228851'], ['892', 'NCT04750226'], ['893', 'NCT00810628'], ['894', 'NCT02108704'], ['895', 'NCT02683629'], ['896', 'NCT00955318'], ['897', 'NCT00914602'], ['898', 'NCT02511015'], ['899', 'NCT03178786'], ['900', 'NCT00977184']]\n"
          ]
        }
      ],
      "source": [
        "temp = pd.DataFrame()\n",
        "for i in range(1,1000, 100):\n",
        "    # print(i)\n",
        "    print(temp)\n",
        "    temp = ct.get_study_fields(\n",
        "    search_expr=\"Parkinson\",\n",
        "    fields=[\"NCTId\"],\n",
        "    max_studies=100,\n",
        "    min_rnk=i,\n",
        "    fmt=\"csv\",\n",
        ")\n",
        " \n",
        " \n",
        "temp = pd.DataFrame.from_records(api_pull_2[1:], columns=api_pull_2[0])"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 17,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "1\n",
            "101\n",
            "201\n",
            "301\n",
            "401\n",
            "501\n",
            "601\n",
            "701\n",
            "801\n",
            "901\n"
          ]
        },
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Rank</th>\n",
              "      <th>NCTId</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>5</td>\n",
              "      <td>NCT02016092</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>6</td>\n",
              "      <td>NCT03888287</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>7</td>\n",
              "      <td>NCT01877148</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>8</td>\n",
              "      <td>NCT03111472</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>9</td>\n",
              "      <td>NCT04994015</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>10</td>\n",
              "      <td>NCT04023201</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>11</td>\n",
              "      <td>NCT02975193</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>12</td>\n",
              "      <td>NCT00037830</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>13</td>\n",
              "      <td>NCT00256204</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>14</td>\n",
              "      <td>NCT04032262</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "  Rank        NCTId\n",
              "0    5  NCT02016092\n",
              "1    6  NCT03888287\n",
              "2    7  NCT01877148\n",
              "3    8  NCT03111472\n",
              "4    9  NCT04994015\n",
              "5   10  NCT04023201\n",
              "6   11  NCT02975193\n",
              "7   12  NCT00037830\n",
              "8   13  NCT00256204\n",
              "9   14  NCT04032262"
            ]
          },
          "execution_count": 17,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "\n",
        "\n",
        "\n",
        "\n",
        "api_pull_2 = ct.get_study_fields(\n",
        "    search_expr=\"Parkinson\",\n",
        "    fields=[\"NCTId\"],\n",
        "    max_studies=10,\n",
        "    min_rnk=5,\n",
        "    fmt=\"csv\",\n",
        ")\n",
        "\n",
        "# ClinicalTrials limits API queries to 1000 records\n",
        "# Count of studies may be useful to build loops when you want to retrieve more than 1000 records\n",
        "\n",
        "\n",
        "\n",
        "# Read the csv data in Pandas\n",
        "import pandas as pd\n",
        "\n",
        "temp = pd.DataFrame.from_records(api_pull_2[1:], columns=api_pull_2[0])\n",
        "temp"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 12,
      "metadata": {
        "id": "-o2YXU2v4Flm"
      },
      "outputs": [],
      "source": [
        "\n",
        "\n",
        "\n",
        "\n",
        "# Get the NCTId, Condition and Brief title fields from 500 studies related to Coronavirus and Covid, in csv format.\n",
        "api_pull_1 = ct.get_study_fields(\n",
        "    search_expr=\"Parkinson\",\n",
        "    fields=[\"NCTId\", \"Condition\", \"OfficialTitle\", \"BriefTitle\" , \"Acronym\" , \"StudyType\",\n",
        "    \"InterventionType\",\"InterventionName\",\"InterventionOtherName\",\"InterventionDescription\",\"Phase\" \n",
        "    ,\"StudyFirstSubmitDate\",\"LastUpdateSubmitDate\",\"CompletionDate\",\"OverallStatus\",\"IsFDARegulatedDrug\",\"IsFDARegulatedDevice\",\"BriefSummary\"],\n",
        "    max_studies=999,\n",
        "    fmt=\"csv\",\n",
        ")\n",
        "\n",
        "# ClinicalTrials limits API queries to 1000 records\n",
        "# Count of studies may be useful to build loops when you want to retrieve more than 1000 records\n",
        "\n",
        "\n",
        "\n",
        "# Read the csv data in Pandas\n",
        "import pandas as pd\n",
        "\n",
        "df1=pd.DataFrame.from_records(api_pull_1[1:], columns=api_pull_1[0])\n",
        "\n",
        "# \n",
        "# df1 = pd.DataFrame.to_frame().reset_index()\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 33,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "{'FullStudiesResponse': {'APIVrs': '1.01.05',\n",
              "  'DataVrs': '2022:04:27 23:03:31.564',\n",
              "  'Expression': 'Parkinson',\n",
              "  'NStudiesAvail': 413210,\n",
              "  'NStudiesFound': 3656,\n",
              "  'MinRank': 1,\n",
              "  'MaxRank': 50,\n",
              "  'NStudiesReturned': 50,\n",
              "  'FullStudies': [{'Rank': 1,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02370134',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '005/58'},\n",
              "       'Organization': {'OrgFullName': 'Chulalongkorn University',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Development of Parkinson's Glove for Detection and Suppression of Hand Tremor\",\n",
              "       'OfficialTitle': \"Development of Parkinson's Glove for Detection and Suppression of Hand Tremor at Rest Among the Tremor-predominant Parkinson's Disease Patients With Medically Intractable Tremor\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'February 2015',\n",
              "       'OverallStatus': 'Unknown status',\n",
              "       'LastKnownStatus': 'Not yet recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'February 2015'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2016',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'May 2017',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'January 15, 2015',\n",
              "       'StudyFirstSubmitQCDate': 'February 23, 2015',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 24, 2015',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'February 23, 2015',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 24, 2015',\n",
              "        'LastUpdatePostDateType': 'Estimate'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Roongroj Bhidayasiri',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Comprehensive Movement Disorders Center',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Chulalongkorn University'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Chulalongkorn University',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
              "      'DescriptionModule': {'BriefSummary': \"This study is aimed to study the feasibility and safety of parkinson's glove that combined 2 module of tremor detection and tremor suppression with electrical muscle stimulation for using as device for rest tremor suppression in parkinson's disease patients\",\n",
              "       'DetailedDescription': \"Study Population\\n\\nTarget: Thai Parkinson's disease (PD) patients with predominant rest tremor : 50 patients\\nPopulation sample: Patients who are getting their treatment at the Chulalongkorn Comprehensive Movement Disorder Clinic at King Chulalongkorn Memorial Hospital.\\n\\nStudy methods as follows:\\n\\nAll PD subjects will be provided the information on this research study and informed consent will be sought for every subjects.\\nAll PD subjects will be interviewed by a movememt disorders specialist or a trained interviewer for their demographic and clinical data.\\nAll PD patients will be examined for the severity of Parkinson's disease by a movement disorders specialist according the Unified Parkinson's disease Rating Scale (UPDRS), Hoehn and Yahr score, and tremor rating scale during the 'on period' in order to determine the additional effect of parkinson's glove and sham glove for suppression of tremor\\nAll PD patients will be randomly allocated into 2 groups (25 Parkinson's glove and 25 sham glove) with block randomization method.\\nAll patients will get Parkinson's glove for home-based usage for 14 days, the appointment for follow -up will be done for 4 times, with once daily phone call from investigators in order to check for improvement symptoms and all adverse events such as pain will be recorded and determined it severity by the visual analog scale.\\n\\nData collection\\n\\nDemographic and clinical data: age, gender, clinical diagnosis, tremor rating scale, pain score by visual analog scale , Parkinson's disease's severity score for each subject according to establishing standard rating scale.\\nTremor parameters form Parkinson's glove will be collected in SD card as 5 parameters: Peak magnitude, RMS, Angle, Frequency, Q. Number of stimulation times will be recorded.\\n\\nData analysis The statistical analysis in this study is based from SPSS program version 17. Categorical data will be analyzed for frequency and percentage. Continuous data will be analyzed by mean and standard deviation (SD). Non-parametric study would be preferred if the small sample size or in case of distribution of data do not present as normal distribution (determined by Kolmogorov-Smirnov test). The repeated ANOVA will be used for determined the efficacy of parkinson's glove in the difference times in follow up periods.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Phase 1']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '50',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Parkinson's glove\",\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': \"Parkinson's glove 14 days use with 4 times follow-up\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Device: Parkinson's glove\"]}},\n",
              "         {'ArmGroupLabel': 'sham glove',\n",
              "          'ArmGroupType': 'Placebo Comparator',\n",
              "          'ArmGroupDescription': 'sham glove (with light and sound)14 days use with 4 times follow-up',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: sham glove']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
              "          'InterventionName': \"Parkinson's glove\",\n",
              "          'InterventionDescription': \"Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Parkinson's glove\"]}},\n",
              "         {'InterventionType': 'Device',\n",
              "          'InterventionName': 'sham glove',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['sham glove']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Number of participants who demonstrate the tremor suppression after use parkinson's glove\",\n",
              "          'PrimaryOutcomeDescription': \"To determine the tremor suppression after use the parkinson's glove by the tremor rating scale\",\n",
              "          'PrimaryOutcomeTimeFrame': 'up to 1 month follow up period'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Number of Participants who report pain or any adverse events from parkinson's glove\",\n",
              "          'SecondaryOutcomeDescription': \"To determine the safety of parkinson's glove\",\n",
              "          'SecondaryOutcomeTimeFrame': \"14 days periods of using parkinson's glove and in subsequent 1 month follow up period\"},\n",
              "         {'SecondaryOutcomeMeasure': \"Determine the severity of pain related with parkinson's glove\",\n",
              "          'SecondaryOutcomeDescription': 'To determine the severity of pain by visual analog scale',\n",
              "          'SecondaryOutcomeTimeFrame': \"14 days periods of using parkinson's glove\"}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\n Adults  18 years old.\\n\\nPatients with Parkinson's disease diagnosed according to the UKPDSBB criteria with predominantly feature of rest tremor that intractable to medically treatment.\\nInformed consent\\n\\nExclusion Criteria:\\n\\nPatients with a history of cardiac arrhythmia, renal failure, hepatic failure, and pregnancy as well as those who had history of seizure or had the risk for tended to become seizure such as those who had focal brain lesions, encephalitis, and stroke patients.\\n\\nPatients with a history of hand surgery and implanted screws or wires in hand area that supposed to place a surface EMG or EMS, as well as those patients who were implanted for electrical devices such as cardiac pacemaker, pulse generator of deep brain stimulation,and intrathecal baclofen pump.\\nPatients who cannot avoid the medication that may potentiate or attenuate tremor such as antihistamines, benzodiazepine, illicit drugs, and thyroid hormone supplement.\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'MaximumAge': '80 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Onanong Jitkritsadakul, MD, MSc',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '0863570212',\n",
              "          'CentralContactEMail': 'onanong.jit@gmail.com'},\n",
              "         {'CentralContactName': 'Roongroj Bhidayasiri, MD, FRCP',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '022564630',\n",
              "          'CentralContactEMail': 'rbh1@ucla.com'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Roongroj Bhidayasiri, MD, FRCP',\n",
              "          'OverallOfficialAffiliation': 'Chulalongkorn University',\n",
              "          'OverallOfficialRole': 'Study Director'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Chulalongkorn University Hospital',\n",
              "          'LocationCity': 'Pathumwan',\n",
              "          'LocationState': 'Bangkok',\n",
              "          'LocationZip': '10330',\n",
              "          'LocationCountry': 'Thailand',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Roongroj Bhidayasiri, MD',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '+662 256 4630',\n",
              "             'LocationContactEMail': 'rbh1@ucla.edu'},\n",
              "            {'LocationContactName': 'Roongroj Bhidayasiri, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'},\n",
              "         {'ConditionMeshId': 'D000014202', 'ConditionMeshTerm': 'Tremor'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'},\n",
              "         {'ConditionAncestorId': 'D000020820',\n",
              "          'ConditionAncestorTerm': 'Dyskinesias'},\n",
              "         {'ConditionAncestorId': 'D000009461',\n",
              "          'ConditionAncestorTerm': 'Neurologic Manifestations'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M16108',\n",
              "          'ConditionBrowseLeafName': 'Tremor',\n",
              "          'ConditionBrowseLeafAsFound': 'Tremor',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M21727',\n",
              "          'ConditionBrowseLeafName': 'Dyskinesias',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11556',\n",
              "          'ConditionBrowseLeafName': 'Neurologic Manifestations',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
              "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 2,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01662427',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '6222012'},\n",
              "       'Organization': {'OrgFullName': 'Chulalongkorn University',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Nocturnal Parkinson's Disease Symptoms Study Group\",\n",
              "       'OfficialTitle': \"Nocturnal Parkinson's Disease Symptoms Study Group\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'August 2013',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'November 2012'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2013',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'August 2013',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'August 7, 2012',\n",
              "       'StudyFirstSubmitQCDate': 'August 9, 2012',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 10, 2012',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'August 18, 2013',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 20, 2013',\n",
              "        'LastUpdatePostDateType': 'Estimate'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Roongroj Bhidayasiri',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Associate Professor',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Chulalongkorn University'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Chulalongkorn University',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {},\n",
              "      'DescriptionModule': {'BriefSummary': \"To study associate factor of Noctural Parkinson's Disease Symptoms and quality of life in Parkinson's disease patients and caregivers.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': ['Quality of life',\n",
              "         \"Noctural Parkinson's Disease Symptoms\"]}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '300',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Questionniare',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Other: Questionaire to assess Noctural Parkinson's Disease Symptoms\"]}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': \"Questionaire to assess Noctural Parkinson's Disease Symptoms\",\n",
              "          'InterventionDescription': \"Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Questionniare']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"To assess Noctural Parkinson's Disease Symptoms\"}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"To assess quality of life in Parkinson's Disease patient\"},\n",
              "         {'SecondaryOutcomeMeasure': \"To assess quality of life in caregiver of Parkinson's Disease patient\"}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nIdiopathic Parkinson's disease patient\\n\\nExclusion Criteria:\\n\\nPatient with Secondary Parkinsonism eg.Drug-induced Parkinsonism, Vascular Parkinsonism, exposure to toxin, Encephalitis\\nPatient with Atypical Parkinsonial Syndromes eg. Parkinson-plus syndrome, Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)\\nPatient with Heredodegenerative parkinsonism eg. Spinocerebellar ataxias, Wilson's disease, Juvenile Huntington's disease\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '30 Years',\n",
              "       'MaximumAge': '90 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': \"Parkinson's disease patient and care givers\",\n",
              "       'SamplingMethod': 'Probability Sample'},\n",
              "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Roongroj Bhidayasiri',\n",
              "          'LocationCity': 'Pathumwan',\n",
              "          'LocationState': 'Bangkok',\n",
              "          'LocationZip': '10330',\n",
              "          'LocationCountry': 'Thailand'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'T6034',\n",
              "          'ConditionBrowseLeafName': 'Quality of Life',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
              "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
              "   {'Rank': 3,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05245955',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'RHK Parkinson'},\n",
              "       'Organization': {'OrgFullName': 'Swiss Federal Institute of Technology',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Robotic Assessments of Hand Function in Patients With Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Feasibility and Validity of Robotic Assessments With the ReHapticKnob to Characterize Kinaesthesia and Haptic Perception of the Hand in Patients With Parkinson's Disease: an Exploratory Study\",\n",
              "       'Acronym': 'RHK Parkinson'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'February 2022',\n",
              "       'OverallStatus': 'Not yet recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'March 2022',\n",
              "        'StartDateType': 'Anticipated'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2023',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'December 2023',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'November 11, 2021',\n",
              "       'StudyFirstSubmitQCDate': 'February 17, 2022',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 18, 2022',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'February 17, 2022',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 18, 2022',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Swiss Federal Institute of Technology',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'CLINICA HILDEBRAND CENTRO DI RIABILITAZIONE BRISSAGO',\n",
              "          'CollaboratorClass': 'UNKNOWN'},\n",
              "         {'CollaboratorName': 'Neurocentro - Istituto di Neuroscienze Cliniche della Svizzera Italiana',\n",
              "          'CollaboratorClass': 'UNKNOWN'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"It has been shown that patients with Parkinson's disease (PD) have impaired kinaesthesia and haptic perception of the upper limbs. In PD patients, these impairments might be involved in the development of hypometria or bradykinesia and may play a role in postural deficits, thereby significantly contributing to the overall disability level.\\n\\nDedicated conventional or robot-assisted training might improve sensory-motor function in PD patients. In order to provide efficient robot-assisted therapy, robotic devices have to be able to tailor the therapy difficulty to the individual impairment profile of each patient. For difficulty adaptation in robot-assisted therapy, it is important to assess the impairment profiles with the same robotic platform that would be used for therapy, therefore minimizing costs or potential errors coming from the use of different devices. However, up to now, little emphasis has been placed on providing sensory-motor robot-assisted therapy for the upper limbs to persons with PD based on their individual level of impairment.\\n\\nThe aim of this study is therefore to evaluate if the assessments of sensory-motor hand function implemented on a robotic device for hand rehabilitation, i.e. the ReHapticKnob, are suitable to measure the impairments of kinaesthesia and haptic perception observed in subjects with Parkinson's disease.\\n\\nIf the assessments implemented in the ReHapticKnob are sensitive enough to detect a difference between the sensory-motor function of PD patients and healthy subjects, the device might in the future be used to assess improvements before and after sensory-motor therapy. This is a necessary step before the investigators can use these assessments to tailor the difficulty level of the therapy performed with the ReHapticKnob and to investigate the benefits and impact of such a therapy on the kinaesthetic and haptic impairments of persons with PD.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': ['Parkinson Disease',\n",
              "         'Sensory impairments',\n",
              "         'Kinaesthesia',\n",
              "         'Haptic perception',\n",
              "         'Robot-assisted assessments',\n",
              "         'Assessment of the hand sensory function']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'N/A',\n",
              "        'DesignInterventionModel': 'Single Group Assignment',\n",
              "        'DesignPrimaryPurpose': 'Other',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '20',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Robotic assessment of sensory hand function',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': \"This arm involves a group of persons with Parkinson's disease and an age-matched control group. Both groups undergo the assessments of kinaesthesia and haptic perception of the hand implemented on the ReHapticKnob.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Assessments of the hand sensory function with the ReHapticKnob']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
              "          'InterventionName': 'Assessments of the hand sensory function with the ReHapticKnob',\n",
              "          'InterventionDescription': 'During the assessment sessions with the ReHapticKnob, subjects sit comfortably on a chair in front of a screen and place the fingers of the hand on the handles of the device. The different assessments consist of moving the hand or forearm of the subjects to two different positions and asking the subject to discriminate between them (discrimination thresholds for the amplitude of grasping and forearm pronosupination positions), of passively moving the hand or forearm of the subject at low velocities and asking the subject to say when he/she detects the movement (detection thresholds for passive movements), or of rendering two objects with different stiffness and asking the subject to discriminate between them (discrimination thresholds for the stiffness of objects pinched with the hand).',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Robotic assessment of sensory hand function']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Detection threshold resulting from the assessment of detection of passive grasping movements - Right hand',\n",
              "          'PrimaryOutcomeDescription': 'Outcome of the assessment for the detection of passive grasping movements performed with the right hand. This threshold is expressed in time until movement detection.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Through study completion, an average of 2 weeks'},\n",
              "         {'PrimaryOutcomeMeasure': 'Detection threshold resulting from the assessment of detection of passive grasping movements - Left hand',\n",
              "          'PrimaryOutcomeDescription': 'Outcome of the assessment for the detection of passive grasping movements performed with the left hand. This threshold is expressed in time until movement detection.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Through study completion, an average of 2 weeks'},\n",
              "         {'PrimaryOutcomeMeasure': 'Detection threshold resulting from the assessment of detection of passive forearm pronosupination movements - Right forearm',\n",
              "          'PrimaryOutcomeDescription': 'Outcome of the assessment for the detection of passive forearm pronosupination movements performed with the right forearm. This threshold is expressed in time until movement detection.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Through study completion, an average of 2 weeks'},\n",
              "         {'PrimaryOutcomeMeasure': 'Detection threshold resulting from the assessment of detection of passive forearm pronosupination movements - Left forearm',\n",
              "          'PrimaryOutcomeDescription': 'Outcome of the assessment for the detection of passive forearm pronosupination movements performed with the left forearm. This threshold is expressed in time until movement detection.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Through study completion, an average of 2 weeks'},\n",
              "         {'PrimaryOutcomeMeasure': 'Discrimination threshold resulting from the assessment of just noticeable difference for grasping positions - Right hand',\n",
              "          'PrimaryOutcomeDescription': 'Outcome of the assessment for the discrimination of grasping positions performed with the right hand. This threshold is expressed in millimeters and represents the minimum difference that the subject can perceive.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Through study completion, an average of 2 weeks'},\n",
              "         {'PrimaryOutcomeMeasure': 'Discrimination threshold resulting from the assessment of just noticeable difference for grasping positions - Left hand',\n",
              "          'PrimaryOutcomeDescription': 'Outcome of the assessment for the discrimination of grasping positions performed with the left hand. This threshold is expressed in millimeters and represents the minimum difference that the subject can perceive.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Through study completion, an average of 2 weeks'},\n",
              "         {'PrimaryOutcomeMeasure': 'Discrimination threshold resulting from the assessment of just noticeable difference for pronosupination positions - Right forearm',\n",
              "          'PrimaryOutcomeDescription': 'Outcome of the assessment for the discrimination of pronosupination positions performed with the right forearm. This threshold is expressed in degrees and represents the minimum difference that the subject can perceive.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Through study completion, an average of 2 weeks'},\n",
              "         {'PrimaryOutcomeMeasure': 'Discrimination threshold resulting from the assessment of just noticeable difference for pronosupination positions - Left forearm',\n",
              "          'PrimaryOutcomeDescription': 'Outcome of the assessment for the discrimination of pronosupination positions performed with the left forearm. This threshold is expressed in degrees and represents the minimum difference that the subject can perceive.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Through study completion, an average of 2 weeks'},\n",
              "         {'PrimaryOutcomeMeasure': 'Discrimination threshold resulting from the assessment of haptic perception - Right hand',\n",
              "          'PrimaryOutcomeDescription': 'Outcome of the assessment for haptic perception performed with the right hand. This threshold is expressed as Weber Fraction and represents the minimum difference in stiffness that the subject can perceive.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Through study completion, an average of 2 weeks'},\n",
              "         {'PrimaryOutcomeMeasure': 'Discrimination threshold resulting from the assessment of haptic perception - Left hand',\n",
              "          'PrimaryOutcomeDescription': 'Outcome of the assessment for haptic perception performed with the left hand. This threshold is expressed as Weber Fraction and represents the minimum difference in stiffness that the subject can perceive.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Through study completion, an average of 2 weeks'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Demographic information',\n",
              "          'SecondaryOutcomeDescription': 'Gender, age, year of birth.',\n",
              "          'SecondaryOutcomeTimeFrame': 'This information is collected during the screening visit performed at the beginning of the study (day 0).'},\n",
              "         {'SecondaryOutcomeMeasure': 'Edinburgh Handedness Inventory Score',\n",
              "          'SecondaryOutcomeDescription': 'Questionnaire to define handedness.',\n",
              "          'SecondaryOutcomeTimeFrame': 'This information is collected during the screening visit performed at the beginning of the study (day 0).This information is collected during the screening visit performed at the beginning of the study (day 0).'},\n",
              "         {'SecondaryOutcomeMeasure': 'Montreal Cognitive Assessment',\n",
              "          'SecondaryOutcomeDescription': 'Assessment of cognitive function (max score = 30, high score = better).',\n",
              "          'SecondaryOutcomeTimeFrame': 'This information is collected during the screening visit performed at the beginning of the study (day 0).This information is collected during the screening visit performed at the beginning of the study (day 0).'},\n",
              "         {'SecondaryOutcomeMeasure': 'Proprioception item of the Nottingham Sensory Assessment',\n",
              "          'SecondaryOutcomeDescription': 'Assessments used to characterize proprioception.',\n",
              "          'SecondaryOutcomeTimeFrame': \"The control group does this assessment during the screening visit (day 0). The group of patients with Parkinson's disease does this during the second examination visit (day 0 to day 0 + 2 days).\"},\n",
              "         {'SecondaryOutcomeMeasure': \"MDS-Unified Parkinson's Disease Rating Scale: items 3.15 to 3.18\",\n",
              "          'SecondaryOutcomeDescription': \"Scale to characterize the state of the Parkinson's disease. This is done for the group of patients with Parkinson's disease only. These items are performed at the beginning as they are considered for the inclusion criteria.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'This information is collected during the screening visit performed at the beginning of the study (day 0).'},\n",
              "         {'SecondaryOutcomeMeasure': \"MDS-Unified Parkinson's Disease Rating Scale III\",\n",
              "          'SecondaryOutcomeDescription': \"Scale to characterize the state of the Parkinson's disease. This is done for the group of patients with Parkinson's disease only.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'This information is collected during the second examination visit (day 0 to day 0 + 2 days).'},\n",
              "         {'SecondaryOutcomeMeasure': 'Hoehn and Yahr stage',\n",
              "          'SecondaryOutcomeDescription': \"Scale to characterize the state of the Parkinson's disease. This is done for the group of patients with Parkinson's disease only.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'This information is collected during the screening visit performed at the beginning of the study (day 0).'},\n",
              "         {'SecondaryOutcomeMeasure': 'Abnormal Involuntary Movement Scale',\n",
              "          'SecondaryOutcomeDescription': \"Scale to characterize the state of the Parkinson's disease. This is done for the group of patients with Parkinson's disease only.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'This information is collected during the screening visit performed at the beginning of the study (day 0).'},\n",
              "         {'SecondaryOutcomeMeasure': 'Levodopa equivalent daily dose',\n",
              "          'SecondaryOutcomeDescription': \"Information used to characterize the state of the Parkinson's disease and the timespan when the patient is in the ON state. This is collected for the group of patients with Parkinson's disease only.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'This information is collected during the second examination visit (day 0 to day 0 + 2 days).'},\n",
              "         {'SecondaryOutcomeMeasure': 'Disease onset',\n",
              "          'SecondaryOutcomeDescription': \"Information used to characterize the state of the Parkinson's disease. This is collected for the group of patients with Parkinson's disease only.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'This information is collected during the second examination visit (day 0 to day 0 + 2 days).'},\n",
              "         {'SecondaryOutcomeMeasure': 'Most affected side',\n",
              "          'SecondaryOutcomeDescription': \"Information used to characterize the side of the body most affected by the Parkinson's disease. This is collected for the group of patients with Parkinson's disease only.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'This information is collected during the second examination visit (day 0 to day 0 + 2 days).'},\n",
              "         {'SecondaryOutcomeMeasure': 'Frontal Assessment Battery',\n",
              "          'SecondaryOutcomeDescription': \"Assessment of cognitive function. This is collected for the group of patients with Parkinson's disease only.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'This assessment is performed once during the study (from day 0 to day 0 + 25 days).'},\n",
              "         {'SecondaryOutcomeMeasure': 'Attentive matrices',\n",
              "          'SecondaryOutcomeDescription': \"Assessment of cognitive function. This is collected for the group of patients with Parkinson's disease only.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'This assessment is performed once during the study (from day 0 to day 0 + 25 days).'},\n",
              "         {'SecondaryOutcomeMeasure': 'Digit span',\n",
              "          'SecondaryOutcomeDescription': \"Assessment of cognitive function. This is collected for the group of patients with Parkinson's disease only.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'This assessment is performed once during the study (from day 0 to day 0 + 25 days).'},\n",
              "         {'SecondaryOutcomeMeasure': 'Fatigue scale for motor and cognitive functions',\n",
              "          'SecondaryOutcomeDescription': \"Assessment of cognitive function. This is collected for the group of patients with Parkinson's disease only.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'This assessment is performed once during the study (from day 0 to day 0 + 25 days).'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Ten patients with Parkinson's disease and 10 age-matched control subjects will be recruited.\\n\\nPatients with Parkinson's disease: inclusion criteria\\n\\nDiagnosis of idiopathic Parkinson's disease according to UK Parkinson's disease society brain bank clinical diagnostic criteria\\nAge between 35 and 80 years\\nHoehn and Yahr stage of I, II or III during the ON state\\nMontreal Cognitive Assessment (MoCA)  26\\n\\nNo tremor, i.e.:\\n\\nPostural tremor for the hand: MDS-UPDRS 3.15 < 1\\nKinetic tremor of the hands: MDS-UPDRS 3.16  1\\nRest tremor amplitude for the extremities: MDS-UPDRS 3.17 < 1\\nConstancy of rest tremor: MDS-UPDRS 3.18 < 1\\nThe subject read, understood and signed the informed consent\\n\\nPatients with Parkinson's disease: exclusion criteria\\n\\nPolyneuropathy registered in the anamnesis or peripheral sensory-motor impairments detected in a neurological clinical examination\\nMild to severe dyskinesia of the upper limbs: point 5 of the Abnormal Involuntary Movement Scale (AIMS) > 1\\nOrthopedic pathologies of the upper limbs or other pathologies possibly interfering with the study\\nPacemaker, deep-brain-stimulator or other active implanted devices\\n\\nControl subjects: inclusion criteria\\n\\nAge between 35 and 80 years\\nMontreal Cognitive Assessment (MoCA)  26\\nThe subject read, understood and signed the informed consent\\n\\nControl subjects: exclusion criteria\\n\\nAny history of neurological, orthopaedic or rheumatologic disease affecting the upper limbs or other pathologies possibly interfering with the study\\nPacemaker or other active implanted devices\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '35 Years',\n",
              "       'MaximumAge': '80 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Giada Devittori, M. Sc.',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '+41 44 510 72 31',\n",
              "          'CentralContactEMail': 'giada.devittori@hest.ethz.ch'},\n",
              "         {'CentralContactName': 'Olivier Lambercy, Dr.',\n",
              "          'CentralContactRole': 'Contact'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Daria Dinacci, Dr. med.',\n",
              "          'OverallOfficialAffiliation': 'Clinica Hildebrand Centro di riabiliazione Brissago',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M9190',\n",
              "          'ConditionBrowseLeafName': 'Hypesthesia',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
              "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 4,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03152721',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'WestPORTSintervention'},\n",
              "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'PARKreg',\n",
              "          'SecondaryIdType': 'Registry Identifier',\n",
              "          'SecondaryIdDomain': 'Svenska Parkinsonregistret'}]},\n",
              "       'Organization': {'OrgFullName': 'Sahlgrenska University Hospital, Sweden',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"The Effect of Parkinson Kinetigraph Recordings on the Management and Outcome in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Interventional Study of the Effect of Parkinson Kinetigraph Recordings on the Clinical Management and Outcome in Parkinson's Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'April 2019',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'April 30, 2017',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 1, 2018',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'February 28, 2019',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'May 10, 2017',\n",
              "       'StudyFirstSubmitQCDate': 'May 12, 2017',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 15, 2017',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'April 2, 2019',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 4, 2019',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Filip Bergquist',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Associate Professor',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Sahlgrenska University Hospital, Sweden'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Sahlgrenska University Hospital, Sweden',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No',\n",
              "       'IsUSExport': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"With time most people with Parkinson's disease (PwP) develop fluctuations in motor symptoms in relation to medication intake. The prevalence may be both under and overestimated as it is based on history rather than observation. Patterns in fluctuations are difficult to determine and it has been demonstrated that every 30-minute diaries need to be kept for 10 days or more to safely represent fluctuation patterns. The Parkinson Kinetigraph (PKG) is an automated system that is carried passively and provides similar information after wearing the device for 6 days. Clinical experience is that most patients agree that results are representative to their experiences. It is not known if using the PKG routinely at any stage of PD will change management of the disease. The hypothesis of this study is that providing PKG information to neurologists will lead to a more active management that may improve outcome in PD patients.\",\n",
              "       'DetailedDescription': \"Patients that have previously not performed a PKG recording will be recruited from the WestPORTS community based cohort of outpatients with PD in West Sweden. The WestPORTS study includes self-assessments like PDQ8 and NMS-Q as well as PKG recordings. On inclusion in WestPORTS-Int subjects will be randomized by minimization for age, gender and disease duration into one of two study arms. In the intervention group the PKG recording of the subject will be made available, together with a summarized interpretation, to the subject's regular neurologist/geriatrician before the next scheduled visit/contact. The neurologist will also be provided with PDQ8 and NMS-Q responses. In the control group only PDQ8 and NMS-Q responses will be available to the treating neurologist/geriatrician.\\n\\nAt the next regular visit/contact the physician will fill out an assessment of the state of the patient, whether stable or in need of change in management. Any contraindications to changed management will be noted and the decision to change or not change management will be recorded as the primary outcome of the study. Secondary outcomes are the patient reported experience of outpatient care according to a modified version of the Generic Short Patient Experiences Questionnaire (GS-PEQ), as well as patient reported (PDQ8, NMS-Q, PRO-PD, EQ5D5L) and PKG outcomes at a time point three months later.\\n\\nChange of management is defined as any of the following:\\n\\nAdding or stopping a dopamine agonist, COMT- or MAO-inhibitor, anticholinergic or amantadine.\\nFractionation or de-fractionation of the current daily levodopa dose\\nChange of current Levodopa Equivalent daily dose by 15% or more\\nStart or stop of night medication\\nReferral for device assisted therapy (LCIG, apomorphine pump or DBS)\\n\\nActual change of management (as opposed to decision to change) will be documented by retrospective review of medical records and prescription records. This will be a secondary measure.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': ['accelerometry',\n",
              "         'home based',\n",
              "         'motor complications',\n",
              "         'Parkinson KinetiGraph',\n",
              "         'Registry']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignInterventionModelDescription': '1:1 randomisation to intervention and control group. The effect of providing the objective measurement and self assessment scales compared to only self assessment scales on the management decisions will be evaluated. A secondary outcome is the ability of the measurement to identify sub-optimally treated individuals in comparison with self assessment scales.',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
              "         'DesignMaskingDescription': 'Patient not aware of which information has been provided to his/her physician. Post data collection the groups will be assigned coded group names so that the conditions are masked to the assessor.',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
              "           'Outcomes Assessor']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '147',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Control',\n",
              "          'ArmGroupType': 'Placebo Comparator',\n",
              "          'ArmGroupDescription': 'Treating physician will in advance of upcoming visit be provided with the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Self assessment']}},\n",
              "         {'ArmGroupLabel': 'Intervention',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'Treating physician will in advance of upcoming visit be provided with a Parkinson KinetiGraph recording report and interpretation in addition to the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Parkinson KinetiGraph',\n",
              "            'Other: Self assessment']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
              "          'InterventionName': 'Parkinson KinetiGraph',\n",
              "          'InterventionDescription': 'The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['Parkinson KinetiGraph Mk II',\n",
              "            'PKG']}},\n",
              "         {'InterventionType': 'Other',\n",
              "          'InterventionName': 'Self assessment',\n",
              "          'InterventionDescription': 'Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control',\n",
              "            'Intervention']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['PDQ8',\n",
              "            'NMS-Questionnaire']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Decision to change management',\n",
              "          'PrimaryOutcomeDescription': \"The decision to change management of Parkinson's disease as reported by the treating physician.\\n\\nChange of management is defined as any of the following:\\n\\nAdding or stopping a dopamine agonist, COMT- or MAO-inhibitor, anticholinergic or amantadine.\\nFractionation or de-fractionation of the current daily levodopa dose\\nChange of current Levodopa Equivalent daily dose by 15% or more\\nStart or stop of night medication\\nReferral for device assisted therapy (LCIG, apomorphine pump or DBS)\",\n",
              "          'PrimaryOutcomeTimeFrame': 'On first regular contact, RC, (telephone or visit) wich takes place within four months after PKG-recording'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Actual change of management',\n",
              "          'SecondaryOutcomeDescription': 'A retrospectively verified (medical and prescription records) change in management of PD as defined in the primary variable',\n",
              "          'SecondaryOutcomeTimeFrame': 'Change should take place within 4 weeks from the RC.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Patient Reported Experience of Care',\n",
              "          'SecondaryOutcomeDescription': 'A modified version of Generic Short Patient Experiences Questionnaire (GS-PEQ), Sjetne et al 2011 will be used. The modified questionnaire has 13 questions that are answered with a 5 grade Likert scale and a 5 grade Likert scale describing the importance of each question. Items will be analyzed separately as well as as summary scores',\n",
              "          'SecondaryOutcomeTimeFrame': 'The assessment will be made within 3 days from the first RC after PKG-recording,'},\n",
              "         {'SecondaryOutcomeMeasure': 'PRO-PD score at 3 months after the first regular visit',\n",
              "          'SecondaryOutcomeDescription': 'The Patient Reported Outcome in PD web questionnaire will be reported as summary score as well as per symptom domain.',\n",
              "          'SecondaryOutcomeTimeFrame': 'The assessment is made 3 months after the RC.'},\n",
              "         {'SecondaryOutcomeMeasure': 'PDQ-8 score at 3 months after the first regular visit',\n",
              "          'SecondaryOutcomeDescription': 'The 8 question version of Parkinson Disease Quality of Life Questionnaire. Reported as index score (0-100%)',\n",
              "          'SecondaryOutcomeTimeFrame': 'The assessment is made 3 months after the RC.'},\n",
              "         {'SecondaryOutcomeMeasure': 'NMSQ score at 3 months after the first regular visit',\n",
              "          'SecondaryOutcomeDescription': 'The Non Motor Symptoms Questionnaire will be administered and the number of reported symptoms within the last month are reported',\n",
              "          'SecondaryOutcomeTimeFrame': 'The assessment is made 3 months after the RC.'},\n",
              "         {'SecondaryOutcomeMeasure': 'EQ5D-5L at 3 months after the first regular visit',\n",
              "          'SecondaryOutcomeDescription': 'The EuroQoL 5 dimension 5 level scale of generic health',\n",
              "          'SecondaryOutcomeTimeFrame': 'The assessment is made 3 months after the RC.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Parkinson Kinetigraph bradykinesia measurement at 3 months after the first regular visit',\n",
              "          'SecondaryOutcomeDescription': 'Median BK score of a 6 day recording.',\n",
              "          'SecondaryOutcomeTimeFrame': 'The assessment is made 3 months after the RC.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Parkinson Kinetigraph dyskinesia measurement at 3 months after the first regular visit',\n",
              "          'SecondaryOutcomeDescription': 'Median DK score of a 6 day recording.',\n",
              "          'SecondaryOutcomeTimeFrame': 'The assessment is made 3 months after the RC.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Parkinson Kinetigraph fluctuation score at 3 months after the first regular visit',\n",
              "          'SecondaryOutcomeDescription': 'Fluctuation dyskinesia score (FDS) of a 6 day recording.',\n",
              "          'SecondaryOutcomeTimeFrame': 'The assessment is made 3 months after the RC.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Parkinson Kinetigraph Tremor measurement at 3 months after the first regular visit',\n",
              "          'SecondaryOutcomeDescription': 'Mean percent day-time (9-18) tremor time in a 6 day recording.',\n",
              "          'SecondaryOutcomeTimeFrame': 'The assessment is made 3 months after the RC.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Parkinson Kinetigraph immobility measurement at 3 months after the first regular visit',\n",
              "          'SecondaryOutcomeDescription': 'Mean percent day-time (9-18) immobility time in a 6 day recording.',\n",
              "          'SecondaryOutcomeTimeFrame': 'The assessment is made 3 months after the RC.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in PDQ8 compared to baseline',\n",
              "          'SecondaryOutcomeDescription': 'The change in PDQ8 index score compared to the baseline assessment that is made at the inclusion visit',\n",
              "          'SecondaryOutcomeTimeFrame': 'Assessed 3 months after the RC and at end of study 12 months after inclusion visit'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in NMSQ compared to baseline',\n",
              "          'SecondaryOutcomeDescription': 'The change in number of reported non-motor symptoms characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit',\n",
              "          'SecondaryOutcomeTimeFrame': 'Assessed 3 months after the RC and at end of study 12 months after inclusion visit'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in EQ5D5L compared to baseline',\n",
              "          'SecondaryOutcomeDescription': 'The change in index score characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit',\n",
              "          'SecondaryOutcomeTimeFrame': 'Assessed 3 months after the RC and at end of study 12 months after inclusion visit'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Parkinson Kinetigraph bradykinesia score compared to baseline',\n",
              "          'SecondaryOutcomeDescription': 'The change in BK score characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit. Improvement defined as abnormal score that has changed to within normal limits, no change defined as normal score that remains within normal limits and deterioration defined as normal score that changes to a score outside normal limits',\n",
              "          'SecondaryOutcomeTimeFrame': 'Assessed 3 months after the RC and at end of study 12 months after inclusion visit'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Parkinson Kinetigraph dyskinesia score compared to baseline',\n",
              "          'SecondaryOutcomeDescription': 'The change in DK score characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit. Improvement defined as abnormal score that has changed to within normal limits, no change defined as normal score that remains within normal limits and deterioration defined as normal score that changes to a score outside normal limits',\n",
              "          'SecondaryOutcomeTimeFrame': 'Assessed 3 months after the RC and at end of study 12 months after inclusion visit'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Parkinson Kinetigraph fluctuation score compared to baseline',\n",
              "          'SecondaryOutcomeDescription': 'The change in FDS score characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit. Improvement defined as abnormal score that has changed to within normal limits, no change defined as normal score that remains within normal limits and deterioration defined as normal score that changes to a score outside normal limits',\n",
              "          'SecondaryOutcomeTimeFrame': 'Assessed 3 months after the RC and at end of study 12 months after inclusion visit'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Parkinson Kinetigraph Tremor measurement compared to baseline',\n",
              "          'SecondaryOutcomeDescription': 'The change in percent tremor time characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit. Improvement defined as a decrease in tremor time which was higher than 0.9% at baseline, no change defined as tremor time that remains lower or equal to 0.9% or remains the same as at baseline. Deterioration defined as an increase in tremor time that results in a tremor time higher than 0.9% at follow up.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Assessed 3 months after the RC and at end of study 12 months after inclusion visit'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Parkinson Kinetigraph Immobility measurement compared to baseline',\n",
              "          'SecondaryOutcomeDescription': 'The change in percent immobility time characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit. Improvement is defined as a decrease in immobility time, no change is defined as immobility time that remains the same as at baseline. Deterioration defined as an increase in immobility time at follow up.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Assessed 3 months after the RC and at end of study 12 months after inclusion visit'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nClinical diagnosis of Parkinson's disease (ICD G209) according to medical records\\nA visit to an outpatient neurological or geriatric clinic in the region Vastra Gotaland, Sweden within the last -1 to -7 months according to medical records.\\nRandomized to invitation to participate in the WestPORTS objective measurement Cohort study (NCT03130595) by 1:4 randomization based on the full population fulfilling criteria 1 and 2.\\nWritten informed consent\\nNo previous PKG recording has been performed with the subject.\\n\\nExclusion Criteria:\\n\\nWithdrawal of consent.\\nUnable to wear a PKG on either wrist.\\nThe patient's physician is the PI of the study (F Bergquist)\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Filip Bergquist',\n",
              "          'OverallOfficialAffiliation': 'Gteborg University',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Sahlgrenska University Hospital',\n",
              "          'LocationCity': 'Gteborg',\n",
              "          'LocationZip': '41345',\n",
              "          'LocationCountry': 'Sweden'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 5,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02016092',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'ECH-13-24'},\n",
              "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '5258',\n",
              "          'SecondaryIdType': 'Other Grant/Funding Number',\n",
              "          'SecondaryIdDomain': 'Berg Pharma, LLC'}]},\n",
              "       'Organization': {'OrgFullName': \"The Parkinson's Institute\",\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Biomarker Discovery in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Proteomics, Metabolomics, Lipidomics and Genetic Analysis for Biomarker DISCOVERY in Parkinson's Disease\",\n",
              "       'Acronym': 'DISCOVERY-PD'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'March 2016',\n",
              "       'OverallStatus': 'Unknown status',\n",
              "       'LastKnownStatus': 'Active, not recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'December 2013'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2016',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'June 2016',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'December 14, 2013',\n",
              "       'StudyFirstSubmitQCDate': 'December 14, 2013',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 19, 2013',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'March 10, 2016',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 14, 2016',\n",
              "        'LastUpdatePostDateType': 'Estimate'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Birgitt Schuele',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Associate Professor',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': \"The Parkinson's Institute\"},\n",
              "       'LeadSponsor': {'LeadSponsorName': \"The Parkinson's Institute\",\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"There are approximately one million Americans who live with Parkinson's disease with 50,000 new cases per year and this rate is expected to rise with an aging population. The underlying pathophysiology and disease understanding of PD still remains elusive due to a combination of disease complexity and lack of predictive capability of existing models.\\n\\nThe Berg Interrogative Biology discovery platform has demonstrated a unique capability in producing drug targets and biomarkers that truly represent a disease phenotype. It has been able to catalyze molecules now in late stage clinical trials in cancer and many pre-clinical candidate therapeutics and biomarkers in endocrinology and central nervous system (CNS) diseases. The platform is able to decipher normal versus disease signatures by integration of data sets from the genome, metabolome, proteome, and lipidome in an agnostic manner that is subjected to Bayesian Artificial Intelligence informatics. The resulting nodes are then put back into wet-lab validation before proceeding to proof-of-principle pre-clinical testing.\\n\\nBy utilizing clinical data and specimens obtained by the medical specialists at The Parkinson's Institute, along with Berg's Interrogative Biology, this study aims to discover a disease biomarker enabling the creation of a diagnostic test for Parkinson's disease.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's disease\",\n",
              "         'biomarkers',\n",
              "         'blood',\n",
              "         'urine,',\n",
              "         'proteomics',\n",
              "         'lipidomics',\n",
              "         'metabolomics']}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'No',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}},\n",
              "       'BioSpec': {'BioSpecRetention': 'Samples With DNA',\n",
              "        'BioSpecDescription': 'Blood & Urine Specimen Collection: Up to 20mL of venous blood samples will be collected for plasma multi-omic analysis, as well as optional genetic, analyses.\\n\\nUrine samples (~50ml) will be collected via sterile urine cup and transferred into appropriate urine tube for multi-omic analysis.\\n\\nAll Samples may be saved for future studies, if consented.'},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '400',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Patients with Parkinson's disease\"},\n",
              "         {'ArmGroupLabel': 'Healthy Controls'}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Biological markers of Parkinson's disease\",\n",
              "          'PrimaryOutcomeDescription': \"To identify biologic markers of Parkinson's Disease (PD) for use in diagnostic testing.\",\n",
              "          'PrimaryOutcomeTimeFrame': '18 months'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Correlation between biologic markers and clinical features of PD',\n",
              "          'SecondaryOutcomeDescription': 'To identify and investigate possible correlations between biologic markers and clinical features of PD.',\n",
              "          'SecondaryOutcomeTimeFrame': '36 months'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nFor PD cases:\\n\\nInclusion Criteria:\\n\\nMen and women with the clinical diagnosis of idiopathic PD\\nWilling and able to give informed consent\\nWilling and able to comply with scheduled visits, required study procedures and laboratory tests\\n\\nExclusion Criteria:\\n\\nPD Subjects with any of the following may not be enrolled:\\n\\nPresence of atypical or secondary parkinsonism\\nInability to provide a blood and/or urine sample\\nHistory of renal failure and/or on dialysis\\nCurrently taking a medication in the following categories: dopamine blockers, neuroleptics, and/or dopamine blocking agents.\\nAny medical, psychiatric or other condition which, in the opinion of the investigator, would preclude participation\\n\\nHealthy Controls:\\n\\nAll of the following criteria must be met for a Healthy Control to be enrolled in the study:\\n\\nHealthy controls with no diagnosis of PD and any of the exclusion criteria\\nWilling and able to give informed consent\\nWilling and able to comply with scheduled visits, required study procedures and laboratory tests\\n\\nHealthy Controls with any of the following may not be enrolled:\\n\\nNo clinically significant or unstable medical or psychiatric condition that would interfere with the conduct of the study\\nDiagnosis of PD or presence of signs of a neurodegenerative disorder, e.g. essential tremor\\nFirst degree relative with PD/parkinsonism\\nInability to provide a blood and/or urine sample\\nHistory of renal failure and/or on dialysis\\nAny medical, psychiatric or other condition which, in the opinion of the investigator, would preclude participation',\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'MaximumAge': '90 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': \"Parkinson's patients\",\n",
              "       'SamplingMethod': 'Probability Sample'},\n",
              "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': \"The Parkinson's Institute and Clinical Center\",\n",
              "          'LocationCity': 'Sunnyvale',\n",
              "          'LocationState': 'California',\n",
              "          'LocationZip': '94085',\n",
              "          'LocationCountry': 'United States'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No',\n",
              "       'IPDSharingDescription': 'Individual participant data will not be made available, summary datasets may be published in peer-review journals.'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 6,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03888287',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'Pro00006159'},\n",
              "       'Organization': {'OrgFullName': 'Hackensack Meridian Health',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Parkinson's Disease Inpatient Clinical Knowledge and Management\",\n",
              "       'OfficialTitle': \"Parkinson's Disease Inpatient Clinical Knowledge and Management\",\n",
              "       'Acronym': 'PICK'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'June 2021',\n",
              "       'OverallStatus': 'Active, not recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'August 1, 2018',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 1, 2023',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'October 1, 2023',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'August 1, 2018',\n",
              "       'StudyFirstSubmitQCDate': 'March 21, 2019',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 25, 2019',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'June 30, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 2, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Hackensack Meridian Health',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'Yes',\n",
              "       'IsUSExport': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"This study will focus on patients with Parkinson's Disease in the adult inpatient units of Hackensack University Medical Center. We are measuring the effect of a Parkinson's Disease Inpatient Clinical Knowledge and Management Program on adherence to Parkinson's Disease medication using a Parkinson's Disease Identification Wrist Band, smartwatch and medication schedule card\",\n",
              "       'DetailedDescription': \"Parkinson's Disease (PD), the second-most common neurodegenerative disorder and is ranked the fourteenth leading cause of death. PD prevalence rate in the United States is estimated to be approximately 0.3% and is ranked the fourteenth leading cause of death (CDC, 2013). Depending on the methodology, the national prevalence data on PD is varied and insufficient. PD is projected to increase by 4% to 5% in age 65 and over 85 years respectively and is associated with a high economic burden exceeding $14.4 billion per year.\\n\\nAdmission to the hospital is identified as a major risk factor due to imprecise timing of medication administration, disruption of sleep pattern, dietary changes, and unfamiliarity of the hospital environment which all contribute to the exacerbation of PD symptoms. Parkinson's disease Foundation, 2015). Hospital length of stay for patients with PD is 1.45 times higher in comparison to non- PD patients.\\n\\nA study by Chou et al., (2011) involving 51 worldwide National Parkinson Foundation Centers found 94% of centers were not confident in the care and knowledge hospital professionals provided specific to: PD medications, complex drug interactions, contraindications and precise timing of medication administration. Hospital co-morbidities could be improved or prevented by adjustment of PD medication and medication adherence, critical in decreasing hospital length of stay.\\n\\nThe retrospective phase will be a data collection of adult patients admitted with a primary and secondary diagnosis of Parkinson's disease during January - June 2015 (6 month period). There will be 150 patients selected by the principal investigator(s) from chart review. In addition, the clinicians chosen for the study will complete a Parkinson's Disease Knowledge Assessment Survey.\\n\\nThe prospective phase will begin after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program for staff nurses, advanced practice nurses (APN), nursing assistants, patient care technicians, case managers, adult inpatient physician assistants, pharmacists, occupational therapists, physical therapists, nurse educators, and dietitians. There will be 150 patients selected from the adult inpatient units by the principal investigator(s) that meet the inclusion criteria and confirm through an informed consent that they will participate in the study.\\n\\nThe selected patients will be registered in a WatchRx interface via website URL by the Principal Investigator(s) and the Transition of Care(TC) Pharmacist and required to wear a Watch Rx smartwatch for the duration of their hospitalization. The Watch Rx Interface will store all medical information, necessary treatments, and daily clinical care for the patient which is synchronized to the smartwatch on the patient's wrist. The smartwatch will send alerts to the patient's assigned nurse's iPad through a Watch Rx app for medication administration, missed PD medications, battery conditions, and enables messaging between the primary nurse and the patient.\\n\\nThe WatchRx smartwatch will remind when it is time to take the medication. If the Parkinson's Disease medication is not administered, it sends missed medication reminder alerts to the nurse. For fixed time medication, the reminder is every 3 minutes up to 10 minutes.\\n\\nDuring the prospective phase, the research team will collect data from multiple sources such as the Watch Rx system, EPIC Hyperspace, and Case Report forms over a 6 month study period. The data will be calculated by using statistical analysis for the continuous variables and categorical variables identified from the collection of data. All study data will be imported into SAS software where data programming will be utilized to flag and generate queries on out-of-range data issues until they are resolved. All analysis will be performed using SAS version 9.4 (SAS Institute Inc. Cary, North Carolina, USA Data will be handled in a confidential manner to meet mandated IT Security standards and to prevent loss of privacy. All electronic files will be stored in an encrypted and password-protected database on a secure medical center server. Only co-investigators, advanced practice nurses, and the data coordinator who contact the subjects will have access to information linked to subject identifiers.\\n\\nThis study will improve timely administration of medications to PD patients. Patients enrolled in the study will have direct monitoring of their medication compliance and adherence. Patients participating in the registry will be gain information from the current research and possibly create a support group amongst themselves. This study will improve knowledge of Parkinson's disease amongst clinicians and better medication management of PD patients\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': ['PICK study', 'Impact of Watch Rx']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
              "        'DesignInterventionModel': 'Single Group Assignment',\n",
              "        'DesignInterventionModelDescription': \"The WatchRx is a smartwatch worn on the patient's wrist which receives alerts and notifications for medication administration scheduling as well as intervention messages from a App to the caregiver\",\n",
              "        'DesignPrimaryPurpose': 'Supportive Care',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '600',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Retrospective Phase',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': \"150 patients with Parkinson disease before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Watch Rx system']}},\n",
              "         {'ArmGroupLabel': 'Prospective Phase-Watch Rx system',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': \"150 patients after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program who are also assigned to a WatchRx system\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Watch Rx system']}},\n",
              "         {'ArmGroupLabel': 'Retrospective Phase - Clinicians',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': \"346 clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Other: Parkinson's Disease Inpatient Clinical Knowledge and Management Program\"]}},\n",
              "         {'ArmGroupLabel': 'Prospective Phase - Clinicians',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': \"346 clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Other: Parkinson's Disease Inpatient Clinical Knowledge and Management Program\"]}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
              "          'InterventionName': 'Watch Rx system',\n",
              "          'InterventionDescription': \"The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Prospective Phase-Watch Rx system',\n",
              "            'Retrospective Phase']}},\n",
              "         {'InterventionType': 'Other',\n",
              "          'InterventionName': \"Parkinson's Disease Inpatient Clinical Knowledge and Management Program\",\n",
              "          'InterventionDescription': \"Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Prospective Phase - Clinicians',\n",
              "            'Retrospective Phase - Clinicians']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Compare the Parkinson's Disease Inpatient Clinical Knowledge of clinicians before and after the Parkinson's Disease Inpatient Clinical Knowledge and Management Program\",\n",
              "          'PrimaryOutcomeDescription': \"Examine the effectiveness of Parkinson's Disease Inpatient Clinical Knowledge and Management Program on PD medication management using a Parkinson's Disease Knowledge Assessment Survey\",\n",
              "          'PrimaryOutcomeTimeFrame': '1 year'},\n",
              "         {'PrimaryOutcomeMeasure': 'Evaluate the Impact of WatchRx system on PD medication adherence during hospitalization',\n",
              "          'PrimaryOutcomeDescription': 'Track number of medication errors as measured by difference in actual and scheduled PD medication administration time and the number of contraindicated medication administrations.',\n",
              "          'PrimaryOutcomeTimeFrame': '6 months'},\n",
              "         {'PrimaryOutcomeMeasure': 'Track adverse events in hospitalized patients',\n",
              "          'PrimaryOutcomeDescription': \"Track adverse events (including number of falls, number of falls with injury, number of patients with positive Confusion Assessment Method/Mini-Cog scores, and length of stay) in hospitalized patients before and after implementation of Parkinson's Disease Inpatient Clinical Knowledge and Management Program and the WatchRx system.\",\n",
              "          'PrimaryOutcomeTimeFrame': '6 months'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Patients with Early Identification of Parkinson's Disease\",\n",
              "          'SecondaryOutcomeDescription': \"number of patients with early identification of Parkinson's Disease\",\n",
              "          'SecondaryOutcomeTimeFrame': '6 Months'},\n",
              "         {'SecondaryOutcomeMeasure': \"Patients Enrolled in Parkinson's Disease Registry at HackensackUMC\",\n",
              "          'SecondaryOutcomeDescription': \"Parkinson's Disease Registry\",\n",
              "          'SecondaryOutcomeTimeFrame': '6 Months'},\n",
              "         {'SecondaryOutcomeMeasure': \"Trend the prevalence of Parkinson's Disease patients at HackensackUMC\",\n",
              "          'SecondaryOutcomeDescription': 'Identify a trend',\n",
              "          'SecondaryOutcomeTimeFrame': '6 Months'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAdult patients diagnosed with primary and secondary diagnosis of Parkinson's disease\\nPatient 22 years old and older\\nPatients admitted to inpatient units\\nPatient who are verbally informed and agree to participate in the study\\n\\nExclusion Criteria:\\n\\nPatients less than or equal to 21 years of age\\nPatients who refuse to wear the PD wrist band.\\nPatients who verbally refuse enrollment in the PD registry.\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '22 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Azmi Hooman, MD',\n",
              "          'OverallOfficialAffiliation': 'Hackensack Meridian Health',\n",
              "          'OverallOfficialRole': 'Principal Investigator'},\n",
              "         {'OverallOfficialName': 'Mohammed Quadri, MD, MBA',\n",
              "          'OverallOfficialAffiliation': 'Hackensack Meridian Health',\n",
              "          'OverallOfficialRole': 'Principal Investigator'},\n",
              "         {'OverallOfficialName': 'Claudia Douglas, DNP',\n",
              "          'OverallOfficialAffiliation': 'Hackensack Meridian Health',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Hackensack University Medical Center',\n",
              "          'LocationCity': 'Hackensack',\n",
              "          'LocationState': 'New Jersey',\n",
              "          'LocationZip': '07601',\n",
              "          'LocationCountry': 'United States'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 7,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01877148',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'Parkinson_tDCS_rehabilitation'},\n",
              "       'Organization': {'OrgFullName': 'Universidade Federal de Pernambuco',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Effects Of tDCS With Physical Therapy On Rehabilitation In Parkinson's Disease\",\n",
              "       'OfficialTitle': 'Effects of Transcranial Direct Current Stimulation Associated With Physical Therapy on Motor Rehabilitation in Parkinsons Disease Patients'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'June 2013',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'January 2010'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2012',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'December 2012',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'June 11, 2013',\n",
              "       'StudyFirstSubmitQCDate': 'June 12, 2013',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 13, 2013',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'ResultsFirstSubmitDate': 'February 26, 2015',\n",
              "       'ResultsFirstSubmitQCDate': 'May 14, 2015',\n",
              "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'May 15, 2015',\n",
              "        'ResultsFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'May 14, 2015',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 15, 2015',\n",
              "        'LastUpdatePostDateType': 'Estimate'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Ktia Monte-Silva',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Doctor',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Universidade Federal de Pernambuco'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Universidade Federal de Pernambuco',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
              "      'DescriptionModule': {'BriefSummary': 'The present study aims to investigate the effect of transcranial direct current stimulation (tDCS) associated with physiotherapy in parkinsons rehabilitation. Previous studies showed that tDCS could reduce the bradykinesia, one of the symptom of Parkinson disease. In this way, this study will combine tDCS with physiotherapy in order to enhance the motor rehabilitation and the quality of life.',\n",
              "       'DetailedDescription': \"12 patients were participated of this study.After screening to check the eligibility criteria and giving informed consent, they were randomized in two groups. All patients were submitted to a 10 therapeutic sessions that occurred 3 times per week.\\n\\nBefore, immediately after and 1 month after the last session patients were submitted to an evaluation with the follow tests: Unified Parkinsons Disease Rating Scale(UPDRS), Jebsen Taylor Test (JTT) and Parkinson's Disease Quality of Life (PDQL). Furthermore, before and after each session the patients were submitted to transcranial magnetic stimulation (TMS) to evaluate cortical excitability through motor threshold and motor evoked potential.\\n\\nIn experimental sessions, the subjects always received physiotherapy with conventional techniques, the protocol followed the clinical practice guideline for physical therapy in Parkinson disease with the Royal Dutch Society Therapy. During tDCS protocol the patients seated in a comfortable chair with head and arm rests. Continuous current was applied using a pair of saline-soaked surface sponge electrodes (surface 35 cm2), the anode electrode was placed over the primary motor cortex and cathode above contralateral orbit. tDCS was applied of twice stimulation of 13 minutes with 20 minutes of interval between them and a current strength of 1mA. Sham tDCS was applied by current flow of 30s.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': ['Parkinson, rehabilitation, tDCS']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Phase 2']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
              "           'Investigator']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '12',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Physiotherapy + anodal tDCS',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: tDCS',\n",
              "            'Behavioral: Physiotherapy']}},\n",
              "         {'ArmGroupLabel': 'Physiotherapy + sham tDCS',\n",
              "          'ArmGroupType': 'Sham Comparator',\n",
              "          'ArmGroupDescription': 'The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: tDCS',\n",
              "            'Behavioral: Physiotherapy']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
              "          'InterventionName': 'tDCS',\n",
              "          'InterventionDescription': 'tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Physiotherapy + anodal tDCS',\n",
              "            'Physiotherapy + sham tDCS']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['non invasive brain stimulation']}},\n",
              "         {'InterventionType': 'Behavioral',\n",
              "          'InterventionName': 'Physiotherapy',\n",
              "          'InterventionDescription': 'Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Physiotherapy + anodal tDCS',\n",
              "            'Physiotherapy + sham tDCS']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change From Unified Parkinsons Disease Rating Scale - UPDRS',\n",
              "          'PrimaryOutcomeDescription': 'Unified Parkinsons Disease Rating Scale is the sum of 27 questions, total score ranging from108 (best possible outcome) to 0 (worst possible outcome)\", as accurate and appropriate',\n",
              "          'PrimaryOutcomeTimeFrame': 'At baseline, after 1 month'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change From Cortical Excitability Via Single Transcranial Magnetic Stimulation',\n",
              "          'SecondaryOutcomeTimeFrame': 'per sesssion: at baseline and after physical therapy'}]},\n",
              "       'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Change From Parkinson Disease Quality of Life - PDQL',\n",
              "          'OtherOutcomeDescription': 'Parkinson disease quality of life is the sum of 37 questions, total score ranging from 0 (best possible outcome) to 185 (worst possible outcome)\", as accurate and appropriate',\n",
              "          'OtherOutcomeTimeFrame': 'at baseline, after 1 month'},\n",
              "         {'OtherOutcomeMeasure': 'Change From Jebsen-Taylor Hand Function Test - Jebsen Test',\n",
              "          'OtherOutcomeDescription': 'The Jebsen-Taylor Hand Function Test assesses a broad range of uni-manual hand functions required for activities of daily living. Seven subtests are performed on both non-dominant and dominant hand: 1. Writing a 24-letter, 3rd grade reading difficulty sentence 2... Total score = sum of times for each subtests. Shorted times are indicative of better hand function',\n",
              "          'OtherOutcomeTimeFrame': 'At baseline, after 1 month'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nParkinson disease comproved by a neurologist Regular treatment with dopamine or other drugs against parkinson -\\n\\nExclusion Criteria:\\n\\npregnant history of convulsion metal implant in the region of skull or face change in medication during the study realize other physical therapy in the same time of the study previous surgery for parkinson disease\\n\\n-',\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '40 Years',\n",
              "       'MaximumAge': '80 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Ktia K Monte-Silva, PhD',\n",
              "          'OverallOfficialAffiliation': 'Universidade Federal de Pernambuco',\n",
              "          'OverallOfficialRole': 'Study Director'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Applied Neuroscience Laboratory',\n",
              "          'LocationCity': 'Recife',\n",
              "          'LocationState': 'Pernambuco',\n",
              "          'LocationZip': '50740-560',\n",
              "          'LocationCountry': 'Brazil'}]}}},\n",
              "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
              "          'FlowGroupTitle': 'Physiotherapy + Anodal tDCS',\n",
              "          'FlowGroupDescription': 'The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy'},\n",
              "         {'FlowGroupId': 'FG001',\n",
              "          'FlowGroupTitle': 'Physiotherapy + Sham tDCS',\n",
              "          'FlowGroupDescription': 'The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy'}]},\n",
              "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
              "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '6'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '6'}]}},\n",
              "            {'FlowMilestoneType': 'COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '5'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '5'}]}},\n",
              "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '1'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '1'}]}}]}}]}},\n",
              "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
              "          'BaselineGroupTitle': 'Physiotherapy + Anodal tDCS',\n",
              "          'BaselineGroupDescription': 'The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy'},\n",
              "         {'BaselineGroupId': 'BG001',\n",
              "          'BaselineGroupTitle': 'Physiotherapy + Sham tDCS',\n",
              "          'BaselineGroupDescription': 'The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy'},\n",
              "         {'BaselineGroupId': 'BG002',\n",
              "          'BaselineGroupTitle': 'Total',\n",
              "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
              "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
              "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
              "             'BaselineDenomCountValue': '5'},\n",
              "            {'BaselineDenomCountGroupId': 'BG001',\n",
              "             'BaselineDenomCountValue': '5'},\n",
              "            {'BaselineDenomCountGroupId': 'BG002',\n",
              "             'BaselineDenomCountValue': '10'}]}}]},\n",
              "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '4'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '1'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '5'}]}},\n",
              "               {'BaselineCategoryTitle': '>=65 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '1'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '4'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '5'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Age, Continuous',\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'years',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '59',\n",
              "                   'BaselineMeasurementSpread': '9.27'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '68.2',\n",
              "                   'BaselineMeasurementSpread': '11.75'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '63.6',\n",
              "                   'BaselineMeasurementSpread': '10.51'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '3'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '1'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '4'}]}},\n",
              "               {'BaselineCategoryTitle': 'Male',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '2'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '4'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '6'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
              "          'BaselineMeasureParamType': 'Number',\n",
              "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Brazil',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '5'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '5'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '10'}]}}]}}]}}]}},\n",
              "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': 'Change From Unified Parkinsons Disease Rating Scale - UPDRS',\n",
              "          'OutcomeMeasureDescription': 'Unified Parkinsons Disease Rating Scale is the sum of 27 questions, total score ranging from108 (best possible outcome) to 0 (worst possible outcome)\", as accurate and appropriate',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'At baseline, after 1 month',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Physiotherapy + Anodal tDCS',\n",
              "             'OutcomeGroupDescription': 'The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Physiotherapy + Sham tDCS',\n",
              "             'OutcomeGroupDescription': 'The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '5'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '5'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '24',\n",
              "                   'OutcomeMeasurementSpread': '12'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '30',\n",
              "                   'OutcomeMeasurementSpread': '23'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'post 1 month',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '21.2',\n",
              "                   'OutcomeMeasurementSpread': '11.12'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '21.8',\n",
              "                   'OutcomeMeasurementSpread': '14.0'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Change From Cortical Excitability Via Single Transcranial Magnetic Stimulation',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'milivolt',\n",
              "          'OutcomeMeasureTimeFrame': 'per sesssion: at baseline and after physical therapy',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Physiotherapy + Anodal tDCS',\n",
              "             'OutcomeGroupDescription': 'The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Physiotherapy + Sham tDCS',\n",
              "             'OutcomeGroupDescription': 'The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '5'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '5'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1.01',\n",
              "                   'OutcomeMeasurementSpread': '0.25'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '1',\n",
              "                   'OutcomeMeasurementSpread': '0.22'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'post 1 month',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1.35',\n",
              "                   'OutcomeMeasurementSpread': '0.24'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '1.15',\n",
              "                   'OutcomeMeasurementSpread': '0.31'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Other Pre-specified',\n",
              "          'OutcomeMeasureTitle': 'Change From Parkinson Disease Quality of Life - PDQL',\n",
              "          'OutcomeMeasureDescription': 'Parkinson disease quality of life is the sum of 37 questions, total score ranging from 0 (best possible outcome) to 185 (worst possible outcome)\", as accurate and appropriate',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'at baseline, after 1 month',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Physiotherapy + Anodal tDCS',\n",
              "             'OutcomeGroupDescription': 'The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Physiotherapy + Sham tDCS',\n",
              "             'OutcomeGroupDescription': 'The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '5'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '5'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '112.8',\n",
              "                   'OutcomeMeasurementSpread': '44.1'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '117.2',\n",
              "                   'OutcomeMeasurementSpread': '45.6'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'post 1 month',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '120.2',\n",
              "                   'OutcomeMeasurementSpread': '35.07'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '125.8',\n",
              "                   'OutcomeMeasurementSpread': '37.83'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Other Pre-specified',\n",
              "          'OutcomeMeasureTitle': 'Change From Jebsen-Taylor Hand Function Test - Jebsen Test',\n",
              "          'OutcomeMeasureDescription': 'The Jebsen-Taylor Hand Function Test assesses a broad range of uni-manual hand functions required for activities of daily living. Seven subtests are performed on both non-dominant and dominant hand: 1. Writing a 24-letter, 3rd grade reading difficulty sentence 2... Total score = sum of times for each subtests. Shorted times are indicative of better hand function',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'minutes',\n",
              "          'OutcomeMeasureTimeFrame': 'At baseline, after 1 month',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Physiotherapy + Anodal tDCS',\n",
              "             'OutcomeGroupDescription': 'The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Physiotherapy + Sham tDCS',\n",
              "             'OutcomeGroupDescription': 'The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '5'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '5'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '106.36',\n",
              "                   'OutcomeMeasurementSpread': '55.93'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '90.63',\n",
              "                   'OutcomeMeasurementSpread': '45.53'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'post 1 month',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '86.62',\n",
              "                   'OutcomeMeasurementSpread': '48.71'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '81.29',\n",
              "                   'OutcomeMeasurementSpread': '27.5'}]}}]}}]}}]}},\n",
              "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
              "       'EventsTimeFrame': 'after tDCS',\n",
              "       'EventsDescription': 'Questionnaire of adverses effects',\n",
              "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
              "          'EventGroupTitle': 'Physiotherapy + Anodal tDCS',\n",
              "          'EventGroupDescription': 'The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy',\n",
              "          'EventGroupSeriousNumAffected': '0',\n",
              "          'EventGroupSeriousNumAtRisk': '6',\n",
              "          'EventGroupOtherNumAffected': '0',\n",
              "          'EventGroupOtherNumAtRisk': '6'},\n",
              "         {'EventGroupId': 'EG001',\n",
              "          'EventGroupTitle': 'Physiotherapy + Sham tDCS',\n",
              "          'EventGroupDescription': 'The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.\\n\\nTranscranial direct current stimulation: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability\\n\\nPhysiotherapy',\n",
              "          'EventGroupSeriousNumAffected': '0',\n",
              "          'EventGroupSeriousNumAtRisk': '6',\n",
              "          'EventGroupOtherNumAffected': '0',\n",
              "          'EventGroupOtherNumAtRisk': '6'}]}},\n",
              "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
              "        'AgreementRestrictiveAgreement': 'No'},\n",
              "       'PointOfContact': {'PointOfContactTitle': 'Ktia Monte-Silva',\n",
              "        'PointOfContactOrganization': 'Universidade Federal de Pernambuco',\n",
              "        'PointOfContactEMail': 'monte.silvakk@gmail.com',\n",
              "        'PointOfContactPhone': '+ 55 (81) 2126-7579'}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 8,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03111472',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '25364'},\n",
              "       'Organization': {'OrgFullName': 'University of Southampton',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Development and Evaluation of a Guide to Help People With Parkinson's and Their Caregivers to Self-manage Falling\",\n",
              "       'OfficialTitle': \"Development and Evaluation of a Self-management Guide for Community-dwelling People With Parkinson's Disease Who Fall and Their Informal Caregivers\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'October 2017',\n",
              "       'OverallStatus': 'Unknown status',\n",
              "       'LastKnownStatus': 'Active, not recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'May 1, 2017',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2018',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'December 2018',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'March 7, 2017',\n",
              "       'StudyFirstSubmitQCDate': 'April 11, 2017',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 12, 2017',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'October 24, 2017',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 26, 2017',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'University of Southampton',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute for Health Research, United Kingdom',\n",
              "          'CollaboratorClass': 'OTHER_GOV'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"This study will investigate whether it is possible, through the development and evaluation of a self-management guide, to improve health related quality of life and concern of falling in people with Parkinson's disease who fall, and reduce caregiver burden in their informal caregivers.\",\n",
              "       'DetailedDescription': \"This study will progress through four phases\\n\\nPhase One\\n\\nEstablish the needs and preferences of people with Parkinson's (PwP) who fall and their informal caregivers for the effective self-management of falls. This will be achieved through questionnaires distributed to 30-40 PwP and their caregivers, with responses analysed through the use of descriptive statistics. A purposive sample of participants, selected through responses to the questionnaire, will be invited to participate in semi-structured interviews. Interviews will be conducted until data saturation has been achieved. These interviews will seek to further identify the thoughts and experiences of PwP and their caregivers in relation to falling, with responses analysed through thematic analysis.\\n\\nPhase Two\\n\\nEstablish the needs and preferences of PwP who fall and their informal caregivers for the effective self-management of falls, as perceived by healthcare professionals specialising in the care of PwP. This will be achieved through semi-structured interviews and focus groups with 10 healthcare professionals involved in the care of PwP who fall. The interviews will be analysed with thematic analysis.\\n\\nPhase Three\\n\\nDevelopment of a prototype of a self-management guide utilising information from phases one and two alongside a systematic review of self-management interventions for people with Parkinson's who fall. The prototype will be distributed to 6-8 dyads of PwP who fall and their caregivers. Feedback will be sought in the form of a questionnaire, with responses analysed through the use of descriptive statistics, and the guide modified accordingly.\\n\\nPhase Four\\n\\nMixed methods acceptability and feasibility study of the modified version of the guide; with a before and after comparison of health related quality of life and concern of falling in PwP, and of caregiver burden in their informal caregivers.\\n\\nThe guide will be distributed to 30-40 pairings of PwP who fall and their caregivers. Baseline assessments of health related quality of life (Parkinson's disease questionnaire 8, PDQ8) and of caregiver burden (Zarit Burden Interview short version) will be completed.\\n\\nAfter three months, participants will complete feedback questionnaires to assess the acceptability and the feasibility of the guide, and will repeat the PDQ8 and zarit burden Interview short version . The responses to the questionnaires will be analysed through the use of descriptive statistics, with a before and after comparison of health related quality of life and of caregiver burden.\\n\\nA purposive sample of participants, selected through their responses to the questionnaires, will be invited to participate in semi-structured interviews, to further explore their thoughts about the guide. Interviews will be conducted until data saturation has been reached, we estimate that we will conduct 12-15 interviews. The interviews will be analysed using thematic analysis.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease',\n",
              "         'Accidental Fall']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'N/A',\n",
              "        'DesignInterventionModel': 'Single Group Assignment',\n",
              "        'DesignInterventionModelDescription': \"30-40 participants will receive the intervention. The intervention will be a guide to help people with Parkinson's and their caregivers to self-manage falls. There will be no control group.\",\n",
              "        'DesignPrimaryPurpose': 'Supportive Care',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '40',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Self-management guide for falls in Parkinson's\",\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': \"A guide for people with Parkinson's and their caregivers to self-manage falls.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Other: Self-management guide for people with Parkinson's who fall and their informal caregivers\"]}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': \"Self-management guide for people with Parkinson's who fall and their informal caregivers\",\n",
              "          'InterventionDescription': \"The self-management guide will be developed utilising information from people with Parkinson's, informal caregivers of people with Parkinson's, healthcare professionals and a systematic review of self-management interventions for people with Parkinson's who fall.\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Self-management guide for falls in Parkinson's\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Feasibility and acceptability of the guide',\n",
              "          'PrimaryOutcomeDescription': 'This will assessed through response to a questionnaire, with responses analysed through descriptive statistics',\n",
              "          'PrimaryOutcomeTimeFrame': '3 months'},\n",
              "         {'PrimaryOutcomeMeasure': 'Feasibility and acceptability of the guide',\n",
              "          'PrimaryOutcomeDescription': 'A purposive sample of participants, selected through their responses to the questionnaire, will be invited to participate in semi-structured interviews. Interviews will explore the experiences and thoughts of the participants further and will be conducted until data saturation has been reached. Responses to the interview will be analysed through thematic analysis.',\n",
              "          'PrimaryOutcomeTimeFrame': '3 months'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Health related quality of life of people with Parkinson's as measured on PDQ8\",\n",
              "          'SecondaryOutcomeDescription': \"As measured on Parkinson's disease quality of life scale 8 (PDQ8)\",\n",
              "          'SecondaryOutcomeTimeFrame': '3 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Caregiver burden of their informal caregivers as measured on the Zarit Burden Interview scale short version',\n",
              "          'SecondaryOutcomeDescription': 'As measured on the Zarit Burden Interview scale short form',\n",
              "          'SecondaryOutcomeTimeFrame': '3 months'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nDiagnosis of idiopathic Parkinson's disease, with or without cognitive impairment\\nPeople with Parkinson's living in their own home\\nAt least one fall in the preceding year, as reported by the person with Parkinson's or the caregiver\\nAble to read a newspaper without severe difficulty, with or without glasses\\n\\nOR\\n\\nAn informal caregiver of a person with Parkinson's meeting the criteria for inclusion in the study\\n\\nExclusion Criteria:\\n\\nDiagnosis of a Parkinson's Plus syndrome\\nPeople with Parkinson's living in a residential or nursing home\\nNo falls in the preceding year\\nNon-fluent in verbal and written English\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'University of Southampton',\n",
              "          'LocationCity': 'Southampton',\n",
              "          'LocationState': 'Hampshire',\n",
              "          'LocationZip': 'SO17 1BJ',\n",
              "          'LocationCountry': 'United Kingdom'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 9,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04994015',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'PDGENE-PF'},\n",
              "       'Organization': {'OrgFullName': \"Parkinson's Foundation\",\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Parkinson's Foundation PD GENEration Genetic Registry\",\n",
              "       'OfficialTitle': \"Parkinson's Foundation PD GENEration Genetic Registry\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'July 2021',\n",
              "       'OverallStatus': 'Recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'December 20, 2020',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2024',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'June 1, 2025',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'July 29, 2021',\n",
              "       'StudyFirstSubmitQCDate': 'July 29, 2021',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 6, 2021',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'August 17, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 24, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': \"Parkinson's Foundation\",\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Indiana University',\n",
              "          'CollaboratorClass': 'OTHER'},\n",
              "         {'CollaboratorName': 'Fulgent Genetics',\n",
              "          'CollaboratorClass': 'UNKNOWN'},\n",
              "         {'CollaboratorName': \"Parkinson's Study Group\",\n",
              "          'CollaboratorClass': 'UNKNOWN'}]}},\n",
              "      'OversightModule': {'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'Yes'},\n",
              "      'DescriptionModule': {'BriefSummary': 'Development of a central repository for PD-related genomic data for future research.',\n",
              "       'DetailedDescription': 'The purpose of this study is to develop a central repository for PD-related genomic data by individuals who consent to deposit their data and bank their residual DNA obtained through clinical genetic testing for future research use.'},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'N/A',\n",
              "        'DesignInterventionModel': 'Single Group Assignment',\n",
              "        'DesignInterventionModelDescription': 'All participants will undergo genetic counseling service post-genetic testing either locally or through central services.',\n",
              "        'DesignPrimaryPurpose': 'Screening',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '15000',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
              "          'InterventionName': \"Lab Assay for seven genetic variants for Parkinson's Disease\",\n",
              "          'InterventionDescription': 'Counseling provided to participant by site clinician/physician/genetic counselor.'}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Prevalence of Parkinson's related genetic mutations in an convenience cohort\",\n",
              "          'PrimaryOutcomeDescription': \"Identify people with Parkinson's who have genetic mutations to advance basic science and clinical research.\",\n",
              "          'PrimaryOutcomeTimeFrame': '6 months'},\n",
              "         {'PrimaryOutcomeMeasure': \"Educating people with Parkinson's of their genetic mutation status through genetic testing and counseling\",\n",
              "          'PrimaryOutcomeDescription': 'People who are informed of their genetic status may be empowered to learn more about their disease and participant in clinical research.',\n",
              "          'PrimaryOutcomeTimeFrame': '6 months'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nStudy Population 1: PWP (open for recruitment)\\n\\nMeet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease: probable diagnosis.\\nWillingness to undergo genetic testing, and choose to be informed of genetic testing results for GBA, LRRK2 and 5 additional PD related genes (SNCA, VPS35, PRKN, PINK-1, PARK7).\\nCapacity to give full informed consent in writing or electronically, and have read and signed the informed consent forms (ICFs) based on site clinician's determination.\\nAble to perform study activities (including completion of either online, in-person or paper surveys).\\n\\nStudy Population 2: People at risk of developing PD (not open for recruitment)\\n\\n1. Family members of Study Population 1 may be invited to participate in the study if confirmatory genetic testing is deemed necessary by the genetic testing laboratory.\\n\\nExclusion Criteria:\\n\\nDiagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome), including that due to medications, metabolic disorders, encephalitis, cerebrovascular disease, or normal pressure hydrocephalus.\\nIndividuals who have received a blood transfusion within the past 3 months.\\nIndividuals who have active hematologic malignancies such as lymphoma or leukemia.\\nIndividuals who have had a bone marrow transplant within the past 5 years.\\nUnder the age of 18\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Kamalini Ghosh, MS',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '1-800-473-4636',\n",
              "          'CentralContactEMail': 'kghosh@parkinson.org'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'James Beck, PhD',\n",
              "          'OverallOfficialAffiliation': \"Parkinson's Foundation\",\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'University of Colorado',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Denver',\n",
              "          'LocationState': 'Colorado',\n",
              "          'LocationZip': '80045',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Robbie Cummins',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'robbie.cummins@cuanschutz.edu'},\n",
              "            {'LocationContactName': 'Jeanne Feuerstein, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Aventura Neurologists-Visionary Investigators Network',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Aventura',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '33180',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jonathan Palmquist',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'jpalmquist@visionaryinvestigators.com'},\n",
              "            {'LocationContactName': 'Julie Schwartzbard, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Morehouse Healthcare',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Atlanta',\n",
              "          'LocationState': 'Georgia',\n",
              "          'LocationZip': '30310',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Sherline Sauveur',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'ssauveur@msm.edu'},\n",
              "            {'LocationContactName': 'Chantale Branson, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': \"St. Elizabeth's Medical Center\",\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Boston',\n",
              "          'LocationState': 'Massachusetts',\n",
              "          'LocationZip': '02136',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kaitlyn Ramsey',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'kaitlyn.ramsey@steward.org'},\n",
              "            {'LocationContactName': 'Eleni Okeanis Vaou, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Beth Israel Deaconess Medical Center (BIDMC)',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Boston',\n",
              "          'LocationState': 'Massachusetts',\n",
              "          'LocationZip': '02215',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hannah Babcock',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'hbabcock@bidmc.harvard.edu'},\n",
              "            {'LocationContactName': 'David Simon, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Inland Northwest Research',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Spokane',\n",
              "          'LocationState': 'Washington',\n",
              "          'LocationZip': '99202',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Melissa Bixby Sanchez, MS',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'mbixby@inwresearch.com'},\n",
              "            {'LocationContactName': 'Jason Aldred, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}}]}}},\n",
              "     'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'ICF',\n",
              "          'LargeDocHasProtocol': 'No',\n",
              "          'LargeDocHasSAP': 'No',\n",
              "          'LargeDocHasICF': 'Yes',\n",
              "          'LargeDocLabel': 'Informed Consent Form',\n",
              "          'LargeDocDate': 'April 26, 2021',\n",
              "          'LargeDocUploadDate': '07/29/2021 15:28',\n",
              "          'LargeDocFilename': 'ICF_000.pdf'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 10,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04023201',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'XHEC-C-2019-094'},\n",
              "       'Organization': {'OrgFullName': 'Xinhua Hospital, Shanghai Jiao Tong University School of Medicine',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Nocturnal Symptoms and Quality of Life in Patients With Parkinson's Disease in Shanghai\",\n",
              "       'OfficialTitle': \"Nocturnal Symptoms and Quality of Life in Patients With Parkinson's Disease in Shanghai\",\n",
              "       'Acronym': 'NQPDSH'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'July 2019',\n",
              "       'OverallStatus': 'Unknown status',\n",
              "       'LastKnownStatus': 'Recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'July 3, 2019',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2019',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'January 31, 2020',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'July 15, 2019',\n",
              "       'StudyFirstSubmitQCDate': 'July 15, 2019',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 17, 2019',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'July 15, 2019',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 17, 2019',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Xinhua Hospital, Shanghai Jiao Tong University School of Medicine',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"This is a cross-sectional, retrospective clinical observation study focusing on the incidence and influencing factors of nocturnal symptoms in patients with Parkinson's disease.\",\n",
              "       'DetailedDescription': \"This study was a cross-sectional, retrospective clinical observation study investigating the incidence and influencing factors of nocturnal symptoms in patients with Parkinson's disease through the Parkinson's disease sleep-related scale. At the same time, the effects of nocturnal symptoms on the quality of life of patients with Parkinson's disease were studied. About 1,500 Parkinson's patients will be recruited into the study who come from Shanghai, China.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'No',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '1500',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Parkinson's disease patients\",\n",
              "          'ArmGroupDescription': \"Parkinson's disease patients with or without nocturnal symptoms\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Nocturnal symptoms']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': 'Nocturnal symptoms',\n",
              "          'InterventionDescription': \"Parkinson's disease patients with or without nocturnal symptoms\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Parkinson's disease patients\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"nocturnal symptoms in patients with Parkinson's disease\",\n",
              "          'PrimaryOutcomeDescription': \"the incidence and influencing factors of nocturnal symptoms in patients with Parkinson's disease\",\n",
              "          'PrimaryOutcomeTimeFrame': 'January 31, 2020'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nParkinson's disease patients diagnosed according to the diagnostic criteria of MDS\\nSigning informed consent\\n\\nExclusion Criteria:\\n\\nclinically suspected Parkinson's disease, has not been diagnosed;\\nsuspected or diagnosed as secondary Parkinson's syndrome (vascular, drug, traumatic, encephalitis, toxic, etc.);\\nsuspected or diagnosed as atypical Parkinson's syndrome (progressive supranuclear palsy, multiple system atrophy, cortical basal ganglia degeneration, etc.);\\nThere is a clear history of stroke, moderate to severe traumatic brain injury, hydrocephalus, brain surgery or history of brain tumors;\\nsevere cognitive impairment or psychiatric symptoms;\\nCan not cooperate with the completion of the study.\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']},\n",
              "       'StudyPopulation': \"Parkinson's disease patients diagnosed according to the diagnostic criteria of MDS\",\n",
              "       'SamplingMethod': 'Probability Sample'},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Yu Zhang',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '8613916006909',\n",
              "          'CentralContactEMail': 'zhangyu0330@126.com'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Zhenguo Liu, Doctor',\n",
              "          'OverallOfficialAffiliation': 'Xinhua Hospital, Shanghai Jiao Tong University School of Medicine',\n",
              "          'OverallOfficialRole': 'Study Chair'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Shanghai',\n",
              "          'LocationState': 'Shanghai',\n",
              "          'LocationZip': '200092',\n",
              "          'LocationCountry': 'China',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yu Zhang, Doctor',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '8613916006909',\n",
              "             'LocationContactEMail': 'zhangyu0330@126.com'}]}}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '15505143',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Grandas F, Iranzo A. Nocturnal problems occurring in Parkinson's disease. Neurology. 2004 Oct 26;63(8 Suppl 3):S8-11. Review.\"}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'T6034',\n",
              "          'ConditionBrowseLeafName': 'Quality of Life',\n",
              "          'ConditionBrowseLeafAsFound': 'Quality of Life',\n",
              "          'ConditionBrowseLeafRelevance': 'high'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
              "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
              "   {'Rank': 11,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02975193',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'IRB201601780'},\n",
              "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'F30NS111841',\n",
              "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
              "          'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/F30NS111841'}]},\n",
              "       'Organization': {'OrgFullName': 'University of Florida',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Neural Correlates of Cognition in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Neural Correlates of Cognition in Parkinson's Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'February 2021',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'February 1, 2017',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 25, 2020',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'October 25, 2020',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'November 10, 2016',\n",
              "       'StudyFirstSubmitQCDate': 'November 28, 2016',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 29, 2016',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'February 11, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 15, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'University of Florida',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Neurological Disorders and Stroke (NINDS)',\n",
              "          'CollaboratorClass': 'NIH'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Cognitive impairment in Parkinson's disease (PD) has far-reaching effects on both motor outcomes and quality of life in PD patients. Furthermore, deep brain stimulation (DBS), now an evidence-based treatment for certain cases of PD, has the risk of causing deficits in multiple areas of cognition.\\n\\nAs such, the purpose of this study is to understand the neuroanatomical and neurophysiologic basis for impaired cognition in PD. The aim is to identify neural correlates of cognition by measuring brain signal activity while PD patients are engaged in cognition on a computer.\",\n",
              "       'DetailedDescription': \"Study Participants: For this study, the investigators will recruit 75 Parkinson's disease (PD) patients that are undergoing deep brain stimulation (DBS) as routine standard of care.\\n\\nScreening: For healthy control participants, investigators will approach adults, aged 18-90, for possible involvement in our study. Potential participants will be asked if they have ever been diagnosed with a movement disorder, psychiatric disorder, or dementia. For PD patients undergoing evaluation for DBS, investigators will first consult with their neurologist and neurosurgeon. Next, investigators will approach the participant and explain the study.\\n\\nPD Participants: As part of the usual DBS process at University of Florida (UF), PD participants will be asked to participate in this trial. There are three evaluation time points: before surgery, during surgery, and possibly after surgery. Before surgery, the PD patients will complete standardized questionnaires and be trained on a computer game to assess cognition. During surgery, the participants will play the same computer game while brain signals are recorded. When the patients return to University of Florida for DBS programming visits within 48 months after surgery, they will repeat the standardized questionnaires and computer game once again.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': ['Parkinsons Disease', 'Cognition']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Basic Science',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '64',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Control group',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': \"Healthy adults ages 18-90 without movement disorders, psychiatric disorders, or dementia. They will complete computer games and questionnaires at one time point.\\n\\nSpecific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Computer task assessing cognition',\n",
              "            \"Behavioral: Impulsive-Compulsive Disorders in Parkinson's Disease\"]}},\n",
              "         {'ArmGroupLabel': \"Parkinson's disease group with DBS\",\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': \"Parkinson's disease patients who have elected to receive DBS for treatment of their side effects of PD consent to complete computer games and questionnaires at baseline, computer games during deep brain stimulation, and computer games and questionnaires up to 2 years after surgery.\\n\\nSpecific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Computer task assessing cognition',\n",
              "            \"Behavioral: Impulsive-Compulsive Disorders in Parkinson's Disease\",\n",
              "            'Procedure: Deep Brain Stimulation Surgery']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
              "          'InterventionName': 'Computer task assessing cognition',\n",
              "          'InterventionDescription': 'Participants will complete a short computer game to assess cognition.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control group',\n",
              "            \"Parkinson's disease group with DBS\"]}},\n",
              "         {'InterventionType': 'Behavioral',\n",
              "          'InterventionName': \"Impulsive-Compulsive Disorders in Parkinson's Disease\",\n",
              "          'InterventionDescription': 'Standard clinical questionnaire',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control group',\n",
              "            \"Parkinson's disease group with DBS\"]},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['QUIP-RS']}},\n",
              "         {'InterventionType': 'Procedure',\n",
              "          'InterventionName': 'Deep Brain Stimulation Surgery',\n",
              "          'InterventionDescription': 'DBS surgery for the implantation of electrodes for the treatment of motor disorders.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Parkinson's disease group with DBS\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in behavioral performance',\n",
              "          'PrimaryOutcomeDescription': 'Behavioral performance will be assessed by the computer game that assess cognition. All computer games used in this study will have a similar form. The computer will record responses to each trial during the computer game.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline, before surgery, during surgery, and up to 2 years after surgery'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Change in Score on Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)\",\n",
              "          'SecondaryOutcomeDescription': 'Assess the scores from a standard clinical questionnaire called QUIP-RS. Scores range from 0 to 112.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, before surgery, during surgery, and up to 2 years after surgery'},\n",
              "         {'SecondaryOutcomeMeasure': 'Local field potential brain signal',\n",
              "          'SecondaryOutcomeDescription': \"Measuring Brain signal while Parkinson's disease patients play a computer game during surgery. Local field potential is measured in Hertz (Hz)\",\n",
              "          'SecondaryOutcomeTimeFrame': 'At time of surgery'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"PD-DBS Participants:\\n\\nInclusion Criteria: Persons undergoing DBS surgery for the implantation of electrodes for the treatment of motor disorders\\nExclusion Criteria: Failure of the DBS surgical candidacy screening process\\n\\nNon-DBS PD Participants:\\n\\nInclusion Criteria:Persons diagnosed with idiopathic Parkinson's disease and have not received and are not currently scheduled for DBS.\\n\\nExclusion Criteria: Individuals that :\\n\\nthat have been diagnosed with dementia or other serious brain diseases or disorders such as strokes, traumatic brain injury, or brain tumor (the exception is Parkinson's disease)\\nwho have had drug or alcohol abuse within the past 12 months\\nwith severe sensory difficulties such as impaired vision or hearing\\ncurrently experiencing significant depression or sadness\\nwith a history of schizophrenia or other serious mental health problems\\nusing cognitive medications (e.g., Aricept) or stimulants (e.g., Adderall)\\nwho have undergone deep brain stimulation, fetal cell implants, or other brain surgeries\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'MaximumAge': '90 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Aysegul Gunduz, PhD',\n",
              "          'OverallOfficialAffiliation': 'University of Florida',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'University of Florida',\n",
              "          'LocationCity': 'Gainesville',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '32611',\n",
              "          'LocationCountry': 'United States'}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '18487069',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Allcock LM, Rowan EN, Steen IN, Wesnes K, Kenny RA, Burn DJ. Impaired attention predicts falling in Parkinson's disease. Parkinsonism Relat Disord. 2009 Feb;15(2):110-5. doi: 10.1016/j.parkreldis.2008.03.010. Epub 2008 May 19.\"},\n",
              "         {'ReferencePMID': '16324792',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Awh E, Vogel EK, Oh SH. Interactions between attention and working memory. Neuroscience. 2006 Apr 28;139(1):201-8. Epub 2005 Dec 1. Review.'},\n",
              "         {'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Baunez, C., & Lardeux, S. (2011, October). Frontal cortex-like functions of the subthalamic nucleus. In Basal Ganglia X-Proceedings of the 10th Triennial Meeting of the International Basal Ganglia Society. Frontiers E-books.'},\n",
              "         {'ReferencePMID': '9260443',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Filoteo JV, Delis DC, Salmon DP, Demadura T, Roman MJ, Shults CW. An examination of the nature of attentional deficits in patients with Parkinson's disease: evidence from a spatial orienting task. J Int Neuropsychol Soc. 1997 Jul;3(4):337-47.\"},\n",
              "         {'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Gabrieli, J. D., Singh, J., Stebbins, G. T., & Goetz, C. G. (1996). Reduced working memory span in Parkinson's disease: Evidence for the role of frontostriatal system in working and strategic memory. Neuropsychology, 10(3), 322.\"},\n",
              "         {'ReferencePMID': '15327739',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Henry JD, Crawford JR. Verbal fluency deficits in Parkinson's disease: a meta-analysis. J Int Neuropsychol Soc. 2004 Jul;10(4):608-22.\"},\n",
              "         {'ReferencePMID': '11256080',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Itti L, Koch C. Computational modelling of visual attention. Nat Rev Neurosci. 2001 Mar;2(3):194-203. Review.'},\n",
              "         {'ReferencePMID': '10825353',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Jahanshahi M, Ardouin CM, Brown RG, Rothwell JC, Obeso J, Albanese A, Rodriguez-Oroz MC, Moro E, Benabid AL, Pollak P, Limousin-Dowsey P. The impact of deep brain stimulation on executive function in Parkinson's disease. Brain. 2000 Jun;123 ( Pt 6):1142-54.\"},\n",
              "         {'ReferencePMID': '26090080',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Kim HJ, Jeon BS, Paek SH. Nonmotor Symptoms and Subthalamic Deep Brain Stimulation in Parkinson's Disease. J Mov Disord. 2015 May;8(2):83-91. doi: 10.14802/jmd.15010. Epub 2015 May 31. Review.\"},\n",
              "         {'ReferencePMID': '18217883',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Klepac N, Trkulja V, Relja M, Babi T. Is quality of life in non-demented Parkinson's disease patients related to cognitive performance? A clinic-based cross-sectional study. Eur J Neurol. 2008 Feb;15(2):128-33. doi: 10.1111/j.1468-1331.2007.02011.x.\"},\n",
              "         {'ReferencePMID': '19896382',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Lord S, Rochester L, Hetherington V, Allcock LM, Burn D. Executive dysfunction and attention contribute to gait interference in 'off' state Parkinson's Disease. Gait Posture. 2010 Feb;31(2):169-74. doi: 10.1016/j.gaitpost.2009.09.019. Epub 2009 Nov 5.\"},\n",
              "         {'ReferencePMID': '10744919',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Middleton FA, Strick PL. Basal ganglia output and cognition: evidence from anatomical, behavioral, and clinical studies. Brain Cogn. 2000 Mar;42(2):183-200. Review.'},\n",
              "         {'ReferencePMID': '16563850',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Mimura M, Oeda R, Kawamura M. Impaired decision-making in Parkinson's disease. Parkinsonism Relat Disord. 2006 Apr;12(3):169-75. Epub 2006 Mar 23.\"},\n",
              "         {'ReferencePMID': '11081799',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Nakano K, Kayahara T, Tsutsumi T, Ushiro H. Neural circuits and functional organization of the striatum. J Neurol. 2000 Sep;247 Suppl 5:V1-15. Review.'},\n",
              "         {'ReferencePMID': '6509309',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Rafal RD, Posner MI, Walker JA, Friedrich FJ. Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease. Brain. 1984 Dec;107 ( Pt 4):1083-94.\"},\n",
              "         {'ReferencePMID': '21316292',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Williams AE, Arzola GM, Strutt AM, Simpson R, Jankovic J, York MK. Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord. 2011 Jun;17(5):321-7. doi: 10.1016/j.parkreldis.2011.01.011. Epub 2011 Feb 11.'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'Yes',\n",
              "       'IPDSharingDescription': 'IPD will be shared only to investigators. It will be deidentified and only accessible through secure, password-protected, encrypted hard drives.'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 12,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00037830',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'R01NS038681',\n",
              "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
              "        'OrgStudyIdLink': 'https://reporter.nih.gov/quickSearch/R01NS038681'},\n",
              "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01NS038681',\n",
              "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
              "          'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/R01NS038681'}]},\n",
              "       'Organization': {'OrgFullName': 'Thomas Jefferson University',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"GM1 Ganglioside Effects on Parkinson's Disease\",\n",
              "       'OfficialTitle': \"The Study of GM1 Ganglioside, A Potential New Parkinson's Disease Medication\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'December 2012',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'November 1999'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2010',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'June 2010',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'May 22, 2002',\n",
              "       'StudyFirstSubmitQCDate': 'May 22, 2002',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 23, 2002',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'ResultsFirstSubmitDate': 'July 13, 2011',\n",
              "       'ResultsFirstSubmitQCDate': 'July 18, 2012',\n",
              "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 9, 2012',\n",
              "        'ResultsFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'December 18, 2012',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 21, 2012',\n",
              "        'LastUpdatePostDateType': 'Estimate'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Thomas Jefferson University',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Neurological Disorders and Stroke (NINDS)',\n",
              "          'CollaboratorClass': 'NIH'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"The purpose of this trial is to examine the short term effects (24 Weeks) of GM1 on Parkinson's disease (PD) symptoms, as well as the effects of long-term treatment (120 Weeks) with GM1 on disease progression, and to examine the extent to which GM1 treatment influences the underlying disease process in PD.\",\n",
              "       'DetailedDescription': 'The study is designed to further examine the extent to which GM1 ganglioside can improve symptoms, delay disease progression, and, perhaps, partially restore damaged brain cells in PD patients. GM1 ganglioside is a chemical that is normally found in the brain and is a normal part of the outer covering or membrane of nerve cells. This study will compare the effectiveness of GM1 to standard PD treatment. In addition to studying clinical measures of motor and cognitive functioning, the investigators will use PET (positron emission tomography) scanning to image the brain and the dopamine nerve endings in a subgroup of patients. Patients with mild to moderate idiopathic PD will be divided into 2 groups. One group will receive GM1 for 24 weeks and the other will receive placebo. At the end of this 24 week period, all patients will enter into a 96 week treatment period in which all patients will receive GM1.\\n\\nIn parallel, a group of standard-of-care patients with mild to moderate PD will be monitored over a 1 to 2 year period to assess the natural progression of PD. These patients will receive the same clinical evaluations as the treatment group subjects but they will not receive the experimental medication.'},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's disease\",\n",
              "         'PD',\n",
              "         'GM1 Ganglioside',\n",
              "         'Sygen']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Phase 2']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Crossover Assignment',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
              "           'Investigator']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '94',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Early-Start Group',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': 'Subjects were randomized to receive GM1 ganglioside for 24 weeks.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: GM1 ganglioside']}},\n",
              "         {'ArmGroupLabel': 'Delayed-Start Group',\n",
              "          'ArmGroupType': 'Placebo Comparator',\n",
              "          'ArmGroupDescription': 'Subjects were randomized to receive placebo for 24 weeks.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Placebo']}},\n",
              "         {'ArmGroupLabel': 'Comparison Group',\n",
              "          'ArmGroupType': 'No Intervention',\n",
              "          'ArmGroupDescription': \"A separate group of Parkinson's disease patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This comparison group was not compared statistically to the treatment groups since they were not randomized.\"}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
              "          'InterventionName': 'GM1 ganglioside',\n",
              "          'InterventionDescription': '100 mg twice per day by subcutaneous injection',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Early-Start Group']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['Sygen']}},\n",
              "         {'InterventionType': 'Drug',\n",
              "          'InterventionName': 'Placebo',\n",
              "          'InterventionDescription': 'Twice per day subcutaneous injection, equal volume as active drug',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Delayed-Start Group']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication.\",\n",
              "          'PrimaryOutcomeDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline to Week 24'},\n",
              "         {'PrimaryOutcomeMeasure': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Scores From Baseline to Week 120 Assessed Off Medication.\",\n",
              "          'PrimaryOutcomeDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline to Week 120'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Change From Baseline to Week 24 in Total Unified Parkinson's Disease Rating Scale (UPDRS)Score Assessed Off Medication\",\n",
              "          'SecondaryOutcomeDescription': \"The total Unified Parkinson's Disease Rating Scale (UPDRS) score is derived from Part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Part I assesses 4 functions; Part II assesses 13 activities of daily living; Part III assesses 14 motor symptoms. Each item is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 176. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline to Week 24'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Total UPDRS Score From Baseline to Week 120 Assessed Off Medication',\n",
              "          'SecondaryOutcomeDescription': \"The total Unified Parkinson's Disease Rating Scale (UPDRS) score is derived from Part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Part I assesses 4 functions; Part II assesses 13 activities of daily living; Part III assesses 14 motor symptoms. Each item is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 176. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline to Week 120'},\n",
              "         {'SecondaryOutcomeMeasure': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication.\",\n",
              "          'SecondaryOutcomeDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline to Week 24'},\n",
              "         {'SecondaryOutcomeMeasure': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 48 Assessed Off Medication.\",\n",
              "          'SecondaryOutcomeDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline to Week 48'},\n",
              "         {'SecondaryOutcomeMeasure': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 72 Assessed Off Medication.\",\n",
              "          'SecondaryOutcomeDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline to Week 72'},\n",
              "         {'SecondaryOutcomeMeasure': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 96 Assessed Off Medication.\",\n",
              "          'SecondaryOutcomeDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline to Week 96'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria:\\n\\nBtwn ages of 39-85 yrs old.\\nFemales: at least 2 years post-menopausal; surgically sterile; or negative pregnancy test by quantitative serum HCG, & follow a reliable method of birth control for at least 2 months prior to entry, agree both to follow a reliable method of birth control, & to desist from breast feeding during, & for 1 month following, the study drug administration.\\nDx of idiopathic PD 6 months prior to screening. The diagnosis requires: the presence of at least 2 of the 4 cardinal clinical manifestations of the disease, tremor, rigidity, bradykinesia, and disturbances of posture or gait, & at least 1 must be rigidity or bradykinesia.\\nModified Hoehn and Yahr Staging between 1 and 3 as rated during an \"off\" period of at least 12 hours.\\nUnified Parkinson\\'s Disease Rating Scale motor component score between 10 and 40 as rated during an \"off\" period of at least 12 hours and a score of 6 or greater during \"on\" period.\\nAntiparkinsonian treatments: stable treatment of l-dopa/carbidopa and/or dopamine agonist for at least 3 months prior to Screening.\\nMini Mental State Exam score > 25.\\nBeck Depression Inventory score < 10.\\nSigned informed consent.\\n\\nExclusion criteria:\\n\\nAbrupt onset of Parkinsonism.\\nFailure of Parkinsonian symptoms to have responded to l-dopa.\\nMotor symptoms (such as peak dose dyskinesias (UPDRS score > 3), & random on-off phenomenon, other than end-of-dose wearing-off, persistently fluctuating over a 6 month or longer period, in response to l-dopa.\\nHx of findings of any movement disorder other than idiopathic PD.\\nA tremor score on the UPDRS motor scale of >5. Tremor score greater than 3 in an individual limb.\\nHigh-dose vitamin E therapy (more than 1000 I.U./day) any time during the period starting 3 months prior baseline.\\nTransient ischemic attack any time during the period starting 6 months prior baseline.\\nHx of 2 or more strokes. Hx of any stroke that resulted in motor deficit, movement disorder, ataxia, cognitive impairment, or a hemi-inattention syndrome. Any stroke with residua at the time of, or within 6 months preceding, study entry.\\nPrevious cerebral infarction, including lacunar infarction, in any area subserving motor function.\\nBinswanger\\'s disease or hx of hypertensive encephalopathy.\\nHx of encephalitis.\\nHx of extended exposure to any known neurotoxin that may cause parkinsonism, or chronic or sufficient use or consumption of any non-medicinal substance that could cause risk of developing a movement disorder or disturbance of posture or gait.\\nUse of the following drugs within 6 months prior to screening: neuroleptics, metoclopramide, clozapine, flunarizine, alpha-methyldopa.\\nPatients actively taking a medicine that is known to compete with the imaging agent for binding sites on the dopamine terminals.\\nHx of medication or drug use that may have caused atypical parkinsonism or history of Substance Use Disorder.\\nHx of a metabolic disorder that resulted or could have resulted in movement disorder or disturbance of posture or gait.\\nAny disease or condition that resulted or could have resulted in a movement disorder or disturbance of posture or gait.\\nHx of intracranial hemorrhage, intracranial neoplasm, significant head trauma with loss of consciousness >24 hrs or other structural brain disease.\\nHx or clinical findings suggestive of progressive supranuclear palsy or multiple system atrophy.\\nAcquired cognitive impairment reasonably possibly due to any cause other than idiopathic PD.\\nHx of a hereditary disorder associated with a movement disorder.\\nNormal or low pressure hydrocephalus.\\nAny ill-defined neuropathic disease, myelopathy, myopathy or other medical disorder or physical condition by history or clinical examination that could be expected to interfere with the diagnosis, treatment or assessment of PD, or with any of the study assessments.\\nHx of Guillain-Barr syndrome, chronic idiopathic polyneuropathy, or relapsing polyneuropathy.\\nHx of Axis I or Axis II major psychiatric disorder.\\nSignificant cardiac, pulmonary, hepatic, gastrointestinal, or renal disease.\\nAny condition that could alter the distribution, accumulation, metabolism, or excretion of the study medication; or result in a life expectancy of less than 2 years.\\nAny primarily non-neurologic medical condition with a significant risk of secondarily causing neurologic dysfunction.\\nMyocardial infarction within 6 months prior to screening.\\nPresence of any medical condition or laboratory test abnormality or use of any licit or illicit substance which could cause unwarranted risk from participation in the study or result in worsening in the patient\\'s medical condition during participation in study. Presence of any of the following laboratory test abnormalities are unwarranted risk: serum transaminase greater than twice the upper limit of normal;serum creatinine greater than 2.0 mg/dl in a man or greater than 1.7 mg/dl in a woman.\\nHx of a life-threatening allergic or immune-mediated reaction.\\nPrevious use of any ganglioside preparation.\\nUse of any experimental drug in the period starting 60 days before Baseline.\\nHx of stereotaxic brain surgery for PD.',\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '39 Years',\n",
              "       'MaximumAge': '85 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jay S. Schneider, Ph.D.',\n",
              "          'OverallOfficialAffiliation': \"Parkinson's Disease Research Unit, Thomas Jefferson University\",\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': \"Parkinson's Disease Research Unit, Thomas Jefferson University\",\n",
              "          'LocationCity': 'Philadelphia',\n",
              "          'LocationState': 'Pennsylvania',\n",
              "          'LocationZip': '19107',\n",
              "          'LocationCountry': 'United States'}]}}},\n",
              "     'ResultsSection': {'ParticipantFlowModule': {'FlowRecruitmentDetails': \"Seventy-seven PD patients were recruited from all across the US for this single center, double-blind, delayed start trial of GM1. Seventeen subjects participated in the comparison group. Enrollment for the study began Nov 1999 and was completed in Jan 2006. Subjects were seen at the Parkinson's Disease Research Unit at Thomas Jefferson University.\",\n",
              "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
              "          'FlowGroupTitle': 'Early-Start Group',\n",
              "          'FlowGroupDescription': 'Phase I: Thirty nine subjects were randomized to receive GM1 for 24 weeks.'},\n",
              "         {'FlowGroupId': 'FG001',\n",
              "          'FlowGroupTitle': 'Delayed-Start Group',\n",
              "          'FlowGroupDescription': 'Phase I: Thiry eight subjects were randomized to receive placebo for 24 weeks.'},\n",
              "         {'FlowGroupId': 'FG002',\n",
              "          'FlowGroupTitle': 'Comparison Group',\n",
              "          'FlowGroupDescription': 'This group of PD patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This group was not statistically compared to the treatment groups since this group was not randomized.'}]},\n",
              "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
              "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '39'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '38'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '17'}]}},\n",
              "            {'FlowMilestoneType': 'COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '29'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '31'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '16'}]}},\n",
              "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '10'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '7'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '1'}]}}]},\n",
              "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Adverse Event',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '2'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '0'}]}},\n",
              "            {'FlowDropWithdrawType': 'Withdrawal by Subject',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '4'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '5'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '1'}]}},\n",
              "            {'FlowDropWithdrawType': 'Protocol Violation',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '2'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '2'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '0'}]}},\n",
              "            {'FlowDropWithdrawType': 'Unrelated Medical Problem',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '2'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG002',\n",
              "                'FlowReasonNumSubjects': '0'}]}}]}}]}},\n",
              "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
              "          'BaselineGroupTitle': 'Early-Start Group',\n",
              "          'BaselineGroupDescription': 'Phase I: Thirty nine subjects were randomized to receive GM1 for 24 weeks.'},\n",
              "         {'BaselineGroupId': 'BG001',\n",
              "          'BaselineGroupTitle': 'Delayed-Start Group',\n",
              "          'BaselineGroupDescription': 'Phase I: Thiry eight subjects were randomized to receive placebo for 24 weeks.'},\n",
              "         {'BaselineGroupId': 'BG002',\n",
              "          'BaselineGroupTitle': 'Comparison Group',\n",
              "          'BaselineGroupDescription': 'This group of PD patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This group was not statistically compared to the treatment groups since this group was not randomized.'},\n",
              "         {'BaselineGroupId': 'BG003',\n",
              "          'BaselineGroupTitle': 'Total',\n",
              "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
              "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
              "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
              "             'BaselineDenomCountValue': '39'},\n",
              "            {'BaselineDenomCountGroupId': 'BG001',\n",
              "             'BaselineDenomCountValue': '38'},\n",
              "            {'BaselineDenomCountGroupId': 'BG002',\n",
              "             'BaselineDenomCountValue': '17'},\n",
              "            {'BaselineDenomCountGroupId': 'BG003',\n",
              "             'BaselineDenomCountValue': '94'}]}}]},\n",
              "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '27'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '29'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '9'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '65'}]}},\n",
              "               {'BaselineCategoryTitle': '>=65 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '12'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '9'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '8'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '29'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Age Continuous',\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'years',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '59.7',\n",
              "                   'BaselineMeasurementSpread': '8.4'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '57.7',\n",
              "                   'BaselineMeasurementSpread': '8.7'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '61.1',\n",
              "                   'BaselineMeasurementSpread': '11.8'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '59.5',\n",
              "                   'BaselineMeasurementSpread': '9.6'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '10'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '9'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '3'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '22'}]}},\n",
              "               {'BaselineCategoryTitle': 'Male',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '29'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '29'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '14'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '72'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
              "          'BaselineMeasureParamType': 'Number',\n",
              "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '39'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '38'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '17'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '94'}]}}]}}]}}]}},\n",
              "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication.\",\n",
              "          'OutcomeMeasureDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'Analysis was per protocol. Two subjects randomized to the Early-Start group withdrew from the study shortly after starting. The comparison group was not compared statistically to the treatment group since they were not randomized.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Least Squares Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Scores on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline to Week 24',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Early-Start Group',\n",
              "             'OutcomeGroupDescription': 'Group that was randomized to receive GM1 ganglioside 24 weeks'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Delayed-Start Group',\n",
              "             'OutcomeGroupDescription': 'Group that was randomized to receive placebo for 24 weeks'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '37'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '38'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-3.57',\n",
              "                   'OutcomeMeasurementSpread': '.503'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '1.85',\n",
              "                   'OutcomeMeasurementSpread': '.497'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001']},\n",
              "             'OutcomeAnalysisGroupDescription': 'The null hypothesis for Phase I was that at week 24, there is no difference between UPDRS motor scores in placebo vs. GM1-treated subjects.',\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '<0.0001',\n",
              "             'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided'}]}},\n",
              "         {'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Scores From Baseline to Week 120 Assessed Off Medication.\",\n",
              "          'OutcomeMeasureDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'Analysis was per protocol. Two subjects randomized to the Early-Start group withdrew from the study shortly after starting. The comparison group was not compared statistically to the treatment group since they were not randomized.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Least Squares Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Scores on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline to Week 120',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Early-Start Group',\n",
              "             'OutcomeGroupDescription': 'Group that was randomized to receive GM1 ganglioside 24 weeks'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Delayed-Start Group',\n",
              "             'OutcomeGroupDescription': 'Group that was randomized to receive placebo for 24 weeks'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '37'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '38'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-1.80',\n",
              "                   'OutcomeMeasurementSpread': '1.117'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '1.53',\n",
              "                   'OutcomeMeasurementSpread': '1.092'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001']},\n",
              "             'OutcomeAnalysisGroupDescription': 'The null hypothesis for Phase II is that long-term use of GM1 does not affect the progression of PD symptoms and that there is no benefit to early start of GM1 use.',\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '0.0368',\n",
              "             'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided'}]}},\n",
              "         {'OutcomeMeasureType': 'Post-Hoc',\n",
              "          'OutcomeMeasureTitle': \"Estimated Change in Points Per Week on Unified Parkinson's Disease Rating Scale (UPDRS) Motor Score Assessed Off Medication\",\n",
              "          'OutcomeMeasureDescription': \"Unified Parkinson's Disease Rating Scale (UPDRS) A four part scale used to assess the severity of Parkinson's disease symptoms. Part I contains questions concerning the patient's mentation, behavior and mood. Part II asks questions about the patient's ability to perform activities of daily living. Part III is the motor examination of the patient's symptoms ranging in scores from 0 to 4 with 0 equaling either normal or absence of symptoms. The minimum score on this section is 0 and the maximum is 108. Part IV asks the patient questions about any complications of therapy they have experienced within the past week. However, for this study the total UPDRS included Parts I, II, and III. A higher the score on the scale indicates more severe symptoms.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'Analysis was per protocol. Two subjects randomized to the Early-Start group withdrew from the study shortly after starting. The comparison group was not compared statistically to the treatment group since they were not randomized.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Scores on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Week 6 to Week 24',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Early-Start Group',\n",
              "             'OutcomeGroupDescription': 'Group that was randomized to receive GM1 ganglioside 24 weeks'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Delayed-Start Group',\n",
              "             'OutcomeGroupDescription': 'Group that was randomized to receive placebo for 24 weeks'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '37'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '38'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '0.04',\n",
              "                   'OutcomeMeasurementSpread': '0.03'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.08',\n",
              "                   'OutcomeMeasurementSpread': '0.03'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']},\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '0.1903',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'estimate of slope of change over time',\n",
              "             'OutcomeAnalysisStatisticalComment': 'random intercept model and a variance components covariance structure'},\n",
              "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']},\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '0.0063',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'estimate slope of change over time',\n",
              "             'OutcomeAnalysisStatisticalComment': 'random intercept model and a variance components covariance structure',\n",
              "             'OutcomeAnalysisCIPctValue': '95'}]}},\n",
              "         {'OutcomeMeasureType': 'Post-Hoc',\n",
              "          'OutcomeMeasureTitle': \"Estimated Rate of Change in Unified Parkinson's Disease Rating Scale (UPDRS)Motor Scores Assessed Off Medication\",\n",
              "          'OutcomeMeasurePopulationDescription': 'Analysis was per protocol. Two subjects randomized to the Early-Start group withdrew from the study shortly after starting. The comparison group was not compared statistically to the treatment group since they were not randomized.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Scores on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Week 36 to Week 120',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Early-Start Group',\n",
              "             'OutcomeGroupDescription': 'Group that was randomized to receive GM1 ganglioside 24 weeks'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Delayed-Start Group',\n",
              "             'OutcomeGroupDescription': 'Group that was randomized to receive placebo for 24 weeks'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '37'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '38'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '0.02',\n",
              "                   'OutcomeMeasurementSpread': '0.01'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.04',\n",
              "                   'OutcomeMeasurementSpread': '0.01'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']},\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '0.0502',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'estimate of slope of change over time',\n",
              "             'OutcomeAnalysisStatisticalComment': 'random intercept model and a variance components covariance structure'},\n",
              "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']},\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '0.0003',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'estimate slope of change over time',\n",
              "             'OutcomeAnalysisStatisticalComment': 'random intercept model and a variance components covariance structure',\n",
              "             'OutcomeAnalysisCIPctValue': '95'}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Change From Baseline to Week 24 in Total Unified Parkinson's Disease Rating Scale (UPDRS)Score Assessed Off Medication\",\n",
              "          'OutcomeMeasureDescription': \"The total Unified Parkinson's Disease Rating Scale (UPDRS) score is derived from Part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Part I assesses 4 functions; Part II assesses 13 activities of daily living; Part III assesses 14 motor symptoms. Each item is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 176. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'Analysis was per protocol. Two subjects randomized to the Early-Start group withdrew from the study shortly after starting. The comparison group was not compared statistically to the treatment group since they were not randomized.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Least Squares Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Scores on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline to Week 24',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Early-Start Group',\n",
              "             'OutcomeGroupDescription': 'Group that was randomized to receive GM1 ganglioside 24 weeks'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Delayed-Start Group',\n",
              "             'OutcomeGroupDescription': 'Group that was randomized to receive placebo for 24 weeks'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '37'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '38'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-5.31',\n",
              "                   'OutcomeMeasurementSpread': '0.84'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '1.88',\n",
              "                   'OutcomeMeasurementSpread': '0.83'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001']},\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '<0.0001',\n",
              "             'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided'}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Change in Total UPDRS Score From Baseline to Week 120 Assessed Off Medication',\n",
              "          'OutcomeMeasureDescription': \"The total Unified Parkinson's Disease Rating Scale (UPDRS) score is derived from Part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Part I assesses 4 functions; Part II assesses 13 activities of daily living; Part III assesses 14 motor symptoms. Each item is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 176. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'Analysis was per protocol. Two subjects randomized to the Early-Start group withdrew from the study shortly after starting. The comparison group was not compared statistically to the treatment group since they were not randomized.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Least Squares Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Scores on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline to Week 120',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Early-Start Group',\n",
              "             'OutcomeGroupDescription': 'Group that was randomized to receive GM1 ganglioside 24 weeks'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Delayed-Start Group',\n",
              "             'OutcomeGroupDescription': 'Group that was randomized to receive placebo for 24 weeks'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '37'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '38'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-1.01',\n",
              "                   'OutcomeMeasurementSpread': '1.764'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '3.56',\n",
              "                   'OutcomeMeasurementSpread': '1.726'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001']},\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '0.1310',\n",
              "             'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided'}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication.\",\n",
              "          'OutcomeMeasureDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Scores on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline to Week 24',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Comparison Group',\n",
              "             'OutcomeGroupDescription': 'This group of PD patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This group was not statistically compared to the treatment groups since this group was not randomized.'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '17'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '2.28',\n",
              "                   'OutcomeMeasurementSpread': '0.866'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']},\n",
              "             'OutcomeAnalysisGroupDescription': 'Analysis was paired sample t-test on change from baseline.',\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '<0.05',\n",
              "             'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided',\n",
              "             'OutcomeAnalysisCIPctValue': '95'}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 48 Assessed Off Medication.\",\n",
              "          'OutcomeMeasureDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Scores on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline to Week 48',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Comparison Group',\n",
              "             'OutcomeGroupDescription': 'This group of PD patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This group was not statistically compared to the treatment groups since this group was not randomized.'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '16'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '4.41',\n",
              "                   'OutcomeMeasurementSpread': '1.434'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']},\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '<0.01',\n",
              "             'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided',\n",
              "             'OutcomeAnalysisCIPctValue': '95'}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 72 Assessed Off Medication.\",\n",
              "          'OutcomeMeasureDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'Number of subjects enrolled at this time point.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Scores on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline to Week 72',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Comparison Group',\n",
              "             'OutcomeGroupDescription': 'This group of PD patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This group was not statistically compared to the treatment groups since this group was not randomized.'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '10'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '5.95',\n",
              "                   'OutcomeMeasurementSpread': '1.220'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']},\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '<0.01',\n",
              "             'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided',\n",
              "             'OutcomeAnalysisCIPctValue': '95'}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 96 Assessed Off Medication.\",\n",
              "          'OutcomeMeasureDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'Number of subjects enrolled at this time point.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Scores on scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline to Week 96',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Comparison Group',\n",
              "             'OutcomeGroupDescription': 'This group of PD patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This group was not statistically compared to the treatment groups since this group was not randomized.'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '8'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '7.81',\n",
              "                   'OutcomeMeasurementSpread': '2.014'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']},\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '<0.01',\n",
              "             'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided',\n",
              "             'OutcomeAnalysisCIPctValue': '95'}]}}]}},\n",
              "      'AdverseEventsModule': {'EventsFrequencyThreshold': '5',\n",
              "       'EventsTimeFrame': 'Adverse events were collected for 2 and a half years beginning at baseline.',\n",
              "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
              "          'EventGroupTitle': 'Early-Start Group',\n",
              "          'EventGroupDescription': 'Phase I: Thirty nine subjects were randomized to receive GM1 for 24 weeks.',\n",
              "          'EventGroupSeriousNumAffected': '2',\n",
              "          'EventGroupSeriousNumAtRisk': '39',\n",
              "          'EventGroupOtherNumAffected': '39',\n",
              "          'EventGroupOtherNumAtRisk': '39'},\n",
              "         {'EventGroupId': 'EG001',\n",
              "          'EventGroupTitle': 'Delayed-Start Group',\n",
              "          'EventGroupDescription': 'Phase I: Thiry eight subjects were randomized to receive placebo for 24 weeks.',\n",
              "          'EventGroupSeriousNumAffected': '1',\n",
              "          'EventGroupSeriousNumAtRisk': '38',\n",
              "          'EventGroupOtherNumAffected': '38',\n",
              "          'EventGroupOtherNumAtRisk': '38'},\n",
              "         {'EventGroupId': 'EG002',\n",
              "          'EventGroupTitle': 'Comparison Group',\n",
              "          'EventGroupDescription': 'This group of PD patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This group was not statistically compared to the treatment groups since this group was not randomized.',\n",
              "          'EventGroupSeriousNumAffected': '0',\n",
              "          'EventGroupSeriousNumAtRisk': '17',\n",
              "          'EventGroupOtherNumAffected': '0',\n",
              "          'EventGroupOtherNumAtRisk': '17'}]},\n",
              "       'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': \"Severe weakness L>R BLC LE's\",\n",
              "          'SeriousEventOrganSystem': 'General disorders',\n",
              "          'SeriousEventSourceVocabulary': 'Asthenia',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '39'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '38'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '17'}]}},\n",
              "         {'SeriousEventTerm': 'CT Scan showed an Ulcerating Mass Fungating in Stomach',\n",
              "          'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
              "          'SeriousEventSourceVocabulary': 'Anastomotic ulcer',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '39'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '38'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '17'}]}},\n",
              "         {'SeriousEventTerm': 'Muscle spasms',\n",
              "          'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'SeriousEventSourceVocabulary': 'Muscle spams',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '39'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '38'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '17'}]}},\n",
              "         {'SeriousEventTerm': 'Muscle pain',\n",
              "          'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'SeriousEventSourceVocabulary': 'Myalgia',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '39'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '38'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '17'}]}},\n",
              "         {'SeriousEventTerm': 'Increase frequency of dyskinesias',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventSourceVocabulary': 'Dyskinesia',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '39'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '38'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '17'}]}},\n",
              "         {'SeriousEventTerm': 'Uncontrollable shaking',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventSourceVocabulary': 'Tremor',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '39'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '38'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '17'}]}},\n",
              "         {'SeriousEventTerm': 'Laproscopic Removal of Stomal Tumor in Stomach',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventSourceVocabulary': 'Tumor excision',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '39'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '38'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '17'}]}}]},\n",
              "       'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Nausea',\n",
              "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '4',\n",
              "             'OtherEventStatsNumAffected': '4',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Diarrhoea',\n",
              "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Vomiting',\n",
              "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Abdominal pain',\n",
              "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Dry mouth',\n",
              "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Injection site pain',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '20',\n",
              "             'OtherEventStatsNumAffected': '20',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '32',\n",
              "             'OtherEventStatsNumAffected': '32',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Injection site erythema',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '18',\n",
              "             'OtherEventStatsNumAffected': '18',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '22',\n",
              "             'OtherEventStatsNumAffected': '22',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Injection site nodule',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '11',\n",
              "             'OtherEventStatsNumAffected': '11',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '17',\n",
              "             'OtherEventStatsNumAffected': '17',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Injection site haemorrhage',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '8',\n",
              "             'OtherEventStatsNumAffected': '8',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '12',\n",
              "             'OtherEventStatsNumAffected': '12',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Injection site haematoma',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '9',\n",
              "             'OtherEventStatsNumAffected': '9',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '8',\n",
              "             'OtherEventStatsNumAffected': '8',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Injection site pruritus',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '11',\n",
              "             'OtherEventStatsNumAffected': '11',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '6',\n",
              "             'OtherEventStatsNumAffected': '6',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Injection site swelling',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '3',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '5',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Injection site urticaria',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '5',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '3',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Fatigue',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '3',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '4',\n",
              "             'OtherEventStatsNumAffected': '4',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Oedema peripheral',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '3',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '3',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Injection site induration',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Oedema',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Gait disturbance',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Feeling abnormal',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Injection site exfoliation',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Fall',\n",
              "          'OtherEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Blood cholesterol increased',\n",
              "          'OtherEventOrganSystem': 'Investigations',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '7',\n",
              "             'OtherEventStatsNumAffected': '7',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '4',\n",
              "             'OtherEventStatsNumAffected': '4',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Blood triglycerides increased',\n",
              "          'OtherEventOrganSystem': 'Investigations',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '6',\n",
              "             'OtherEventStatsNumAffected': '6',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '5',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Eosinophil count increased',\n",
              "          'OtherEventOrganSystem': 'Investigations',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '3',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '3',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Blood pressure increased',\n",
              "          'OtherEventOrganSystem': 'Investigations',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Crystal urine present',\n",
              "          'OtherEventOrganSystem': 'Investigations',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Alkaline amniotransferase increased',\n",
              "          'OtherEventOrganSystem': 'Investigations',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Aspartate amnotransferase increased',\n",
              "          'OtherEventOrganSystem': 'Investigations',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Muscle spasms',\n",
              "          'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '3',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Pain in extremity',\n",
              "          'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '4',\n",
              "             'OtherEventStatsNumAffected': '4',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Arthralgia',\n",
              "          'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Parkinsonism',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '9',\n",
              "             'OtherEventStatsNumAffected': '9',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '5',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Tremor',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '5',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '5',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Dizziness',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '3',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '4',\n",
              "             'OtherEventStatsNumAffected': '4',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Dyskinesia',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '4',\n",
              "             'OtherEventStatsNumAffected': '4',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Paresthesia',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '3',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Balance disorder',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Freezing phenomenon',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Headache',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Hypoaesthesia',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Insomnia',\n",
              "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '4',\n",
              "             'OtherEventStatsNumAffected': '4',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '3',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Depression',\n",
              "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Anxiety',\n",
              "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Vivid dreams',\n",
              "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '3',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Rash',\n",
              "          'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Skin exfoliation',\n",
              "          'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}},\n",
              "         {'OtherEventTerm': 'Injection site erythema',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (Unspecified)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '2',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '39'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '1',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '38'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '0',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '17'}]}}]}},\n",
              "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
              "        'AgreementRestrictiveAgreement': 'No'},\n",
              "       'PointOfContact': {'PointOfContactTitle': 'Dr. Jay Schneider',\n",
              "        'PointOfContactOrganization': 'Thomas Jefferson University',\n",
              "        'PointOfContactEMail': 'jay.schneider@jefferson.edu',\n",
              "        'PointOfContactPhone': '215-503-0370'}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 13,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00256204',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'TVP-1012/500 (ADAGIO)'},\n",
              "       'Organization': {'OrgFullName': 'Teva Branded Pharmaceutical Products R&D, Inc.',\n",
              "        'OrgClass': 'INDUSTRY'},\n",
              "       'BriefTitle': \"A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease\",\n",
              "       'OfficialTitle': \"A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects\",\n",
              "       'Acronym': 'ADAGIO'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'January 2012',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'November 2005'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2008',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'June 2009',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'November 16, 2005',\n",
              "       'StudyFirstSubmitQCDate': 'November 18, 2005',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 21, 2005',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'ResultsFirstSubmitDate': 'March 8, 2010',\n",
              "       'ResultsFirstSubmitQCDate': 'May 20, 2011',\n",
              "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'June 21, 2011',\n",
              "        'ResultsFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'January 10, 2012',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 12, 2012',\n",
              "        'LastUpdatePostDateType': 'Estimate'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Teva Branded Pharmaceutical Products R&D, Inc.',\n",
              "        'LeadSponsorClass': 'INDUSTRY'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
              "      'DescriptionModule': {'BriefSummary': \"A 2 phase study to evaluate disease progression in Parkinson's disease patients taking rasagiline\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's\", 'Rasagiline Mesylate']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Phase 3']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
              "           'Investigator']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '1174',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '1mg rasagiline',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': '1mg early start active treatment arm (72 weeks active)followed by 1mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Rasagiline Mesylate']}},\n",
              "         {'ArmGroupLabel': '2mg rasagiline',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': '2mg early start active treatment arm (72 weeks active)followed by 2mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Rasagiline Mesylate']}},\n",
              "         {'ArmGroupLabel': 'Placebo',\n",
              "          'ArmGroupType': 'Placebo Comparator',\n",
              "          'ArmGroupDescription': 'Each arm is followed by 36 weeks of placebo',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Placebo']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
              "          'InterventionName': 'Rasagiline Mesylate',\n",
              "          'InterventionDescription': 'tablet, 1mg once daily',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1mg rasagiline']}},\n",
              "         {'InterventionType': 'Drug',\n",
              "          'InterventionName': 'Rasagiline Mesylate',\n",
              "          'InterventionDescription': 'tablet, 2mg once daily',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2mg rasagiline']}},\n",
              "         {'InterventionType': 'Other',\n",
              "          'InterventionName': 'Placebo',\n",
              "          'InterventionDescription': 'Placebo',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline\",\n",
              "          'PrimaryOutcomeDescription': \"The primary efficacy endpoint was defined as the change in Total UPDRS from Baseline. Subjects were assessed according to the United Parkinson's Disease Rating Scale (UPDRS,(version 3;) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario.\",\n",
              "          'PrimaryOutcomeTimeFrame': '12w, 24w, 36w, 42w, 48w, 54w, 60w, 66w, 72w'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to Last Observed Value in the Placebo Phase\",\n",
              "          'SecondaryOutcomeDescription': \"Subjects were assessed according to the United Parkinson's Disease Rating Scale UPDRS,(version 3;) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario.\",\n",
              "          'SecondaryOutcomeTimeFrame': '36 weeks'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nMen and women with idiopathic PD whose diagnosis is confirmed at screening, with at least two cardinal signs without any other known or suspected cause of parkinsonism. If tremor is not present, subjects must have unilateral onset and persistent asymmetry.\\nSubjects with a diagnosis of early idiopathic PD of less than 1 years duration from time of documented diagnosis.\\nSubjects whose clinical condition at the time of enrollment does not require anti-PD treatment and will not require for the next 9 months.\\nWilling and able to give informed consent.\\n\\nExclusion Criteria:\\n\\nSubjects younger than 30 or older than 80 years.\\nSubjects with loss of postural reflexes.\\nSubjects with UPDRS Tremor score of 3 or greater in any limb.\\nSubjects with Hoehn &Yahr Stage III or greater at screening.\\nSubjects with freezing while walking.\\nSubjects with any of the following features that tend to exclude PD as the cause of Parkinsonism:\\nHistory of repeated strokes with stepwise progression of Parkinsonian features\\nHistory of repeated head injury or history of definite encephalitis\\nSustained remission\\nSupranuclear gaze palsy\\nCerebellar signs\\nEarly severe autonomic involvement\\nBabinski's sign\\nPresence of a cerebral tumour or communicating hydrocephalus\\nMPTP exposure\\nOculogyric crises\\nSubjects who have had previous use of rasagiline or selegiline\\nSubjects having used other anti-PD medication basis at any time prior to baseline\\nSubjects having used other anti-PD medication (including anticholinergics) for less than 3 weeks during the 3 month period prior to baseline. (not including a single L-Dopa dose as part of L-Dopa test)\\nSubjects having used any other anti-PD medication (including anticholinergics) for less than 3 weeks prior to the 3 month period preceding baseline whose anti-PD medication is intentionally ceased in order for the subject to enter the study.\\nSubjects who have a clinically significant or unstable medical or surgical condition that may preclude safe and complete participation\\nHypertensive subjects whose BP is not well controlled according to the medical record or as observed during the week of home BP recording prior to baseline\\nSubjects diagnosed with melanoma based on the screening dermatologic examination, or with a history of melanoma. Subjects with suspicious lesions at baseline who do not undergo biopsy\\nSubjects with significant cognitive impairment as defined by MMSE score < 26\\nSubjects with clinically significant psychiatric illness, including major depression [Beck Depression Inventory (short form) 15\\nSubjects with a history of alcohol or substance abuse within the past 2 years\\nSubjects who have taken any experimental medications within 60 days prior to baseline\\nSubjects who have used coenzyme Q10 (in daily doses > 300 mg) within 120 days prior to baseline\\nSubjects who have used sympathomimetics (including over-the-counter remedies - nasal or oral), dextromethorphan, pethidine or St. John's Wort within the 7 days prior to baseline\\nSubjects who have used antidepressants within 42 days prior to baseline\\nSubjects who have used ciprofloxacin, a potent CYP 1A2 inhibitor within 7 days prior to baseline\\nSubjects who have used MAO inhibitors including reserpine or methyldopa within the three months prior to baseline, or treatment with an anti-emetic or antipsychotic medication with central dopamine antagonist activity within the six months prior to baseline\\nWomen who are not postmenopausal, surgically sterilized, or using adequate birth control [oral birth control pills, IUD, or a long acting injectable form of contraception; barrier methods alone (i.e., condom) are not sufficient]. Women of childbearing potential without a negative pregnancy test at screening. Nursing women\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '30 Years',\n",
              "       'MaximumAge': '80 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Yoni Weiss, MD',\n",
              "          'OverallOfficialAffiliation': 'Teva Branded Pharmaceutical Products R&D, Inc.',\n",
              "          'OverallOfficialRole': 'Study Director'}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '27190009',\n",
              "          'ReferenceType': 'derived',\n",
              "          'ReferenceCitation': \"Masellis M, Collinson S, Freeman N, Tampakeras M, Levy J, Tchelet A, Eyal E, Berkovich E, Eliaz RE, Abler V, Grossman I, Fitzer-Attas C, Tiwari A, Hayden MR, Kennedy JL, Lang AE, Knight J; ADAGIO investigators. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. Brain. 2016 Jul;139(Pt 7):2050-62. doi: 10.1093/brain/aww109. Epub 2016 May 13.\"},\n",
              "         {'ReferencePMID': '25420207',\n",
              "          'ReferenceType': 'derived',\n",
              "          'ReferenceCitation': 'Smith KM, Eyal E, Weintraub D; ADAGIO Investigators. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol. 2015 Jan;72(1):88-95. doi: 10.1001/jamaneurol.2014.2472.'},\n",
              "         {'ReferencePMID': '21482191',\n",
              "          'ReferenceType': 'derived',\n",
              "          'ReferenceCitation': \"Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011 May;10(5):415-23. doi: 10.1016/S1474-4422(11)70073-4. Epub 2011 Apr 7. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.\"},\n",
              "         {'ReferencePMID': '19776408',\n",
              "          'ReferenceType': 'derived',\n",
              "          'ReferenceCitation': \"Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24;361(13):1268-78. doi: 10.1056/NEJMoa0809335. Erratum in: N Engl J Med. 2011 May 12;364(19):1882.\"}]},\n",
              "       'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Unified Parkinsons Disease Ratings Scale',\n",
              "          'SeeAlsoLinkURL': 'http://www.mdvu.org/library/ratingscales/pd/updrs.pdf'},\n",
              "         {'SeeAlsoLinkLabel': \"Unified Parkinson's Disease Rating Scale\",\n",
              "          'SeeAlsoLinkURL': \"http://en.wikipedia.org/wiki/Unified_Parkinson's_Disease_Rating_Scale\"}]}}},\n",
              "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
              "          'FlowGroupTitle': '1mg Delayed Start',\n",
              "          'FlowGroupDescription': '1mg Rasagiline tablet QD 36 week delayed start active treatment arms (36 weeks placebo followed by 36 weeks Rasagiline)'},\n",
              "         {'FlowGroupId': 'FG001',\n",
              "          'FlowGroupTitle': '1mg Early Start',\n",
              "          'FlowGroupDescription': '1mg Rasagiline tablet QD early start active treatment arm (72 weeks active)'},\n",
              "         {'FlowGroupId': 'FG002',\n",
              "          'FlowGroupTitle': '2mg Delayed Start',\n",
              "          'FlowGroupDescription': '2mg Rasagiline tablet QD 36 week delayed start active treatment arms (36 weeks placebo followed by 36 weeks Rasagiline)'},\n",
              "         {'FlowGroupId': 'FG003',\n",
              "          'FlowGroupTitle': '2mg Early Start',\n",
              "          'FlowGroupDescription': '2mg Rasagiline tablet QD early start active treatment arm (72 weeks active)'}]},\n",
              "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
              "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '298'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '288'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '295'},\n",
              "               {'FlowAchievementGroupId': 'FG003',\n",
              "                'FlowAchievementNumSubjects': '293'}]}},\n",
              "            {'FlowMilestoneType': 'COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '231'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '238'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '241'},\n",
              "               {'FlowAchievementGroupId': 'FG003',\n",
              "                'FlowAchievementNumSubjects': '244'}]}},\n",
              "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '67'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '50'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '54'},\n",
              "               {'FlowAchievementGroupId': 'FG003',\n",
              "                'FlowAchievementNumSubjects': '49'}]}}]},\n",
              "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Adverse Event',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '10'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '14'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '16'},\n",
              "               {'FlowReasonGroupId': 'FG003',\n",
              "                'FlowReasonNumSubjects': '14'}]}},\n",
              "            {'FlowDropWithdrawType': 'Death',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '0'}]}},\n",
              "            {'FlowDropWithdrawType': 'Lost to Follow-up',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '2'}]}},\n",
              "            {'FlowDropWithdrawType': 'Protocol Violation',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '2'},\n",
              "               {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '1'}]}},\n",
              "            {'FlowDropWithdrawType': 'Physician Decision',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '2'}]}},\n",
              "            {'FlowDropWithdrawType': 'Withdrawal by Subject',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '17'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '6'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '7'},\n",
              "               {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '5'}]}},\n",
              "            {'FlowDropWithdrawType': 'Need for additional prohibited treatment',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '38'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '28'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '27'},\n",
              "               {'FlowReasonGroupId': 'FG003',\n",
              "                'FlowReasonNumSubjects': '25'}]}}]}}]}},\n",
              "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
              "          'BaselineGroupTitle': '1mg Delayed Start',\n",
              "          'BaselineGroupDescription': '1mg Rasagiline tablet QD 36 week delayed start active treatment arms (36 weeks placebo followed by 36 weeks Rasagiline)'},\n",
              "         {'BaselineGroupId': 'BG001',\n",
              "          'BaselineGroupTitle': '1mg Early Start',\n",
              "          'BaselineGroupDescription': '1mg Rasagiline tablet QD early start active treatment arm (72 weeks active)'},\n",
              "         {'BaselineGroupId': 'BG002',\n",
              "          'BaselineGroupTitle': '2mg Early Start',\n",
              "          'BaselineGroupDescription': '2mg Rasagiline tablet QD early start active treatment arm (72 weeks active)'},\n",
              "         {'BaselineGroupId': 'BG003',\n",
              "          'BaselineGroupTitle': '2mg Delayed Start',\n",
              "          'BaselineGroupDescription': '2mg Rasagiline tablet QD 36 week delayed start active treatment arms (36 weeks placebo followed by 36 weeks Rasagiline)'},\n",
              "         {'BaselineGroupId': 'BG004',\n",
              "          'BaselineGroupTitle': 'Total',\n",
              "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
              "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
              "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
              "             'BaselineDenomCountValue': '298'},\n",
              "            {'BaselineDenomCountGroupId': 'BG001',\n",
              "             'BaselineDenomCountValue': '288'},\n",
              "            {'BaselineDenomCountGroupId': 'BG002',\n",
              "             'BaselineDenomCountValue': '293'},\n",
              "            {'BaselineDenomCountGroupId': 'BG003',\n",
              "             'BaselineDenomCountValue': '295'},\n",
              "            {'BaselineDenomCountGroupId': 'BG004',\n",
              "             'BaselineDenomCountValue': '1174'}]}}]},\n",
              "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '175'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '163'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '169'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '173'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '680'}]}},\n",
              "               {'BaselineCategoryTitle': '>=65 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '123'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '125'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '124'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '122'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '494'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Age Continuous',\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'years',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '61.9',\n",
              "                   'BaselineMeasurementSpread': '9.6'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '62.4',\n",
              "                   'BaselineMeasurementSpread': '9.7'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '62.3',\n",
              "                   'BaselineMeasurementSpread': '9.6'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '62.4',\n",
              "                   'BaselineMeasurementSpread': '9.7'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '62.2',\n",
              "                   'BaselineMeasurementSpread': '9.6'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '113'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '113'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '118'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '113'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '457'}]}},\n",
              "               {'BaselineCategoryTitle': 'Male',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '185'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '175'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '175'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '182'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '717'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
              "          'BaselineMeasureParamType': 'Number',\n",
              "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '102'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '91'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '94'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '98'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '385'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Portugal',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '4'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '4'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '4'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '4'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '16'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Spain',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '12'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '12'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '12'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '12'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '48'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Austria',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '2'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '2'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '2'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '2'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '8'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Israel',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '22'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '23'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '21'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '21'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '87'}]}}]}},\n",
              "            {'BaselineClassTitle': 'United Kingdom',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '7'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '7'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '9'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '8'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '31'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Italy',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '24'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '25'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '28'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '25'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '102'}]}}]}},\n",
              "            {'BaselineClassTitle': 'France',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '11'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '11'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '12'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '14'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '48'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Hungary',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '8'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '8'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '6'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '7'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '29'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Canada',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '28'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '27'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '29'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '25'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '109'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Argentina',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '17'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '17'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '16'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '18'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '68'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Romania',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '25'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '24'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '25'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '24'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '98'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Germany',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '27'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '28'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '26'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '28'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '109'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Netherlands',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '9'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '9'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '9'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '9'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '36'}]}}]}}]}}]}},\n",
              "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': \"Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline\",\n",
              "          'OutcomeMeasureDescription': \"The primary efficacy endpoint was defined as the change in Total UPDRS from Baseline. Subjects were assessed according to the United Parkinson's Disease Rating Scale (UPDRS,(version 3;) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario.\",\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Scores on a scale',\n",
              "          'OutcomeMeasureTimeFrame': '12w, 24w, 36w, 42w, 48w, 54w, 60w, 66w, 72w',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': '1mg Delayed Start',\n",
              "             'OutcomeGroupDescription': '1mg Rasagiline tablet QD 36 week delayed start active treatment arms (36 weeks placebo followed by 36 weeks Rasagiline)'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': '1mg Early Start',\n",
              "             'OutcomeGroupDescription': '1mg Rasagiline tablet QD early start active treatment arm (72 weeks active)'},\n",
              "            {'OutcomeGroupId': 'OG002',\n",
              "             'OutcomeGroupTitle': '2mg Early Start',\n",
              "             'OutcomeGroupDescription': '2mg Rasagiline tablet QD early start active treatment arm (72 weeks active)'},\n",
              "            {'OutcomeGroupId': 'OG003',\n",
              "             'OutcomeGroupTitle': '2mg Delayed Start',\n",
              "             'OutcomeGroupDescription': '2mg Rasagiline tablet QD 36 week delayed start active treatment arms (36 weeks placebo followed by 36 weeks Rasagiline)'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '298'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '288'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG002',\n",
              "                'OutcomeDenomCountValue': '293'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG003',\n",
              "                'OutcomeDenomCountValue': '295'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Week 12',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '0.9',\n",
              "                   'OutcomeMeasurementSpread': '4.9'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-1.2',\n",
              "                   'OutcomeMeasurementSpread': '5.6'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '-0.7',\n",
              "                   'OutcomeMeasurementSpread': '4.8'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG003',\n",
              "                   'OutcomeMeasurementValue': '0.7',\n",
              "                   'OutcomeMeasurementSpread': '5.6'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Week 24',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '3.0',\n",
              "                   'OutcomeMeasurementSpread': '6.5'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-1.1',\n",
              "                   'OutcomeMeasurementSpread': '5.6'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '-0.5',\n",
              "                   'OutcomeMeasurementSpread': '5.6'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG003',\n",
              "                   'OutcomeMeasurementValue': '2.2',\n",
              "                   'OutcomeMeasurementSpread': '6.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Week 36',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '3.7',\n",
              "                   'OutcomeMeasurementSpread': '7.2'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.6',\n",
              "                   'OutcomeMeasurementSpread': '5.9'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '0.8',\n",
              "                   'OutcomeMeasurementSpread': '6.5'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG003',\n",
              "                   'OutcomeMeasurementValue': '3.0',\n",
              "                   'OutcomeMeasurementSpread': '6.9'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Week 42',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '2.4',\n",
              "                   'OutcomeMeasurementSpread': '7.4'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.2',\n",
              "                   'OutcomeMeasurementSpread': '6.7'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '0.4',\n",
              "                   'OutcomeMeasurementSpread': '7.2'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG003',\n",
              "                   'OutcomeMeasurementValue': '1.7',\n",
              "                   'OutcomeMeasurementSpread': '6.6'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Week 48',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1.9',\n",
              "                   'OutcomeMeasurementSpread': '6.9'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.7',\n",
              "                   'OutcomeMeasurementSpread': '7.0'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '0.5',\n",
              "                   'OutcomeMeasurementSpread': '7.1'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG003',\n",
              "                   'OutcomeMeasurementValue': '1.4',\n",
              "                   'OutcomeMeasurementSpread': '6.8'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Week 54',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1.9',\n",
              "                   'OutcomeMeasurementSpread': '7.3'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.7',\n",
              "                   'OutcomeMeasurementSpread': '7.1'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '0.8',\n",
              "                   'OutcomeMeasurementSpread': '7.2'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG003',\n",
              "                   'OutcomeMeasurementValue': '1.1',\n",
              "                   'OutcomeMeasurementSpread': '7.0'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Week 60',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1.9',\n",
              "                   'OutcomeMeasurementSpread': '7.5'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '1.1',\n",
              "                   'OutcomeMeasurementSpread': '7.3'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '1.2',\n",
              "                   'OutcomeMeasurementSpread': '7.9'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG003',\n",
              "                   'OutcomeMeasurementValue': '1.6',\n",
              "                   'OutcomeMeasurementSpread': '7.4'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Week 66',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '2.5',\n",
              "                   'OutcomeMeasurementSpread': '8.1'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '1.5',\n",
              "                   'OutcomeMeasurementSpread': '7.7'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '1.5',\n",
              "                   'OutcomeMeasurementSpread': '8.0'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG003',\n",
              "                   'OutcomeMeasurementValue': '2.0',\n",
              "                   'OutcomeMeasurementSpread': '8.2'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Week 72',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '3.3',\n",
              "                   'OutcomeMeasurementSpread': '8.9'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '1.9',\n",
              "                   'OutcomeMeasurementSpread': '8.1'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '2.2',\n",
              "                   'OutcomeMeasurementSpread': '8.1'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG003',\n",
              "                   'OutcomeMeasurementValue': '2.3',\n",
              "                   'OutcomeMeasurementSpread': '7.8'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001',\n",
              "               'OG003']},\n",
              "             'OutcomeAnalysisGroupDescription': 'Hypothesis #1: Slopes Superiority of 1mg Rasagiline over Placebo in the PC Phase Where slope is the model estimate of the change from baseline in total UPDRS per week.\\n\\nIn this analysis, all available post-baseline observations in the PC Phase of the trial are analyzed (ITT efficacy data analysis set, weeks 12, 24 and 36). The placebo groups for rasagiline 1mg (delayed-start) and 2mg (delayed-start)are combined to one placebo group.',\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '0.0133',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'Repeated Measures Mixed Linear Model'},\n",
              "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG002',\n",
              "               'OG003']},\n",
              "             'OutcomeAnalysisGroupDescription': 'Hypothesis #1: Slopes Superiority of 2mg Rasagiline over Placebo in the PC Phase Where slope is the model estimate of the change from baseline in total UPDRS per week.\\n\\nIn this analysis, all available post-baseline observations in the PC Phase of the trial are analyzed (ITT efficacy data analysis set, weeks 12, 24 and 36). The placebo groups for rasagiline 1mg (delayed-start)and 2mg (delayed-start) are combined to one placebo group.',\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '0.0001',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'Repeated Measures Mixed Linear Model',\n",
              "             'OutcomeAnalysisCIPctValue': '95'},\n",
              "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001']},\n",
              "             'OutcomeAnalysisGroupDescription': 'Hypothesis #2: Superiority of Early over Delayed Start at Week 72 In this analysis, observations of subjects entering the active phase with at least 24 weeks of treatment during the PC Phase and at least one available Total UPDRS measurement during the active-treatment phase from weeks 48, 54, 60, 66 or 72, are analyzed (ACTE data analysis set).',\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '0.0250',\n",
              "             'OutcomeAnalysisPValueComment': 'The analysis was performed on separate datasets and not on the combined dataset as was pre-specified to account for unexpected interactions of dose level by baseline UPDRS and of dose level by center .',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'Repeated Measures',\n",
              "             'OutcomeAnalysisCIPctValue': '95'},\n",
              "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG002',\n",
              "               'OG003']},\n",
              "             'OutcomeAnalysisGroupDescription': 'Hypothesis #2:Superiority of Early over Delayed Start at Week 72 In this analysis, observations of subjects entering the active phase with at least 24 weeks of treatment during the PC Phase and at least one available Total UPDRS measurement during the active-treatment phase from weeks 48, 54, 60, 66 or 72, are analyzed (ACTE data analysis set.)',\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '0.6028',\n",
              "             'OutcomeAnalysisPValueComment': 'The analysis was performed on separate datasets and not on the combined dataset as was pre-specified to account for unexpected interactions of dose level by baseline UPDRS and of dose level by center',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'Repeated Measures',\n",
              "             'OutcomeAnalysisCIPctValue': '95'},\n",
              "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001']},\n",
              "             'OutcomeAnalysisGroupDescription': 'Hypothesis #3: Slopes Non-Inferiority of Early Start over Delayed Start in the Active Phase.\\n\\nWhere slope is the model estimate of the change from baseline in total UPDRS per week. In this analysis, observations of all subjects entering the active phase with at least 24 weeks of treatment during the PC Phase and at least one available Total UPDRS measurement during the active treatment phase from weeks 48, 54, 60, 66 or 72, are analyzed (ACTE data analysis set).',\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'Yes',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Non-Inferiority or Equivalence',\n",
              "             'OutcomeAnalysisNonInferiorityComment': 'Non-Inf Test for difference in slopes between treatment groups. One sided 95% CI calculated for difference between slopes of the 1mg early-start group and the 1mg delayed-start group. The inferiority null hypothesis of the early-start group slope over delayed-start group slope is rejected, if the upper limit of one sided 95% CI for difference in slopes does not cross non-inferiority margin of 0.15 UPDRS points per week.',\n",
              "             'OutcomeAnalysisParamType': 'Slope',\n",
              "             'OutcomeAnalysisParamValue': '0.000',\n",
              "             'OutcomeAnalysisCIPctValue': '90',\n",
              "             'OutcomeAnalysisCILowerLimit': '-0.036',\n",
              "             'OutcomeAnalysisCIUpperLimit': '0.036'},\n",
              "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG002',\n",
              "               'OG003']},\n",
              "             'OutcomeAnalysisGroupDescription': 'Hypothesis #3: Slopes Non-Inferiority of Early Start over Delayed Start in the Active Phase.\\n\\nWhere slope is the model estimate of the change from baseline in total UPDRS per week. In this analysis, observations of all subjects entering the active phase with at least 24 weeks of treatment during the PC Phase and at least one available Total UPDRS measurement during the active treatment phase from weeks 48, 54, 60, 66 or 72, are analyzed (ACTE data analysis set).',\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'Yes',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Non-Inferiority or Equivalence',\n",
              "             'OutcomeAnalysisNonInferiorityComment': 'Non-Inf Test for difference in slopes between treatment groups. One sided 95% CI calculated for difference between slopes of the 2mg early-start group and the 2mg delayed-start group. The inferiority null hypothesis of the early-start group slope over delayed-start group slope is rejected, if the upper limit of one sided 95% CI for difference in slopes does not cross non-inferiority margin of 0.15 UPDRS points per week.',\n",
              "             'OutcomeAnalysisParamType': 'Slope',\n",
              "             'OutcomeAnalysisParamValue': '0.029',\n",
              "             'OutcomeAnalysisCIPctValue': '90',\n",
              "             'OutcomeAnalysisCILowerLimit': '-0.005',\n",
              "             'OutcomeAnalysisCIUpperLimit': '0.062'}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to Last Observed Value in the Placebo Phase\",\n",
              "          'OutcomeMeasureDescription': \"Subjects were assessed according to the United Parkinson's Disease Rating Scale UPDRS,(version 3;) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario.\",\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Scores on a scale',\n",
              "          'OutcomeMeasureTimeFrame': '36 weeks',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': '1mg Delayed Start',\n",
              "             'OutcomeGroupDescription': '+ 2 mg Delayed Start: 36 week combined placebo group.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': '1mg Early Start',\n",
              "             'OutcomeGroupDescription': '1mg early start active treatment arm (72 weeks active)'},\n",
              "            {'OutcomeGroupId': 'OG002',\n",
              "             'OutcomeGroupTitle': '2mg Early Start',\n",
              "             'OutcomeGroupDescription': '2mg early start active treatment arm (72 weeks active)'},\n",
              "            {'OutcomeGroupId': 'OG003',\n",
              "             'OutcomeGroupTitle': '2mg Delayed Start',\n",
              "             'OutcomeGroupDescription': '+1mg Delayed Start: see 1st column'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '588'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '286'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG002',\n",
              "                'OutcomeDenomCountValue': '290'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG003',\n",
              "                'OutcomeDenomCountValue': '0'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '3.9',\n",
              "                   'OutcomeMeasurementSpread': '7.2'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '1.0',\n",
              "                   'OutcomeMeasurementSpread': '6.0'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '0.8',\n",
              "                   'OutcomeMeasurementSpread': '6.5'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001',\n",
              "               'OG003']},\n",
              "             'OutcomeAnalysisGroupDescription': \"The adjusted means of the changes in Total UPDRS from baseline to LOV in the placebo-controlled phase, observed in the 1 mg and 2 mg rasagiline early-start groups are compared (two contrasts) to the combined placebo group (1 mg and 2 mg rasagiline delayed-start groups), by applying an Analysis of Covariance model. The model includes treatment group, center and baseline Total UPDRS as covariates. For this analysis, both delayed start arms are pooled as a 'placebo arm'\",\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '<0.0001',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'ANCOVA',\n",
              "             'OutcomeAnalysisParamType': 'Mean Difference (Final Values)',\n",
              "             'OutcomeAnalysisParamValue': '-3.005',\n",
              "             'OutcomeAnalysisCIPctValue': '95',\n",
              "             'OutcomeAnalysisCILowerLimit': '-3.857',\n",
              "             'OutcomeAnalysisCIUpperLimit': '-2.153'},\n",
              "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG002',\n",
              "               'OG003']},\n",
              "             'OutcomeAnalysisGroupDescription': \"The adjusted means of the changes in Total UPDRS from baseline to LOV in the placebo-controlled phase, observed in the 1 mg and 2 mg rasagiline early-start groups are compared (two contrasts) to the combined placebo group (1 mg and 2 mg rasagiline delayed-start groups), by applying an Analysis of Covariance model. The model includes treatment group, center and baseline Total UPDRS as covariates.\\n\\nFor this analysis, both delayed start arms are pooled as a 'placebo arm'\",\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '<0.0001',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'ANCOVA',\n",
              "             'OutcomeAnalysisParamType': 'Mean Difference (Final Values)',\n",
              "             'OutcomeAnalysisParamValue': '-3.154',\n",
              "             'OutcomeAnalysisCIPctValue': '95',\n",
              "             'OutcomeAnalysisCILowerLimit': '-4.004',\n",
              "             'OutcomeAnalysisCIUpperLimit': '-2.305'}]}}]}},\n",
              "      'AdverseEventsModule': {'EventsFrequencyThreshold': '5',\n",
              "       'EventsTimeFrame': '2 years, 6 months',\n",
              "       'EventsDescription': 'Each Delayed Start arm was preceded by 36 weeks placebo followed by 36 weeks Rasagiline either 1mg or 2mg; therefore, the placebo groups were combined into one group for the placebo analysis.',\n",
              "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
              "          'EventGroupTitle': 'Placebo Combined Group',\n",
              "          'EventGroupDescription': '1mg & 2mg combined placebo group includes those patients in 1mg Delayed start and the 2mg Delayed start arms who received placebo for the first 36 weeks.',\n",
              "          'EventGroupSeriousNumAffected': '22',\n",
              "          'EventGroupSeriousNumAtRisk': '593',\n",
              "          'EventGroupOtherNumAffected': '82',\n",
              "          'EventGroupOtherNumAtRisk': '593'},\n",
              "         {'EventGroupId': 'EG001',\n",
              "          'EventGroupTitle': '1mg Active Treatment',\n",
              "          'EventGroupDescription': '1mg Active & 1mg Delayed. This group includes those patients who received 1mg Rasagiline in both the early start active treatment arm (72 weeks active)and those patients who transitioned to active treatment in the 1mg Delayed start treatment arm (36 weeks active treatment)',\n",
              "          'EventGroupSeriousNumAffected': '37',\n",
              "          'EventGroupSeriousNumAtRisk': '288',\n",
              "          'EventGroupOtherNumAffected': '40',\n",
              "          'EventGroupOtherNumAtRisk': '288'},\n",
              "         {'EventGroupId': 'EG002',\n",
              "          'EventGroupTitle': '2mg Active Treatment',\n",
              "          'EventGroupDescription': '2mg Active & 2mg Delayed. This group includes those patients who received 2mg Rasagiline in both the early start active treatment arm (72 weeks active)and those patients who transitioned to active treatment in the 2mg Delayed start treatment arm (36 weeks active treatment)',\n",
              "          'EventGroupSeriousNumAffected': '44',\n",
              "          'EventGroupSeriousNumAtRisk': '293',\n",
              "          'EventGroupOtherNumAffected': '34',\n",
              "          'EventGroupOtherNumAtRisk': '293'}]},\n",
              "       'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Coronary Artery Disease',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Cardiac failure',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Angina Pectoris',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Myocardial Infarction',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '2',\n",
              "             'SeriousEventStatsNumAffected': '2',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Atrial Fibrilation',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Atrial Flutter',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Vitreous Haemorrhage',\n",
              "          'SeriousEventOrganSystem': 'Eye disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Eyelid Ptosis',\n",
              "          'SeriousEventOrganSystem': 'Eye disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Abdominal Pain',\n",
              "          'SeriousEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Abdominal Pain Lower',\n",
              "          'SeriousEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Parasthesia Oral',\n",
              "          'SeriousEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Pyrexia',\n",
              "          'SeriousEventOrganSystem': 'General disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '2',\n",
              "             'SeriousEventStatsNumAffected': '2',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Chest Discomfort',\n",
              "          'SeriousEventOrganSystem': 'General disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Chest pain',\n",
              "          'SeriousEventOrganSystem': 'General disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '4',\n",
              "             'SeriousEventStatsNumAffected': '4',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Non-Cardiac Chest Pain',\n",
              "          'SeriousEventOrganSystem': 'General disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Drug Hypersensitivity',\n",
              "          'SeriousEventOrganSystem': 'Immune system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '2',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Appendicitis',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Cellulitis',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Labyrinthitis',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Bronchitis',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Pneumonia',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '2',\n",
              "             'SeriousEventStatsNumAffected': '2',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Urosepsis',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Laryngitis',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Femur Fracture',\n",
              "          'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Hip Fracture',\n",
              "          'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Fall',\n",
              "          'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '2',\n",
              "             'SeriousEventStatsNumAffected': '2',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Hypokalaemia',\n",
              "          'SeriousEventOrganSystem': 'Metabolism and nutrition disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Hyponatraemia',\n",
              "          'SeriousEventOrganSystem': 'Metabolism and nutrition disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Dehydration',\n",
              "          'SeriousEventOrganSystem': 'Metabolism and nutrition disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '2',\n",
              "             'SeriousEventStatsNumAffected': '2',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Myalgia',\n",
              "          'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Muscle Hemorrhage',\n",
              "          'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Osteoarthritis',\n",
              "          'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '3',\n",
              "             'SeriousEventStatsNumAffected': '3',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Diffuse Large B-Cell Lymphoma',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Thyroid Neoplasm',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Endometrial Cancer Stage I',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Lung Adenocarcinoma Metastic',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Benign Laryngeal Neoplasm',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Rectal cancer Metastic',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Cerebral Haemorrhage',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Subarachnoid Haemorrhage',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Lacunar Infarction',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Syncope',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Akinesia',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Headache',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Hydrocephalus',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': \"Parkinson's Disease\",\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Major Depression',\n",
              "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Alcohol Abuse',\n",
              "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Renal Colic',\n",
              "          'SeriousEventOrganSystem': 'Renal and urinary disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Dyspnoea',\n",
              "          'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Laryngeal Leukoplakia',\n",
              "          'SeriousEventOrganSystem': 'Reproductive system and breast disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Atelectasis',\n",
              "          'SeriousEventOrganSystem': 'Reproductive system and breast disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Hypoaesthesia Facial',\n",
              "          'SeriousEventOrganSystem': 'Skin and subcutaneous tissue disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '2',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Coronary Artery Bypass',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Cardioversion',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Open reduction of fracture',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Incisional Hernia Repair',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Inguinal Hernia Repair',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Knee Operation',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Colon Polypectomy',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Hysterectomy',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Hypotension',\n",
              "          'SeriousEventOrganSystem': 'Vascular disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Cardiac Failure Congestive',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Myocardial Ischaemia',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Tachycardia',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Vertigo',\n",
              "          'SeriousEventOrganSystem': 'Ear and labyrinth disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Cataract',\n",
              "          'SeriousEventOrganSystem': 'Eye disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Retinal Vein Occlusion',\n",
              "          'SeriousEventOrganSystem': 'Eye disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Duodenal Ulcer Haemorrhage',\n",
              "          'SeriousEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Gastritis',\n",
              "          'SeriousEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Heus',\n",
              "          'SeriousEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Inguinal Hernia',\n",
              "          'SeriousEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Gastrointestinal Haemorrhage',\n",
              "          'SeriousEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Malaise',\n",
              "          'SeriousEventOrganSystem': 'General disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Diverticulitis',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Rectal Abscess',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Peridiverticular Abscess',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Lower respiratory Tract Infection',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Erysipelas',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Femoral Neck Fracture',\n",
              "          'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Arteriogram Coronary Abnormal',\n",
              "          'SeriousEventOrganSystem': 'Investigations',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Back Pain',\n",
              "          'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Breast cancer',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Colon Cancer',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Squamous Cell Carcinoma',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Ovarian Epithelial Cancer Metastatic',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Prostrate Cancer',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Renal cancer',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Basal Cell Carcinoma',\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '2',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Carotid Artery Stenosis',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Loss of Consciousness',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Sciatica',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Aphasia',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Transient Ischaemic Attack',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Neurosis',\n",
              "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Hallucination, Visual',\n",
              "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Suicidal Ideation',\n",
              "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Nephrolithiasis',\n",
              "          'SeriousEventOrganSystem': 'Renal and urinary disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Colpocele',\n",
              "          'SeriousEventOrganSystem': 'Reproductive system and breast disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Pulmonary Embolism',\n",
              "          'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Pulmonary Infarction',\n",
              "          'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Rash',\n",
              "          'SeriousEventOrganSystem': 'Skin and subcutaneous tissue disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Abdominal Operation',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Arterial Stent Insertion',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Coronary Angioplasty',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Bone operation',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Hip Arthroplasty',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Hip Surgery',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Knee Arthroplasty',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '2',\n",
              "             'SeriousEventStatsNumAffected': '2',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Cataract Operation',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Transurethral Prostatectomy',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Aortic Aneurysm',\n",
              "          'SeriousEventOrganSystem': 'Vascular disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Aortic Aneurysm Rupture',\n",
              "          'SeriousEventOrganSystem': 'Vascular disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Deep Vein Thrombosis',\n",
              "          'SeriousEventOrganSystem': 'Vascular disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Thrombophlebitis',\n",
              "          'SeriousEventOrganSystem': 'Vascular disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}},\n",
              "         {'SeriousEventTerm': 'Hypertension',\n",
              "          'SeriousEventOrganSystem': 'Vascular disorders',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '593'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '288'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '293'}]}}]},\n",
              "       'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Back Pain',\n",
              "          'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '34',\n",
              "             'OtherEventStatsNumAffected': '32',\n",
              "             'OtherEventStatsNumAtRisk': '593'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '14',\n",
              "             'OtherEventStatsNumAffected': '14',\n",
              "             'OtherEventStatsNumAtRisk': '288'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '15',\n",
              "             'OtherEventStatsNumAffected': '15',\n",
              "             'OtherEventStatsNumAtRisk': '293'}]}},\n",
              "         {'OtherEventTerm': 'Headache',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '39',\n",
              "             'OtherEventStatsNumAffected': '37',\n",
              "             'OtherEventStatsNumAtRisk': '593'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '15',\n",
              "             'OtherEventStatsNumAffected': '14',\n",
              "             'OtherEventStatsNumAtRisk': '288'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '15',\n",
              "             'OtherEventStatsNumAffected': '15',\n",
              "             'OtherEventStatsNumAtRisk': '293'}]}},\n",
              "         {'OtherEventTerm': 'Fatigue',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumEvents': '18',\n",
              "             'OtherEventStatsNumAffected': '17',\n",
              "             'OtherEventStatsNumAtRisk': '593'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumEvents': '18',\n",
              "             'OtherEventStatsNumAffected': '17',\n",
              "             'OtherEventStatsNumAtRisk': '288'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumEvents': '10',\n",
              "             'OtherEventStatsNumAffected': '10',\n",
              "             'OtherEventStatsNumAtRisk': '293'}]}}]}},\n",
              "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
              "        'AgreementRestrictionType': 'OTHER',\n",
              "        'AgreementRestrictiveAgreement': 'Yes',\n",
              "        'AgreementOtherDetails': 'Should the Oversight Committee wish to publish the results of this study, the Oversight Committee agrees to provide Teva with a manuscript for review 60 days prior to submission for publication. Teva retains the right to delete from the manuscript confidential information and to object to suggested publication and/or its timing (at the sole discretion of Teva).'},\n",
              "       'PointOfContact': {'PointOfContactTitle': 'Dennis Ahern, MS, Director',\n",
              "        'PointOfContactOrganization': 'Teva Branded Pharmaceutical Products R&D',\n",
              "        'PointOfContactEMail': 'dennis.ahern@tevausa.com',\n",
              "        'PointOfContactPhone': '215-293-6339'}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022',\n",
              "       'RemovedCountryList': {'RemovedCountry': ['Argentina',\n",
              "         'Austria',\n",
              "         'Canada',\n",
              "         'France',\n",
              "         'Germany',\n",
              "         'Hungary',\n",
              "         'Israel',\n",
              "         'Italy',\n",
              "         'Netherlands',\n",
              "         'Portugal',\n",
              "         'Romania',\n",
              "         'Spain',\n",
              "         'United Kingdom',\n",
              "         'United States']}},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M19712',\n",
              "          'ConditionBrowseLeafName': 'Disease Progression',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
              "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}},\n",
              "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'C000031967',\n",
              "          'InterventionMeshTerm': 'Rasagiline'}]},\n",
              "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000008996',\n",
              "          'InterventionAncestorTerm': 'Monoamine Oxidase Inhibitors'},\n",
              "         {'InterventionAncestorId': 'D000004791',\n",
              "          'InterventionAncestorTerm': 'Enzyme Inhibitors'},\n",
              "         {'InterventionAncestorId': 'D000045504',\n",
              "          'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'},\n",
              "         {'InterventionAncestorId': 'D000018696',\n",
              "          'InterventionAncestorTerm': 'Neuroprotective Agents'},\n",
              "         {'InterventionAncestorId': 'D000020011',\n",
              "          'InterventionAncestorTerm': 'Protective Agents'},\n",
              "         {'InterventionAncestorId': 'D000045505',\n",
              "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]},\n",
              "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M213836',\n",
              "          'InterventionBrowseLeafName': 'Rasagiline',\n",
              "          'InterventionBrowseLeafAsFound': 'Injection site',\n",
              "          'InterventionBrowseLeafRelevance': 'high'},\n",
              "         {'InterventionBrowseLeafId': 'M11112',\n",
              "          'InterventionBrowseLeafName': 'Monoamine Oxidase Inhibitors',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M19926',\n",
              "          'InterventionBrowseLeafName': 'Neuroprotective Agents',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M21022',\n",
              "          'InterventionBrowseLeafName': 'Protective Agents',\n",
              "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
              "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'NeuroAg',\n",
              "          'InterventionBrowseBranchName': 'Neuroprotective Agents'},\n",
              "         {'InterventionBrowseBranchAbbrev': 'All',\n",
              "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}},\n",
              "   {'Rank': 14,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04032262',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'PARKIDF00001'},\n",
              "       'Organization': {'OrgFullName': 'Augusta University',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Parkinson's Disease and Digestive Health\",\n",
              "       'OfficialTitle': \"Characterization of Gastrointestinal and Neuroenteric Dysfunction in Parkinson's Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'January 2021',\n",
              "       'OverallStatus': 'Active, not recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'October 4, 2017',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 30, 2020',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'January 30, 2021',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'April 19, 2018',\n",
              "       'StudyFirstSubmitQCDate': 'July 23, 2019',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 25, 2019',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'January 11, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 12, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Augusta University',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': \"Parkinson's Disease Foundation\",\n",
              "          'CollaboratorClass': 'OTHER'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'Yes'},\n",
              "      'DescriptionModule': {'BriefSummary': \"This study focuses on the relationship between the brain and the gut, and additionally will foster collaboration between Movement Disorder experts and Neurogastroenterologists to provide critical information and lead to innovative therapies in the future to treat GI dysfunction of Parkinson's Disease.\",\n",
              "       'DetailedDescription': \"Parkinson's disease affects 1 million people in the US with a rising prevalence. In addition to neurological problems, patients with Parkinson's Disease often suffer from debilitating gastrointestinal (GI) symptoms related to delayed stomach emptying, gas/bloating, and constipation. GI complaints of patients suffering from Parkinson's Disease are poorly understood. This proposal aims to characterize GI disturbance in patients with Parkinson's Disease and provide deeper understanding by investigating symptoms, regional and whole gut transit, anorectal physiology, and the brain-gut axis. The investigator believes patients with Parkinson's Disease will show altered GI sensation, slower GI motility and demonstrate deranged regulation of the brain-gut axis correlated to severity of Parkinson's disease. Results from this study of GI motility and brain-gut axis will define a subset of Parkinson's Disease patients that can benefit from tailored treatment. This study will foster collaboration between Movement Disorder experts and Neurogastroenterologists to provide critical information and lead to innovative therapies in the future to treat GI dysfunction of Parkinson's Disease.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease',\n",
              "         'Constipation',\n",
              "         'Gastro-Intestinal Disorder']},\n",
              "       'KeywordList': {'Keyword': ['Brain-Gut Relationship',\n",
              "         'Anorectal Manometry']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'N/A',\n",
              "        'DesignInterventionModel': 'Single Group Assignment',\n",
              "        'DesignPrimaryPurpose': 'Diagnostic',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '25',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Parkinson's Disease Relationship to the GI track\",\n",
              "          'ArmGroupType': 'Other',\n",
              "          'ArmGroupDescription': \"Patients with Parkinson's.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Diagnostic Test: Gastrointestinal and Parkinson's Disease\"]}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test',\n",
              "          'InterventionName': \"Gastrointestinal and Parkinson's Disease\",\n",
              "          'InterventionDescription': \"Subjects with Parkinson's disease will come for visits that will contain questionnaires about their PD, their bowel movements, and do further tests using anal rectal probes to understand further their constipation, and other tests to gather data on their digestion.\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Parkinson's Disease Relationship to the GI track\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Cortical Evoked Potential (CEP)',\n",
              "          'PrimaryOutcomeDescription': 'Bilateral amplitude (microvolts) for ano-rectal CEP responses',\n",
              "          'PrimaryOutcomeTimeFrame': 'Single Visit, 3 hours'},\n",
              "         {'PrimaryOutcomeMeasure': 'Motor Evoked Potential (MEP)',\n",
              "          'PrimaryOutcomeDescription': 'Bilateral amplitude (microvolts) for ano-rectal MEP responses',\n",
              "          'PrimaryOutcomeTimeFrame': 'Single visit, 2 hours'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Gastrointestinal motor function and transit',\n",
              "          'SecondaryOutcomeDescription': 'The measurements to be obtained are gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT) and whole gut transit time (WGTT) over a period of 5 days. Tool to be used includes wireless motility capsule and corresponding recorder swallowed on initial visit and returned 5 days later. Specific measurements obtained include time in hours of GET, SBTT, CTT, WGTT. These outcome will only be measured once per subject and not be reassessed.',\n",
              "          'SecondaryOutcomeTimeFrame': '2 visits, 1hour'},\n",
              "         {'SecondaryOutcomeMeasure': 'Rectal sensorimotor function',\n",
              "          'SecondaryOutcomeDescription': 'Rectal sustained squeeze pressure (mmHg) measure from Anal rectal manometry study',\n",
              "          'SecondaryOutcomeTimeFrame': 'Single visit, 2 hours'},\n",
              "         {'SecondaryOutcomeMeasure': 'Anal sensorimotor function',\n",
              "          'SecondaryOutcomeDescription': 'Anal sustained squeeze pressure (mmHg) measure from Anal rectal manometry study',\n",
              "          'SecondaryOutcomeTimeFrame': 'Single visit, 2 hours'},\n",
              "         {'SecondaryOutcomeMeasure': 'Unified Parkinson Disease Rating Scale (UPDRS)',\n",
              "          'SecondaryOutcomeDescription': \"Used to follow the longitudinal course of Parkinson's disease. The UPDRS scale consists of the following five segments: 1) Mentation, Behavior, and Mood, 2) ADL, 3) Motor sections, 4) Modified Hoehn and Yahr Scale, and 5) Schwab and England ADL scale. Some sections of the UPDRS scale require multiple grades assigned to each extremity with a possible maximum of 199 points. A score of 199 on the UPDRS scale represents the worst (total disability) with a score of zero representing (no disability).\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Single visit, 1 hour'},\n",
              "         {'SecondaryOutcomeMeasure': 'Montreal Cognitive Assessment (MoCA)',\n",
              "          'SecondaryOutcomeDescription': 'Screening assessment for detecting cognitive impairment. MoCA scores range between 0 and 30. A final total score of 26 and above is considered normal.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Single visit, 1 hour'},\n",
              "         {'SecondaryOutcomeMeasure': 'Non-motor symptoms questionnaire',\n",
              "          'SecondaryOutcomeDescription': 'A 30-item screening patient-based questionnaire used to determine the non-motor symptoms experienced by the patient. The points should be totalled to give a score out of 30. A score of under 10 is mild, 10-20 moderate and over 20, severe.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Single visit, 1 hour'},\n",
              "         {'SecondaryOutcomeMeasure': '36-Item Short Form Survey (SF-36)',\n",
              "          'SecondaryOutcomeDescription': 'SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Single visit, 1 hour'},\n",
              "         {'SecondaryOutcomeMeasure': 'Stool diary',\n",
              "          'SecondaryOutcomeDescription': 'The measurement to be obtained is bowel pattern. Tool to be used include 2-week stool diary. Specific measurements obtained include number of complete spontaneous bowel movements (CSBMs) a week. These outcome will only be measured once per subject and not be reassessed.',\n",
              "          'SecondaryOutcomeTimeFrame': '2 visits, 1 hour'},\n",
              "         {'SecondaryOutcomeMeasure': 'Gastroparesis Cardinal Symptom Index (GCSI)',\n",
              "          'SecondaryOutcomeDescription': 'The GCSI is based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). A six-point Likert response scale, ranging from 0 (none) to 5 (very severe), with a 2-week recall period, was used to rate the severity of each symptom. The GCSI total score was constructed as the average of the three symptom sub-scales. GCSI total scores were in the range 0-5, with higher scores reflecting greater symptom severity.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Single visit, 1 hour'},\n",
              "         {'SecondaryOutcomeMeasure': 'Eckdart score (ESS)',\n",
              "          'SecondaryOutcomeDescription': 'The ESS is a 4 item self-report scale measuring weight loss in kilograms, chest pain, regurgitation, and dysphagia. Each item is graded on a score of 0 to 3, with a maximum score of 12. Scores greater than or equal to 3 are considered suggestive of active achalasia. The ESS is widely used in both clinical and research settings as a gold standard for measuring achalasia symptom severity.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Single visit, 1 hour'},\n",
              "         {'SecondaryOutcomeMeasure': 'Breath testing',\n",
              "          'SecondaryOutcomeDescription': 'The measurement to be obtained is presence of bacterial overgrowth. Tool to be used include breath testing via gas chromatography. Specific measurements obtained hydrogen and methane in parts per million (ppm) at baseline and every 30 minutes for 2-3 hours. These outcome will only be measured once per subject and not be reassessed.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Single visit, 3 hours'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPresence of 2 of 3 cardinal features of PD (resting tremor, bradykinesia, and rigidity)\\nHoehn and Yahr Scale stage I-IV\\nMen or women aged 18+\\nStable dopaminergic treatment for 4 weeks.\\nWomen of childbearing potential must agree to a urine pregnancy test at screening and to avoid pregnancy throughout the study.\\n\\nExclusion Criteria:\\n\\nSecondary parkinsonism.\\nParkinson-plus syndromes.\\nMontreal Cognitive Assessment score <17.\\nUnstable dosage of drugs active in the cns (e.g., anxiolytics, antidepressants) during the 60 days before the visit.\\nParticipation in drug studies within 30 days of screening.\\nStructural brain disease.\\nWomen who are pregnant or likely to conceive (women with potential for pregnancy must use contraceptive measures to be included);\\nActive or personal history of epilepsy.\\nAcute illness or active, confounding medical, neurologic, or musculoskeletal conditions.\\nAlcoholism or other forms of drug addiction.\\nSignificant prior gastrointestinal surgery.\\nOngoing chemotherapy or other treatment for cancer.\\nDysphagia\\nimplanted or externally worn medical device such as, but not limited to, a pacemaker. (gastric stimulators, bladder stimulators, spinal stimulators, medication infusion devices, insulin pumps, continuous glucose monitors are permitted).',\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Amol Sharma, MD',\n",
              "          'OverallOfficialAffiliation': 'Augusta University',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Augusta University Digestive Health Research',\n",
              "          'LocationCity': 'Augusta',\n",
              "          'LocationState': 'Georgia',\n",
              "          'LocationZip': '30912',\n",
              "          'LocationCountry': 'United States'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No',\n",
              "       'IPDSharingDescription': \"Parkinson's Disease foundation sponsored this study they will most likely be made aware about how recruitment went, participation, and ending results.\"}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000007410',\n",
              "          'ConditionMeshTerm': 'Intestinal Diseases'},\n",
              "         {'ConditionMeshId': 'D000005767',\n",
              "          'ConditionMeshTerm': 'Gastrointestinal Diseases'},\n",
              "         {'ConditionMeshId': 'D000004066',\n",
              "          'ConditionMeshTerm': 'Digestive System Diseases'},\n",
              "         {'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'},\n",
              "         {'ConditionMeshId': 'D000003248',\n",
              "          'ConditionMeshTerm': 'Constipation'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'},\n",
              "         {'ConditionAncestorId': 'D000012817',\n",
              "          'ConditionAncestorTerm': 'Signs and Symptoms, Digestive'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5624',\n",
              "          'ConditionBrowseLeafName': 'Constipation',\n",
              "          'ConditionBrowseLeafAsFound': 'Constipation',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M9596',\n",
              "          'ConditionBrowseLeafName': 'Intestinal Diseases',\n",
              "          'ConditionBrowseLeafAsFound': 'Intestinal Disorder',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M8035',\n",
              "          'ConditionBrowseLeafName': 'Gastrointestinal Diseases',\n",
              "          'ConditionBrowseLeafAsFound': 'Gastro-Intestinal Disorder',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M6407',\n",
              "          'ConditionBrowseLeafName': 'Digestive System Diseases',\n",
              "          'ConditionBrowseLeafAsFound': 'Gastro-Intestinal Disorder',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M14774',\n",
              "          'ConditionBrowseLeafName': 'Signs and Symptoms, Digestive',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23',\n",
              "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC06',\n",
              "          'ConditionBrowseBranchName': 'Digestive System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 15,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04648150',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'CHH_2020_32'},\n",
              "       'Organization': {'OrgFullName': 'Fondation Ophtalmologique Adolphe de Rothschild',\n",
              "        'OrgClass': 'NETWORK'},\n",
              "       'BriefTitle': \"Evaluation of a Millimeter Wave Emission Bracelet for Improving Parkinson's Disease Symptoms\",\n",
              "       'OfficialTitle': \"Evaluation of a Millimeter Wave Emission Bracelet -Type Medical Device for Improving Parkinson's Disease Symptoms: Multicenter, Double-blind Randomized Controlled Trial\",\n",
              "       'Acronym': 'BOMP'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'July 2021',\n",
              "       'OverallStatus': 'Recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'May 18, 2021',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2023',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'January 2024',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'November 19, 2020',\n",
              "       'StudyFirstSubmitQCDate': 'November 27, 2020',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 1, 2020',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'July 16, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 19, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Fondation Ophtalmologique Adolphe de Rothschild',\n",
              "        'LeadSponsorClass': 'NETWORK'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Remedee SA',\n",
              "          'CollaboratorClass': 'INDUSTRY'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Idiopathic Parkinson's disease is a common neurodegenerative disease, with a prevalence of around 2% in people over 65 years of age in France.\\n\\nThis pathology affects the dopaminergic pathway but also other systems: cholinergic, noradrenergic and serotoninergic.\\n\\nThe symptoms of Parkinson's disease are motor but also non-motor with sleep, smell, cognitive, psychiatric, digestive, urinary, dysautonomic, painful disorders. The discomfort can be such that invasive and expensive solutions have been developed. Invasive or expensive techniques (deep brain stimulation, lesional microsurgery by gamma knife or ultrasound, duodopa or apokinon pumps) brought significant benefits to patients. Opportunities for clinical improvement using less expensive and lighter devices should be sought.\\n\\nThe Remedee endorphin band device is a device that emits millimeter-band electromagnetic waves on the wrist. The device stimulates subcutaneous nerve endings and activates a physiological response leading to the release of endorphins in the brain. Endorphins are involved in several physiological processes, including pain control.\\n\\nMu-opioid receptor (MOR) agonists do not only relieve pain, but have effects related to mesolimbic dopaminergic pathways. Indeed, the opioid and dopaminergic systems are closely linked at the cellular level. Endorphins, through inhibition of the release of the neurotransmitter GABA upon binding to the  receptor, are also linked to an increase in dopamine.\",\n",
              "       'DetailedDescription': 'Intervention 1 Name : VERUM\\n\\nDescription :\\n\\nExperimental arm (VERUM): delivery of an active medical device for a period of 2 months. Then delivery of a second active medical device for a period of 4 months.\\n\\nIntervention 2 Name : SHAM\\n\\nDescription:\\n\\nControl arm (SHAM): delivery of an inactive medical device for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion'},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignInterventionModelDescription': 'Experimental arm (VERUM): delivery of an active medical device for a period of 2 months. Then delivery of a second active medical device for a period of 4 months.\\n\\nControl arm (SHAM): delivery of an inactive medical device for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion.',\n",
              "        'DesignPrimaryPurpose': 'Other',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Triple',\n",
              "         'DesignMaskingDescription': 'ratio 1 :1 in each centre on an online randomization module',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
              "           'Care Provider',\n",
              "           'Investigator']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '60',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'VERUM',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'An active wave emission bracelet for a period of 2 months. Then delivery of a second active medical device for a period of 4 months',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Device: Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms\"]}},\n",
              "         {'ArmGroupLabel': 'SHAM',\n",
              "          'ArmGroupType': 'Sham Comparator',\n",
              "          'ArmGroupDescription': 'An inactive wave emission bracelet for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Device: Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms\"]}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
              "          'InterventionName': \"Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms\",\n",
              "          'InterventionDescription': \"Evaluation of a millimeter wave emission bracelet -type medical device for improving Parkinson's disease symptoms: multicenter, double-blind randomized controlled trial\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['SHAM',\n",
              "            'VERUM']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Assessment of the effectiveness of two months of use of the Remedee Endorphin Band medical device in improving motor disorders in patients with Parkinson's disease\",\n",
              "          'PrimaryOutcomeDescription': \"The Movement Disorder Society Unified Parkinson Disease Rating Scale III (MDS-UPDRS III score evaluation see Appendix 1) will be performed under ON Dopa conditions and blinded from the randomization arm.\\n\\nThe MDS-UPDRS III evaluates various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications. Each parkinsonian sign or symptom is rated on a 5-point Likert-type scale (ranging from 0 to 4), with higher scores indicating more severe impairment. The maximum total MDS-UPDRS III score is 199, indicating the worst possible disability from Parkinson disease.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'two months after inclusion'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nPatient over 18 years old\\nFollow-up for Parkinson's disease for more than 5 years\\nTreatment stable for at least 3 months\\nHaving retained sufficient autonomy to allow participation in the study\\nHoehn and Yahr score in ON DOPA <4\\n\\nExclusion Criteria:\\n\\nGenetic forms of the disease\\nEVA> 7 over the previous week\\nModerate to severe cognitive impairment\\nPathology or condition (other than Parkinson's disease) that can generate motor disorders\\nAllergy to metals and / or silicone\\nDermatological pathology on the wrists\\nMetal object at one of the wrists (implanted metal material, piercing)\\nPresence of a tattoo on one of the wrists\\nWrist circumference <14.5 cm or> 21 cm i.e. wrist incompatible with the MD template\\nInability of the patient to put on and / or wear the template of the medical device\\nPregnant or breastfeeding woman\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Amelie Yavchitz, PhD',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '01 48 03 64 54',\n",
              "          'CentralContactEMail': 'ayavchitz@for.paris'},\n",
              "         {'CentralContactName': 'Cecile HUBSCH, PhD',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '01 48 03 68 90',\n",
              "          'CentralContactEMail': 'chubsch@for.paris'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Hopital Fondation Adolphe de Rothschild',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Paris',\n",
              "          'LocationZip': '75019',\n",
              "          'LocationCountry': 'France',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Amlie Yavchitz',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '01 48 03 64 54',\n",
              "             'LocationContactEMail': 'ayavchitz@for.paris'},\n",
              "            {'LocationContactName': 'Ccile Hubsch',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '01 48 03 68 90',\n",
              "             'LocationContactEMail': 'chubsch@for.paris'},\n",
              "            {'LocationContactName': 'Ccile Hubsch',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Centre Hospitalier de Voiron',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Voiron',\n",
              "          'LocationZip': '38506',\n",
              "          'LocationCountry': 'France',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Amlie YAVCHITZ',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '01 48 03 64 54',\n",
              "             'LocationContactEMail': 'ayavchitz@for.paris'},\n",
              "            {'LocationContactName': 'Grard Mick',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 16,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04903769',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '663519'},\n",
              "       'Organization': {'OrgFullName': 'Stony Brook University',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Stress Management and Resiliency Training Program for Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Stress Management and Resiliency Training Program for Parkinson's Disease Patients and Their Caregivers (SMART-PD)\",\n",
              "       'Acronym': 'SMART-PD'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'September 2021',\n",
              "       'OverallStatus': 'Recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'August 3, 2020',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2021',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'January 31, 2022',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'May 24, 2021',\n",
              "       'StudyFirstSubmitQCDate': 'May 24, 2021',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 27, 2021',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'September 20, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 21, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Adam Gonzalez',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Associate Professor of Psychiatry & Behavioral Health',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Stony Brook University'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Stony Brook University',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': \"Parkinson's Disease Foundation\",\n",
              "          'CollaboratorClass': 'OTHER'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"SMART-PD is an 8-session program designed to decrease the physiological, emotional, cognitive and behavioral effects of stress in participants with Parkinson's disease and their caregivers by teaching cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors and access social support. The SMART program has been shown to be effective for reducing mental health symptoms such as depression and anxiety as well as physical symptoms such as pain and in promoting positive health behaviors.\",\n",
              "       'DetailedDescription': \"This is an interventional study sponsored by the Parkinson's Foundation designed to measure the feasibility, acceptability, and initial impact of the SMART-PD program on participants with a recent (less than five years) diagnosis of Parkinson's disease and their caregivers. This program provides information and tools to help patients and their caregivers cope with the new PD diagnosis and manage the stress and negative mental health symptoms (such as anxiety and depression) associated with the diagnosis.\\n\\nSMART-PD is a manualized 8-week intervention that teaches cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors (i.e., sleep, nutrition, physical activity) and access social support.\\n\\nParticipants will take baseline and follow-up questionnaires to ascertain the impact of the program on outcomes such as quality of life, emotional health, coping skills, and healthy lifestyle behaviors.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'N/A',\n",
              "        'DesignInterventionModel': 'Single Group Assignment',\n",
              "        'DesignInterventionModelDescription': 'All participants will receive the SMART-PD intervention and will take baseline and follow-up assessments to determine the impact of the program',\n",
              "        'DesignPrimaryPurpose': 'Supportive Care',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '60',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Parkinson's Patients and Caregivers\",\n",
              "          'ArmGroupType': 'Other',\n",
              "          'ArmGroupDescription': \"Will participate in the 8-session SMART-PD program as a participant with Parkinson's disease or as a caregiver of a participant with Parkinson's disease\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Behavioral: Stress Management and Resiliency Training Program for Parkinson's Disease (SMART-PD)\"]}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
              "          'InterventionName': \"Stress Management and Resiliency Training Program for Parkinson's Disease (SMART-PD)\",\n",
              "          'InterventionDescription': 'SMART-PD is a manualized intervention that teaches cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors (i.e., sleep, nutrition, physical activity) and access social support.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Parkinson's Patients and Caregivers\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Enrollment and participation',\n",
              "          'PrimaryOutcomeDescription': \"The number of participants who enroll and fully participate in the program will be used to measure the feasibility of using SMART-PD for patients with Parkinson's disease and their caregivers.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'One year'},\n",
              "         {'PrimaryOutcomeMeasure': 'SMART Group Feedback Form',\n",
              "          'PrimaryOutcomeDescription': 'Designed to assess the accessibility of the SMART-PD program, The SMART Group Feedback form contains six Likert-scale questions such as, \"On a 10-point scale, how would you rate the following items: helpfulness/effectiveness of SMART group\" and four open-ended questions such as, \"What has been the most helpful part of the group for you?\"',\n",
              "          'PrimaryOutcomeTimeFrame': 'Eight weeks'},\n",
              "         {'PrimaryOutcomeMeasure': 'Change from Baseline General Quality of Life at 1-week post-intervention',\n",
              "          'PrimaryOutcomeDescription': 'The Short Form Health Survey (SF-36) is a quality of life measure that assesses eight aspects of health through the use of 36 multiple choice, yes/no, and Likert-scale items. An example question is, \"Compared to one year ago, how would you rate your health in general now?\" The SF-36 consists of eight scales (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health). Scores are converted into z-scores with a scale of 0-100 with 0 indicating the greatest level of disability and 100 the least.',\n",
              "          'PrimaryOutcomeTimeFrame': '1-week post-intervention'},\n",
              "         {'PrimaryOutcomeMeasure': \"Change from Baseline Parkinson's disease Quality of Life at 1-week post-intervention\",\n",
              "          'PrimaryOutcomeDescription': 'The Parkinson\\'s Disease Quality of Life Questionnaire (PDQ-39) consists of 39 Likert-scale questions asking how often in the last month the participant experienced something due to having Parkinson\\'s disease. An example question is, \"Had difficulty doing leisure activities which you would like to do?\" with response options for all questions being \"never\", \"occasionally\", \"sometimes\", \"Often\", and \"always or cannot do at all\". The overall score from the PDQ-39 can be used for a global assessment, and scores can also be broken down into the following individual scales: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communications and bodily discomfort.',\n",
              "          'PrimaryOutcomeTimeFrame': '1-week post-intervention'},\n",
              "         {'PrimaryOutcomeMeasure': 'Change from Baseline Healthy Lifestyle Behaviors at 1-week post-intervention',\n",
              "          'PrimaryOutcomeDescription': 'The Lifestyle Profile II contains 52 Likert-scale items pertaining to healthy lifestyle behaviors in the areas of healthy eating, physical activity, spirituality, stress management, health responsibility, and interpersonal relations. Respondents are asked to indicate the frequency with which they engage in behaviors with the response options of \"Never\", \"Sometimes\", \"Often\", and \"Routinely\". An example question is, \"Take some time for relaxation each day.\" Scores range from 52-208 and fall into the categories of poor (52-90), moderate (91-129), good (130-168), an excellent (169-208).',\n",
              "          'PrimaryOutcomeTimeFrame': '1-week post-intervention'},\n",
              "         {'PrimaryOutcomeMeasure': 'Change from Baseline Caregiver Burden at 1-week post-intervention',\n",
              "          'PrimaryOutcomeDescription': 'The Zarit Burden Interview Short Form (ZBI-12) is designed to measure caregiver burden and consists of 12 Likert-scale items that ask respondents to if they feel a certain way \"Never\", \"Rarely\", \"Sometimes\", \"Quite Frequently\" or \"Nearly Always\". An example question is, \"That because of the time you spend with your relative that you don\\'t have enough time for yourself?\" Scores range from 0-48 and are grouped into the categories of mild burden (0-10), mild to moderate burden (10-20), and high burden (>20).',\n",
              "          'PrimaryOutcomeTimeFrame': '1-week post-intervention'},\n",
              "         {'PrimaryOutcomeMeasure': 'Change from Baseline cognitive functioning at 1-week post-intervention',\n",
              "          'PrimaryOutcomeDescription': 'The Montreal Cognitive Assessment (MoCA) is a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Examples of questions include drawing a clock at ten past eleven and serial subtraction starting at 100. Scores on the MoCA range form 0-30 with a score of 26 or higher generally considered normal.',\n",
              "          'PrimaryOutcomeTimeFrame': '1-week post-intervention'},\n",
              "         {'PrimaryOutcomeMeasure': 'Change from Baseline Coping at 1-week post-intervention',\n",
              "          'PrimaryOutcomeDescription': 'Ways of Coping is a 66 Likert-scale item instrument that assesses behaviors used to cope with everyday stressful encounters. Response options are \"Not Used\", \"Used Somewhat\", \"Used Quite A Bit\", and \"Used A Great Deal\". Respondents are asked to describe a stressful situation they experienced in the past week and to respond to each item asking to what extent they used that way of coping in that situation. Examples of items are, \"Turned to work or substitute activity to take my mind off things\" and \"Found new faith\". The items comprise eight scales: confrontive coping, distancing, self-controlling, seeking social support, accepting responsibility, escape-avoidance, planful problem solving, and positive reappraisal.',\n",
              "          'PrimaryOutcomeTimeFrame': '1-week post-intervention'},\n",
              "         {'PrimaryOutcomeMeasure': 'Change from Baseline Depression Symptoms at 1-week post-intervention',\n",
              "          'PrimaryOutcomeDescription': 'The Patient Health Questionnaire (PHQ-9) is used to measure depressive symptoms. The nine Likert-scale items have response options of, \"Not at all\", \"Several days\", \"More than half the days\", and \"Nearly every day\" and include questions such as, \"Little interest or pleasure in doing things\" and \"Poor appetite or overeating.\" Scores range from 0-27 with 0 indicating no depression and five bands of scores ranges indicating minimal (1-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe depression (20-27).',\n",
              "          'PrimaryOutcomeTimeFrame': '1-week post-intervention'},\n",
              "         {'PrimaryOutcomeMeasure': 'Change from Baseline Anxiety Symptoms at 1-week post-intervention',\n",
              "          'PrimaryOutcomeDescription': 'The Generalized Anxiety Disorder (GAD-7) consists of seven Likert-scale items designed to measure anxiety. Response options are, \"Not at all\", \"Several Days\", \"More than half the days\", and \"Nearly every day\" and item examples are, \"Trouble relaxing\" and \"Becoming easily annoyed or irritated\". Scores range form 0-21 with scores of 8 or higher indicating a probable anxiety disorder.',\n",
              "          'PrimaryOutcomeTimeFrame': '1-week post-intervention'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nDiagnosis of Parkinson's Disease within the past three years or caregiver of someone with a recent diagnosis of Parkinson's disease\\nAbility to participate in 8 weekly program sessions via Microsoft Teams or in-person (as available)\\nAbility to provide informed consent\\n\\nExclusion Criteria:\\n\\nPrevious participation in the SMART program\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Lucero Molina',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '631-632-3797',\n",
              "          'CentralContactEMail': 'lucero.molina@stonybrookmedicine.edu'},\n",
              "         {'CentralContactName': 'Sandra Skinner, PhD',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '631-444-7513',\n",
              "          'CentralContactEMail': 'sandra.skinner@stonybrookmedicine.edu'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Adam Gonzalez, PhD',\n",
              "          'OverallOfficialAffiliation': 'Stony Brook Medical Center',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Stony Brook Medical Center',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Stony Brook',\n",
              "          'LocationState': 'New York',\n",
              "          'LocationZip': '11794',\n",
              "          'LocationCountry': 'United States'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 17,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04176302',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'INV_PROC_A118'},\n",
              "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'DTS17/00195',\n",
              "          'SecondaryIdType': 'Other Grant/Funding Number',\n",
              "          'SecondaryIdDomain': 'Instituto de Salud Carlos III - European Regional Development Fund (ERDF)'}]},\n",
              "       'Organization': {'OrgFullName': \"Consorci Sanitari de l'Alt Peneds i Garraf\",\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Monitoring of Mobility of Parkinson's Patients for Therapeutic Purposes - Clinical Trial\",\n",
              "       'OfficialTitle': \"Monitoring of Mobility of Parkinson's Patients for Therapeutic Purposes - Clinical Trial\",\n",
              "       'Acronym': 'MoMoPa-EC'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'April 2021',\n",
              "       'OverallStatus': 'Recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'November 26, 2019',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 30, 2022',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'December 30, 2022',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'November 18, 2019',\n",
              "       'StudyFirstSubmitQCDate': 'November 21, 2019',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 25, 2019',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'March 9, 2022',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 10, 2022',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': \"Consorci Sanitari de l'Alt Peneds i Garraf\",\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Instituto de Salud Carlos III',\n",
              "          'CollaboratorClass': 'OTHER_GOV'},\n",
              "         {'CollaboratorName': 'European Regional Development Fund',\n",
              "          'CollaboratorClass': 'OTHER'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"When Parkinson Disease is mild, it responds well to treatment with drugs (L-Dopa and dopamine antagonists). However, as the disease progresses, the effect of the drugs diminishes and lasts for a shorter time (wearing-off), which require physicians to progressively increase and/or break up the dosage of dopamine drugs, to control symptoms over the course of the entire day. Despite this, most patients present motor fluctuations after 10 years. These fluctuations consist of changes between what are known as Off periods, when the medication does not produce an effect and mobility is hindered, and On periods when patients can move smoothly, with the medication producing its best effect.\\n\\nThe timeline of these motor fluctuations over the course of the day and also on different days is very valuable to precisely adjust the medication. Nevertheless, neurologists do not currently have detailed information on the timeline of the symptoms of their patients, which means that they have serious difficulties to obtain good results with the adjustment of medication. Currently, the neurologist's information on the time progression of the motor fluctuations is drawn from what the patient indicates in the office visit, or in the best case, from diaries that the patient fills out at home, periodically (e.g. every hour) noting the motor state (On or Off). Although the latter method is still the gold standard in research and in care, it has serious limitations, because patients often forget to record the information (especially when they are in Off), many do not recognize their motor states well, and few can maintain adherence to such a laborious system for more than a few days.\\n\\nThe Parkinson Holter (STAT-ON ) is a wearable device, which objectively measures and records the motor fluctuations of the patients. It does not require intervention by the patient, and can, therefore, be used in daily life, long term if necessary. However, the concept that detailed knowledge of motor fluctuations of patients will lead to better control of the disease, thanks to optimisation of the therapeutic regimen, is still a hypothesis. To demonstrate or refute this hypothesis, we are now conducting a clinical trial, with this medical device, to study the clinical effectiveness in patients with moderate Parkinson's disease and motor fluctuations. This trial will show whether using the Parkinson Holter is better than the clinical interview used in traditional clinical practice (primary objective), and whether it is not inferior to the On-Off diary recorded by the patients at home (exploratory objective)\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': ['Motor fluctuation',\n",
              "         'Parkinson',\n",
              "         'Accelerometer',\n",
              "         'Parkinson diary']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Diagnostic',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Triple',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
              "           'Investigator',\n",
              "           'Outcomes Assessor']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '162',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Parkinson Holter',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': 'The neurologists in the study will receive information from the Parkinson Holter (device being studied)',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Parkinson Holter']}},\n",
              "         {'ArmGroupLabel': \"Parkinson's diary\",\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': 'The neurologists in the study will receive information from a motor fluctuations diary',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Motor fluctuations diary']}},\n",
              "         {'ArmGroupLabel': 'Traditional clinical practice',\n",
              "          'ArmGroupType': 'Placebo Comparator',\n",
              "          'ArmGroupDescription': 'The neurologists in the study will receive no additional information other than what is obtained during the visit',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Traditional clinical practice']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
              "          'InterventionName': 'Parkinson Holter',\n",
              "          'InterventionDescription': \"The neurologists will receive the wearable report (for medication adjustment, if any as per physician's criteria/judgement)\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Parkinson Holter']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['STAT-ON  sensor']}},\n",
              "         {'InterventionType': 'Diagnostic Test',\n",
              "          'InterventionName': 'Motor fluctuations diary',\n",
              "          'InterventionDescription': \"The neurologists will receive the patient's diary report (for medication adjustment, if any as per physician's criteria/judgement).\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Parkinson's diary\"]},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': [\"Parkinson's diary\"]}},\n",
              "         {'InterventionType': 'Other',\n",
              "          'InterventionName': 'Traditional clinical practice',\n",
              "          'InterventionDescription': \"The neurologists will receive the patient & caregiver report at the time of the visit (for medication adjustment, if any as per physician's criteria/judgement).\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Traditional clinical practice']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['Clinical interview']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Daily time in Off',\n",
              "          'PrimaryOutcomeDescription': 'Changes from baseline to last visit in daily hours in Off',\n",
              "          'PrimaryOutcomeTimeFrame': '7 days'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Number of clinical contacts',\n",
              "          'SecondaryOutcomeDescription': 'Number of patient visits and telephone controls to adjust medication',\n",
              "          'SecondaryOutcomeTimeFrame': '6 months'},\n",
              "         {'SecondaryOutcomeMeasure': \"Patient's adherence to the MF measurement system\",\n",
              "          'SecondaryOutcomeDescription': 'Total hour/days with information registered.',\n",
              "          'SecondaryOutcomeTimeFrame': '7 days'},\n",
              "         {'SecondaryOutcomeMeasure': 'Number of therapeutic changes.',\n",
              "          'SecondaryOutcomeDescription': 'Number of therapeutic changes done to improve symptoms.',\n",
              "          'SecondaryOutcomeTimeFrame': '6 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Motor complications',\n",
              "          'SecondaryOutcomeDescription': \"Changes from baseline to last visit in motor complications, assessed by means of Unified Parkinson's Disease Rating Scale - part IV\",\n",
              "          'SecondaryOutcomeTimeFrame': '6 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Daily time in On',\n",
              "          'SecondaryOutcomeDescription': 'Changes from baseline to last visit in daily hours in On',\n",
              "          'SecondaryOutcomeTimeFrame': '7 days'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change of presence and severity of freezing of gait episodes',\n",
              "          'SecondaryOutcomeDescription': 'Changes from baseline to last visit in the number and severity of freezing of gait episodes, assessed by means of Freezing of Gait Questionnaire',\n",
              "          'SecondaryOutcomeTimeFrame': '7 days'},\n",
              "         {'SecondaryOutcomeMeasure': 'Reported quality of life',\n",
              "          'SecondaryOutcomeDescription': \"Changes from baseline to last visit in quality of life, assessed by menas of Parkinson's Disease Questionnaire-39\",\n",
              "          'SecondaryOutcomeTimeFrame': '1 month'},\n",
              "         {'SecondaryOutcomeMeasure': 'Activities of Daily Living',\n",
              "          'SecondaryOutcomeDescription': \"Changes from baseline to last visit in dependence for Activities of Daily Living assessed by means of Unified Parkinson's Disease Rating Scale - part II\",\n",
              "          'SecondaryOutcomeTimeFrame': '6 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'User satisfaction: Quebec User Evaluation of Satisfaction with assistive Technology',\n",
              "          'SecondaryOutcomeDescription': 'Physician and patient satisfaction with the Parkinson Holter will be assessed by means of the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST)',\n",
              "          'SecondaryOutcomeTimeFrame': '7 days'},\n",
              "         {'SecondaryOutcomeMeasure': 'System usability: System Usability Scale',\n",
              "          'SecondaryOutcomeDescription': 'Usability of the system will be assessed by System Usability Scale (SUS)',\n",
              "          'SecondaryOutcomeTimeFrame': '7 days'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nIdeopathic Parkinson's Disease\\nDisease in the moderate-severe phase (Hoehn & Yahr  2 en Off)\\nMotor fluctuations (with at least 2h/day in Off)\\nAgree to participate voluntarily and will sign a written consent form\\n\\nExclusion Criteria:\\n\\nIncapable of walking independently or H&Y=5\\nParticipating in another clinical trial\\nPatients with acute intercurrent disease\\nPsychiatric or cognitive disorders that prevent collaboration (MMSE <24)\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Alejandro Rodrguez-Molinero, PhD/MD',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '34-938940025',\n",
              "          'CentralContactEMail': 'arodriguez@csapg.cat'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Alejandro Rodrguez-Molinero, PhD/MD',\n",
              "          'OverallOfficialAffiliation': \"Consorci Sanitari de l'Alt Peneds i Garraf\",\n",
              "          'OverallOfficialRole': 'Study Director'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': \"Hospital General de l'Hospitalet. CS Integral\",\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Hospitalet de Llobregat',\n",
              "          'LocationState': 'Barcelona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Asuncin vila, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Consorci Sanitari del Maresme. Hospital de Matar',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Matar',\n",
              "          'LocationState': 'Barcelona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Pilar M Sanz Cartagena, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitari Mtua Terrassa',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Terrassa',\n",
              "          'LocationState': 'Barcelona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Pau Pastor, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'},\n",
              "            {'LocationContactName': 'Maria Teresa Buongiorno, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': \"Consorci Sanitari de l'Alt Peneds i Garraf\",\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Vilafranca Del Peneds',\n",
              "          'LocationState': 'Barcelona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Alfons Moral, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario Marqus de Valdecilla',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Santander',\n",
              "          'LocationState': 'Cantabria',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jon Infante Ceberio, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital General La Mancha-Centro, Alczar de San Juan',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Alczar De San Juan',\n",
              "          'LocationState': 'Ciudad Real',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Marta Recio Bermejo, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario Lucus August',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Lugo',\n",
              "          'LocationState': 'Galicia',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jessica Gonzlez Ardura, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario de Donostia',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Donostia',\n",
              "          'LocationState': 'Guipzkoa',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Javier Ruz Martnez, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario Fundacin Alcorcn',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Alcorcn',\n",
              "          'LocationState': 'Madrid',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lydia M Vela Desojo, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario Puerta de Hierro, Majadahonda',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Majadahonda',\n",
              "          'LocationState': 'Madrid',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Pilar Snchez Alonso, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Univesitario Virgen de la Arrixaca',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'El Palmar',\n",
              "          'LocationState': 'Murcia',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jos Mara Lpez, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital lvaro Cunqueiro',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Vigo',\n",
              "          'LocationState': 'Pontevedra',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Antonio Kouloulis Fernndez, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Verge de la Cinta',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Tortosa',\n",
              "          'LocationState': 'Tarragona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Sonia M Escalante Arroyo, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital General de Elche',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Alicante',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Mara lvarez Saco, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital General Universitario de Alicante',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Alicante',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Silvia Mart Martnez, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitari Germans Trias i Pujol',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Badalona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lourdes M Ispierto Gonzlez, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital de la Santa Creu i Sant Pau',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Barcelona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Alexandre Gironell Carrer, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital del Mar',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Barcelona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Vctor M Puente Periz, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Moiss Broggi - CS Integral',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Barcelona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Nuria Caballol Pons, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Sanitas CIMA',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Barcelona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Pilar M Quilez Ferrer, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': \"Hospital Universitari Vall d'Hebron\",\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Barcelona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jorge Hernndez-Vara, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Terapia Integral UParkinson, SL',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Barcelona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Angels M Bays Rusiol, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario de Burgos',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Burgos',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Esther M Cubo Delgado, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitari dr. Josep Trueta',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Girona',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Berta M Solano Vila, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario Juan Ramn Jimnez',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Huelva',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Juan Manuel Oropesa Ruiz, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Clnico San Carlos',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Madrid',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Roco Garca Ramos, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario 12 de Octubre',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Madrid',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'David A Prez-Martnez, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario del Henares',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Madrid',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Elvira Garca Cobos, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario Fundacin Jimnez Daz',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Madrid',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Pedro J. Garca Ruz Espiga, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario La Moraleja',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Madrid',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Esteban M Pea Llamas, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario La Princesa',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Madrid',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lydia M Lpez Manzanares, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario Ramn y Cajal',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Madrid',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Juan Carlos Martnez-Castrillo, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Regional Universitario de Mlaga',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Mlaga',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Teresa Muoz Ruiz, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario Virgen de la Victoria',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Mlaga',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'M Jos Gmez Heredia, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario Infanta Sofa',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'San Sebastin De Los Reyes',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Marina M Mata lvarez-Santullano, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital General Parc Sanitari Sant Joan de Du',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Sant Boi De Llobregat',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Antoni M Calln Soto, Phd/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitari General de Catalunya',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Sant Cugat Del Valls',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ernest M Balaguer Martnez, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Universitario Virgen del Roco',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Sevilla',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Pablo Mir Rivera, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Consorci Sanitari de Terrassa',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Terrassa',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Gabriel M Salazar Tortolero, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Virgen de la Salud',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Toledo',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Nria Lpez Ariztegui, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Clnico Universitario de Valencia',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Valencia',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jos Mara Salom, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital de Llria',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Valencia',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'M Pilar Sols Prez, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Hospital Royo de Vilanova',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Zaragoza',\n",
              "          'LocationCountry': 'Spain',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Alfredo Lpez Lpez, PhD/MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '34281918',\n",
              "          'ReferenceType': 'derived',\n",
              "          'ReferenceCitation': \"Rodrguez-Molinero A, Hernndez-Vara J, Miarro A, Prez-Lpez C, Bayes-Rusiol , Martnez-Castrillo JC, Prez-Martnez DA; Monitoring Parkinson's patients Mobility for therapeutic purposes research group. Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinson's symptoms against other clinical monitoring methods: study protocol. BMJ Open. 2021 Jul 19;11(7):e045272. doi: 10.1136/bmjopen-2020-045272.\"}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 18,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02283073',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'PDx001'},\n",
              "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '82/14',\n",
              "          'SecondaryIdType': 'Other Identifier',\n",
              "          'SecondaryIdDomain': 'Assaf HaRofeh'},\n",
              "         {'SecondaryId': 'TASMC -14-TG-0489-14-TLV-CTIL',\n",
              "          'SecondaryIdType': 'Other Identifier',\n",
              "          'SecondaryIdDomain': 'Tel Aviv Sourasky Medical Center'},\n",
              "         {'SecondaryId': '1735-14-SMC',\n",
              "          'SecondaryIdType': 'Other Identifier',\n",
              "          'SecondaryIdDomain': 'Sheba Medical Center'},\n",
              "         {'SecondaryId': '0463-14-RMB',\n",
              "          'SecondaryIdType': 'Other Identifier',\n",
              "          'SecondaryIdDomain': 'Rambam Health Care Campus'}]},\n",
              "       'Organization': {'OrgFullName': 'Bio Shai Ltd.',\n",
              "        'OrgClass': 'INDUSTRY'},\n",
              "       'BriefTitle': \"Study for the Early Diagnosis of Parkinson's Disease\",\n",
              "       'OfficialTitle': \"PDx Biomarker Assay Study for the Diagnosis of Parkinson's Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'July 2018',\n",
              "       'OverallStatus': 'Unknown status',\n",
              "       'LastKnownStatus': 'Active, not recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'November 2014'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2019',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'December 2019',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'October 27, 2014',\n",
              "       'StudyFirstSubmitQCDate': 'November 2, 2014',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 5, 2014',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'July 9, 2018',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 10, 2018',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Bio Shai Ltd.',\n",
              "        'LeadSponsorClass': 'INDUSTRY'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"The main objective of the study is to design and validate the blood based PDx gene expression and miRNA assay for the early diagnosis of Parkinson's disease patients. Differential diagnosis includes patients with Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration, Lewy Body Dementia, Essential Tremor and Normal Controls.\",\n",
              "       'DetailedDescription': \"In this study, the PDx assay will be designed and validated in order to distinguish between Idiopathic Parkinson's disease (PD) to patients with similar symptoms and healthy controls. The differential diagnosis cohort includes patients diagnosed with Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Essential Tremor (ET) or Lewy Body Dementia (LBD) and Healthy Controls.\\n\\nThis is a prospective observational study. Blood samples and clinical data will be collected at the first and only study visit. The expression levels of 5 to 6 genes will be analyzed by blinding technicians concerning the diagnosis, demographic data and clinical data, which will be revealed after sending PDx gene expression values to the clinical sites. The gene expression levels will be compared between Parkinson's disease patients to the differential diagnosis cohort and healthy controls. Additional mRNA and miRNA markers will be explored. The primary aim of the study is to design and validate a clinical classifier that will aid the physician in the diagnosis of Parkinson's disease patients. The analysis will be performed in two stages: Stage 1) Exploration analysis and Stage 2) Validation. After one year of taking a blood sample, the study physician will contacted to confirm the patient's diagnosis.\\n\\nBlood samples will be collected at specialized movement disorder clinics.\\n\\nMedical history, clinical diagnostic features, family history in regard to Parkinson's disease, use of medication and routine imaging assessment (not mandatory) will be collected at the first and only patient visit.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease, Idiopathic\"]},\n",
              "       'KeywordList': {'Keyword': ['Diagnosis']}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'No',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
              "       'BioSpec': {'BioSpecRetention': 'Samples Without DNA',\n",
              "        'BioSpecDescription': 'The mRNA in blood samples will be transcribed to cDNA.'},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '410',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Idiopathic Parkinson's disease\",\n",
              "          'ArmGroupDescription': \"Patient with clinical diagnosis of Idiopathic Parkinson's Disease according to Queen Square Brain Bank Criteria up to one year prior to enrollment in study.\"},\n",
              "         {'ArmGroupLabel': 'Differential Diagnosis Group',\n",
              "          'ArmGroupDescription': 'MSA, PSP, CBD, Lewy body dementia, Essential Tremor, and Healthy Controls'}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"The Diagnostic Accuracy of PDx mRNA Assay in Diagnosing Idiopathic Parkinson's Disease\",\n",
              "          'PrimaryOutcomeDescription': \"Investigate the diagnostic accuracy of the PDx gene expression assay, comprised of 5-6 expressed genes (mRNA - RQ-PCR), to differentiate patients with Idiopathic Parkinson's disease from the Differential Diagnosis Group. Diagnostic Accuracy includes sensitivity, specificity, likelihood ratios and the area under the receiver operating characteristic (ROC) curve. Diagnostic Accuracy will be calculated by comparing the PDx assay results to the Gold Standard Diagnosis, which will be the Clinical diagnosis of the Patient one year after the first and only visit (day of blood collection). The physician investigator will be contacted if there was any change in the baseline diagnosis one year after blood collection according to routine clinical findings.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'One year from enrollment'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Diagnostic Accuracy of each one of the PDx assay's expressed genes for Differentiating Idiopathic Parkinson's Disease Patients from Atypical Parkinsonism Patients.\",\n",
              "          'SecondaryOutcomeDescription': \"Investigate the diagnostic accuracy (sensitivity, specificity, likelihood ratios and AUC) of each one of the PDx assay expressed genes (RQ-PCR) to differentiate Idiopathic Parkinson's Disease Patients from Atypical Parkinsonism Patients.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'One year from enrollment'},\n",
              "         {'SecondaryOutcomeMeasure': \"Diagnostic Accuracy of each one of the PDx assay's expressed genes for Differentiating Idiopathic Parkinson's Disease Patients from Essential Tremor Patients.\",\n",
              "          'SecondaryOutcomeDescription': \"Investigate the diagnostic accuracy (sensitivity, specificity, likelihood ratios and AUC) of each one of the PDx assay expressed genes (RQ-PCR) to differentiate Idiopathic Parkinson's Disease Patients from Essential Tremor Patients.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'One year from enrollment'},\n",
              "         {'SecondaryOutcomeMeasure': \"Diagnostic Accuracy of each one of the PDx assay's expressed genes for Differentiating Idiopathic Parkinson's Disease Patients from Healthy Controls.\",\n",
              "          'SecondaryOutcomeDescription': \"Investigate the diagnostic accuracy (sensitivity, specificity, likelihood ratios and AUC) of each one of the PDx assay expressed genes (RQ-PCR) to differentiate Idiopathic Parkinson's Disease Patients from Healthy Controls.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'One year from enrollment'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nPatient is able and willing to read the informed consent form\\nPatient with clinical diagnosis of Idiopathic Parkinson's Disease according to Queen Square Brain Bank Criteria up to one year prior to enrollment in study\\nPatient with diagnosis of MSA, PSP, CBD, Lewy Body Dementia, Essential Tremor or Healthy Control\\nMen and Women aged 40-80 years\\nWilling and able to comply with procurement of blood sample\\n\\nExclusion Criteria:\\n\\nAny medical, psychiatric or other conditions which, in the opinion of the investigator, would preclude participation\\nPregnancy\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '40 Years',\n",
              "       'MaximumAge': '80 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': 'Movement disorder clinics',\n",
              "       'SamplingMethod': 'Probability Sample'},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Ofer Gonen, MD',\n",
              "          'OverallOfficialAffiliation': 'Assaf-Harofeh Medical Center',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Rambam Health Care Campus',\n",
              "          'LocationCity': 'Haifa',\n",
              "          'LocationZip': '31096,',\n",
              "          'LocationCountry': 'Israel'},\n",
              "         {'LocationFacility': 'Rabin Medical Center',\n",
              "          'LocationCity': 'Petach Tikvah',\n",
              "          'LocationZip': '4941492',\n",
              "          'LocationCountry': 'Israel'},\n",
              "         {'LocationFacility': 'Tel Aviv Sourasky Medical Center',\n",
              "          'LocationCity': 'Tel Aviv',\n",
              "          'LocationZip': '64239',\n",
              "          'LocationCountry': 'Israel'},\n",
              "         {'LocationFacility': 'Chaim Sheba Medical Center',\n",
              "          'LocationCity': 'Tel HaShomer',\n",
              "          'LocationZip': '52621',\n",
              "          'LocationCountry': 'Israel'},\n",
              "         {'LocationFacility': 'Assaf Harofeh Medical Center',\n",
              "          'LocationCity': 'Tsrifin',\n",
              "          'LocationZip': '70300',\n",
              "          'LocationCountry': 'Israel'},\n",
              "         {'LocationFacility': 'Pisa University Hospital',\n",
              "          'LocationCity': 'Pisa',\n",
              "          'LocationZip': '56126',\n",
              "          'LocationCountry': 'Italy'}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '23279440',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):16-34. doi: 10.1111/ene.12022. Review. Erratum in: Eur J Neurol. 2013 Feb;20(2):406.\"}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 19,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02917122',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'A-BR-103-079'},\n",
              "       'Organization': {'OrgFullName': 'National Cheng-Kung University Hospital',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease\",\n",
              "       'Acronym': \"Parkinson's\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'September 2021',\n",
              "       'OverallStatus': 'Terminated',\n",
              "       'WhyStopped': 'Funding is insufficient.',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'August 2015'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2021',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'August 2021',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'June 30, 2016',\n",
              "       'StudyFirstSubmitQCDate': 'September 27, 2016',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 28, 2016',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'ResultsFirstSubmitDate': 'August 26, 2021',\n",
              "       'ResultsFirstSubmitQCDate': 'September 22, 2021',\n",
              "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'October 20, 2021',\n",
              "        'ResultsFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'September 22, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 20, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Kao Chin, Chen',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'assistant professor',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'National Cheng-Kung University Hospital'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'National Cheng-Kung University Hospital',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Parkinson's disease (PD) is one of the most common neurological diseases manifested by movement disturbance. The concomitant psychiatric symptoms, especially depression, are often observed and have also great impact on patients' quality of life. The treatment of depressive symptoms in PD with antidepressants as the majority remains variable and inefficient, which complicates the disease prognosis. Transcranial direct current stimulation (tDCS) is a non-invasive brain modulation technique and has been demonstrated to improve psychiatric diseases such as major depression. In this study the investigators will assess the combined effects of tDCS on sertraline for the treatment of depression in PD. Ten sessions of tDCS in two weeks will be applied and the follow-up evaluation will continue bi-weekly for one month after completing all sessions. The efficacy of tDCS vs sertraline will be compared and evaluated with behavioral and cognitive outcome. In addition, the investigators will evaluate if the baseline dopaminergic activity in brain could predict the treatment outcome by using SPECT imaging. The investigators aim to establish the therapeutic parameters and safety criteria of tDCS as an add-on or alternative therapy, and further enhance the overall clinical efficacy in the treatment of depression in PD.\",\n",
              "       'DetailedDescription': \"Study design\\n\\nThis study is a factorial randomized, placebo-control trial, including 2 groups: 'sertraline only' (sertraline + sham tDCS), and 'combined treatment' (sertraline + active tDCS). It is planned to recruit 20 subjects for each group, which results in all together 40 participants. Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment. Both pharmacological and tDCS intervention will be started simultaneously on the first day of the treatment.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease',\n",
              "         'Depression']},\n",
              "       'KeywordList': {'Keyword': ['Parkinson disease',\n",
              "         'transcranial direct current stimulation',\n",
              "         'depression',\n",
              "         'dopamine transporter',\n",
              "         'single photon emission computerized tomography']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Phase 1', 'Phase 2']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '15',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'sertraline + sham tDCS',\n",
              "          'ArmGroupType': 'Placebo Comparator',\n",
              "          'ArmGroupDescription': 'Patients will take sham tDCS.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Sertraline',\n",
              "            'Device: sham tDCS']}},\n",
              "         {'ArmGroupLabel': 'sertraline + active tDCS',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': 'Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: active tDCS',\n",
              "            'Drug: Sertraline']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
              "          'InterventionName': 'active tDCS',\n",
              "          'InterventionDescription': 'Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['sertraline + active tDCS']}},\n",
              "         {'InterventionType': 'Drug',\n",
              "          'InterventionName': 'Sertraline',\n",
              "          'InterventionDescription': 'Patients will take Sertraline.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['sertraline + active tDCS',\n",
              "            'sertraline + sham tDCS']}},\n",
              "         {'InterventionType': 'Device',\n",
              "          'InterventionName': 'sham tDCS',\n",
              "          'InterventionDescription': 'Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['sertraline + sham tDCS']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Change of Modified-Unified Parkinson's Disease Rating Scale Among Different Weeks\",\n",
              "          'PrimaryOutcomeDescription': \"mds: modified-Unified Parkinson's Disease\\n\\nmds1 non-motor experiences of daily living: summed, 0-52 mds2 motor experiences of daily living: summed, 0-52 mds3 motor examination: summed, 0-132 mds4 motor complications: summed, 0-24\\n\\nhigher value is worse\",\n",
              "          'PrimaryOutcomeTimeFrame': 'week 0 and 6'},\n",
              "         {'PrimaryOutcomeMeasure': 'Change of Hamilton Rating Scale for Depression Among Different Weeks',\n",
              "          'PrimaryOutcomeDescription': 'Hamilton Rating Scale for Depression: summed, 0-50\\n\\nhigher value is worse',\n",
              "          'PrimaryOutcomeTimeFrame': 'week 0 and 6'},\n",
              "         {'PrimaryOutcomeMeasure': 'Change of Taiwanese Depression Questionnaire Among Different Weeks',\n",
              "          'PrimaryOutcomeDescription': 'Taiwanese Depression Questionnaire: summed, 0-54\\n\\nhigher value is worse',\n",
              "          'PrimaryOutcomeTimeFrame': 'week 0 and 6'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nIn the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.\\nThe participant or, when applicable, the participant\\'s legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.\\nSuffers from Parkinson\\'s disease fulfill the Parkinson\\'s Disease Society Brain Bank clinical criteria with insidious 2 or more PD symptoms (bradykinesia, tremor, or rigidity).\\nSuffers from \"DSM-IV major depressive disorder, single episode\" or \"DSM-IV major depressive disorder, recurrent\" according to Diagnostic & Statistical Manual of Mental Disorders, 4th Edition - Text Revision (DSM-IV-TR) criteria.\\nReported duration of the current episode is 4 weeks and has not been treated with antidepressants.\\nHas a Montgomery-sberg Depression Rating Scale (MADRS) total score 20 at the screening (baseline) visit.\\nIs a man or woman aged 18 to 75 years, inclusive.\\n\\nExclusion criteria:\\n\\nSubjects known to have allergies to sertraline and pimozide.\\nSubjects showed any signs of substantial risk of suicide during the trial.\\nSubjects ever received electroconvulsive treatment.\\nSubjects co-morbid with other major mental disorders or with substance/alcohol dependence or abuse in the past 6 months per DSM-IV criteria.\\nNursing women, pregnant women or patients suspected pregnant.\\nHistory or presence of clinically significant hepatic, cardiovascular or renal disease, or other serious medical disease that might compromise the study.\\nHistory of seizure disorder or need to taking medications that increase the risk of seizure.\\nHistory or presence of dementia and any previous history of brain tumor, brain arteriovenous malformation, encephalitis or meningitis.\\nSubjects ever received or plan to receive brain surgery during the trial.\\nSubjects with pacemaker or are contraindicated for MRI.',\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'MaximumAge': '75 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kao Chin Chen, PhD',\n",
              "          'OverallOfficialAffiliation': 'National Cheng-Kung University Hospital',\n",
              "          'OverallOfficialRole': 'Study Chair'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
              "          'FlowGroupTitle': 'Sertraline + Sham tDCS',\n",
              "          'FlowGroupDescription': 'Patients will take sham tDCS.\\n\\nSertraline: Patients will take Sertraline.\\n\\nsham tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.'},\n",
              "         {'FlowGroupId': 'FG001',\n",
              "          'FlowGroupTitle': 'Sertraline + Active tDCS',\n",
              "          'FlowGroupDescription': 'Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.\\n\\nactive tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.\\n\\nSertraline: Patients will take Sertraline.'}]},\n",
              "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
              "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '8'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '7'}]}},\n",
              "            {'FlowMilestoneType': 'COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '8'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '7'}]}},\n",
              "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '0'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '0'}]}}]}}]}},\n",
              "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
              "          'BaselineGroupTitle': 'Sertraline + Sham tDCS',\n",
              "          'BaselineGroupDescription': 'Patients will take sham tDCS.\\n\\nSertraline: Patients will take Sertraline.\\n\\nsham tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.'},\n",
              "         {'BaselineGroupId': 'BG001',\n",
              "          'BaselineGroupTitle': 'Sertraline + Active tDCS',\n",
              "          'BaselineGroupDescription': 'Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.\\n\\nactive tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.\\n\\nSertraline: Patients will take Sertraline.'},\n",
              "         {'BaselineGroupId': 'BG002',\n",
              "          'BaselineGroupTitle': 'Total',\n",
              "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
              "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
              "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
              "             'BaselineDenomCountValue': '8'},\n",
              "            {'BaselineDenomCountGroupId': 'BG001',\n",
              "             'BaselineDenomCountValue': '7'},\n",
              "            {'BaselineDenomCountGroupId': 'BG002',\n",
              "             'BaselineDenomCountValue': '15'}]}}]},\n",
              "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous',\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'years',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '62.00',\n",
              "                   'BaselineMeasurementSpread': '8.50'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '61.86',\n",
              "                   'BaselineMeasurementSpread': '9.82'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '61.93',\n",
              "                   'BaselineMeasurementSpread': '8.80'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineMeasureCalculatePct': 'No',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '8'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '3'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '11'}]}},\n",
              "               {'BaselineCategoryTitle': 'Male',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '4'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '4'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Race/Ethnicity, Customized',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineMeasureCalculatePct': 'No',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Asian',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '8'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '7'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '15'}]}}]}}]}}]}},\n",
              "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': \"Change of Modified-Unified Parkinson's Disease Rating Scale Among Different Weeks\",\n",
              "          'OutcomeMeasureDescription': \"mds: modified-Unified Parkinson's Disease\\n\\nmds1 non-motor experiences of daily living: summed, 0-52 mds2 motor experiences of daily living: summed, 0-52 mds3 motor examination: summed, 0-132 mds4 motor complications: summed, 0-24\\n\\nhigher value is worse\",\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'score on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'week 0 and 6',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Sertraline + Sham tDCS',\n",
              "             'OutcomeGroupDescription': 'Patients will take sham tDCS.\\n\\nSertraline: Patients will take Sertraline.\\n\\nsham tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Sertraline + Active tDCS',\n",
              "             'OutcomeGroupDescription': 'Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.\\n\\nactive tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.\\n\\nSertraline: Patients will take Sertraline.'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '6'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '4'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'mds1 non-motor experiences of daily living-week0',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '9.00',\n",
              "                   'OutcomeMeasurementSpread': '5.48'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '10.00',\n",
              "                   'OutcomeMeasurementSpread': '4.83'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'mds1 non-motor experiences of daily living-week6',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '6.17',\n",
              "                   'OutcomeMeasurementSpread': '3.43'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '8.25',\n",
              "                   'OutcomeMeasurementSpread': '3.10'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'mds2 motor experiences of daily living-week0',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '5.33',\n",
              "                   'OutcomeMeasurementSpread': '3.50'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '2.25',\n",
              "                   'OutcomeMeasurementSpread': '2.06'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'mds2 motor experiences of daily living-week6',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '2.17',\n",
              "                   'OutcomeMeasurementSpread': '1.33'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '4.75',\n",
              "                   'OutcomeMeasurementSpread': '3.20'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'mds3 motor examination-week0',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '23.50',\n",
              "                   'OutcomeMeasurementSpread': '12.93'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '18.75',\n",
              "                   'OutcomeMeasurementSpread': '6.40'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'mds3 motor examination-week6',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '22.17',\n",
              "                   'OutcomeMeasurementSpread': '10.34'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '19.50',\n",
              "                   'OutcomeMeasurementSpread': '5.00'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'mds4 motor complications-week0',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '0.50',\n",
              "                   'OutcomeMeasurementSpread': '1.22'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '2.75',\n",
              "                   'OutcomeMeasurementSpread': '3.77'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'mds4 motor complications-week6',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1.00',\n",
              "                   'OutcomeMeasurementSpread': '1.55'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '1.25',\n",
              "                   'OutcomeMeasurementSpread': '2.50'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': 'Change of Hamilton Rating Scale for Depression Among Different Weeks',\n",
              "          'OutcomeMeasureDescription': 'Hamilton Rating Scale for Depression: summed, 0-50\\n\\nhigher value is worse',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'score on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'week 0 and 6',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Sertraline + Sham tDCS',\n",
              "             'OutcomeGroupDescription': 'Patients will take sham tDCS.\\n\\nSertraline: Patients will take Sertraline.\\n\\nsham tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Sertraline + Active tDCS',\n",
              "             'OutcomeGroupDescription': 'Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.\\n\\nactive tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.\\n\\nSertraline: Patients will take Sertraline.'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '5'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '6'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'week0',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '21.83',\n",
              "                   'OutcomeMeasurementSpread': '4.79'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '27.40',\n",
              "                   'OutcomeMeasurementSpread': '4.22'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'week6',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '5.83',\n",
              "                   'OutcomeMeasurementSpread': '4.36'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '10.20',\n",
              "                   'OutcomeMeasurementSpread': '7.69'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': 'Change of Taiwanese Depression Questionnaire Among Different Weeks',\n",
              "          'OutcomeMeasureDescription': 'Taiwanese Depression Questionnaire: summed, 0-54\\n\\nhigher value is worse',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'score on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'week 0 and 6',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Sertraline + Sham tDCS',\n",
              "             'OutcomeGroupDescription': 'Patients will take sham tDCS.\\n\\nSertraline: Patients will take Sertraline.\\n\\nsham tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Sertraline + Active tDCS',\n",
              "             'OutcomeGroupDescription': 'Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.\\n\\nactive tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.\\n\\nSertraline: Patients will take Sertraline.'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '6'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '5'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'week0',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '25.50',\n",
              "                   'OutcomeMeasurementSpread': '11.64'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '24.80',\n",
              "                   'OutcomeMeasurementSpread': '11.19'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'week6',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '14.83',\n",
              "                   'OutcomeMeasurementSpread': '12.34'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '18.60',\n",
              "                   'OutcomeMeasurementSpread': '16.01'}]}}]}}]}}]}},\n",
              "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
              "       'EventsTimeFrame': 'week -1, 0, 2, 4, 6',\n",
              "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
              "          'EventGroupTitle': 'Sertraline + Sham tDCS',\n",
              "          'EventGroupDescription': 'Patients will take sham tDCS.\\n\\nSertraline: Patients will take Sertraline.\\n\\nsham tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.',\n",
              "          'EventGroupDeathsNumAffected': '0',\n",
              "          'EventGroupDeathsNumAtRisk': '8',\n",
              "          'EventGroupSeriousNumAffected': '0',\n",
              "          'EventGroupSeriousNumAtRisk': '8',\n",
              "          'EventGroupOtherNumAffected': '0',\n",
              "          'EventGroupOtherNumAtRisk': '8'},\n",
              "         {'EventGroupId': 'EG001',\n",
              "          'EventGroupTitle': 'Sertraline + Active tDCS',\n",
              "          'EventGroupDescription': 'Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.\\n\\nactive tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.\\n\\nSertraline: Patients will take Sertraline.',\n",
              "          'EventGroupDeathsNumAffected': '0',\n",
              "          'EventGroupDeathsNumAtRisk': '7',\n",
              "          'EventGroupSeriousNumAffected': '0',\n",
              "          'EventGroupSeriousNumAtRisk': '7',\n",
              "          'EventGroupOtherNumAffected': '0',\n",
              "          'EventGroupOtherNumAtRisk': '7'}]}},\n",
              "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
              "        'AgreementRestrictiveAgreement': 'No'},\n",
              "       'PointOfContact': {'PointOfContactTitle': 'Dr. Kao Chin Chen',\n",
              "        'PointOfContactOrganization': 'National Cheng Kung University',\n",
              "        'PointOfContactEMail': 'andchen@mail.ncku.edu.tw',\n",
              "        'PointOfContactPhone': '+886-6-2353535',\n",
              "        'PointOfContactPhoneExt': '5213'}}},\n",
              "     'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'Prot_SAP_ICF',\n",
              "          'LargeDocHasProtocol': 'Yes',\n",
              "          'LargeDocHasSAP': 'Yes',\n",
              "          'LargeDocHasICF': 'Yes',\n",
              "          'LargeDocLabel': 'Study Protocol, Statistical Analysis Plan, and Informed Consent Form',\n",
              "          'LargeDocDate': 'November 21, 2017',\n",
              "          'LargeDocUploadDate': '09/22/2021 19:55',\n",
              "          'LargeDocFilename': 'Prot_SAP_ICF_000.pdf'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'},\n",
              "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
              "         {'ConditionMeshId': 'D000003866',\n",
              "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
              "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
              "         {'ConditionAncestorId': 'D000019964',\n",
              "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001523',\n",
              "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
              "         {'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6213',\n",
              "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
              "          'ConditionBrowseLeafAsFound': 'Depression',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M6210',\n",
              "          'ConditionBrowseLeafName': 'Depression',\n",
              "          'ConditionBrowseLeafAsFound': 'Depression',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M3970',\n",
              "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20988',\n",
              "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M13625',\n",
              "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3967',\n",
              "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
              "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}},\n",
              "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000020280',\n",
              "          'InterventionMeshTerm': 'Sertraline'}]},\n",
              "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000928',\n",
              "          'InterventionAncestorTerm': 'Antidepressive Agents'},\n",
              "         {'InterventionAncestorId': 'D000011619',\n",
              "          'InterventionAncestorTerm': 'Psychotropic Drugs'},\n",
              "         {'InterventionAncestorId': 'D000017367',\n",
              "          'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'},\n",
              "         {'InterventionAncestorId': 'D000014179',\n",
              "          'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'},\n",
              "         {'InterventionAncestorId': 'D000049990',\n",
              "          'InterventionAncestorTerm': 'Membrane Transport Modulators'},\n",
              "         {'InterventionAncestorId': 'D000045504',\n",
              "          'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'},\n",
              "         {'InterventionAncestorId': 'D000018377',\n",
              "          'InterventionAncestorTerm': 'Neurotransmitter Agents'},\n",
              "         {'InterventionAncestorId': 'D000018490',\n",
              "          'InterventionAncestorTerm': 'Serotonin Agents'},\n",
              "         {'InterventionAncestorId': 'D000045505',\n",
              "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]},\n",
              "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M6625',\n",
              "          'InterventionBrowseLeafName': 'Dopamine',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M21253',\n",
              "          'InterventionBrowseLeafName': 'Sertraline',\n",
              "          'InterventionBrowseLeafAsFound': 'Pregnant women',\n",
              "          'InterventionBrowseLeafRelevance': 'high'},\n",
              "         {'InterventionBrowseLeafId': 'M3399',\n",
              "          'InterventionBrowseLeafName': 'Antidepressive Agents',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M13626',\n",
              "          'InterventionBrowseLeafName': 'Psychotropic Drugs',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M14664',\n",
              "          'InterventionBrowseLeafName': 'Serotonin',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M18801',\n",
              "          'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M19657',\n",
              "          'InterventionBrowseLeafName': 'Neurotransmitter Agents',\n",
              "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
              "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'CaAg',\n",
              "          'InterventionBrowseBranchName': 'Cardiotonic Agents'},\n",
              "         {'InterventionBrowseBranchAbbrev': 'All',\n",
              "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'},\n",
              "         {'InterventionBrowseBranchAbbrev': 'PsychDr',\n",
              "          'InterventionBrowseBranchName': 'Psychotropic Drugs'}]}}}}},\n",
              "   {'Rank': 20,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02012647',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '21-2013'},\n",
              "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '40115065-2',\n",
              "          'SecondaryIdType': 'Other Identifier',\n",
              "          'SecondaryIdDomain': 'UF Research and Compliance Number'}]},\n",
              "       'Organization': {'OrgFullName': 'University of Florida',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Evaluating Cortical Physiology Following Unilateral and Bilateral Subthalamic Deep Brain Stimulation in Parkinson's Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'September 2020',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'August 2013'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2016',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'June 2016',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'November 1, 2013',\n",
              "       'StudyFirstSubmitQCDate': 'December 10, 2013',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 16, 2013',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'September 8, 2020',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 9, 2020',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'University of Florida',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
              "      'DescriptionModule': {'BriefSummary': \"The purpose of this study is to examine the brain changes in people with Parkinson's Disease (PD) after they get deep brain stimulation (DBS) surgery, compared with people who do not have Parkinson's Disease. Treatment of Parkinson's disease is often difficult and challenging. Deep brain stimulation is an established surgical treatment that is effective for the treatment of PD, but the details of why it helps are not known. In order to achieve maximum benefits from this treatment, it is important to understand how it changes the brain. Specifically, the investigators will study electrophysiology, which is the study of how the brain conducts electrical messages to the rest of the body. To do this, the investigators will use transcranial magnetic stimulation (TMS), which is a painless and non-invasive procedure. They will also conduct motor physiology experiments of the upper and lower limbs to collect data about skeletal muscle movement. The data from this study will help explain whether the electrical changes in the brain have any relation to the physical benefits patients with Parkinson's Disease sometimes receive from DBS surgery.\",\n",
              "       'DetailedDescription': \"Screening evaluation: The Investigators will ask questions to see if the participant qualifies to be in the study. The screening visit will occur up to 4 months before the first study visit, and can be scheduled to occur on the same day as the first study visit. This evaluation will include a review of medical history and clinical findings related to Parkinson's Disease (if applicable). There may be a neurological exam (physical exam). Women of child bearing potential will take a urine pregnancy test. If applicable, the medications currently used to treat Parkinson's Disease symptoms will be reviewed and subjects will be asked to discontinue them for some hours on the days of the study visits. The investigators do not expect concerns or unwanted consequences arising either from discontinuing the Parkinson's Disease medications or turning off the DBS stimulator for the duration of time proposed in the study.\\n\\nParticipants will be studied under 4 conditions, over a span of as few as two days to as long as two months. The four Conditions are : 1) The DBS stimulator will be turned OFF for both sides. 2) The DBS stimulator will be turned ON for the right side. 3) The DBS stimulator will be turned ON for the left side. 4) The DBS stimulator will be turned ON for both sides. The order of these conditions will be picked randomly.\\n\\nParticipants will be asked not to take PD medications for approximately 12 hours prior to the scheduled visit time, and until after the physiological testing.\\n\\nHealthy controls will be studied on only one occasion, as they do not have DBS.\\n\\nTests performed for each study condition:\\n\\nParkinson's Participants Only: A neurological examination will be performed by administering several clinical scaled. These clinical scales include the Unified Parkinson's Disease Rating Scale (UPDRS), the self-report Parkinson's Disease Quality of life scale (PDQ-39), MMSE instrument for cognitive (or memory) testing, and Beck Depression Inventory (BDI II) for evaluation of mood and depressive symptoms. The PDQ-39, MMSE, and BDI will each only be administered once and therefore will not be repeated at every study visit.\\nThe investigators will determine individual motor evoked potential (MEP) thresholds before beginning the study treatment. MEP will be recorded from a muscle located between the right thumb and index finger, and then from the left thumb and index finger. MEP threshold refers to the amount of stimulation to the brain that is required to activate muscle cells enough to appear on an electromyography (EMG), which records electrical potential in muscle through electrodes placed on the skin.\\nThe investigators will use TMS to test motor cortex functions. For these tests, participants will sit in a chair that looks like the one at the dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp.\\nThe investigators will collect data about the muscles of both the upper and lower limbs with a wireless EMG procedure. To do this, small wireless sensors will be placed on the skin over both arm and leg muscles. Participants will be asked to sit in a chair and perform movements with the upper and lower limbs while the EMG records measurements about movement activity. This procedure will be conducted separately for the upper and lower limbs.\\nParticipants who have provided consent will be videotaped during the visits.\\nSide effects and adverse events pertaining to this study will be recorded at each visit.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': ['parkinson',\n",
              "         'PD',\n",
              "         'parkinson disease',\n",
              "         \"parkinson's\",\n",
              "         \"parkinson's disease\",\n",
              "         'parkinsons',\n",
              "         'parkinsons disease',\n",
              "         'TMS',\n",
              "         'DBS',\n",
              "         'transcranial magnetic stimulation',\n",
              "         'deep brain stimulation']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Early Phase 1']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Other',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '4', 'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'People with Parkinsons Disease',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': \"Participants have been diagnosed with Parkinson's Disease, and as recommended by their physicians, have undergone DBS surgery for both sides of the brain. These participants will undergo TMS and motor physiology testing, and results will be compared to participants without Parkinson's Disease.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Transcranial Magnetic Stimulation (TMS)',\n",
              "            'Procedure: Motor Physiology Testing']}},\n",
              "         {'ArmGroupLabel': 'Healthy Controls',\n",
              "          'ArmGroupType': 'Placebo Comparator',\n",
              "          'ArmGroupDescription': \"These participants do not have Parkinson's Disease, nor have they had DBS surgery, and are a healthy controls. These participants will undergo TMS and motor physiology testing, and results will be compared to participants with Parkinson's Disease.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Transcranial Magnetic Stimulation (TMS)',\n",
              "            'Procedure: Motor Physiology Testing']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Procedure',\n",
              "          'InterventionName': 'Transcranial Magnetic Stimulation (TMS)',\n",
              "          'InterventionDescription': \"Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy Controls',\n",
              "            'People with Parkinsons Disease']}},\n",
              "         {'InterventionType': 'Procedure',\n",
              "          'InterventionName': 'Motor Physiology Testing',\n",
              "          'InterventionDescription': 'Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy Controls',\n",
              "            'People with Parkinsons Disease']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Motor Cortex Excitability',\n",
              "          'PrimaryOutcomeDescription': \"We will measure Motor Cortex Excitability by examining circuitries of inhibition found in the motor cortex which have a reduced function in Parkinson's Disease.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'As few as 1 days and up to 4 months'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Relation between Unified Parkinson's Disease Rating Scale outcomes and physiological measures\",\n",
              "          'SecondaryOutcomeDescription': \"The Unified Parkinson's Disease Rating Scale (UPDRS) is used by neurologists to rate the motor impairment of people with Parkinson's Disease. The rater obtains the score by observation and questioning the participant. Higher scores represent greater impairment and scores range from 0-108.\\n\\nThe data collected from the UPDRS will be compared to physiological data collected with EMG during limb movement tasks. These tasks are used to gather data about skeletal muscle movements. The EMG data will be evaluated individually with an EMG paradigm considering velocity of movement and both antagonist and agonist burst patterns.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'As few as 2 days and up to 4 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Transcallosal Pathway Excitability',\n",
              "          'SecondaryOutcomeDescription': 'The investigators will examine the effects of unilateral and bilateral stimulation on the excitability of transcallosal pathway, using specific parameters of Transcranial Magnetic Stimulation (TMS).',\n",
              "          'SecondaryOutcomeTimeFrame': 'As few as 2 days and up to 4 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Physiological Measures',\n",
              "          'SecondaryOutcomeDescription': 'Physiological data will be collected from healthy controls with EMG during limb movement tasks. These tasks are used to gather data about skeletal muscle movements. The EMG data will be evaluated individually with an EMG paradigm considering velocity of movement and both antagonist and agonist burst patterns.',\n",
              "          'SecondaryOutcomeTimeFrame': 'One day'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAged 18-80 years\\nDiagnosis of Parkinson's Disease with bilateral subthalamic nucleus (STN) DBS\\n\\nExclusion Criteria:\\n\\nCardiac pacemakers\\nNeed for diathermy\\nRepeat MRI scanning\\nAnticoagulant therapy\\nPrevious neuro surgical procedure or ablative therapy\\nFrank dementia according to cognitive screening\\nHistory of seizures\\nPregnancy\\nPresence of a terminal illness\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'MaximumAge': '80 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Aparna Wagle Shukla, MD',\n",
              "          'OverallOfficialAffiliation': 'University of Florida Center for Movement Disorders and Neurorestoration',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'University of Florida',\n",
              "          'LocationCity': 'Gainesville',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '32607',\n",
              "          'LocationCountry': 'United States'}]}},\n",
              "      'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'UF Center for Movement Disorders & Neurorestoration',\n",
              "          'SeeAlsoLinkURL': 'http://movementdisorders.ufhealth.org/'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 21,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04057794',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'PDGene-01'},\n",
              "       'Organization': {'OrgFullName': \"Parkinson's Foundation\",\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"PDGeneration: Mapping the Future of Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Parkinson's Foundation: PD Generation: Mapping the Future of Parkinson's Disease\",\n",
              "       'Acronym': 'PDGENE'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'March 2021',\n",
              "       'OverallStatus': 'Recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'August 15, 2019',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 15, 2024',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'April 15, 2025',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'August 6, 2019',\n",
              "       'StudyFirstSubmitQCDate': 'August 14, 2019',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 15, 2019',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'March 8, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 10, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': \"Parkinson's Foundation\",\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Rochester - CHeT/CTCC',\n",
              "          'CollaboratorClass': 'UNKNOWN'},\n",
              "         {'CollaboratorName': 'Fulgent Laboratories',\n",
              "          'CollaboratorClass': 'UNKNOWN'},\n",
              "         {'CollaboratorName': 'Indiana University',\n",
              "          'CollaboratorClass': 'OTHER'},\n",
              "         {'CollaboratorName': 'The Parkinson Study Group',\n",
              "          'CollaboratorClass': 'NETWORK'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'Yes',\n",
              "       'IsUnapprovedDevice': 'Yes',\n",
              "       'IsUSExport': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"To assess the feasibility, impact, and participant satisfaction of offering Clinical Laboratory Improvement Amendments (CLIA) certified genetic testing as part of clinical care for People with Parkinson's disease (PWP).\",\n",
              "       'DetailedDescription': \"The purpose of this study is to evaluate how offering Clinical Laboratory Improvement Amendments (CLIA) certified genetic testing for Parkinson's Disease (PD) genes to people with Parkinson's Disease impacts clinical care and potential enrollment in clinical trials. This multi-center study will assess the impact and satisfaction of the mode of genetic counseling by comparing counseling conducted by a clinician versus centralized genetic counseling conducted through Indiana University. The study will also assess knowledge gained by administering a knowledge survey pre- and post-genetic testing. All genetic test results will be returned to participants through a genetic counseling visit.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease and Parkinsonism\"]},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's\", 'Genetics', 'PD Genetics']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
              "        'DesignInterventionModel': 'Single Group Assignment',\n",
              "        'DesignInterventionModelDescription': 'All participants will undergo genetic counseling service post-genetic testing either locally or through central services.',\n",
              "        'DesignPrimaryPurpose': 'Screening',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '15000',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Site-Based Genetic Counseling',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': 'Participants randomized to this arm will receive genetic counseling for genetic results through the enrolling site.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Device: Lab Assay for seven genetic variants for Parkinson's Disease\"]}},\n",
              "         {'ArmGroupLabel': 'Centralized Genetic Counseling',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': 'Participants randomized to this arm will receive genetic counseling for genetic results through a centralized genetic counseling group at Indiana University.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Device: Lab Assay for seven genetic variants for Parkinson's Disease\"]}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
              "          'InterventionName': \"Lab Assay for seven genetic variants for Parkinson's Disease\",\n",
              "          'InterventionDescription': 'Counseling provided to participant by site clinician/physician/genetic counselor.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Site-Based Genetic Counseling']}},\n",
              "         {'InterventionType': 'Device',\n",
              "          'InterventionName': \"Lab Assay for seven genetic variants for Parkinson's Disease\",\n",
              "          'InterventionDescription': 'Counseling provided to participant by centralized genetic counseling group at Indiana University.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Centralized Genetic Counseling']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Feasibility',\n",
              "          'PrimaryOutcomeDescription': 'The total number of participants who receive genetic testing and counseling.',\n",
              "          'PrimaryOutcomeTimeFrame': 'up to 24 weeks'},\n",
              "         {'PrimaryOutcomeMeasure': 'Impact Evaluation',\n",
              "          'PrimaryOutcomeDescription': \"The impact of knowledge gained by people with Parkinson's by assessing returned survey responses regarding their behavior and follow-up to clinical care after receipt of genetic counseling.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'up to 6 months'},\n",
              "         {'PrimaryOutcomeMeasure': 'Satisfaction Comparison',\n",
              "          'PrimaryOutcomeDescription': 'Differences in satisfaction of receiving genetic test results and genetic counseling by enrolling site (clinician/genetic counselor) or centralized counseling group using the Clinical Genetic Counseling Satisfaction Score.',\n",
              "          'PrimaryOutcomeTimeFrame': 'up to 6 months'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Number of participants that enroll in precision medicine trials',\n",
              "          'SecondaryOutcomeDescription': 'Number of participants that enroll in precision medicine trials',\n",
              "          'SecondaryOutcomeTimeFrame': 'up to 12 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Time it takes between first contact to the return of genetic test results',\n",
              "          'SecondaryOutcomeDescription': 'Number of weeks it takes between participant consent to return of genetic test results.',\n",
              "          'SecondaryOutcomeTimeFrame': 'up to 12 months'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nMeet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease: probable diagnosis.\\nWillingness to undergo genetic testing, and choose to be informed of genetic testing results for Glucosylceramidase Beta (GBA), LRRK2 and 5 additional PD related genes (SNCA, VPS35, PRKN, PINK-1, PARK7).\\nCapacity to give full informed consent in writing, and have read and signed the informed consent forms (ICFs) based on clinician's determination.\\nAble to perform study activities (including completion of either online, in-person or paper surveys).\\nIndividuals must speak and understand the language of the informed consent.\\n\\nExclusion Criteria:\\n\\nDiagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome), including that due to medications, metabolic disorders, encephalitis, cerebrovascular disease, or normal pressure hydrocephalus.\\nIndividuals who have received a blood transfusion within the past 3 months.\\nIndividuals who have active hematologic malignancies such as lymphoma or leukemia.\\nIndividuals who have had a bone marrow transplant within the past 5 years.\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Elizabeth U Lyda, BS',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '585-273-4038',\n",
              "          'CentralContactEMail': 'elizabeth.lyda@chet.rochester.edu'},\n",
              "         {'CentralContactName': 'Karen C Hodgeman',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '585-273-5365',\n",
              "          'CentralContactEMail': 'karen.hodgeman@chet.rochester.edu'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Roy N Alcalay, MD, MS',\n",
              "          'OverallOfficialAffiliation': 'Columbia University',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Barrow Neurological Institute',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Phoenix',\n",
              "          'LocationState': 'Arizona',\n",
              "          'LocationZip': '85013',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Farah Ismail',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '602-406-3343',\n",
              "             'LocationContactEMail': 'farah.ismail@dignityhealth.org'},\n",
              "            {'LocationContactName': 'Ruby Rendon',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '602-406-7423',\n",
              "             'LocationContactEMail': 'ruby.rendon@dignityhealth.org'},\n",
              "            {'LocationContactName': 'Holly Shill, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'},\n",
              "            {'LocationContactName': 'Guillermo Moguel-Cobos, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'}]}},\n",
              "         {'LocationFacility': 'University of California San Diego (UCSD)',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'La Jolla',\n",
              "          'LocationState': 'California',\n",
              "          'LocationZip': '92093',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lisa Damron',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '858-822-5873',\n",
              "             'LocationContactEMail': 'ldamron@ucsd.edu'},\n",
              "            {'LocationContactName': 'Ileana Rubio',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '858-246-2505',\n",
              "             'LocationContactEMail': 'irubio@ucsd.edu'},\n",
              "            {'LocationContactName': 'Irene Litvan, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'},\n",
              "            {'LocationContactName': 'David Coughlin, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Brenton Wright, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Caitlin Mulligan, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Katherine Longardener, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'}]}},\n",
              "         {'LocationFacility': 'University of Miami',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Fort Lauderdale',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '33308',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Letty Ginsburg',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '954-629-1353',\n",
              "             'LocationContactEMail': 'lginsburg@miami.edu'},\n",
              "            {'LocationContactName': 'Carlos Singer, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Cleveland Clinic Florida-Weston',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Weston',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '33331',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Sheilla Jerome',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '954-659-5671',\n",
              "             'LocationContactEMail': 'jeromes@ccf.org'},\n",
              "            {'LocationContactName': 'Nestor Galvez-Jimenez, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'},\n",
              "            {'LocationContactName': 'Tarannum Khan, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'}]}},\n",
              "         {'LocationFacility': 'Northwestern University Feinberg School of Medicine',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Chicago',\n",
              "          'LocationState': 'Illinois',\n",
              "          'LocationZip': '60611',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Karen Williams',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '312-503-5645',\n",
              "             'LocationContactEMail': 'k-williams8@northwestern.edu'},\n",
              "            {'LocationContactName': 'Max Galarce',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '312-503-4270',\n",
              "             'LocationContactEMail': 'max.galarce@northwestern.edu'},\n",
              "            {'LocationContactName': 'Tanya Simuni, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'},\n",
              "            {'LocationContactName': 'Danny Bega, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Danielle Larson, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Niccolo Mencacci, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Neil Shetty, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'}]}},\n",
              "         {'LocationFacility': 'University of Kansas Medical Center',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Kansas City',\n",
              "          'LocationState': 'Kansas',\n",
              "          'LocationZip': '66160',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Patricia Brady, RN',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '913-588-0013',\n",
              "             'LocationContactEMail': 'pbrady3@kumc.edu'},\n",
              "            {'LocationContactName': 'April Langhammer',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'alanghammer@kumc.edu'},\n",
              "            {'LocationContactName': 'Rajesh Pahwa, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Massachusetts General Hospital',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Boston',\n",
              "          'LocationState': 'Massachusetts',\n",
              "          'LocationZip': '02129',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Remy Johnson',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '617-726-4936',\n",
              "             'LocationContactEMail': 'rhjohnson@mgh.harvard.edu'},\n",
              "            {'LocationContactName': 'Mansi Sharma',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '508-395-3479',\n",
              "             'LocationContactEMail': 'msharma13@mgh.harvard.edu'},\n",
              "            {'LocationContactName': 'Anne-Marie Wills, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'},\n",
              "            {'LocationContactName': 'Michael Schwartzschild, MD/PhD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Ann Hunt, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Albert Hung, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Todd Herrington, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Grace Crotty, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'}]}},\n",
              "         {'LocationFacility': \"Health Partners/Park Nicollet: Struthers Parkinson's Center\",\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Minneapolis',\n",
              "          'LocationState': 'Minnesota',\n",
              "          'LocationZip': '55427',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelsey Peirson',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '952-993-5903',\n",
              "             'LocationContactEMail': 'kelsey.peirson@parknicollet.com'},\n",
              "            {'LocationContactName': 'Martha Nance, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Beth Israel Medical Center',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'New York',\n",
              "          'LocationState': 'New York',\n",
              "          'LocationZip': '10003',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Deborah Raymond, CGC',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'draymond@chpnet.org'},\n",
              "            {'LocationContactName': 'Theresa Lin',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'theresa.lin@mountsinai.org'},\n",
              "            {'LocationContactName': 'Susan Bressman, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'},\n",
              "            {'LocationContactName': 'Rachel Saunders-Pullman, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'}]}},\n",
              "         {'LocationFacility': 'Columbia University',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'New York',\n",
              "          'LocationState': 'New York',\n",
              "          'LocationZip': '10032',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Amanda Chan',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '212-305-4233',\n",
              "             'LocationContactEMail': 'akc2177@cumc.columbia.edu'},\n",
              "            {'LocationContactName': 'Roy Alcalay, MD, MSC',\n",
              "             'LocationContactRole': 'Principal Investigator'},\n",
              "            {'LocationContactName': 'Linn Katus, DO',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Jill Goldman, CGC',\n",
              "             'LocationContactRole': 'Sub-Investigator'}]}},\n",
              "         {'LocationFacility': 'Cleveland Clinic',\n",
              "          'LocationStatus': 'Enrolling by invitation',\n",
              "          'LocationCity': 'Cleveland',\n",
              "          'LocationState': 'Ohio',\n",
              "          'LocationZip': '44195',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of Pennsylvania',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Philadelphia',\n",
              "          'LocationState': 'Pennsylvania',\n",
              "          'LocationZip': '19107',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Noah Han',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '215-829-6500',\n",
              "             'LocationContactEMail': 'noah.han@pennmedicine.upenn.edu'},\n",
              "            {'LocationContactName': 'Thomas Tropea, DO, MPH',\n",
              "             'LocationContactRole': 'Principal Investigator'},\n",
              "            {'LocationContactName': 'Andrew Siderowf, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Rachel Paul, CGC',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Tanya BARDAKJIAN, CGC',\n",
              "             'LocationContactRole': 'Sub-Investigator'}]}},\n",
              "         {'LocationFacility': 'Baylor College of Medicine',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Houston',\n",
              "          'LocationState': 'Texas',\n",
              "          'LocationZip': '77030',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Rory Mahabir',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'rory.mahabir@bcm.edu'},\n",
              "            {'LocationContactName': 'Mamie Hylton',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '713-798-8513',\n",
              "             'LocationContactEMail': 'mamie.hylton@bcm.edu'},\n",
              "            {'LocationContactName': 'Nora Vanegas-Arroyave, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'},\n",
              "            {'LocationContactName': 'Steven Bellows, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Joseph Jankovic, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Joshua Shulman, MD, PhD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Arjun Tarakad, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'}]}}]}},\n",
              "      'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'For more information and to enroll, please visit the website.',\n",
              "          'SeeAlsoLinkURL': 'http://www.parkinson.org/PDGENEration'}]}}},\n",
              "     'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'ICF',\n",
              "          'LargeDocHasProtocol': 'No',\n",
              "          'LargeDocHasSAP': 'No',\n",
              "          'LargeDocHasICF': 'Yes',\n",
              "          'LargeDocLabel': 'Informed Consent Form',\n",
              "          'LargeDocDate': 'June 3, 2020',\n",
              "          'LargeDocUploadDate': '09/09/2020 10:58',\n",
              "          'LargeDocFilename': 'ICF_000.pdf'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'},\n",
              "         {'ConditionMeshId': 'D000020734',\n",
              "          'ConditionMeshTerm': 'Parkinsonian Disorders'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafAsFound': 'Parkinsonism',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 22,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01835652',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'H13-00276'},\n",
              "       'Organization': {'OrgFullName': \"Pacific Parkinson's Research Centre\",\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"The Effects of Exercise in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"The Effects of Exercise in Parkinson's Disease.\",\n",
              "       'Acronym': 'PET'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'March 2021',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'April 2013'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2015',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'March 2015',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'April 16, 2013',\n",
              "       'StudyFirstSubmitQCDate': 'April 18, 2013',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 19, 2013',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'March 15, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 17, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'A. Jon Stoessl',\n",
              "        'ResponsiblePartyInvestigatorTitle': \"Director, Pacific Parkinson's Research Centre\",\n",
              "        'ResponsiblePartyInvestigatorAffiliation': \"Pacific Parkinson's Research Centre\"},\n",
              "       'LeadSponsor': {'LeadSponsorName': \"Pacific Parkinson's Research Centre\",\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Parkinson's disease is caused by a reduction of dopamine causing motor deficits. The investigators are studying how exercise can help PD patients by increasing dopamine release in an area of the brain that coordinates movement, the striatum. The investigators will enroll PD patients into two groups; one group will complete a 12-week aerobic exercise program and the other will complete a 12-week control program including yoga and stretching only. The investigators will measure changes in dopamine release before and after either 12-week intervention. Subjects will complete motor and cognitive questionnaires in addition to functional magnetic resonance imaging and positron emission tomography neuroimaging.\",\n",
              "       'DetailedDescription': \"The purpose of this study is to determine the basis for symptomatic and disease modifying benefits of exercise in Parkinson's disease (PD).\\n\\nAlthough the benefits of exercise in PD have been purported for several decades, only recently have there been controlled reports of symptomatic benefits in Parkinson's disease in terms of bradykinesia, postural balance and quality of life. There have been unsubstantiated suggestions that exercise may improve cognition and mood in PD.\\n\\nThe mechanisms underlying such benefits are poorly understood. Exercise may induce dopamine release, thereby contributing to improved motor function in the dorsal striatum, and to enhanced mood and reduced apathy in the ventral striatum.\\n\\nWe will test the hypotheses that exercise results in altered synaptic plasticity in the form of altered connectivity in response to aerobic exercise and reward-induced dopamine release. We will assess networks of functional connectivity using functional magnetic resonance imaging and measure dopamine release with positron emission tomography (PET).\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease 10']},\n",
              "       'KeywordList': {'Keyword': ['Exercise',\n",
              "         \"Parkinson's Disease\",\n",
              "         'Positron Emission Tomography',\n",
              "         'fMRI']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Basic Science',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '18',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Active Exercise',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': 'Aerobic Exercise Intervention (stationary cycling)',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Active Exercise']}},\n",
              "         {'ArmGroupLabel': 'Passive Exercise',\n",
              "          'ArmGroupType': 'Other',\n",
              "          'ArmGroupDescription': 'Passive Exercise (stretching and balance based exercise)',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Passive Exercise']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': 'Active Exercise',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Active Exercise']}},\n",
              "         {'InterventionType': 'Other',\n",
              "          'InterventionName': 'Passive Exercise',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Passive Exercise']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'PET',\n",
              "          'PrimaryOutcomeDescription': 'Dopamine release will be assessed using positron emission tomography (PET)',\n",
              "          'PrimaryOutcomeTimeFrame': '3 months'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'fMRI',\n",
              "          'SecondaryOutcomeDescription': 'fMRI will be performed to record response to rewarding stimuli',\n",
              "          'SecondaryOutcomeTimeFrame': '3 months'}]},\n",
              "       'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Clinical Measures',\n",
              "          'OtherOutcomeDescription': \"Motor function will be assessed using the MDS-Unified Parkinson's Disease Rating Scale, finger tapping and Purdue Pegboard. Cognitive function will be assessed using the Montreal Cognitive Assessment, Wisconsin Card-Sorting Task, Trail-Making B Test and a computerized reaction time test. Mood and apathy will be assessed using the Beck Depression Inventory and Starkstein Apathy Scale.\",\n",
              "          'OtherOutcomeTimeFrame': '3 months'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nIdiopathic PD according to UK Brain Bank criteria (modified to permit inclusion of subjects with a family history)\\nAges 40-70\\nMild to moderate Parkinsonism (Hoehn & Yahr stages I-III)\\n\\nExclusion Criteria:\\n\\nGeneral exclusion criteria will include:\\n\\nmore than 120 minutes per week of activities >3 MET or a score exceeding 4 on the \"Baseline Exercise Screening Tool\" (Appendix, Fig. 1);\\natypical Parkinson syndrome (progressive supranuclear palsy, multiple system atrophy, drug-induced etc.);\\nsignificant osteoporosis or arthritis;\\nother neurological disease (e.g. myopathy);\\nself-reports claustrophobia;\\nhistory of cancer within 5 years of study participation;\\nhigh dose of radiation from other procedures within the year;\\ntaking rasagiline or selegiline for PD therapy;\\ndiabetic;\\nnot able to tolerate being off PD medication for up to 24 hours;\\nBMI of 35 or more; and\\na female subject who is breast-feeding or pregnant.\\n\\nExclusion criteria for MRI scanning and magnetic stimulation from rTMS scanning includes:\\n\\nartificial heart valve;\\nbrain aneurysm clip;\\nelectrical stimulator for nerves or bones;\\near or eye implant;\\nimplanted drug infusion pump;\\ncoil, catheter, or filter in any blood vessel;\\northopedic hardware (artificial joint, plate, screws);\\nother metallic prostheses;\\nshrapnel, bullets, or other metal fragments;\\nsurgery or tattoos (including tattooed eyeliner) in the last six weeks;\\nhave a cardiac pacemaker, wires or defibrillator;\\nhave had an injury where a piece of metal lodged in your eye or orbit;\\nhave a ferromagnetic aneurysm clip; and\\nhave a history of seizures.\\n\\nSubjects may be excluded following study enrollment if they meet any of the following exclusion criteria:\\n\\nsignificant cognitive impairment (Montreal Cognitive Assessment score < 24) or depression (Beck Depression Inventory score > 18);\\nsignificant or unstable cardiovascular or respiratory disease - all subjects will undergo a screening exercise bicycle stress test; or\\nfailure to comply with the exercise or yoga/stretching intervention program, including missing 5 sessions or missing three sessions in a row.',\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '40 Years',\n",
              "       'MaximumAge': '70 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jessamyn McKenzie',\n",
              "          'OverallOfficialAffiliation': \"Pacific Parkinson's Research Centre\",\n",
              "          'OverallOfficialRole': 'Study Director'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': \"Pacific Parkinson's Research Centre\",\n",
              "          'LocationCity': 'Vancouver',\n",
              "          'LocationState': 'British Columbia',\n",
              "          'LocationZip': 'V6T 2B5',\n",
              "          'LocationCountry': 'Canada'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 23,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03830190',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'NICE-PD'},\n",
              "       'Organization': {'OrgFullName': 'Radboud University Medical Center',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': 'Cost-effectiveness of Nursing Interventions for Patients With PD',\n",
              "       'OfficialTitle': \"Cost-Effectiveness of Specialized Nursing Interventions for Patients With Parkinson's Disease\",\n",
              "       'Acronym': 'NICE-PD'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'October 2020',\n",
              "       'OverallStatus': 'Recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'January 7, 2019',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 1, 2022',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'October 31, 2022',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'December 20, 2018',\n",
              "       'StudyFirstSubmitQCDate': 'February 4, 2019',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 5, 2019',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'October 29, 2020',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 30, 2020',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Radboud University Medical Center',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'ZonMw: The Netherlands Organisation for Health Research and Development',\n",
              "          'CollaboratorClass': 'OTHER'},\n",
              "         {'CollaboratorName': 'Zambon SpA',\n",
              "          'CollaboratorClass': 'INDUSTRY'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Background: Current guidelines recommend that every person with Parkinson's disease (PD) should have access to Parkinson's Disease Nurse Specialist (PDNS) care. Thus, hospitals increasingly offer PDNS care to their patients with PD. However, there is currently little scientific evidence on the cost-effectiveness of PDNS care. Consequently, many hospitals lack the nursing capacity to offer PDNS care to all patients, which creates unequal access to care and possibly avoidable disability and costs.\\n\\nObjective: The investigators aim to study the (cost-)effectiveness of specialized nursing care provided by a PDNS as compared to no PDNS care for people with PD in all disease stages. To gain more insight into the used interventions and their effects, a subgroup analysis will be performed based on disease duration (diagnosis made <5, 5-10, or >10 years ago).\\n\\nMethods: The investigators will perform an 18-month, single-blind, randomized controlled clinical trial in eight community hospitals in the Netherlands. A total of 240 people with idiopathic PD that have not been treated by a PDNS over the past two years will be included, independent of disease severity or duration. In each hospital, 30 patients will randomly be allocated in a 1:1 ratio to either PDNS care according to the Dutch Guideline on PDNS care or no nursing intervention (continuing usual care). For the allocation of participants, a computer-generated list of random numbers will be used. The co-primary outcome measures are Quality of Life (QoL) and motor symptoms. Secondary outcomes include PD symptoms, mobility, non-motor symptoms, health-related quality of life, experienced quality of care, self-management, medication adherence, caregiver quality of life, coping skills and caregiver burden. Data will be collected after 12 months and 18 months. A healthcare utilization and productivity loss questionnaire will be completed every 3 months by both the patient and the caregiver.\\n\\nHypothesis: The investigators hypothesize that, by offering more patients access to PDNS care, QoL will increase with equal healthcare costs. Increasing direct medical costs (for nurse staffing) will be offset by a reduced number of consultations with the general practitioner and neurologist. If these outcomes are reached, wide implementation of PDNS care is needed.\",\n",
              "       'DetailedDescription': \"Background The Parkinson's Disease Nurse Specialist (PDNS) can fulfill a pivotal role in the multidisciplinary team of people with PD. The PDNS was introduced in 1989 in the United Kingdom to bridge the gap between medical management and the unique personal needs of patients. To obtain greater uniformity in care delivery by a PDNS and to facilitate the efficacy of nursing care in PD, the Dutch Guideline 'Nursing care in Parkinson's disease' was published in 2016. The main roles of the PDNS are clearly described in the Guideline, and include 1) providing information, education and instruction; 2) supporting the patient and caregiver in the promotion of self-management; 3) supporting psychosocial care questions; 4) prevention; 5) specialized diagnostic strategies and therapeutic nursing interventions; and 6) multidisciplinary collaboration.\\n\\nBased on expert opinion from healthcare professionals, the Dutch guideline advises that every person with PD could benefit from PDNS care, including those in early-stage disease where delivery of information, education about medication compliance and support in self-management are critical. So far, only three studies have evaluated PDNS care and they have found inconsistent results. Overall, they indicate that PDNS care may improve patient wellbeing, physical functioning and general health status and reduce anxiety and depression, but definite conclusions could not be drawn. Moreover, there is little evidence that shows that quality of life actually improves with PDNS care and to date, no studies have been performed that evaluated the cost-effectiveness of PDNS care.\\n\\nCurrently, most hospitals in The Netherlands offer PDNS care, since it is advised in the Dutch Multidisciplinary Guideline. However many centers still lack the nursing capacity to offer PDNS care to all patients because the scientific evidence is inconclusive. This situation creates an undesirable inequality in access to care and presumably leads to avoidable disability and costs (e.g. from early admissions to nursing homes or crisis admissions to the hospital). Therefore, the investigators aim to study the cost-effectiveness of specialized nursing care provided by a PDNS as compared to no PDNS care for people with PD.\\n\\nStudy design The NICE-PD study is an 18-month, single-blind randomized controlled clinical trial that will be performed in eight community hospitals in the Netherlands. A total of 240 people with PD will be included (120 in each group) and equally distributed over the participating hospitals. The investigators have selected hospitals where, due to lack of sufficient PDNS staff, only a proportion of PD patients currently has access to PDNS care. This provides the investigators with a unique opportunity to identify patients who at present have no access to PDNS care, and to randomize them within hospitals (at the patient level) between PDNS care and no nursing intervention.\\n\\nEligible patients will be allocated randomly to either PDNS care or usual care in a 1:1 ratio, using a computer-generated list of random numbers. To ascertain an equal representation of patients, the investigators will stratify for disease duration (according to pre-defined subgroups, i.e. disease duration <5 years, 5-10 years and >10 years). The PDNS intervention will be carried out according to the Dutch 'Guideline Nursing care in PD'. A blinded researcher will perform the clinical assessments at baseline (t0), after 12 months (t1) and after 18 months (t2). Patients and caregivers will also be asked to complete a set of questionnaires at t0, t1 and t2. Finally, every three months patients and their caregivers will complete an online questionnaire about healthcare utilization, costs and productivity loss.\\n\\nIntervention\\n\\nThe PDNS intervention will be performed according to the Dutch 'Guideline Nursing care in PD' published in 2015. The intervention is not standardized, but tailored to the patients' and caregivers' needs. This includes the following:\\n\\nAssessment of individual care needs of people with PD and their caregivers. The PDNS performs a specific nursing assessment related to the medical, physical, psychological and social domains.\\nDevelopment of a patient-centered treatment plan that supports the patient and caregiver in self-management. The PDNS composes a multidisciplinary plan, based on the results of the individual assessment, and as prioritized by the patient and caregiver (shared decision making). The treatment plan is developed according to the national self-management framework.\\nSpecific nursing interventions. The intervention varies across disease stages and is tailored to the specific problems and needs of individual patients and their caregivers. The Guideline on PDNS care describes general- and specific nursing interventions. General interventions consist of providing information and education, disease management (e.g. considering advanced treatment options such as DBS) and monitoring (e.g. of caregiver burden). Specific nursing interventions are described for the following areas: mental functions, fatigue, sleep, urogenital functions, sexuality, medication adherence, orthostatic hypotension, caregiver burden, coping, mobility, self-management and dietary issues (table 2 provides examples of such interventions).\\nCollaboration with other healthcare professionals. The PDNS stimulates and supports multidisciplinary collaboration between healthcare professionals based on the individual patient-centered treatment plan. The PDNS also plays a pivotal role in the timely referral to other healthcare professionals.\\n\\nThe PDNS will keep a pre-defined electronic study report according to a structured format for each PD patient, documenting the individual care needs, present symptoms, performed interventions and (changes in) the individual care plan. This report will be started at the initial assessment and updated at every follow-up contact with the patient, e.g. at the outpatient clinic, during a telephone consultation or at a home visit. This data will be purposefully collected for a possible process analysis at the end of the study.\\n\\nPatients will have regular contact with their PDNS about the progress and realization of the personal goals, both during face-to-face contacts and by telephone, and sometimes during additional home visits. The frequency and type of contact will be optimized for each patient depending on disease stage and individual patient needs. The Guideline on PDNS care advises that each patient has a minimum of one contact with the PDNS each year. Currently in the Netherlands, patients are seen on average twice a year by their PDNS, with an additional two interim telephone consultations per year.\\n\\nThe control group will receive ongoing/ usual care which is otherwise comparable, but without a nursing intervention. This involves regular consultations with a neurologist in their own community hospital (typically 2-4 times per year, depending on patient preferences and health status). In addition, control patients will have no other restrictions considering any other medical treatments (e.g. by a psychologist or social worker). Importantly, many important elements of care (including in particular the treating neurologist) remain comparable between the two intervention arms because of the randomization at patient level within hospitals.\\n\\nClinical assessments At baseline, t1 and t2 all patients will visit their own hospital for the study assessments which are performed by a blinded researcher (PDQ-39, MDS-UPDRS, and TUG). Furthermore, the patients and their caregivers will complete additional home questionnaires. In addition, every three months, patients will receive a questionnaire at home regarding healthcare utilization, costs and productivity loss over the past three months. Caregivers will complete a cost questionnaire including healthcare utilization, costs and productivity loss specifically related to caregiver burden. Patients can choose if they want to fill out digital or paper questionnaires.\\n\\nData analysis The economic evaluation investigates, alongside the clinical trial, the value for money of full implementation of the PDNS into PD care from a societal and healthcare perspective. The investigators will take all relevant costs into account. The cost-effectiveness timeframe adheres to the clinical study protocol and evaluates cost-effectiveness up to 18 months after randomization. Cost will be measured using a healthcare utilization questionnaire (e.g. including medical consultations, hospital admissions, medication, travel costs, etc.) and a questionnaire measuring productivity loss while working of both patients and caregivers. Per item of healthcare consumption, standard cost-prices will be determined using the guideline for performing economic evaluations. If standardized prices are not available, full cost prices will be determined using activity based costing. Costs will be analyzed using a mixed model approach or a general linear model approach with a gamma distribution using a log link to account for possible skewness of the cost data.\\n\\nThe investigators will use a PD-specific quality of life measure (PDQ-39) and a generic health-related quality of life scale (EQ5D) to evaluate the quality of the health status of patients. The potential difference in Quality-Adjusted Life Years (QALYs) measured with the EQ5D will be analyzed with a regression approach. The investigators will use a linear mixed model with repeated measurements to test for differences in quality of life (measured with the PDQ-39) between both groups. The same analysis will be used to measure differences between groups in the secondary outcome measures. The investigators will include study center as a random effect and fixed effects for group, time and the interaction between group and time. Each of the outcomes will be included as dependent variable. Statistical analyses will be performed based on the intention-to-treat principle.\\n\\nBesides the overall cost-effectiveness evaluation, the investigators will perform a pre-planned subgroup analysis based on disease duration (diagnosis made <5 years, 5-10 years or >10 years ago) to obtain more insight into the nursing interventions used in each disease stage and the effects of PDNS care in these different groups of patients. This subgroup analysis will be performed because, for example, for the more severely affected patients the nursing intervention is expected to become more intensive and possibly more effective, but also more expensive. When different patterns of this kind are found, this should be investigated further in future trials that are powered adequately to address such group differences.\\n\\nDiscussion The investigators hypothesize that offering PDNS care will lead to higher quality of life with equal healthcare costs. Increasing direct medical costs (for nurse staffing) are expected to be offset by a reduced number of (telephone) consultations with the general practitioner and neurologist. These short-term goals are the focus of the present NICE-PD proposal. In addition to the short-term effects, the investigators also expect long-term benefits, which are out of scope of the present project. Examples of potential long-term benefits include a reduction in the number of nursing home admissions and fewer emergency visits to the hospital, which would lead to a substantial cost reduction.\\n\\nIn conclusion, this study will generate new insights into the cost-effectiveness of specialized PD nursing interventions for people with PD. If positive results are found, a large shift in the organization of PD care is needed to warrant equal access to PDNS care for every person with PD.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's disease\",\n",
              "         \"Parkinson's disease nurse specialist\",\n",
              "         'Nursing',\n",
              "         'Quality of life',\n",
              "         'Cost-effectiveness',\n",
              "         'Multidisciplinary care']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignInterventionModelDescription': 'Randomized controlled trial with 2 study arms: the intervention group and the control group. Participants are allocated to each arm in a 1:1 ratio.',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
              "         'DesignMaskingDescription': \"Due to the type of intervention (Parkinson's disease nurse specialist care), the participant and care provider cannot be masked. The investigator and outcome assessor (conducting the questionnaires) will be blinded.\",\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator',\n",
              "           'Outcomes Assessor']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '240',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention group',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': \"Parkinson's disease nurse specialist care\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Other: Parkinson's disease nurse specialist care\"]}},\n",
              "         {'ArmGroupLabel': 'Control group',\n",
              "          'ArmGroupType': 'No Intervention',\n",
              "          'ArmGroupDescription': 'No intervention'}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': \"Parkinson's disease nurse specialist care\",\n",
              "          'InterventionDescription': \"Specialized nursing care provided by a Parkinson's disease nurse specialist\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention group']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['PDNS care']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Disease-specific health-related quality of life: Parkinson's disease Questionnaire (PDQ-39)\",\n",
              "          'PrimaryOutcomeDescription': \"Parkinson's disease Questionnaire (PDQ-39). Total score range: 0-100, including 8 subcategories. Subcategories are summed to compute the total score. A lower score means a better outcome.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline, change from baseline quality of life at 12 months, change from baseline quality of life at 18 months'},\n",
              "         {'PrimaryOutcomeMeasure': 'Motor symptoms',\n",
              "          'PrimaryOutcomeDescription': \"Movement Disorders Society-sponsored revision of the Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS part III). Total score range: 0-132. A lower score means a better outcome.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline, change from baseline motor symptoms at 12 months, change from baseline motor symptoms at 18 months'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Longitudinal Parkinson's disease symptoms\",\n",
              "          'SecondaryOutcomeDescription': \"Movement Disorders Society-sponsored revision of the Unified Parkinson's Disease Rating Scale part I, II, IV (MDS-UPDRS part I, II, IV). Total score range: 0-260 (including the MDS-UPDRS part III), including 4 subcategories. Subcategories are summed to compute the total score. A lower score means a better outcome.\",\n",
              "          'SecondaryOutcomeTimeFrame': \"Baseline, change from baseline Parkinson's disease symptoms at 12 months, change from baseline Parkinson's disease symptoms at 18 months\"},\n",
              "         {'SecondaryOutcomeMeasure': 'Mobility',\n",
              "          'SecondaryOutcomeDescription': 'Timed up and Go (TUG). A lower score means a better outcome.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline TUG at 12 months, change from baseline TUG at 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Non-motor symptoms (anxiety and depression)',\n",
              "          'SecondaryOutcomeDescription': 'Hamilton Anxiety and Depression Scale (HADS). Total score range: 0-21, including 2 subcategories. Subcategories are summed to compute the total score. A lower score means a better outcome.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, 12 months, 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Non-motor symptoms',\n",
              "          'SecondaryOutcomeDescription': \"Scales for Outcomes in Parkinson's disease - Autonomic Questionnaire (SCOPA-AUT). Total score range: 0-69, including 6 subcategories. Subcategories are summed to compute the total score. A lower score means a better outcome.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 12 months, change from baseline at 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Health-related quality of life: EuroQoL5D (EQ5D)',\n",
              "          'SecondaryOutcomeDescription': 'EuroQoL5D (EQ5D). Summary index with a maximum score of 1, including 5 dimensions. A higher score means a better outcome. In addition, there is a visual analogue scale (VAS) to indicate general health status with a total score range of 0-100. A higher score means a better outcome.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 12 months, change from baseline at 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Experienced quality of and experience with provided healthcare: Consumer Quality Index (CQI)',\n",
              "          'SecondaryOutcomeDescription': 'Consumer Quality Index (CQI). There is no minimum or maximum score (the measure consists of a number of qualitative and experience questions). Therefore, higher values do not correlate with a better or worse outcome.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 12 months, change from baseline at 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Self-management',\n",
              "          'SecondaryOutcomeDescription': 'Patient Activation Measure (PAM13). Total score range: 0-100, including a division in 4 activation levels. A higher score means a higher activation level (= the patient has made most of the necessary behavior changes to manage their disease).',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 12 months, change from baseline at 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Medication adherence',\n",
              "          'SecondaryOutcomeDescription': 'Morisky Medication Adherence Scale (MMAS). Total score range: 0-8. A higher score means a better outcome.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 12 months, change from baseline at 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Health-related quality of life of the caregiver: EuroQoL5D (EQ5D)',\n",
              "          'SecondaryOutcomeDescription': 'EuroQoL5D (EQ5D). Summary index with a maximum score of 1, including 5 dimensions. A higher score means a better outcome. In addition, there is a visual analogue scale (VAS) to indicate general health status with a total score range of 0-100. A higher score means a better outcome.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 12 months, change from baseline at 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Caregiver burden',\n",
              "          'SecondaryOutcomeDescription': 'Zarit Caregiver Burden Index (ZBI). Total score range: 0-88. A lower score means a better outcome.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 12 months, change from baseline at 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Caregiver quality of life: CarerQol-7D',\n",
              "          'SecondaryOutcomeDescription': 'CarerQol-7D. Total score range: 0-14 (weighted sum score: 0-100). A higher score means a better outcome. In addition, there is a visual analogue scale (VAS) to indicate general well-being with a total score range of 0-10. A higher score means a better outcome.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 12 months, change from baseline at 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Skills of proactive coping of the caregiver',\n",
              "          'SecondaryOutcomeDescription': 'Utrecht Proactive Coping Competence Scale (UPCC). Total score range: 21-84. A higher score means a better outcome.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 12 months, change from baseline at 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Medical consumption of the patient',\n",
              "          'SecondaryOutcomeDescription': 'Medical Consumption Questionnaire (MCQ). There is no minimum or maximum score, this scale is a generic instrument for measuring medical costs.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 3 months, 6 months, 9 months, 12 months, 15 months and 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Productivity loss of the patient',\n",
              "          'SecondaryOutcomeDescription': 'Productivity Cost Questionnaire (PCQ). There is no minimum or maximum score, this scale is a generic instrument to measure productivity losses related to the disease.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 3 months, 6 months, 9 months, 12 months, 15 months and 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Medical consumption of the caregiver related to providing care to the patient',\n",
              "          'SecondaryOutcomeDescription': 'Adjusted version of the Medical Consumption Questionnaire (MCQ). There is no minimum or maximum score, this scale is a generic instrument for measuring medical costs.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 3 months, 6 months, 9 months, 12 months, 15 months and 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Productivity loss of the caregiver related to providing care to the patient',\n",
              "          'SecondaryOutcomeDescription': 'Adjusted version of the Productivity Cost Questionnaire (PCQ). There is no minimum or maximum score, this scale is a generic instrument to measure productivity losses related to being a caregiver.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 3 months, 6 months, 9 months, 12 months, 15 months and 18 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Nighttime sleep problems and daytime sleepiness',\n",
              "          'SecondaryOutcomeDescription': \"Scales for Outcomes in Parkinson's disease - Sleep Questionnaire (SCOPA-SLEEP). Total score range: 0-33, including 2 subcategories. Subcategories are summed to compute the total score. A lower score means a better outcome.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline, change from baseline at 12 months, change from baseline at 18 months'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nA diagnosis of idiopathic PD;\\nSufficient knowledge of the Dutch language to fill out questionnaires;\\nAge 18 years or older at the time of diagnosis;\\nAll disease stages, regardless of disease severity or disease duration;\\nNot having received care from a PDNS in the past two years;\\nA score of  18 on the Mini-Mental State Examination (MMSE13) and  12 on the Frontal Assessment Battery (FAB14).\\n\\nExclusion Criteria:\\n\\nA type of atypical parkinsonism caused by medication (e.g. neuroleptics), a metabolic disorder (e.g. Wilson's disease), encephalitis or a neurodegenerative disorder (e.g. multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome).\\nResiding in a nursing home or another type of residential care facility (because the PDNS is not operational there).\\nAny other medical or psychiatric disorder that, in the opinion of the researcher, may compromise participation in the study.\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Nienke M de Vries, PhD',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '003124-3615213',\n",
              "          'CentralContactEMail': 'nienke.devries-farrouh@radboudumc.nl'},\n",
              "         {'CentralContactName': 'Danique LM Radder, MD',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '003124-3655345',\n",
              "          'CentralContactEMail': 'danique.radder@radboudumc.nl'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Bastiaan R Bloem, MD, PhD',\n",
              "          'OverallOfficialAffiliation': 'Department of Neurology, Radboudumc, Nijmegen, The Netherlands.',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Radboud University Medical Center, Department of Neurology',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Nijmegen',\n",
              "          'LocationState': 'Gelderland',\n",
              "          'LocationZip': '6525 GC',\n",
              "          'LocationCountry': 'Netherlands',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Nienke M de Vries, PhD',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '003124-3615213',\n",
              "             'LocationContactEMail': 'nienke.devries-farrouh@radboudumc.nl'},\n",
              "            {'LocationContactName': 'Danique LM Radder, MD',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '003124-3655345',\n",
              "             'LocationContactEMail': 'danique.radder@radboudumc.nl'},\n",
              "            {'LocationContactName': 'Bastiaan R Bloem, MD, PhD',\n",
              "             'LocationContactRole': 'Principal Investigator'},\n",
              "            {'LocationContactName': 'Nienke M de Vries, PhD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Danique LM Radder, MD',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Herma H Lennaerts, MSc',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Linda ter Brake, MSc',\n",
              "             'LocationContactRole': 'Sub-Investigator'},\n",
              "            {'LocationContactName': 'Marten Munneke, PhD',\n",
              "             'LocationContactRole': 'Sub-Investigator'}]}}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28800338',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Lennaerts H, Groot M, Rood B, Gilissen K, Tulp H, van Wensen E, Munneke M, van Laar T, Bloem BR. A Guideline for Parkinson's Disease Nurse Specialists, with Recommendations for Clinical Practice. J Parkinsons Dis. 2017;7(4):749-754. doi: 10.3233/JPD-171195. Review.\"},\n",
              "         {'ReferencePMID': '24487336',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Jahanshahi M, Brown RG, Whitehouse C, Quinn N, Marsden CD. Contact with a nurse practitioner: a short-term evaluation study in Parkinson's disease and dystonia. Behav Neurol. 1994;7(3):189-96. doi: 10.3233/BEN-1994-73-414.\"},\n",
              "         {'ReferencePMID': '10760541',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Reynolds H, Wilson-Barnett J, Richardson G. Evaluation of the role of the Parkinson's disease nurse specialist. Int J Nurs Stud. 2000 Aug;37(4):337-49.\"},\n",
              "         {'ReferencePMID': '11991913',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Jarman B, Hurwitz B, Cook A, Bajekal M, Lee A. Effects of community based nurses specialising in Parkinson's disease on health outcome and costs: randomised controlled trial. BMJ. 2002 May 4;324(7345):1072-5.\"},\n",
              "         {'ReferencePMID': '31941538',\n",
              "          'ReferenceType': 'derived',\n",
              "          'ReferenceCitation': \"Radder DLM, Lennaerts HH, Vermeulen H, van Asseldonk T, Delnooz CCS, Hagen RH, Munneke M, Bloem BR, de Vries NM. The cost-effectiveness of specialized nursing interventions for people with Parkinson's disease: the NICE-PD study protocol for a randomized controlled clinical trial. Trials. 2020 Jan 15;21(1):88. doi: 10.1186/s13063-019-3926-y.\"}]},\n",
              "       'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': \"Dutch Multidisciplinary Guideline for Parkinson's disease\",\n",
              "          'SeeAlsoLinkURL': 'http://parkinsonnet.info/media/2733747/7994_multidisciplin_rl_parkinson_c_-_2011.pdf'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'Prot_SAP',\n",
              "          'LargeDocHasProtocol': 'Yes',\n",
              "          'LargeDocHasSAP': 'Yes',\n",
              "          'LargeDocHasICF': 'No',\n",
              "          'LargeDocLabel': 'Study Protocol and Statistical Analysis Plan',\n",
              "          'LargeDocDate': 'June 26, 2018',\n",
              "          'LargeDocUploadDate': '01/15/2019 05:35',\n",
              "          'LargeDocFilename': 'Prot_SAP_000.pdf'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'T6034',\n",
              "          'ConditionBrowseLeafName': 'Quality of Life',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
              "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
              "   {'Rank': 24,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02038959',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'AD-12-11-4701'},\n",
              "       'Organization': {'OrgFullName': 'University of Rochester',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': 'Connect.Parkinson: Connecting Individuals With Parkinson Disease to Specialists in Their Homes',\n",
              "       'OfficialTitle': 'Using Technology to Deliver Multi-disciplinary Care to Individuals With Parkinson Disease in Their Homes: the Connect.Parkinson Study'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'December 2016',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'March 2014'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2016',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'August 2016',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'January 8, 2014',\n",
              "       'StudyFirstSubmitQCDate': 'January 15, 2014',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 17, 2014',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'ResultsFirstSubmitDate': 'September 28, 2016',\n",
              "       'ResultsFirstSubmitQCDate': 'December 1, 2016',\n",
              "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'January 27, 2017',\n",
              "        'ResultsFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'December 1, 2016',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 27, 2017',\n",
              "        'LastUpdatePostDateType': 'Estimate'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Ray Dorsey',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Director, Center for Human Experimental Therapeutics; Professor of Neurology',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'University of Rochester'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'University of Rochester',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Patient-Centered Outcomes Research Institute',\n",
              "          'CollaboratorClass': 'OTHER'},\n",
              "         {'CollaboratorName': 'National Parkinson Foundation',\n",
              "          'CollaboratorClass': 'OTHER'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Connect.Parkinson is a randomized comparative effectiveness study, comparing usual care enhanced with educational materials to usual care, educational materials, and the delivery of specialty care via telemedicine into patient's homes. The study's specific aims are the following:\\n\\nTo demonstrate the feasibility of using telemedicine to deliver specialty care into the homes of individuals with Parkinson disease who have limited access to care;\\nTo show that such an approach can improve quality of life;\\nTo establish that the telemedicine can enhance the quality of care; and\\nTo demonstrate that this remote approach to care saves time, reduces travel, and decreases care partner burden.\",\n",
              "       'DetailedDescription': 'Connect.Parkinson is a national study examining the feasibility and effectiveness of using video calls to bring expert Parkinson disease care directly into patients\\' homes. Currently, access to care for Parkinson disease is limited by distance, disability, and the distribution of doctors. Approximately 200 individuals with Parkinson disease (who due to distance, disability, disparity, or doctor distribution have limited access to care) will be randomized to one of two arms in this comparative effectiveness study. The first (control) arm will be the individual\\'s \"usual care\" supplemented by educational materials on their condition. This usual care may include care from a generalist, care from a neurologist, or in-person care from a Parkinson specialist. The care received by the control group will vary but will be an accurate reflection of usual care in this country. The second (intervention) arm will be usual care supplemented by educational materials and care from a Parkinson disease specialist delivered via web-based video conferencing into the patient\\'s home. The participants will also be asked with they have a primary care partner, and care partners will be invited to enroll, for a total of approximately 400 participants.'},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': ['Parkinson disease',\n",
              "         \"Parkinson's\",\n",
              "         \"Parkinson's disease\",\n",
              "         'telemedicine',\n",
              "         'virtual visits',\n",
              "         'video calls',\n",
              "         'video conferencing',\n",
              "         'virtual house calls']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Health Services Research',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '210',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Usual Care and Educational Materials',\n",
              "          'ArmGroupType': 'No Intervention',\n",
              "          'ArmGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "         {'ArmGroupLabel': 'Virtual Visits and Educational Materials',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Virtual Visits']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': 'Virtual Visits',\n",
              "          'InterventionDescription': 'Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Virtual Visits and Educational Materials']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['Telemedicine',\n",
              "            'Teleneurology',\n",
              "            'Video call',\n",
              "            'Video conferencing']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Feasibility of Virtual Visits for Parkinson Disease',\n",
              "          'PrimaryOutcomeDescription': 'Feasibility of virtual visits will be determined by the number of participants who complete at least one virtual visit successfully.',\n",
              "          'PrimaryOutcomeTimeFrame': 'One year'},\n",
              "         {'PrimaryOutcomeMeasure': 'Change From Baseline in the Quality of Life Measured by Parkinson Disease Questionnaire 39',\n",
              "          'PrimaryOutcomeDescription': \"Assessed as the change in quality of life, measured by the Parkinson Disease Questionnaire 39 (PDQ-39). The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month. Assesses how often patients experience difficulties across the 8 quality of life dimensions. Assesses impact of Parkinson's Disease (PD) on specific dimensions of functioning and well-being. The score ranges from 0-100 with lower scores reflecting better quality of life.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline to One year'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in EQ-5D Index Value',\n",
              "          'SecondaryOutcomeDescription': 'EuroQol five dimensions questionnaire (EQ-5D) is a standardized instrument for measuring generic health status. Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scale ranges from 11111 to 55555 with higher numbers indicating worse health status. The five-digit descriptors are converted to EQ-5D Index Values, which range from -0.109 (corresponding to 55555, the worst possible health) to 1.000 (corresponding to 11111, the best possible health).',\n",
              "          'SecondaryOutcomeTimeFrame': 'baseline to one year'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Montreal Cognition Assessment',\n",
              "          'SecondaryOutcomeDescription': 'We will assess changes in cognition from baseline to the end of the study using the Montreal Cognitive Assessment (MoCA), administered remotely. The scale ranges from 0-30 with higher numbers indicating better cognition.',\n",
              "          'SecondaryOutcomeTimeFrame': 'baseline to one year'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part IA',\n",
              "          'SecondaryOutcomeDescription': 'Parkinson disease clinical characteristics will be assessed by a physician independent rater, blinded to treatment group, at baseline and at the conclusion of the study, using the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). Part I concerns nonmotor experiences of daily living. The scale ranges from 0 to 24 with higher numbers indicated more severe disease.',\n",
              "          'SecondaryOutcomeTimeFrame': 'baseline to one year'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Patient Assessment of Chronic Illness Care',\n",
              "          'SecondaryOutcomeDescription': 'We will assess change in the perceived quality of care using the Patient Assessment of Chronic Illness Care (PACIC). Each scale is scored by averaging the items completed within that scale, and the overall PACIC is scored by averaging scores across all 20 items. The scale ranges from 1-5 with higher scores indicating better care by the health team.',\n",
              "          'SecondaryOutcomeTimeFrame': 'baseline to one year'},\n",
              "         {'SecondaryOutcomeMeasure': \"Minutes Spend on Last Parkinson's Disease Provider Visit\",\n",
              "          'SecondaryOutcomeTimeFrame': 'One year'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part IB',\n",
              "          'SecondaryOutcomeDescription': 'Parkinson disease clinical characteristics will be assessed by a physician independent rater, blinded to treatment group, at baseline and at the conclusion of the study, using the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). Part I concerns nonmotor experiences of daily living. The scale ranges from 0 to 52 with higher numbers indicated more severe disease.',\n",
              "          'SecondaryOutcomeTimeFrame': 'baseline to one year'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part 2',\n",
              "          'SecondaryOutcomeDescription': 'Parkinson disease clinical characteristics will be assessed by a physician independent rater, blinded to treatment group, at baseline and at the conclusion of the study, using the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). Part II concerns motor experiences of daily living. The scale ranges from 0 to 52 with higher numbers indicated more severe disease.',\n",
              "          'SecondaryOutcomeTimeFrame': 'baseline to one year'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part 3',\n",
              "          'SecondaryOutcomeDescription': 'Parkinson disease clinical characteristics will be assessed by a physician independent rater, blinded to treatment group, at baseline and at the conclusion of the study, using the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). Part III is retained as the motor examination. The scale ranges from 0 to 108 with higher numbers indicated more severe disease.',\n",
              "          'SecondaryOutcomeTimeFrame': 'baseline to one year'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part 4',\n",
              "          'SecondaryOutcomeDescription': 'Parkinson disease clinical characteristics will be assessed by a physician independent rater, blinded to treatment group, at baseline and at the conclusion of the study, using the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). Part IV concerns motor complications. The scale ranges from 0 to 24 with higher numbers indicated more severe disease.',\n",
              "          'SecondaryOutcomeTimeFrame': 'baseline to one year'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nIndividuals with clinically diagnosed Idiopathic Parkinson disease in the judgment of the independent rater\\nNo better alternative explanation for the parkinsonism\\nAccess to a non-public, internet-enabled device (e.g., computer, tablet computer, smart phone) that has the capacity for web-based video conferencing\\nBe physically located at time visits are conducted in a state where the participating physician is licensed to practice medicine\\nHave a local care provider that the study team can contact\\nLive at home, in a senior housing complex, or assisted living facility\\nBe fluent in English (all participating states) or Spanish (participants in Florida and Massachusetts only)\\nWilling and able to provide informed consent\\nCare partner (if applicable) must be able and willing to provide informed consent to participate if he or she so chooses.\\n\\nExclusion Criteria:\\n\\nCurrently hospitalized\\nCondition (e.g., prominent psychosis) that precludes study participation as identified by the medical professional (site investigator or nurse).\\nParticipation in another telemedicine study.',\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '30 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'E. Ray Dorsey, MD, MBA',\n",
              "          'OverallOfficialAffiliation': 'University of Rochester',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'University of California San Francisco',\n",
              "          'LocationCity': 'San Francisco',\n",
              "          'LocationState': 'California',\n",
              "          'LocationZip': '94143',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': \"The Parkinson's Institute and Clinical Center\",\n",
              "          'LocationCity': 'Sunnyvale',\n",
              "          'LocationState': 'California',\n",
              "          'LocationZip': '94083',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of Florida',\n",
              "          'LocationCity': 'Gainsville',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '32610',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of Miami',\n",
              "          'LocationCity': 'Miami',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '33136',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Georgia Regents University',\n",
              "          'LocationCity': 'Augusta',\n",
              "          'LocationState': 'Georgia',\n",
              "          'LocationZip': '30912',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Northwestern University',\n",
              "          'LocationCity': 'Chicago',\n",
              "          'LocationState': 'Illinois',\n",
              "          'LocationZip': '60611',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of Kansas Medical Center',\n",
              "          'LocationCity': 'Kansas City',\n",
              "          'LocationState': 'Kansas',\n",
              "          'LocationZip': '66160',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Johns Hopkins',\n",
              "          'LocationCity': 'Baltimore',\n",
              "          'LocationState': 'Maryland',\n",
              "          'LocationZip': '21287',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Massachusetts General Hospital',\n",
              "          'LocationCity': 'Boston',\n",
              "          'LocationState': 'Massachusetts',\n",
              "          'LocationZip': '02114',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Beth Israel Deaconess Medical Center',\n",
              "          'LocationCity': 'Boston',\n",
              "          'LocationState': 'Massachusetts',\n",
              "          'LocationZip': '02215',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Struthers Parkinson Center',\n",
              "          'LocationCity': 'Golden Valley',\n",
              "          'LocationState': 'Minnesota',\n",
              "          'LocationZip': '55427',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'The Mayo Clinic',\n",
              "          'LocationCity': 'Rochester',\n",
              "          'LocationState': 'Minnesota',\n",
              "          'LocationZip': '55905',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Northshore Long Island Jewish - Feinstein Institute',\n",
              "          'LocationCity': 'Manhasset',\n",
              "          'LocationState': 'New York',\n",
              "          'LocationZip': '11030',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of Rochester Medical Center',\n",
              "          'LocationCity': 'Rochester',\n",
              "          'LocationState': 'New York',\n",
              "          'LocationZip': '14642',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Duke University Medical Center',\n",
              "          'LocationCity': 'Durham',\n",
              "          'LocationState': 'North Carolina',\n",
              "          'LocationZip': '27710',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Oregon Health & Science University',\n",
              "          'LocationCity': 'Portland',\n",
              "          'LocationState': 'Oregon',\n",
              "          'LocationZip': '97239',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of Pennsylvania',\n",
              "          'LocationCity': 'Philadelphia',\n",
              "          'LocationState': 'Pennsylvania',\n",
              "          'LocationZip': '19104',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Medical University of South Carolina',\n",
              "          'LocationCity': 'Charleston',\n",
              "          'LocationState': 'South Carolina',\n",
              "          'LocationZip': '29425',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Baylor College of Medicine',\n",
              "          'LocationCity': 'Houston',\n",
              "          'LocationState': 'Texas',\n",
              "          'LocationZip': '77030',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Northwest Neurological, PLLC',\n",
              "          'LocationCity': 'Spokane',\n",
              "          'LocationState': 'Washington',\n",
              "          'LocationZip': '99202',\n",
              "          'LocationCountry': 'United States'}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '23479138',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Dorsey ER, Venkataraman V, Grana MJ, Bull MT, George BP, Boyd CM, Beck CA, Rajan B, Seidmann A, Biglan KM. Randomized controlled clinical trial of \"virtual house calls\" for Parkinson disease. JAMA Neurol. 2013 May;70(5):565-70. doi: 10.1001/jamaneurol.2013.123.'},\n",
              "         {'ReferencePMID': '22991090',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Grana MJ, Bull MT, Venkataraman V, Dorsey ER, Biglan KM. Web-based clinical assessments for Parkinson's disease: reliable and feasible. Mov Disord. 2012 Sep 15;27(11):1466. doi: 10.1002/mds.25121. Epub 2012 Sep 18.\"},\n",
              "         {'ReferencePMID': '23102808',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Abdolahi A, Scoglio N, Killoran A, Dorsey ER, Biglan KM. Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely. Parkinsonism Relat Disord. 2013 Feb;19(2):218-21. doi: 10.1016/j.parkreldis.2012.10.008. Epub 2012 Oct 25.\"},\n",
              "         {'ReferencePMID': '23054239',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Willis AW, Schootman M, Tran R, Kung N, Evanoff BA, Perlmutter JS, Racette BA. Neurologist-associated reduction in PD-related hospitalizations and health care expenditures. Neurology. 2012 Oct 23;79(17):1774-80. doi: 10.1212/WNL.0b013e3182703f92. Epub 2012 Oct 10.'},\n",
              "         {'ReferencePMID': '21832214',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Willis AW, Schootman M, Evanoff BA, Perlmutter JS, Racette BA. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology. 2011 Aug 30;77(9):851-7. doi: 10.1212/WNL.0b013e31822c9123. Epub 2011 Aug 10.'},\n",
              "         {'ReferencePMID': '24790799',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Venkataraman V, Donohue SJ, Biglan KM, Wicks P, Dorsey ER. Virtual visits for Parkinson disease: A case series. Neurol Clin Pract. 2014 Apr;4(2):146-152.'},\n",
              "         {'ReferencePMID': '25431346',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Achey MA, Beck CA, Beran DB, Boyd CM, Schmidt PN, Willis AW, Riggare SS, Simone RB, Biglan KM, Dorsey ER. Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial. Trials. 2014 Nov 27;15:465. doi: 10.1186/1745-6215-15-465. Erratum in: Trials. 2016;17:7.'},\n",
              "         {'ReferencePMID': '26733455',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Achey MA, Beck CA, Beran DB, Boyd CM, Schmidt PN, Willis AW, Riggare SS, Simone RB, Biglan KM, Dorsey ER. Erratum To: Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial. Trials. 2016 Jan 5;17:7. doi: 10.1186/s13063-015-0984-7.'},\n",
              "         {'ReferencePMID': '26886406',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemed J E Health. 2016 Jul;22(7):590-8. doi: 10.1089/tmj.2015.0191. Epub 2016 Feb 17.\"},\n",
              "         {'ReferencePMID': '25894028',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Daschle T, Dorsey ER. The return of the house call. Ann Intern Med. 2015 Apr 21;162(8):587-8. doi: 10.7326/M14-2769.'},\n",
              "         {'ReferencePMID': '27410924',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Dorsey ER, Topol EJ. State of Telehealth. N Engl J Med. 2016 Jul 14;375(2):154-61. doi: 10.1056/NEJMra1601705. Review.'},\n",
              "         {'ReferencePMID': '28814455',\n",
              "          'ReferenceType': 'derived',\n",
              "          'ReferenceCitation': 'Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W; Connect.Parkinson Investigators. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017 Sep 12;89(11):1152-1161. doi: 10.1212/WNL.0000000000004357. Epub 2017 Aug 16.'}]}}},\n",
              "     'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': '272 individuals were referred to 18 sites to be consented. Two hundred ten individuals with Parkinson disease enrolled in the study, and 195 were eventually randomized.',\n",
              "       'FlowRecruitmentDetails': 'Individuals with Parkinson disease were recruited and enrolled remotely and sent educational materials about Parkinson disease created by the National Parkinson Foundation. Recruitment for the study began in February 2014.',\n",
              "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
              "          'FlowGroupTitle': 'Usual Care and Educational Materials',\n",
              "          'FlowGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "         {'FlowGroupId': 'FG001',\n",
              "          'FlowGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "          'FlowGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'}]},\n",
              "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
              "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '98'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '97'}]}},\n",
              "            {'FlowMilestoneType': 'COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '92'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '89'}]}},\n",
              "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '6'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '8'}]}}]},\n",
              "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Withdrawal by Subject',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '6'},\n",
              "               {'FlowReasonGroupId': 'FG001',\n",
              "                'FlowReasonNumSubjects': '8'}]}}]}}]}},\n",
              "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
              "          'BaselineGroupTitle': 'Usual Care and Educational Materials',\n",
              "          'BaselineGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "         {'BaselineGroupId': 'BG001',\n",
              "          'BaselineGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "          'BaselineGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'},\n",
              "         {'BaselineGroupId': 'BG002',\n",
              "          'BaselineGroupTitle': 'Total',\n",
              "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
              "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
              "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
              "             'BaselineDenomCountValue': '98'},\n",
              "            {'BaselineDenomCountGroupId': 'BG001',\n",
              "             'BaselineDenomCountValue': '97'},\n",
              "            {'BaselineDenomCountGroupId': 'BG002',\n",
              "             'BaselineDenomCountValue': '195'}]}}]},\n",
              "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous',\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'years',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '66.9',\n",
              "                   'BaselineMeasurementSpread': '8.5'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '65.9',\n",
              "                   'BaselineMeasurementSpread': '7.8'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '66.4',\n",
              "                   'BaselineMeasurementSpread': '8.1'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Gender',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '42'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '49'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '91'}]}},\n",
              "               {'BaselineCategoryTitle': 'Male',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '56'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '48'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '104'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '98'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '97'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '195'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Minutes spent with Parkinson disease provider',\n",
              "          'BaselineMeasureDescription': 'Time spent with the provider at the participants last appointment was collected in minutes. At baseline this would be the time the participant spent with their provider at their last appointment prior to enrolling in the study.',\n",
              "          'BaselineMeasureParamType': 'Median',\n",
              "          'BaselineMeasureDispersionType': 'Inter-Quartile Range',\n",
              "          'BaselineMeasureUnitOfMeasure': 'minutes',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '30',\n",
              "                   'BaselineMeasurementLowerLimit': '20',\n",
              "                   'BaselineMeasurementUpperLimit': '45'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '30',\n",
              "                   'BaselineMeasurementLowerLimit': '20',\n",
              "                   'BaselineMeasurementUpperLimit': '45'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '30',\n",
              "                   'BaselineMeasurementLowerLimit': '20',\n",
              "                   'BaselineMeasurementUpperLimit': '45'}]}}]}}]}}]}},\n",
              "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': 'Feasibility of Virtual Visits for Parkinson Disease',\n",
              "          'OutcomeMeasureDescription': 'Feasibility of virtual visits will be determined by the number of participants who complete at least one virtual visit successfully.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Number',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'participants',\n",
              "          'OutcomeMeasureTimeFrame': 'One year',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Usual Care and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '98'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '97'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '0'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '95'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': 'Change From Baseline in the Quality of Life Measured by Parkinson Disease Questionnaire 39',\n",
              "          'OutcomeMeasureDescription': \"Assessed as the change in quality of life, measured by the Parkinson Disease Questionnaire 39 (PDQ-39). The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month. Assesses how often patients experience difficulties across the 8 quality of life dimensions. Assesses impact of Parkinson's Disease (PD) on specific dimensions of functioning and well-being. The score ranges from 0-100 with lower scores reflecting better quality of life.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'Data was not collected on 17 participants in the usual care arm and 18 participants in the virtual visits arm.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline to One year',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Usual Care and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '81'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '79'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.7512',\n",
              "                   'OutcomeMeasurementSpread': '0.9472'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.4123',\n",
              "                   'OutcomeMeasurementSpread': '1.0029'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001']},\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '>0.05',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'ANCOVA'}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Change in EQ-5D Index Value',\n",
              "          'OutcomeMeasureDescription': 'EuroQol five dimensions questionnaire (EQ-5D) is a standardized instrument for measuring generic health status. Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scale ranges from 11111 to 55555 with higher numbers indicating worse health status. The five-digit descriptors are converted to EQ-5D Index Values, which range from -0.109 (corresponding to 55555, the worst possible health) to 1.000 (corresponding to 11111, the best possible health).',\n",
              "          'OutcomeMeasurePopulationDescription': 'Data was not collected in 6 participants from the usual care arm and 9 participants from the virtual visits arm.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'baseline to one year',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Usual Care and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '92'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '88'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.04122',\n",
              "                   'OutcomeMeasurementSpread': '0.01074'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.02728',\n",
              "                   'OutcomeMeasurementSpread': '0.01139'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Change in Montreal Cognition Assessment',\n",
              "          'OutcomeMeasureDescription': 'We will assess changes in cognition from baseline to the end of the study using the Montreal Cognitive Assessment (MoCA), administered remotely. The scale ranges from 0-30 with higher numbers indicating better cognition.',\n",
              "          'OutcomeMeasurePopulationDescription': 'Data was not collected on 6 participants in the usual care arm and 9 participants in the virtual visits arm.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'baseline to one year',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Usual Care and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '92'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '88'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '0.2072',\n",
              "                   'OutcomeMeasurementSpread': '0.243'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.6485',\n",
              "                   'OutcomeMeasurementSpread': '0.2566'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part IA',\n",
              "          'OutcomeMeasureDescription': 'Parkinson disease clinical characteristics will be assessed by a physician independent rater, blinded to treatment group, at baseline and at the conclusion of the study, using the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). Part I concerns nonmotor experiences of daily living. The scale ranges from 0 to 24 with higher numbers indicated more severe disease.',\n",
              "          'OutcomeMeasurePopulationDescription': 'Data was not collected in 6 participants from the usual care arm and 8 participants from the virtual visits arm.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'baseline to one year',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Usual Care and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '92'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '89'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-1.0122',\n",
              "                   'OutcomeMeasurementSpread': '0.2979'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.8546',\n",
              "                   'OutcomeMeasurementSpread': '0.3117'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Change in Patient Assessment of Chronic Illness Care',\n",
              "          'OutcomeMeasureDescription': 'We will assess change in the perceived quality of care using the Patient Assessment of Chronic Illness Care (PACIC). Each scale is scored by averaging the items completed within that scale, and the overall PACIC is scored by averaging scores across all 20 items. The scale ranges from 1-5 with higher scores indicating better care by the health team.',\n",
              "          'OutcomeMeasurePopulationDescription': 'Data was not collected in 16 participants from the usual care arm and 12 participants from the virtual visits arm.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'baseline to one year',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Usual Care and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '82'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '85'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '0.2456',\n",
              "                   'OutcomeMeasurementSpread': '0.1001'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.2795',\n",
              "                   'OutcomeMeasurementSpread': '0.1035'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Minutes Spend on Last Parkinson's Disease Provider Visit\",\n",
              "          'OutcomeMeasurePopulationDescription': 'Data was not collected on 10 participants in the usual care arm and 28 participants in the virtual visits arm.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Median',\n",
              "          'OutcomeMeasureDispersionType': 'Inter-Quartile Range',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'minutes',\n",
              "          'OutcomeMeasureTimeFrame': 'One year',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Usual Care and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '88'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '69'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '30',\n",
              "                   'OutcomeMeasurementLowerLimit': '20',\n",
              "                   'OutcomeMeasurementUpperLimit': '45'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '30',\n",
              "                   'OutcomeMeasurementLowerLimit': '20',\n",
              "                   'OutcomeMeasurementUpperLimit': '40'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001']},\n",
              "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
              "             'OutcomeAnalysisPValue': '<0.0001',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'ANCOVA'}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part IB',\n",
              "          'OutcomeMeasureDescription': 'Parkinson disease clinical characteristics will be assessed by a physician independent rater, blinded to treatment group, at baseline and at the conclusion of the study, using the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). Part I concerns nonmotor experiences of daily living. The scale ranges from 0 to 52 with higher numbers indicated more severe disease.',\n",
              "          'OutcomeMeasurePopulationDescription': 'Data was not collected in 11 participants from the usual care arm and 7 participants from the virtual visits arm.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'baseline to one year',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Usual Care and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '87'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '90'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '0.389',\n",
              "                   'OutcomeMeasurementSpread': '0.3701'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.1243',\n",
              "                   'OutcomeMeasurementSpread': '0.3786'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part 2',\n",
              "          'OutcomeMeasureDescription': 'Parkinson disease clinical characteristics will be assessed by a physician independent rater, blinded to treatment group, at baseline and at the conclusion of the study, using the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). Part II concerns motor experiences of daily living. The scale ranges from 0 to 52 with higher numbers indicated more severe disease.',\n",
              "          'OutcomeMeasurePopulationDescription': 'Data was not collected in 12 participants from the usual care arm and 7 participants from the virtual visits arm.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'baseline to one year',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Usual Care and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '86'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '90'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.3266',\n",
              "                   'OutcomeMeasurementSpread': '0.5084'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.1378',\n",
              "                   'OutcomeMeasurementSpread': '0.512'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part 3',\n",
              "          'OutcomeMeasureDescription': 'Parkinson disease clinical characteristics will be assessed by a physician independent rater, blinded to treatment group, at baseline and at the conclusion of the study, using the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). Part III is retained as the motor examination. The scale ranges from 0 to 108 with higher numbers indicated more severe disease.',\n",
              "          'OutcomeMeasurePopulationDescription': 'Data was not collected in 9 participants from the usual care arm and 9 participants from the virtual visits arm.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'baseline to one year',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Usual Care and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '89'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '88'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-4.9164',\n",
              "                   'OutcomeMeasurementSpread': '0.9782'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-5.7495',\n",
              "                   'OutcomeMeasurementSpread': '1.0106'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part 4',\n",
              "          'OutcomeMeasureDescription': 'Parkinson disease clinical characteristics will be assessed by a physician independent rater, blinded to treatment group, at baseline and at the conclusion of the study, using the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). Part IV concerns motor complications. The scale ranges from 0 to 24 with higher numbers indicated more severe disease.',\n",
              "          'OutcomeMeasurePopulationDescription': 'Data was not collected in 6 participants from the usual care arm and 9 participants from the virtual visits arm.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'baseline to one year',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Usual Care and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "             'OutcomeGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '92'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '88'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.2075',\n",
              "                   'OutcomeMeasurementSpread': '0.4042'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.1825',\n",
              "                   'OutcomeMeasurementSpread': '0.425'}]}}]}}]}}]}},\n",
              "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
              "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
              "          'EventGroupTitle': 'Usual Care and Educational Materials',\n",
              "          'EventGroupDescription': 'Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.',\n",
              "          'EventGroupSeriousNumAffected': '0',\n",
              "          'EventGroupSeriousNumAtRisk': '98',\n",
              "          'EventGroupOtherNumAffected': '0',\n",
              "          'EventGroupOtherNumAtRisk': '98'},\n",
              "         {'EventGroupId': 'EG001',\n",
              "          'EventGroupTitle': 'Virtual Visits and Educational Materials',\n",
              "          'EventGroupDescription': 'Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.\\n\\nVirtual Visits: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).',\n",
              "          'EventGroupSeriousNumAffected': '0',\n",
              "          'EventGroupSeriousNumAtRisk': '97',\n",
              "          'EventGroupOtherNumAffected': '0',\n",
              "          'EventGroupOtherNumAtRisk': '97'}]}},\n",
              "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'},\n",
              "       'PointOfContact': {'PointOfContactTitle': 'Ray Dorsey, MD',\n",
              "        'PointOfContactOrganization': 'University of Rochester',\n",
              "        'PointOfContactEMail': 'ray.dorsey@chet.rochester.edu',\n",
              "        'PointOfContactPhone': '585-276-6824'}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 25,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04729010',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'ITCM0005'},\n",
              "       'Organization': {'OrgFullName': 'Xiamen University',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Acupuncture for Anxiety in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Acupuncture as a Symptomatic Treatment for Anxiety in Parkinson's Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'January 2021',\n",
              "       'OverallStatus': 'Not yet recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'October 2021',\n",
              "        'StartDateType': 'Anticipated'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2023',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'May 2024',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'January 25, 2021',\n",
              "       'StudyFirstSubmitQCDate': 'January 25, 2021',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 28, 2021',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'January 28, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 2, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Kim Yun Jin',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Associate Professor',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Xiamen University Malaysia'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Xiamen University',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"This is a single-center, double-blind, placebo-controlled trial to see if acupuncture can safely and effectively manage anxiety in Parkinson's Disease. Eligible subjects will receive either real or sham acupuncture THREE times weekly for a total of SIX weeks.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease',\n",
              "         'Anxiety']},\n",
              "       'KeywordList': {'Keyword': [\"Acupuncture, Anxiety, Parkinson's Disease\"]}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
              "           'Investigator']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '30',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Randomized Subjects receive a sham acupuncture.',\n",
              "          'ArmGroupType': 'Sham Comparator',\n",
              "          'ArmGroupDescription': 'Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Acupuncture to treat anxiety in Parkinson disease']}},\n",
              "         {'ArmGroupLabel': 'Randomized Subjects receive a real acupuncture.',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': 'Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Acupuncture to treat anxiety in Parkinson disease']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': 'Acupuncture to treat anxiety in Parkinson disease',\n",
              "          'InterventionDescription': 'Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Randomized Subjects receive a real acupuncture.',\n",
              "            'Randomized Subjects receive a sham acupuncture.']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in the Hamilton Anxiety Scale (HAM-A) between the treatment group.',\n",
              "          'PrimaryOutcomeDescription': 'The primary outcome measure will be the change between the baseline visit and the SIX-week time point in the Hamilton Anxiety Scale (HAM-A) between the treatment group. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity, and 25-30 moderate to severe.',\n",
              "          'PrimaryOutcomeTimeFrame': 'SIX weeks'},\n",
              "         {'PrimaryOutcomeMeasure': 'Change in the Generalized Anxiety Disorder 7-Item (GAD-7) scale between the treatment group.',\n",
              "          'PrimaryOutcomeDescription': 'The primary outcome measure will be the change between the baseline visit and the SIX-week time point in the Generalized Anxiety Disorder 7-Item (GAD-7) scale between the treatment group. Each item is scored on a scale of 0 (not at all) to 3 (Nearly Every Day), with a total score range of 0-56, where <4 indicates Minimal Anxiety, 5-9 Mild Anxiety, 10-14 Moderate Anxiety, and 15-21 Severe Anxiety.',\n",
              "          'PrimaryOutcomeTimeFrame': 'SIX Weeks'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Change in the Unified Parkinson's Disease Rating Scale between the treatment group.\",\n",
              "          'SecondaryOutcomeDescription': 'A comprehensive assessment of both motor and non-motor symptoms associated with Parkinson\\'s. The Unified Parkinson\\'s Disease Rating Scale is made up of 42 items. These items are divided into six sections which are separately \"evaluation of mentation, behavior, and mood\", \"self-evaluation of the activities of daily life\", \"clinician-scored monitored motor evaluation\", \"complications of therapy\", \"Hoehn and Yahr staging of severity of Parkinson\\'s disease\" and \"Schwab and England ADL scale\". The evaluation score for the first item to the 39th item is 0 to 4 points. The evaluation score for the 40th to the 42th item is 0 to 1 points. The higher score means the worse condition. This scores indicate severe symptoms.',\n",
              "          'SecondaryOutcomeTimeFrame': 'THREE months'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nPatients diagnosed with Parkinson's Disease by authorized Neurologist.\\nPatients 40-75 years of age\\nPatients who have significant anxiety symptom\\nPatients must be on a stable medication regimen for the treatment of PD\\n\\nExclusion Criteria:\\n\\nPatients who have had previous acupuncture within the past SIX months\\nPatients with dementia, depression, or sleep disorder\\nPatients who are currently taking medications known to affect anxiety\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '40 Years',\n",
              "       'MaximumAge': '75 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Yun Jin Kim, Ph.D',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '603-87055098',\n",
              "          'CentralContactEMail': 'neurokim@gmail.com'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'Yes',\n",
              "       'IPDSharingInfoTypeList': {'IPDSharingInfoType': ['Study Protocol',\n",
              "         'Clinical Study Report (CSR)']}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'},\n",
              "         {'ConditionMeshId': 'D000001008',\n",
              "          'ConditionMeshTerm': 'Anxiety Disorders'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001523',\n",
              "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
              "         {'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M3476',\n",
              "          'ConditionBrowseLeafName': 'Anxiety Disorders',\n",
              "          'ConditionBrowseLeafAsFound': 'Anxiety',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M13625',\n",
              "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3967',\n",
              "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
              "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 26,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02896816',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '2015-P-002526'},\n",
              "       'Organization': {'OrgFullName': 'Spaulding Rehabilitation Hospital',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"EMG Modules as a Novel Biomarker of Basal Ganglia Plasticity in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"EMG Modules as a Novel Biomarker of Basal Ganglia Plasticity in Parkinson's Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'September 2021',\n",
              "       'OverallStatus': 'Terminated',\n",
              "       'WhyStopped': 'No more funding',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'August 2016',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 25, 2021',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'May 25, 2021',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'June 29, 2016',\n",
              "       'StudyFirstSubmitQCDate': 'September 9, 2016',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 12, 2016',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'September 27, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 4, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Paolo Bonato',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Spaulding Rehabilitation Hospital'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Spaulding Rehabilitation Hospital',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': \"Michael J. Fox Foundation for Parkinson's Research\",\n",
              "          'CollaboratorClass': 'OTHER'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Study Purpose:\\n\\nParkinson's disease leads to severally impaired motor control. The purpose of this study is to better understand and analyze the characteristics of arm muscle activity while doing some reaching tasks and of leg muscles while walking. This will allow the investigators to improve understanding of the mechanisms underlying the motor impairments in Parkinson's disease.\",\n",
              "       'DetailedDescription': \"More details:\\n\\nA total of 20 participants with Parkinson's disease and 20 age- and gender-matched healthy controls will be included in this study. The participants with Parkinson's disease should have symptoms only on one side of the body, and they should not be taking any dopamine replacement medication such as levodopa or dopamine agonists. The study will take place at the Motion Analysis Laboratory of Spaulding Rehabilitation Hospital in Charlestown, Massachusetts. It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed. In addition, individuals with Parkinson's disease will undergo brain scans at Massachusetts General Hospital to examine whether there are any relationships between muscle activity and brain function.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson']},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's\"]}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Screening',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '17',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Parkinson's subjects\",\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': \"The participants with Parkinson's disease should have symptoms only on one side of the body, and they should not be taking any dopamine replacement medication such as levodopa or dopamine agonists.\\n\\nSurface EMG, MRI and PET scan will be performed at baseline.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Surface EMG, MRI and PET Scan']}},\n",
              "         {'ArmGroupLabel': 'Control subjects',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': 'Participants not affected by neurological disorders. Surface EMG will be performed at baseline.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Surface EMG']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': 'Surface EMG, MRI and PET Scan',\n",
              "          'InterventionDescription': \"It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed. In addition, individuals with Parkinson's disease will undergo brain scans at Massachusetts General Hospital to examine whether there are any relationships between muscle activity and brain function.\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Parkinson's subjects\"]}},\n",
              "         {'InterventionType': 'Other',\n",
              "          'InterventionName': 'Surface EMG',\n",
              "          'InterventionDescription': 'It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control subjects']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Surface electromyography recording',\n",
              "          'PrimaryOutcomeDescription': 'Surface EMG upper and lower extremities',\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Structural MRI',\n",
              "          'SecondaryOutcomeDescription': 'T1 and T2 structural MRI will be performed.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline'},\n",
              "         {'SecondaryOutcomeMeasure': 'Functional MRI',\n",
              "          'SecondaryOutcomeDescription': 'Resting state and task functional MRI will be performed to obtain BOLD signals.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline'},\n",
              "         {'SecondaryOutcomeMeasure': 'Diffusion weighted imaging',\n",
              "          'SecondaryOutcomeDescription': 'Diffusion weighted imaging will be performed to obtain connectivity measures.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline'},\n",
              "         {'SecondaryOutcomeMeasure': 'Altropane PET scan',\n",
              "          'SecondaryOutcomeDescription': 'Altropane PET scan will be performed to assess dopamine transport',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria for Parkinson's volunteers:\\n\\nMale and female, age 18-80\\nMotor symptoms only on one side of the body\\nNo use of dopaminergic replacement therapy or other medication related to PD\\n\\nExclusion Criteria for Parkinson's volunteers:\\n\\nCognitive impairments that may interfere with understanding instructions as needed during the performance of the study (MMSE<23)\\nSubjects who are unable to perform arm reaching movements\\nSelf-report of any condition that could affect walking\\nNo fractures or skin lesions in the upper or lower limbs\\nInfectious diseases requiring contact precautions\\nSubjects with contraindications to MRI cannot participate (i.e., implanted metal including pacemakers, cerebral spinal fluid shunts, aneurysm clips, artificial heart valves, ear implants or metal/foreign objects in the eyes and those with a history of claustrophobia)\\nPregnancy: If the possibility of pregnancy of a female participant cannot be excluded by: 1) surgical history (e.g., tubal ligation or hysterectomy) or 2) post menopausal status with a minimum of 1 year without menses, then a pregnancy test by stat serum testing must be performed on site the morning of any PET visit and the negative result is required prior to the administration or any radiopharmaceutical\\nSubstance abuse within the past 2 years as it may alter neurotransmitter function\\nActive hematological, renal, pulmonary, endocrine or hepatic disorders\\nEvidence of cortical infarcts or strategically placed lacunar infarct (e.g. dorsal medial nucleus of thalamus)\\nActive cancer, metabolic encephalopathy, infection\\nActive cardiovascular disease, stroke, congestive heart failure\\nDiagnosis of MCI or dementia\\n\\nInclusion criteria for healthy volunteers:\\n\\nMale and female, age 18-80\\nAge and gender-matched to PD patients\\nNo use of dopaminergic replacement therapy or other medication related to PD\\n\\nExclusion criteria for healthy volunteers:\\n\\nCognitive impairments that may interfere with understanding instructions as needed during the performance of the study (MMSE<23)\\nSubjects who are unable to perform arm reaching movements\\nSelf-report of any condition that could affect walking\\nNo fractures or skin lesions in the upper or lower limbs\\nInfectious diseases requiring contact precautions\\nDiagnosis of MCI or dementia\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'MaximumAge': '80 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Paolo Bonato, PhD',\n",
              "          'OverallOfficialAffiliation': 'Spaulding Rehabilitation Hospital',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Spaulding Rehabilitation Hospital',\n",
              "          'LocationCity': 'Boston',\n",
              "          'LocationState': 'Massachusetts',\n",
              "          'LocationZip': '02129',\n",
              "          'LocationCountry': 'United States'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}},\n",
              "      'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M6625',\n",
              "          'InterventionBrowseLeafName': 'Dopamine',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M10134',\n",
              "          'InterventionBrowseLeafName': 'Levodopa',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M19748',\n",
              "          'InterventionBrowseLeafName': 'Dopamine Agonists',\n",
              "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
              "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'CaAg',\n",
              "          'InterventionBrowseBranchName': 'Cardiotonic Agents'},\n",
              "         {'InterventionBrowseBranchAbbrev': 'All',\n",
              "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'},\n",
              "         {'InterventionBrowseBranchAbbrev': 'AnDyAg',\n",
              "          'InterventionBrowseBranchName': 'Anti-Dyskinesia Agents'}]}}}}},\n",
              "   {'Rank': 27,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00282802',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'R01NS040467',\n",
              "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
              "        'OrgStudyIdLink': 'https://reporter.nih.gov/quickSearch/R01NS040467'},\n",
              "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01NS040467-01',\n",
              "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
              "          'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/R01NS040467-01'}]},\n",
              "       'Organization': {'OrgFullName': \"The Parkinson's Institute\",\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Twins and the Risk of Parkinson's Disease: A Clinical and Imaging Study\",\n",
              "       'OfficialTitle': 'Twins and the Risk of PD: A Clinical and Imaging Study'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'July 2009',\n",
              "       'OverallStatus': 'Unknown status',\n",
              "       'LastKnownStatus': 'Active, not recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'April 2001'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'July 2010',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'January 26, 2006',\n",
              "       'StudyFirstSubmitQCDate': 'January 26, 2006',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 27, 2006',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'July 1, 2009',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 2, 2009',\n",
              "        'LastUpdatePostDateType': 'Estimate'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyOldNameTitle': 'Caroline M. Tanner, MD, PhD, Director of Clinical Research',\n",
              "        'ResponsiblePartyOldOrganization': \"The Parkinson's Institute\"},\n",
              "       'LeadSponsor': {'LeadSponsorName': \"The Parkinson's Institute\",\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Neurological Disorders and Stroke (NINDS)',\n",
              "          'CollaboratorClass': 'NIH'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"The purpose of this study is to examine the role of genetic and environmental factors in the cause of Parkinson's disease.\",\n",
              "       'DetailedDescription': 'Parkinson\\'s disease (PD) is a growing health problem in the elderly, and genetic factors may provide substantial clues toward eventual treatment and/or prevention of the disorder. The National Academy of Sciences/National Resource Council (NAS/NRC) World War II (WWII) Veteran Twins Cohort Registry is one of the few population-based groups of elderly twins. Previous studies in this group indicated that genetic factors were involved only in early-onset PD, however there was no follow-up to these studies.\\n\\nThe purpose of the \"Twins and the Risk of PD\" study is to follow-up previous studies and confirm the initial findings. In this study, investigators will use the NAS/NRC WWII Veteran Twin Cohort Registry to compare the concordance rates for PD in monozygotic and dizygotic twins-at least one of whom has PD.\\n\\nThe overall goal of this research is determine the contributions of genetic and environmental factors in the cause of PD.\\n\\nThe study will involve traditional clinical research methods, such as a clinical examination, as well as innovative imaging techniques, such as single photon emission computed tomography (SPECT). SPECT-a nuclear imaging test involving blood flow to tissue-is used to evaluate certain brain functions.\\n\\nFindings from this study may help to set research priorities in PD, and to develop tools for early detection of the disorder.'},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's Disease\",\n",
              "         'twins',\n",
              "         'SPECT',\n",
              "         'National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort Registry',\n",
              "         'NAS/NRC',\n",
              "         'World War II Veteran Twins']}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '250',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '1',\n",
              "          'ArmGroupDescription': 'National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort'}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Onset of Parkinson's disease\",\n",
              "          'PrimaryOutcomeTimeFrame': 'duration of the project'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Age of Parkinson's disease onset\",\n",
              "          'SecondaryOutcomeTimeFrame': 'duration of the project'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion:\\n\\nParticipants will be recruited from a closed cohort-the National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort',\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'Male',\n",
              "       'MinimumAge': '77 Years',\n",
              "       'MaximumAge': '88 Years',\n",
              "       'StdAgeList': {'StdAge': ['Older Adult']},\n",
              "       'StudyPopulation': 'Participants will be recruited from a closed cohort-the National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort',\n",
              "       'SamplingMethod': 'Probability Sample'},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Caroline M. Tanner, MD',\n",
              "          'OverallOfficialAffiliation': \"The Parkinson's Institute\",\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': \"The Parkinson's Institute, 675 Almanor Avene\",\n",
              "          'LocationCity': 'Sunnyvale',\n",
              "          'LocationState': 'California',\n",
              "          'LocationZip': '94085',\n",
              "          'LocationCountry': 'United States'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 28,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05164783',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'Z2021125'},\n",
              "       'Organization': {'OrgFullName': 'Zuyderland Medisch Centrum',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Multicenter Implementation of E-monitoring in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Multicenter Implementation of E-monitoring in Parkinson's Disease\",\n",
              "       'Acronym': 'EPD'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'March 2022',\n",
              "       'OverallStatus': 'Recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'November 23, 2021',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2025',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'April 2025',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'October 28, 2021',\n",
              "       'StudyFirstSubmitQCDate': 'December 20, 2021',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 21, 2021',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'March 21, 2022',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 22, 2022',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Gerrit Tissingh',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Dr. G. Tissingh, neurologist',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Zuyderland Medisch Centrum'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Zuyderland Medisch Centrum',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'AbbVie',\n",
              "          'CollaboratorClass': 'INDUSTRY'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Introduction and rationale:\\n\\nParkinsons disease (PD) is a slowly progressive and chronic disease, characterized by a range of motor and non-motor symptoms such as bradykinesia, tremor and falls, but also sleep disturbance, cognitive decline, behavioral problems and autonomic failure. These symptoms often fluctuate over time and between patients. These fluctuating and often debilitating symptoms necessitate proper monitoring. Due to this complexity, most patients require long-term specialized care. The current prevalence of PD in the Netherlands is estimated at 600-775 per 100.000 persons. This figure is expected to increase with > 50% in 2040. Combined with rising healthcare costs and a projected reduction in the number of available healthcare professionals, a system of frequent outpatient visits with a movement disorder specialist, as is currently the standard of care for PD in most (Dutch) hospitals, will likely not be sustainable.\\n\\nAdditionally, improvements can be made in the quality of care for PD-patients. The most important aspect mentioned by patients is improved self-management. Other points of improvement are: communication between different healthcare professionals involved; advanced care planning and having a single point of access / personal case manager. Recently an international group of experts in the field of PD have published a viewpoint article concerning their ideas for the optimization of the care for PD-patients. In addition to the previous points, these experts mention: providing care at home rather than in hospital; pro-active instead of reactive care and improvement of the expertise of healthcare professionals.\\n\\nA possible solution to improving the sustainability of care for PD-patients, and addressing several of the issues concerning quality of care, lies in the use of telemedicine (or eHealth): the remote diagnosis and treatment of patients by means of telecommunications technology. Telemedicine exists in a wide variety of forms, one of which is 'telemonitoring'; the home monitoring of patients. In 2017 it was shown that telemonitoring is save and led to a significant reduction in health care consumption in patients with inflammatory bowel disease. Furthermore, studies in several chronic diseases have shown that telemonitoring leads to better patient empowerment and improved self-management. Self-management is in itself associated with improved health status and well-being in patients with a chronic disease as well as with a reduction in healthcare consumption.\\n\\nIn collaboration with Sananet, Zuyderland Medical Center has developed a telemonitoring tool for PD called 'SanaCoach Parkinson' (SCP). It is, to the investigators knowledge, the first telemonitoring tool for PD that uses anamnestic data from targeted questionnaires to monitor patients with PD. Trough the SCP both motor and non-motor aspects of PD are screened pro-actively. It allows patients to remain at home rather that visit the outpatient clinic. Additionally, proactive monitoring of symptoms leads to earlier detection of deterioration. This gives the neurologist the possibility to optimize (medical) treatment before further, costly, complications arise. Furthermore, the SCP improves patients' insight in their disease, supporting self-management.\\n\\nA previous pilot-study into the effect of implementation of this tool showed that the use of the SCP was feasible in an outpatient care setting and that patient satisfaction and experienced quality of care were high. Additionally, the use of the SCP led to a significant reduction in the number of outpatient visits as well as the PD-related healthcare costs in Zuyderland Medical Center in the first year of use of the SCP.\\n\\nHypotheses:\\n\\nThe investigators hypothesize that implementation of telemonitoring via the SCP will be non-inferior to treatment as usual (TAU) with regards to the quality of care as experienced by PD-patients, while reducing the PD-related healthcare consumption and costs.\\n\\nSecondly the investigators hypothesize that telemonitoring via the SCP will improve the quality of care for PD-patients compared to TAU.\\n\\nStudy Design and procedures:\\n\\nThis will be a non-randomized, prospective, multi-center, non-inferiority, implementation study. During 1 year, all consecutive PD-patients in the neurology outpatient clinic of each participating hospital that meet the in- and exclusion criteria will be invited to join this study. Participants will be monitored via the SCP for 2 years. During this time, PD-related outpatient visits with either a neurologist of specialized nurse will be set at 1-2 per patient per year, with a maximum total planned duration of 60 minutes. If this is not feasible, the primary reason for this will be recorded.\\n\\nNew hospitals may join the study until 6 months after the inclusion of the first patient.\\n\\nAssessments will take place at baseline, 1 year and 2 years.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's Disease\",\n",
              "         'Telemonitoring',\n",
              "         'Cost effectiveness',\n",
              "         'Quality of care',\n",
              "         'eHealth']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'N/A',\n",
              "        'DesignInterventionModel': 'Single Group Assignment',\n",
              "        'DesignInterventionModelDescription': 'Implementation study with stepwise approach',\n",
              "        'DesignPrimaryPurpose': 'Other',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '450',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Participants',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'Intervention: use of SCP',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Combination Product: Sanacoach Parkinson (SCP)']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Combination Product',\n",
              "          'InterventionName': 'Sanacoach Parkinson (SCP)',\n",
              "          'InterventionDescription': \"A web-based monitoring tool for patients with PD, using questionnaires. It includes nine parts: 1) A 89-question, quarterly questionnaire about PD-symptoms. 2) Questionnaire responses are converted to scores on 16 PD-related domains. Both the current score and the score's change compared to the previous questionnaire are visible. 3) An interim evaluation is sent after 6 weeks with questions on any domains where a patient indicated problems. 4) A medication monitor can be initialized by the treating physician to evaluate the effect of a therapeutic change. 5) A consultation preparation module allows patients to indicate which topics they want to discuss during an outpatient visit. 6) Patients can ask for 'calling advise' if they are unsure whether to contact their physician. 7) Patients and healthcare providers can send each other text messages. 8) Interactive learning modules about PD. 9) Annual evaluation regarding patient satisfaction, self-management and healthcare consumption.\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Participants']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Patient-experienced quality of care',\n",
              "          'PrimaryOutcomeDescription': 'Measured by the net-promoter score. Each patient rates their care received on a scale of 0 to 10. Detractors (scoring 0-6) are subtracted from promoters (scoring 9-10), leaving the net-promoter score. The score ranges from -100 to +100, with higher scores indicating better patient-experienced quality of care.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Change between baseline and after two years of using the Sanacoach Parkinson'},\n",
              "         {'PrimaryOutcomeMeasure': 'Patient-satisfaction with the Sanacoach Parkinson',\n",
              "          'PrimaryOutcomeDescription': 'Measured by an 11-item patient satisfaction questionnaire. Score range = 1-45, with higher scores indicating better patient satisfaction.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Measured after 2 years of using the Sanacoach Parkinson'},\n",
              "         {'PrimaryOutcomeMeasure': 'Disease-related quality of life',\n",
              "          'PrimaryOutcomeDescription': \"Measured by the 8-item Parkinson's disease questionnaire (PDQ-8), range 0-32, higher scores indicate worse quality of life\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Change between baseline and after two years of using the Sanacoach Parkinson'},\n",
              "         {'PrimaryOutcomeMeasure': 'Disease-related health care costs',\n",
              "          'PrimaryOutcomeDescription': 'Calculated by measuring the number of PD-relates visits, telephone contacts and e-mail contacts with a neurologist, specialized nurse or general practitioner; number of hospitalizations, hospitalization days and emergency room visits related to PD, head trauma, hip fracture, pneumonia or psychosis; number of visits to a physiotherapist, occupational therapist, speech therapist or psychologist; number of days receiving inpatient of outpatient care at a rehabilitation center or nursing home; hours of formal and informal care received, days of labor missed and time spent by neurologists and specialized nurses on monitoring the Sanacoach Parkinson and follow-up activities. All these variables will be converted to costs per year (in euros).',\n",
              "          'PrimaryOutcomeTimeFrame': 'Change of average costs per year during the two years of using the Sanacoach Parkinson, compared to a 6 month period before use of the Sanacoach Parkinson'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Patient self-management',\n",
              "          'SecondaryOutcomeDescription': 'Measured by the Partners In Health scale, range 0-96, higher scores indicate better self-management',\n",
              "          'SecondaryOutcomeTimeFrame': 'Change between baseline and after two years of using the Sanacoach Parkinson'},\n",
              "         {'SecondaryOutcomeMeasure': 'Caregiver burden',\n",
              "          'SecondaryOutcomeDescription': 'Measured by the Caregiver Strain Index, range 0-13, higher scores indicate higher caregiver burden',\n",
              "          'SecondaryOutcomeTimeFrame': 'Change between baseline and after two years of using the Sanacoach Parkinson'},\n",
              "         {'SecondaryOutcomeMeasure': 'Disease-severity',\n",
              "          'SecondaryOutcomeDescription': \"Measured by the Unified Parkinson's Disease Rating Scale (UPDRS), range 0-260, higher scores indicate increased disease-severity\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Change between baseline and after two years of using the Sanacoach Parkinson'},\n",
              "         {'SecondaryOutcomeMeasure': \"Healthcare professional's attitude towards the Sanacoach Parkinson\",\n",
              "          'SecondaryOutcomeDescription': 'Measured by a 9-item questionnaire, range 0-36, higher scores indicate better satisfaction with the Sanacoach Parkinson',\n",
              "          'SecondaryOutcomeTimeFrame': 'Measured 6-monthly during 3 years of working with the Sanacoach Parkinson'}]},\n",
              "       'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Compliance with Sanacoach Parkinson',\n",
              "          'OtherOutcomeDescription': 'Number of periodic questionnaires completed, patients completing <3 questionnaires a year are defined as non-compliant',\n",
              "          'OtherOutcomeTimeFrame': 'During the 2 years of using the Sanacoach Parkinson'},\n",
              "         {'OtherOutcomeMeasure': 'Number of patients requiring additional outpatient visits',\n",
              "          'OtherOutcomeDescription': '% of patient years in which a patient requires more than 2 outpatient visits',\n",
              "          'OtherOutcomeTimeFrame': 'During the 2 years of using the Sanacoach Parkinson'},\n",
              "         {'OtherOutcomeMeasure': 'Reasons for additional outpatient visits',\n",
              "          'OtherOutcomeDescription': 'Descriptive summary of the reasons patient required additional outpatient visits, as specified by healthcare providers. Pre-specified options are: 1) Doctor-initiated, physical examination needed 2) Doctor-initiated, deepen history 3) Doctor-initiated, nature of problem 4) Patient-initiated and 5) Caregiver-initiated',\n",
              "          'OtherOutcomeTimeFrame': 'During the 2 years of using the Sanacoach Parkinson'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nDiagnosis according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease\\nDisease duration  3 months.\\nAble to complete the questionnaires and use the Sanacoach Parkinson, independently or with the help of an informal caregiver.\\n\\nExclusion Criteria:\\n\\nNot able to understand and/or sign the informed consent.\\nNo access to the internet via computer, tablet or smartphone.\\nParticipating in other trial\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '30 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Anke Wijers, MD',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '+31884599717',\n",
              "          'CentralContactEMail': 'a.wijers@zuyderland.nl'},\n",
              "         {'CentralContactName': 'Tiny Simons, BSc',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '+31884596717',\n",
              "          'CentralContactEMail': 't.sporken@zuyderland.nl'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Gerrit Tissingh, MD, PhD',\n",
              "          'OverallOfficialAffiliation': 'Zuyderland MC',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Meander Medical Center',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Amersfoort',\n",
              "          'LocationCountry': 'Netherlands',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ponsen, MD, PhD',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '0031338505050',\n",
              "             'LocationContactEMail': 'MM.Ponsen@meandermc.nl'},\n",
              "            {'LocationContactName': 'Ponsen, MD, PhD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Onze Lieve Vrouwe Hospital',\n",
              "          'LocationStatus': 'Not yet recruiting',\n",
              "          'LocationCity': 'Amsterdam',\n",
              "          'LocationCountry': 'Netherlands',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hans Bosboom, MD, PhD',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '+31205108883',\n",
              "             'LocationContactEMail': 'J.L.W.Bosboom@olvg.nl'},\n",
              "            {'LocationContactName': 'Hans Bosboom, MD, PhD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Rode Kruis Hospital',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Beverwijk',\n",
              "          'LocationCountry': 'Netherlands',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Willem van der Meulen, MD',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '+31251265695',\n",
              "             'LocationContactEMail': 'wvandermeulen@rkz.nl'},\n",
              "            {'LocationContactName': 'Willem van der Meulen, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Zuyderland Medical Center',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Geleen',\n",
              "          'LocationCountry': 'Netherlands',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Anke Wijers, MD',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '+31884599717',\n",
              "             'LocationContactEMail': 'a.wijers@zuyderland.nl'},\n",
              "            {'LocationContactName': 'Tiny Simons, BSc',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '+3188546717',\n",
              "             'LocationContactEMail': 't.sporken@zuyderland.nl'},\n",
              "            {'LocationContactName': 'Gerrit Tissingh, MD, PhD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Zuyderland Medical Center',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Heerlen',\n",
              "          'LocationCountry': 'Netherlands',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Anke Wijers, MD',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '+31884599717',\n",
              "             'LocationContactEMail': 'a.wijers@zuyderland.nl'},\n",
              "            {'LocationContactName': 'Tiny Simons, BSc',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '+31884596717',\n",
              "             'LocationContactEMail': 't.sporken@zuyderland.nl'},\n",
              "            {'LocationContactName': 'Gerrit Tissingh, MD, PhD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}},\n",
              "         {'LocationFacility': 'Elkerliek Hospital',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Helmond',\n",
              "          'LocationCountry': 'Netherlands',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Rinske van Koningsveld, MD, PhD',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '+31492595954',\n",
              "             'LocationContactEMail': 'r.vankoningsveld@elkerliek.nl'},\n",
              "            {'LocationContactName': 'Rinske van Koningsveld',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28332488',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13. Review.'},\n",
              "         {'ReferencePMID': '17762036',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Clarke CE. Parkinson's disease. BMJ. 2007 Sep 1;335(7617):441-5. Review.\"},\n",
              "         {'ReferencePMID': '21832214',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Willis AW, Schootman M, Evanoff BA, Perlmutter JS, Racette BA. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology. 2011 Aug 30;77(9):851-7. doi: 10.1212/WNL.0b013e31822c9123. Epub 2011 Aug 10.'},\n",
              "         {'ReferencePMID': '23054239',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Willis AW, Schootman M, Tran R, Kung N, Evanoff BA, Perlmutter JS, Racette BA. Neurologist-associated reduction in PD-related hospitalizations and health care expenditures. Neurology. 2012 Oct 23;79(17):1774-80. doi: 10.1212/WNL.0b013e3182703f92. Epub 2012 Oct 10.'},\n",
              "         {'ReferencePMID': '23436720',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord. 2013 Mar;28(3):311-8. doi: 10.1002/mds.25292. Epub 2013 Feb 21.\"},\n",
              "         {'ReferencePMID': '30373962',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Vlaanderen FP, Rompen L, Munneke M, Stoffer M, Bloem BR, Faber MJ. The Voice of the Parkinson Customer. J Parkinsons Dis. 2019;9(1):197-201. doi: 10.3233/JPD-181431.'},\n",
              "         {'ReferencePMID': '32464101',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Bloem BR, Henderson EJ, Dorsey ER, Okun MS, Okubadejo N, Chan P, Andrejack J, Darweesh SKL, Munneke M. Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care. Lancet Neurol. 2020 Jul;19(7):623-634. doi: 10.1016/S1474-4422(20)30064-8. Epub 2020 May 25. Review.\"},\n",
              "         {'ReferencePMID': '28716313',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M, van Bodegraven AA, Mahmmod N, Markus T, Hameeteman WM, Dijkstra G, Masclee AA, Boonen A, Winkens B, van Tubergen A, Jonkers DM, Pierik MJ. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017 Sep 2;390(10098):959-968. doi: 10.1016/S0140-6736(17)31327-2. Epub 2017 Jul 14.'},\n",
              "         {'ReferencePMID': '17233653',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Wilde MH, Garvin S. A concept analysis of self-monitoring. J Adv Nurs. 2007 Feb;57(3):339-50. Review. Erratum in: J Adv Nurs. 2007 Jun;58(6):616.'},\n",
              "         {'ReferencePMID': '31293241',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Qian W, Lam TT, Lam HHW, Li CK, Cheung YT. Telehealth Interventions for Improving Self-Management in Patients With Hemophilia: Scoping Review of Clinical Studies. J Med Internet Res. 2019 Jul 10;21(7):e12340. doi: 10.2196/12340. Review.'},\n",
              "         {'ReferencePMID': '25677954',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Jalil S, Myers T, Atkinson I. A meta-synthesis of behavioral outcomes from telemedicine clinical trials for type 2 diabetes and the Clinical User-Experience Evaluation (CUE). J Med Syst. 2015 Mar;39(3):28. doi: 10.1007/s10916-015-0191-9. Epub 2015 Feb 13.'},\n",
              "         {'ReferencePMID': '12401421',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management approaches for people with chronic conditions: a review. Patient Educ Couns. 2002 Oct -Nov;48(2):177-87. Review.'},\n",
              "         {'ReferencePMID': '12867348',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Lorig KR, Holman H. Self-management education: history, definition, outcomes, and mechanisms. Ann Behav Med. 2003 Aug;26(1):1-7. Review.'},\n",
              "         {'ReferencePMID': '30601717',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Allegrante JP, Wells MT, Peterson JC. Interventions to Support Behavioral Self-Management of Chronic Diseases. Annu Rev Public Health. 2019 Apr 1;40:127-146. doi: 10.1146/annurev-publhealth-040218-044008. Epub 2019 Jan 2. Review.'},\n",
              "         {'ReferencePMID': '12435261',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA. 2002 Nov 20;288(19):2469-75.'},\n",
              "         {'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Jie L, Jie A, Hoff J, Tissingh G. Telemonitoring verbetert parkinsonzorg. Medisch Contact. 2016; 14:7'},\n",
              "         {'ReferencePMID': '34631943',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Wijers A, Hochstenbach L, Tissingh G. Telemonitoring via Questionnaires Reduces Outpatient Healthcare Consumption in Parkinson's Disease. Mov Disord Clin Pract. 2021 Jul 19;8(7):1075-1082. doi: 10.1002/mdc3.13280. eCollection 2021 Oct.\"}]},\n",
              "       'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': \"Information on the epidemiology of Parkinson's Disease in the Netherlands, from the 'Rijksinstituut voor Volksgezondheid en Milieu' (RIVM), the Dutch National Institute for Health and Environment\",\n",
              "          'SeeAlsoLinkURL': 'https://www.volksgezondheidenzorg.info/onderwerp/ziekte-van-parkinson/cijfers-context/huidige-situatie'},\n",
              "         {'SeeAlsoLinkLabel': \"Report on prognosis of epidemiology diseases, including Parkinson's Disease, in the Netherlands from 2018 to 2040, from the 'Rijksinstituut voor Volksgezondheid en Milieu' (RIVM), the Dutch National Institute for Health and Environment\",\n",
              "          'SeeAlsoLinkURL': 'https://www.volksgezondheidenzorg.info/bestanden/documenten/20210311demografischeprognoseziekten2018-2040ods'},\n",
              "         {'SeeAlsoLinkLabel': \"Report on demographic changes in the Netherlands from 2010 to 2040, by the 'Planbureau voor de Leefomgeving', the Dutch national institute for strategic policy analysis in the field of environment, nature and space\",\n",
              "          'SeeAlsoLinkURL': 'https://www.pbl.nl/sites/default/files/downloads/PBL_2013_Demografische_ontwikkelingen-2010-2040_1044.pdf'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 29,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00880620',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'IPX066-B08-05'},\n",
              "       'Organization': {'OrgFullName': 'Impax Laboratories, LLC',\n",
              "        'OrgClass': 'INDUSTRY'},\n",
              "       'BriefTitle': \"A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease\",\n",
              "       'OfficialTitle': \"A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease\",\n",
              "       'Acronym': 'APEX-PD'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'August 2017',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'April 2009'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2010',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'November 2010',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'April 3, 2009',\n",
              "       'StudyFirstSubmitQCDate': 'April 13, 2009',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 14, 2009',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'ResultsFirstSubmitDate': 'December 7, 2015',\n",
              "       'ResultsFirstSubmitQCDate': 'January 25, 2016',\n",
              "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'February 22, 2016',\n",
              "        'ResultsFirstPostDateType': 'Estimate'},\n",
              "       'DispFirstSubmitDate': 'September 27, 2013',\n",
              "       'DispFirstSubmitQCDate': 'September 27, 2013',\n",
              "       'DispFirstPostDateStruct': {'DispFirstPostDate': 'October 28, 2013',\n",
              "        'DispFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'October 25, 2019',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 29, 2019',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Impax Laboratories, LLC',\n",
              "        'LeadSponsorClass': 'INDUSTRY'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"This study examines the efficacy of three doses of IPX066 as compared to placebo in Parkinson's disease.\",\n",
              "       'DetailedDescription': \"A randomized, double-blind, placebo-controlled, fixed-dose, parallel-arm study of three doses of IPX066 versus placebo.\\n\\nTotal of 427 subjects were screened and 381 were randomized and received one of the four treatment groups (1) placebo (N=92), (2) IPX066 145 mg LD (N=87) (3) IPX066 245 mg LD (N=104) (4) IPX066 390 mg LD (N=98) three times a day.\\n\\nStudy duration is approximately 30 weeks for each subject including 4 weeks of titration (up to 3 weeks of dose escalation and I week of stabilization for safe escalation to the allocated dose), and 26 weeks of maintenance.\\n\\nDuring the titration phase:\\n\\nThe following dose strengths were used to titrate up to the final three strengths that were assigned to the three IPX066 treatment arms.\\n\\nIPX066 95 mg LD capsule containing 95 mg LD and 23.75 mg CD. IPX066 145 mg LD capsule containing 145 mg LD and 36.25 mg CD. IPX066 195 mg LD capsule containing 195 mg LD and 48.75 mg CD. IPX066 245 mg LD capsule containing 245 mg LD and 61.25 mg CD.\\n\\nDuring the maintenance phase:\\n\\nIPX066 145 mg LD treatment arm received 145 mg LD and 36.25 mg CD. IPX066 245 mg LD treatment arm received 245 mg LD and 61.25 mg CD. IPX066 390 mg LD treatment arm received 390 mg LD and 97.50 mg CD.\\n\\nPrimary efficacy outcome measure was change from baseline in the sum of UPDRS Part II and Part III scores at the end of study or last value reported if subject discontinued prematurely.\\n\\nSummary of Change From Baseline to End of Study in Mean Parkinson's Disease Questionnaire-39 (PDQ-39) Score.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's disease\"]}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Phase 3']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Quadruple',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
              "           'Care Provider',\n",
              "           'Investigator',\n",
              "           'Outcomes Assessor']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '381',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Placebo',\n",
              "          'ArmGroupType': 'Placebo Comparator',\n",
              "          'ArmGroupDescription': 'One Placebo capsule was given TID for the first 21 days. Two placebo capsules were given TID on days 22 till end of study (week 30).',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Placebo']}},\n",
              "         {'ArmGroupLabel': 'IPX066 145 mg LD',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-21. One IPX066 145 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Placebo',\n",
              "            'Drug: IPX066 95 mg LD',\n",
              "            'Drug: IPX066 145 mg LD']}},\n",
              "         {'ArmGroupLabel': 'IPX066 245 mg LD',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. One IPX066 245 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Placebo',\n",
              "            'Drug: IPX066 95 mg LD',\n",
              "            'Drug: IPX066 145 mg LD',\n",
              "            'Drug: IPX066 195 mg LD',\n",
              "            'Drug: IPX066 245 mg LD']}},\n",
              "         {'ArmGroupLabel': 'IPX066 390 mg LD',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. Two IPX066 195 mg LD capsules were given TID on days 22 till end of study (week 30).',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: IPX066 95 mg LD',\n",
              "            'Drug: IPX066 145 mg LD',\n",
              "            'Drug: IPX066 195 mg LD',\n",
              "            'Drug: IPX066 245 mg LD']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
              "          'InterventionName': 'Placebo',\n",
              "          'InterventionDescription': 'Placebo',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['IPX066 145 mg LD',\n",
              "            'IPX066 245 mg LD',\n",
              "            'Placebo']}},\n",
              "         {'InterventionType': 'Drug',\n",
              "          'InterventionName': 'IPX066 95 mg LD',\n",
              "          'InterventionDescription': 'IPX066 capsule containing 95 mg LD/23.75 mg CD',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['IPX066 145 mg LD',\n",
              "            'IPX066 245 mg LD',\n",
              "            'IPX066 390 mg LD']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['CD-LD ER 95 mg']}},\n",
              "         {'InterventionType': 'Drug',\n",
              "          'InterventionName': 'IPX066 145 mg LD',\n",
              "          'InterventionDescription': 'IPX066 capsule containing 145 mg LD/36.25 mg CD',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['IPX066 145 mg LD',\n",
              "            'IPX066 245 mg LD',\n",
              "            'IPX066 390 mg LD']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['CD-LD ER 145 mg']}},\n",
              "         {'InterventionType': 'Drug',\n",
              "          'InterventionName': 'IPX066 195 mg LD',\n",
              "          'InterventionDescription': 'IPX066 capsule containing 195 mg LD/48.75 mg CD',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['IPX066 245 mg LD',\n",
              "            'IPX066 390 mg LD']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['CD-LD ER 195 mg']}},\n",
              "         {'InterventionType': 'Drug',\n",
              "          'InterventionName': 'IPX066 245 mg LD',\n",
              "          'InterventionDescription': 'IPX066 capsule containing 245 mg LD/61.25 mg CD',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['IPX066 245 mg LD',\n",
              "            'IPX066 390 mg LD']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['CD-LD ER 245 mg']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30',\n",
              "          'PrimaryOutcomeDescription': \"Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) + UPDRS Part III (Motor Examination) at Week 30 (End of Study).\\n\\nUnified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome.\\n\\nSubscales II and III were summed:\\n\\nPart I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Week 30'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Summary of Change From Baseline to End of Study in Mean Parkinson's Disease Questionnaire-39 (PDQ-39) Score\",\n",
              "          'SecondaryOutcomeDescription': 'Change from Baseline in Parkinson\\'s disease Questionnaire 39 (PDQ-39) at Weeks 4, 9, 16, 23 and 30 or early discontinuation was collected. The PDQ-39 is a self-reported questionnaire consisting of 39 questions regarding the subjects mobility and the responses consist of \"Never\" (better in outcome), (value 0), \"Occasionally\" (value 1), \"Sometimes\" (value 2), , \"Often\" (value 3), and \"Always\" (value 4), (worse in outcome). The minimum possible score is \"0\" and the maximum is \"156\". The outcome measure calculated was the change from baseline to end of study in mean PDQ-39 score. Negative values indicate a better result.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline and Week 30 (or End of Study)'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAble to understand and willing to voluntarily sign an informed consent form (ICF) and Health Insurance Portability and Accountability Act (HIPAA) authorization or local equivalent if applicable.\\nDiagnosed with idiopathic PD.\\nLD-nave: defined as subjects not exposed to LD or catechol-O-methyl transferase inhibitors for more than 30 days and the exposure is not within 4 weeks prior to study enrollment.\\nIf currently taking anticholinergic therapy, amantadine, or a monoamine oxidase type B (MAO-B) inhibitor, maintains a stable regimen for at least 4 weeks prior to Baseline, and agrees to maintain the stable regimen throughout study participation.\\nAgrees to use a medically acceptable method of contraception throughout the study and for 1 month after completing the study.\\nAble and willing to comply with the protocol, including availability for all scheduled clinic visits and telephone calls.\\n\\nExclusion Criteria:\\n\\nPregnant or breastfeeding.\\nDiagnosed with atypical Parkinsonism or any known secondary parkinsonian syndrome.\\nPrior functional neurosurgical treatment for PD or if such procedures are anticipated during study participation.\\nUse of nonselective MAO inhibitors.\\nUse of dopamine agonists within 30 days prior to Screening.\\nUnable to tolerate a placebo regimen, in the Investigator's opinion.\\nTreatment of psychosis with any antipsychotic.\\nHistory of seizure or epilepsy.\\nActive or prior medical condition or prior surgical procedure that would interfere with LD absorption.\\nHistory of narrow-angle glaucoma.\\nSubjects with a history of malignant melanoma.\\nHistory of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome.\\nReceived any investigational medications during the 30 days prior to Screening.\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '30 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Impax Study Director',\n",
              "          'OverallOfficialAffiliation': 'Impax Laboratories, LLC',\n",
              "          'OverallOfficialRole': 'Study Director'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'University of Alabama at Birmingham, Dept. of Neurology',\n",
              "          'LocationCity': 'Birmingham',\n",
              "          'LocationState': 'Alabama',\n",
              "          'LocationZip': '35233',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'HOPE Research Institute, LLC',\n",
              "          'LocationCity': 'Phoenix',\n",
              "          'LocationState': 'Arizona',\n",
              "          'LocationZip': '85050',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Collaborative NeuroScience Network, Inc.',\n",
              "          'LocationCity': 'Garden Grove',\n",
              "          'LocationState': 'California',\n",
              "          'LocationZip': '92845',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Coastal Neurological Medical Group',\n",
              "          'LocationCity': 'La Jolla',\n",
              "          'LocationState': 'California',\n",
              "          'LocationZip': '92037',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Coordinated Clinical Research',\n",
              "          'LocationCity': 'La Jolla',\n",
              "          'LocationState': 'California',\n",
              "          'LocationZip': '92037',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': \"The Parkinson's Institute\",\n",
              "          'LocationCity': 'Sunnyvale',\n",
              "          'LocationState': 'California',\n",
              "          'LocationZip': '94085',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Yale Neurology Clinics, Temple Medical Center',\n",
              "          'LocationCity': 'New Haven',\n",
              "          'LocationState': 'Connecticut',\n",
              "          'LocationZip': '06510',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Bradenton Research Center, Inc.',\n",
              "          'LocationCity': 'Bradenton',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '34205',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Sunrise Clinical Research, Inc.',\n",
              "          'LocationCity': 'Hollywood',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '23021',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Renstar Medical Research',\n",
              "          'LocationCity': 'Ocala',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '34471',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Charlotte Neurological Services',\n",
              "          'LocationCity': 'Port Charlotte',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '33952',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Suncoast Neuroscience Associates, Inc.',\n",
              "          'LocationCity': 'Saint Petersburg',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '33713',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of South Florida',\n",
              "          'LocationCity': 'Tampa',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '33612',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Idaho Elks Rehabilitation Hospital',\n",
              "          'LocationCity': 'Boise',\n",
              "          'LocationState': 'Idaho',\n",
              "          'LocationZip': '83702',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Rush University Medical Center, Dept. of Neurological Sciences',\n",
              "          'LocationCity': 'Chicago',\n",
              "          'LocationState': 'Illinois',\n",
              "          'LocationZip': '60612',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': \"Landon Center on Aging, Dept. of Neurology, Parkinson's Disease Center\",\n",
              "          'LocationCity': 'Kansas City',\n",
              "          'LocationState': 'Kansas',\n",
              "          'LocationZip': '66160-7314',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Boston University School of Medicine',\n",
              "          'LocationCity': 'Boston',\n",
              "          'LocationState': 'Massachusetts',\n",
              "          'LocationZip': '02118',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Quest Research Institute',\n",
              "          'LocationCity': 'Bingham Farms',\n",
              "          'LocationState': 'Michigan',\n",
              "          'LocationZip': '48025',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': \"Struthers Parkinson's Center\",\n",
              "          'LocationCity': 'Golden Valley',\n",
              "          'LocationState': 'Minnesota',\n",
              "          'LocationZip': '55427',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'UMDNJ Robert Wood Johnson Medical Center, Department of Neurology',\n",
              "          'LocationCity': 'New Brunswick',\n",
              "          'LocationState': 'New Jersey',\n",
              "          'LocationZip': '08901',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Mount Sinai School of Medicine',\n",
              "          'LocationCity': 'New York',\n",
              "          'LocationState': 'New York',\n",
              "          'LocationZip': '10029',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Columbia University',\n",
              "          'LocationCity': 'New York',\n",
              "          'LocationState': 'New York',\n",
              "          'LocationZip': '10032',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'State University of New York Upstate Medical University, Dept. of Neurology',\n",
              "          'LocationCity': 'Syracuse',\n",
              "          'LocationState': 'New York',\n",
              "          'LocationZip': '13210',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Duke University Medical Center Movement Disorders Center',\n",
              "          'LocationCity': 'Durham',\n",
              "          'LocationState': 'North Carolina',\n",
              "          'LocationZip': '27705',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of Toledo',\n",
              "          'LocationCity': 'Toledo',\n",
              "          'LocationState': 'Ohio',\n",
              "          'LocationZip': '43614',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': \"Baylor College of Medicine, Parkinson's Disease Center\",\n",
              "          'LocationCity': 'Houston',\n",
              "          'LocationState': 'Texas',\n",
              "          'LocationZip': '77030',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Wisconsin Institute for Neurologic and Sleep Disorders',\n",
              "          'LocationCity': 'Milwaukee',\n",
              "          'LocationState': 'Wisconsin',\n",
              "          'LocationZip': '53233',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Movement Disorders Clinic, Glenrose Rehabilitation Hospital',\n",
              "          'LocationCity': 'Edmonton',\n",
              "          'LocationState': 'Alberta',\n",
              "          'LocationZip': 'T5G 0B7',\n",
              "          'LocationCountry': 'Canada'},\n",
              "         {'LocationFacility': 'Saint Boniface Clinic',\n",
              "          'LocationCity': 'Winnipeg',\n",
              "          'LocationState': 'Manitoba',\n",
              "          'LocationZip': 'R3J2H7',\n",
              "          'LocationCountry': 'Canada'},\n",
              "         {'LocationFacility': 'London Health Science Center',\n",
              "          'LocationCity': 'London',\n",
              "          'LocationState': 'Ontario',\n",
              "          'LocationZip': 'N6A 5A5',\n",
              "          'LocationCountry': 'Canada'},\n",
              "         {'LocationFacility': \"Parkinson's and Neurodegenerative Disorders Clinic\",\n",
              "          'LocationCity': 'Ottawa',\n",
              "          'LocationState': 'Ontario',\n",
              "          'LocationZip': 'K1G 4G3',\n",
              "          'LocationCountry': 'Canada'},\n",
              "         {'LocationFacility': 'Ottawa Hospital Civic Site',\n",
              "          'LocationCity': 'Ottawa',\n",
              "          'LocationState': 'Ontario',\n",
              "          'LocationZip': 'K1Y 4E9',\n",
              "          'LocationCountry': 'Canada'},\n",
              "         {'LocationFacility': 'Toronto Western Hospital',\n",
              "          'LocationCity': 'Toronto',\n",
              "          'LocationState': 'Ontario',\n",
              "          'LocationZip': 'M5T 2S8',\n",
              "          'LocationCountry': 'Canada'},\n",
              "         {'LocationFacility': 'University of Sherbrooke',\n",
              "          'LocationCity': 'Sherbrooke',\n",
              "          'LocationState': 'Quebec',\n",
              "          'LocationZip': 'J1H 5N4',\n",
              "          'LocationCountry': 'Canada'},\n",
              "         {'LocationFacility': 'Memory and Motor Skills Clinic',\n",
              "          'LocationCity': 'Quebec',\n",
              "          'LocationZip': 'G1R 3X5',\n",
              "          'LocationCountry': 'Canada'},\n",
              "         {'LocationFacility': 'East Tallinn Central Hospital',\n",
              "          'LocationCity': 'Tallinn',\n",
              "          'LocationZip': '10138',\n",
              "          'LocationCountry': 'Estonia'},\n",
              "         {'LocationFacility': 'West Tallin Central Hopsital',\n",
              "          'LocationCity': 'Tallinn',\n",
              "          'LocationZip': '10617',\n",
              "          'LocationCountry': 'Estonia'},\n",
              "         {'LocationFacility': 'P.Stradina university hospital',\n",
              "          'LocationCity': 'Riga',\n",
              "          'LocationZip': '1002',\n",
              "          'LocationCountry': 'Latvia'},\n",
              "         {'LocationFacility': 'Gailezers hospital',\n",
              "          'LocationCity': 'Riga',\n",
              "          'LocationCountry': 'Latvia'},\n",
              "         {'LocationFacility': 'Kaunas Medical University Hospital',\n",
              "          'LocationCity': 'Kaunas',\n",
              "          'LocationZip': 'LT-50009',\n",
              "          'LocationCountry': 'Lithuania'},\n",
              "         {'LocationFacility': 'Siauliai Regional Hospital',\n",
              "          'LocationCity': 'Siauliai',\n",
              "          'LocationZip': 'LT- 76231',\n",
              "          'LocationCountry': 'Lithuania'},\n",
              "         {'LocationFacility': 'Vilnius University Emergency Hospital',\n",
              "          'LocationCity': 'Vilnius',\n",
              "          'LocationZip': 'LT-04130',\n",
              "          'LocationCountry': 'Lithuania'},\n",
              "         {'LocationFacility': 'Vilnius University Centre of Gerontology and Rehabilitation',\n",
              "          'LocationCity': 'Vilnius',\n",
              "          'LocationZip': 'LT-08420',\n",
              "          'LocationCountry': 'Lithuania'},\n",
              "         {'LocationFacility': 'Vilnius University Hospital Santariskiu klinikos',\n",
              "          'LocationCity': 'Vilnius',\n",
              "          'LocationZip': 'LT-08661',\n",
              "          'LocationCountry': 'Lithuania'},\n",
              "         {'LocationFacility': 'Psychiatry and Neurology Hospital, Neurology Department',\n",
              "          'LocationCity': 'Brasov',\n",
              "          'LocationZip': '500123',\n",
              "          'LocationCountry': 'Romania'},\n",
              "         {'LocationFacility': 'Colentina Clinical Hospital Bucharest, II Neurology Department',\n",
              "          'LocationCity': 'Bucharest',\n",
              "          'LocationZip': '020125',\n",
              "          'LocationCountry': 'Romania'},\n",
              "         {'LocationFacility': 'County Emergency Clinical Hospital Cluj-Napoca, I Neurology Clinic',\n",
              "          'LocationCity': 'Cluj Napoca',\n",
              "          'LocationZip': '400012',\n",
              "          'LocationCountry': 'Romania'},\n",
              "         {'LocationFacility': 'CFR Clinical Hospital Constanta',\n",
              "          'LocationCity': 'Constanta',\n",
              "          'LocationZip': '900123',\n",
              "          'LocationCountry': 'Romania'},\n",
              "         {'LocationFacility': 'Clinical Rehabilitation Hospital Iasi, Neurology Department',\n",
              "          'LocationCity': 'Iasi',\n",
              "          'LocationCountry': 'Romania'},\n",
              "         {'LocationFacility': 'County Clinical Emergency Hospital, Targu Mures, II Neurology Department,',\n",
              "          'LocationCity': 'Targu Mures',\n",
              "          'LocationZip': '540136',\n",
              "          'LocationCountry': 'Romania'},\n",
              "         {'LocationFacility': 'County Clinical Emergency Hospital Timisoara',\n",
              "          'LocationCity': 'Timisoara',\n",
              "          'LocationZip': '300736',\n",
              "          'LocationCountry': 'Romania'},\n",
              "         {'LocationFacility': 'Neurology department of Regional hospital named after Mechnikov',\n",
              "          'LocationCity': 'Dnepropetrovsk',\n",
              "          'LocationZip': '49005',\n",
              "          'LocationCountry': 'Ukraine'},\n",
              "         {'LocationFacility': 'Department of Psychiatry and Medical Psychology of Donetsk National Medical University',\n",
              "          'LocationCity': 'Donetsk',\n",
              "          'LocationZip': '83037',\n",
              "          'LocationCountry': 'Ukraine'},\n",
              "         {'LocationFacility': 'Department of Neurological Diseases and Medical Genetic of Donetsk National Medical University',\n",
              "          'LocationCity': 'Donetsk',\n",
              "          'LocationZip': '83099',\n",
              "          'LocationCountry': 'Ukraine'},\n",
              "         {'LocationFacility': '1st neurology department of Central Clinical Hospital of Ukrzaliznytsya',\n",
              "          'LocationCity': 'Kharkiv',\n",
              "          'LocationZip': 'Kharkiv',\n",
              "          'LocationCountry': 'Ukraine'},\n",
              "         {'LocationFacility': \"Institute of Gerontology Parkinson's Disease Center\",\n",
              "          'LocationCity': 'Kiev',\n",
              "          'LocationZip': '04114',\n",
              "          'LocationCountry': 'Ukraine'},\n",
              "         {'LocationFacility': 'Neurology department of Lviv regional clinical hospital',\n",
              "          'LocationCity': 'Lviv',\n",
              "          'LocationZip': '79010',\n",
              "          'LocationCountry': 'Ukraine'},\n",
              "         {'LocationFacility': 'Neurology department of Medical Dental Academy based on Poltava regional hospital',\n",
              "          'LocationCity': 'Poltava',\n",
              "          'LocationZip': '36000',\n",
              "          'LocationCountry': 'Ukraine'},\n",
              "         {'LocationFacility': 'Neurology department of Vinnitsa Medical University',\n",
              "          'LocationCity': 'Vinnitsa',\n",
              "          'LocationZip': '21018',\n",
              "          'LocationCountry': 'Ukraine'},\n",
              "         {'LocationFacility': 'Neurology department, Zaporozhye State Medical University',\n",
              "          'LocationCity': 'Zaporozhye',\n",
              "          'LocationZip': '69035',\n",
              "          'LocationCountry': 'Ukraine'}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24055014',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, Hsu A, O'Connell M, Kell S, Gupta S; APEX-PD Investigators. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014 Feb;20(2):142-8. doi: 10.1016/j.parkreldis.2013.08.017. Epub 2013 Sep 5.\"}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'Following enrollment, subjects were randomized into one of the four treatment groups.',\n",
              "       'FlowRecruitmentDetails': 'First patient enrolled: 4/13/2009 Last patient out 10/05/2010',\n",
              "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
              "          'FlowGroupTitle': 'Placebo',\n",
              "          'FlowGroupDescription': 'Placebo capsules were used'},\n",
              "         {'FlowGroupId': 'FG001',\n",
              "          'FlowGroupTitle': 'IPX066 145 mg LD',\n",
              "          'FlowGroupDescription': 'IPX066 capsule containing 145 mg levodopa and 36.25 mg carbidopa'},\n",
              "         {'FlowGroupId': 'FG002',\n",
              "          'FlowGroupTitle': 'IPX066 245 mg LD',\n",
              "          'FlowGroupDescription': 'IPX066 capsules containing 245 mg levodopa and 61.25 mg carbidopa'},\n",
              "         {'FlowGroupId': 'FG003',\n",
              "          'FlowGroupTitle': 'IPX066 390 mg LD',\n",
              "          'FlowGroupDescription': 'IPX066 capsules that contained 390 mg levodopa and 97.5 mg carbidopa'}]},\n",
              "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
              "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
              "             'FlowMilestoneComment': 'Baseline',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '92'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '87'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '104'},\n",
              "               {'FlowAchievementGroupId': 'FG003',\n",
              "                'FlowAchievementNumSubjects': '98'}]}},\n",
              "            {'FlowMilestoneType': 'Week 4',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '88'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '79'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '94'},\n",
              "               {'FlowAchievementGroupId': 'FG003',\n",
              "                'FlowAchievementNumSubjects': '86'}]}},\n",
              "            {'FlowMilestoneType': 'Week 9',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '80'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '73'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '88'},\n",
              "               {'FlowAchievementGroupId': 'FG003',\n",
              "                'FlowAchievementNumSubjects': '78'}]}},\n",
              "            {'FlowMilestoneType': 'Week 16',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '74'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '73'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '87'},\n",
              "               {'FlowAchievementGroupId': 'FG003',\n",
              "                'FlowAchievementNumSubjects': '74'}]}},\n",
              "            {'FlowMilestoneType': 'Week 23',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '71'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '72'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '85'},\n",
              "               {'FlowAchievementGroupId': 'FG003',\n",
              "                'FlowAchievementNumSubjects': '74'}]}},\n",
              "            {'FlowMilestoneType': 'COMPLETED',\n",
              "             'FlowMilestoneComment': 'Week 30',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '71'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '72'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '83'},\n",
              "               {'FlowAchievementGroupId': 'FG003',\n",
              "                'FlowAchievementNumSubjects': '74'}]}},\n",
              "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '21'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '15'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '21'},\n",
              "               {'FlowAchievementGroupId': 'FG003',\n",
              "                'FlowAchievementNumSubjects': '24'}]}}]},\n",
              "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Adverse Event',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '4'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '5'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '15'},\n",
              "               {'FlowReasonGroupId': 'FG003',\n",
              "                'FlowReasonNumSubjects': '15'}]}},\n",
              "            {'FlowDropWithdrawType': 'Death',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '0'}]}},\n",
              "            {'FlowDropWithdrawType': 'Lack of Efficacy',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '12'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '4'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '1'}]}},\n",
              "            {'FlowDropWithdrawType': 'Lost to Follow-up',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '0'}]}},\n",
              "            {'FlowDropWithdrawType': 'Protocol Violation',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '2'}]}},\n",
              "            {'FlowDropWithdrawType': 'Withdrawal by Subject',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '4'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '3'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '3'}]}},\n",
              "            {'FlowDropWithdrawType': 'Noncompliance',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '1'}]}},\n",
              "            {'FlowDropWithdrawType': 'Other',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '2'},\n",
              "               {'FlowReasonGroupId': 'FG003',\n",
              "                'FlowReasonNumSubjects': '2'}]}}]}}]}},\n",
              "      'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'Baseline Analysis Population is all treated',\n",
              "       'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
              "          'BaselineGroupTitle': 'Placebo',\n",
              "          'BaselineGroupDescription': 'Placebo capsules were used'},\n",
              "         {'BaselineGroupId': 'BG001',\n",
              "          'BaselineGroupTitle': 'IPX066 145 mg LD',\n",
              "          'BaselineGroupDescription': 'IPX066 capsules containing 145 mg levodopa and 36.25 mg carbidopa'},\n",
              "         {'BaselineGroupId': 'BG002',\n",
              "          'BaselineGroupTitle': 'IPX066 245 mg LD',\n",
              "          'BaselineGroupDescription': 'IPX066 capsules containing 245 mg levodopa and 61.25 mg carbidopa'},\n",
              "         {'BaselineGroupId': 'BG003',\n",
              "          'BaselineGroupTitle': 'IPX066 390 mg LD',\n",
              "          'BaselineGroupDescription': 'IPX066 capsules containing 390 mg levodopa and 97.5 mg carbidopa'},\n",
              "         {'BaselineGroupId': 'BG004',\n",
              "          'BaselineGroupTitle': 'Total',\n",
              "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
              "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
              "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
              "             'BaselineDenomCountValue': '92'},\n",
              "            {'BaselineDenomCountGroupId': 'BG001',\n",
              "             'BaselineDenomCountValue': '87'},\n",
              "            {'BaselineDenomCountGroupId': 'BG002',\n",
              "             'BaselineDenomCountValue': '104'},\n",
              "            {'BaselineDenomCountGroupId': 'BG003',\n",
              "             'BaselineDenomCountValue': '98'},\n",
              "            {'BaselineDenomCountGroupId': 'BG004',\n",
              "             'BaselineDenomCountValue': '381'}]}}]},\n",
              "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous',\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'years',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '65.4',\n",
              "                   'BaselineMeasurementSpread': '9.43'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '63.8',\n",
              "                   'BaselineMeasurementSpread': '9.81'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '65.2',\n",
              "                   'BaselineMeasurementSpread': '9.73'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '64.8',\n",
              "                   'BaselineMeasurementSpread': '9.32'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '64.8',\n",
              "                   'BaselineMeasurementSpread': '9.55'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '40'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '40'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '45'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '44'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '169'}]}},\n",
              "               {'BaselineCategoryTitle': 'Male',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '52'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '47'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '59'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '54'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '212'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '3'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '5'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '7'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '4'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '19'}]}},\n",
              "               {'BaselineCategoryTitle': 'Not Hispanic or Latino',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '87'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '78'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '91'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '89'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '345'}]}},\n",
              "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '2'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '4'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '6'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '5'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '17'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Race/Ethnicity, Customized',\n",
              "          'BaselineMeasureParamType': 'Number',\n",
              "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Asian',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '1'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '1'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '2'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Black or African American',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '2'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '2'}]}}]}},\n",
              "            {'BaselineClassTitle': 'White',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '90'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '87'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '102'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '96'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '375'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Other',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '1'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '1'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '2'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
              "          'BaselineMeasureParamType': 'Number',\n",
              "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Canada',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '10'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '9'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '9'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '9'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '37'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Latvia',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '1'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '1'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '2'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Romania',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '13'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '13'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '15'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '14'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '55'}]}}]}},\n",
              "            {'BaselineClassTitle': 'United States',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '30'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '29'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '37'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '38'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '134'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Ukraine',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '28'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '29'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '32'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '26'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '115'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Lithuania',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '7'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '4'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '8'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '8'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '27'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Estonia',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '3'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '2'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '3'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '3'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '11'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': \"Age at Parkinson's disease onset\",\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'years',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '63.7',\n",
              "                   'BaselineMeasurementSpread': '9.48'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '61.7',\n",
              "                   'BaselineMeasurementSpread': '10.71'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '63.6',\n",
              "                   'BaselineMeasurementSpread': '10.43'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '63.0',\n",
              "                   'BaselineMeasurementSpread': '9.38'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '63.0',\n",
              "                   'BaselineMeasurementSpread': '10.00'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': \"Duration of Parkinson's disease\",\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'years',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '1.8',\n",
              "                   'BaselineMeasurementSpread': '2.01'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '2.3',\n",
              "                   'BaselineMeasurementSpread': '3.08'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '1.8',\n",
              "                   'BaselineMeasurementSpread': '1.85'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '2.0',\n",
              "                   'BaselineMeasurementSpread': '2.33'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '2.0',\n",
              "                   'BaselineMeasurementSpread': '2.34'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'UPDRS Parts II and III Score',\n",
              "          'BaselineMeasureDescription': \"Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome.\\n\\nSubscales II and III were summed:\\n\\nPart I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25\",\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '36.3',\n",
              "                   'BaselineMeasurementSpread': '11.89'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '36.1',\n",
              "                   'BaselineMeasurementSpread': '13.56'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '38.1',\n",
              "                   'BaselineMeasurementSpread': '15.63'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '36.3',\n",
              "                   'BaselineMeasurementSpread': '13.04'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '36.7',\n",
              "                   'BaselineMeasurementSpread': '13.63'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Hoehn and Yahr Stage',\n",
              "          'BaselineMeasureDescription': \"Hoehn and Yahr Staging of Parkinson's Disease: Stages move from 1 - 5 with the worse outcome stage being Stage 5.\\n\\nStage 1 = Symptoms on one side of the body only. Stage 2 = Symptoms on both sides of the body, No impairment of balance. Stage 3 = Balance impairment. Mild to moderate disease. Physically independent. Stage 4 = Severe disability but still able to walk or stand unassisted. Stage 5 = Wheelchair bound or bedridden unless assisted.\",\n",
              "          'BaselineMeasureParamType': 'Number',\n",
              "          'BaselineMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Stage I',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '7'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '6'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '13'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '14'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '40'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Stage II',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '69'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '62'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '65'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '62'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '258'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Remaining',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '16'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '19'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '26'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '22'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '83'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'MMSE',\n",
              "          'BaselineMeasureDescription': 'The Mini-Mental State Examination (MMSE) is a 30-point questionnaire that is used extensively to measure cognitive impairment. Any score greater than or equal to 24 points (out of 30) indicates a normal cognition. Below this, scores can indicate severe (9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment.',\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '28.9',\n",
              "                   'BaselineMeasurementSpread': '1.18'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '29.0',\n",
              "                   'BaselineMeasurementSpread': '1.27'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '28.7',\n",
              "                   'BaselineMeasurementSpread': '1.21'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '28.9',\n",
              "                   'BaselineMeasurementSpread': '1.18'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG004',\n",
              "                   'BaselineMeasurementValue': '28.9',\n",
              "                   'BaselineMeasurementSpread': '1.21'}]}}]}}]}}]}},\n",
              "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': 'Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30',\n",
              "          'OutcomeMeasureDescription': \"Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) + UPDRS Part III (Motor Examination) at Week 30 (End of Study).\\n\\nUnified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome.\\n\\nSubscales II and III were summed:\\n\\nPart I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25\",\n",
              "          'OutcomeMeasurePopulationDescription': 'Analysis included all treated subjects with at least one efficacy measurement after dosing. Subjects who had no post-baseline efficacy assessments (N4) and those who had early termination assessments>3 days after last dose and no other post-baseline measurements (N16) were not included in the efficacy analysis set. Randomized (381)-(4+16) = 361.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Week 30',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Placebo',\n",
              "             'OutcomeGroupDescription': 'Placebo capsules were used'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'IPX066 145mg LD',\n",
              "             'OutcomeGroupDescription': 'IPX066 capsules containing 145 mg levodopa and 36.25 mg carbidopa'},\n",
              "            {'OutcomeGroupId': 'OG002',\n",
              "             'OutcomeGroupTitle': 'IPX066 245 mg LD',\n",
              "             'OutcomeGroupDescription': 'IPX066 capsules containing 245 mg levodopa and 61.25 mg carbidopa'},\n",
              "            {'OutcomeGroupId': 'OG003',\n",
              "             'OutcomeGroupTitle': 'IPX066 390 mg LD',\n",
              "             'OutcomeGroupDescription': 'IPX066 capsules containing 390 mg levodopa and 97.5 mg carbidopa'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '90'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '82'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG002',\n",
              "                'OutcomeDenomCountValue': '99'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG003',\n",
              "                'OutcomeDenomCountValue': '90'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.6',\n",
              "                   'OutcomeMeasurementSpread': '10.37'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-11.7',\n",
              "                   'OutcomeMeasurementSpread': '10.97'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '-12.9',\n",
              "                   'OutcomeMeasurementSpread': '11.42'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG003',\n",
              "                   'OutcomeMeasurementValue': '-14.9',\n",
              "                   'OutcomeMeasurementSpread': '11.85'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Summary of Change From Baseline to End of Study in Mean Parkinson's Disease Questionnaire-39 (PDQ-39) Score\",\n",
              "          'OutcomeMeasureDescription': 'Change from Baseline in Parkinson\\'s disease Questionnaire 39 (PDQ-39) at Weeks 4, 9, 16, 23 and 30 or early discontinuation was collected. The PDQ-39 is a self-reported questionnaire consisting of 39 questions regarding the subjects mobility and the responses consist of \"Never\" (better in outcome), (value 0), \"Occasionally\" (value 1), \"Sometimes\" (value 2), , \"Often\" (value 3), and \"Always\" (value 4), (worse in outcome). The minimum possible score is \"0\" and the maximum is \"156\". The outcome measure calculated was the change from baseline to end of study in mean PDQ-39 score. Negative values indicate a better result.',\n",
              "          'OutcomeMeasurePopulationDescription': 'Subjects who had no postbaseline efficacy assessments (N=4) and those who had early termination assessments >3 days after last dose and no other postbaseline measurements (N=16) were not included in the efficacy analysis. 2 subjects without a baseline measurement, 1 each from 145mg and 390mg arm were also excluded. Randomized 381-4-16-2=359.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'score on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline and Week 30 (or End of Study)',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'IPX066 145 mg LD',\n",
              "             'OutcomeGroupDescription': 'IPX066 capsules containing 145 mg levodopa and 36.25 mg carbidopa'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'IPX066 245 mg LD',\n",
              "             'OutcomeGroupDescription': 'IPX066 capsules containing 245 mg levodopa and 61.25 mg carbidopa'},\n",
              "            {'OutcomeGroupId': 'OG002',\n",
              "             'OutcomeGroupTitle': 'IPX066 390 mg LD',\n",
              "             'OutcomeGroupDescription': 'IPX066 capsules containing 390 mg levodopa and 97.5 mg carbidopa'},\n",
              "            {'OutcomeGroupId': 'OG003',\n",
              "             'OutcomeGroupTitle': 'Placebo',\n",
              "             'OutcomeGroupDescription': 'Placebo capsules were used'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '81'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '99'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG002',\n",
              "                'OutcomeDenomCountValue': '89'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG003',\n",
              "                'OutcomeDenomCountValue': '90'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-4.4',\n",
              "                   'OutcomeMeasurementSpread': '12.18'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-3.8',\n",
              "                   'OutcomeMeasurementSpread': '12.16'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '-6.0',\n",
              "                   'OutcomeMeasurementSpread': '12.30'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG003',\n",
              "                   'OutcomeMeasurementValue': '0.6',\n",
              "                   'OutcomeMeasurementSpread': '11.10'}]}}]}}]}}]}},\n",
              "      'AdverseEventsModule': {'EventsFrequencyThreshold': '5',\n",
              "       'EventsTimeFrame': '1 year, 6 months',\n",
              "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
              "          'EventGroupTitle': 'Placebo',\n",
              "          'EventGroupDescription': 'Placebo capsules were used',\n",
              "          'EventGroupSeriousNumAffected': '3',\n",
              "          'EventGroupSeriousNumAtRisk': '92',\n",
              "          'EventGroupOtherNumAffected': '26',\n",
              "          'EventGroupOtherNumAtRisk': '92'},\n",
              "         {'EventGroupId': 'EG001',\n",
              "          'EventGroupTitle': 'IPX066 145 mg LD',\n",
              "          'EventGroupDescription': 'IPX066 capsules containing 145 mg levodopa and 36.25 mg carbidopa',\n",
              "          'EventGroupSeriousNumAffected': '4',\n",
              "          'EventGroupSeriousNumAtRisk': '87',\n",
              "          'EventGroupOtherNumAffected': '27',\n",
              "          'EventGroupOtherNumAtRisk': '87'},\n",
              "         {'EventGroupId': 'EG002',\n",
              "          'EventGroupTitle': 'IPX066 245 mg LD',\n",
              "          'EventGroupDescription': 'IPX066 capsules containing 245 mg levodopa and 61.25 mg carbidopa',\n",
              "          'EventGroupSeriousNumAffected': '5',\n",
              "          'EventGroupSeriousNumAtRisk': '104',\n",
              "          'EventGroupOtherNumAffected': '47',\n",
              "          'EventGroupOtherNumAtRisk': '104'},\n",
              "         {'EventGroupId': 'EG003',\n",
              "          'EventGroupTitle': 'IPX066 390 mg LD',\n",
              "          'EventGroupDescription': 'IPX066 capsules containing 390 mg levodopa and 97.5 mg carbidopa',\n",
              "          'EventGroupSeriousNumAffected': '2',\n",
              "          'EventGroupSeriousNumAtRisk': '98',\n",
              "          'EventGroupOtherNumAffected': '48',\n",
              "          'EventGroupOtherNumAtRisk': '98'}]},\n",
              "       'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Acute myocardial infarction',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Atrioventricular block complete',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Coronary artery disease',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Myocardial infarction',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Abdominal strangulated hernia',\n",
              "          'SeriousEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Escherichia urinary tract infection',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Urinary tract infection',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Urosepsis',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Osteoarthritis',\n",
              "          'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': \"Non-Hodgkin's Lymphoma\",\n",
              "          'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Cerebrovascular accident',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Chronic obstructive pulmonary disease',\n",
              "          'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Emphysema',\n",
              "          'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Coronary Artery Bypass',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}},\n",
              "         {'SeriousEventTerm': 'Prostatectomy',\n",
              "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumEvents': '1',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '92'},\n",
              "            {'SeriousEventStatsGroupId': 'EG001',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '87'},\n",
              "            {'SeriousEventStatsGroupId': 'EG002',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '104'},\n",
              "            {'SeriousEventStatsGroupId': 'EG003',\n",
              "             'SeriousEventStatsNumEvents': '0',\n",
              "             'SeriousEventStatsNumAffected': '0',\n",
              "             'SeriousEventStatsNumAtRisk': '98'}]}}]},\n",
              "       'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Nausea',\n",
              "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '8',\n",
              "             'OtherEventStatsNumAtRisk': '92'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumAffected': '12',\n",
              "             'OtherEventStatsNumAtRisk': '87'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumAffected': '20',\n",
              "             'OtherEventStatsNumAtRisk': '104'},\n",
              "            {'OtherEventStatsGroupId': 'EG003',\n",
              "             'OtherEventStatsNumAffected': '20',\n",
              "             'OtherEventStatsNumAtRisk': '98'}]}},\n",
              "         {'OtherEventTerm': 'Headache',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '10',\n",
              "             'OtherEventStatsNumAtRisk': '92'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumAffected': '6',\n",
              "             'OtherEventStatsNumAtRisk': '87'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumAffected': '13',\n",
              "             'OtherEventStatsNumAtRisk': '104'},\n",
              "            {'OtherEventStatsGroupId': 'EG003',\n",
              "             'OtherEventStatsNumAffected': '17',\n",
              "             'OtherEventStatsNumAtRisk': '98'}]}},\n",
              "         {'OtherEventTerm': 'Dizziness',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '92'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumAffected': '8',\n",
              "             'OtherEventStatsNumAtRisk': '87'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumAffected': '20',\n",
              "             'OtherEventStatsNumAtRisk': '104'},\n",
              "            {'OtherEventStatsGroupId': 'EG003',\n",
              "             'OtherEventStatsNumAffected': '12',\n",
              "             'OtherEventStatsNumAtRisk': '98'}]}},\n",
              "         {'OtherEventTerm': 'Insomnia',\n",
              "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '92'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '87'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumAffected': '9',\n",
              "             'OtherEventStatsNumAtRisk': '104'},\n",
              "            {'OtherEventStatsGroupId': 'EG003',\n",
              "             'OtherEventStatsNumAffected': '6',\n",
              "             'OtherEventStatsNumAtRisk': '98'}]}},\n",
              "         {'OtherEventTerm': 'Abnormal dreams',\n",
              "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '92'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '87'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumAffected': '6',\n",
              "             'OtherEventStatsNumAtRisk': '104'},\n",
              "            {'OtherEventStatsGroupId': 'EG003',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '98'}]}},\n",
              "         {'OtherEventTerm': 'Dry Mouth',\n",
              "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '92'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '87'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '104'},\n",
              "            {'OtherEventStatsGroupId': 'EG003',\n",
              "             'OtherEventStatsNumAffected': '7',\n",
              "             'OtherEventStatsNumAtRisk': '98'}]}},\n",
              "         {'OtherEventTerm': 'Vomiting',\n",
              "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '92'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '87'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '104'},\n",
              "            {'OtherEventStatsGroupId': 'EG003',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '98'}]}},\n",
              "         {'OtherEventTerm': 'Constipation',\n",
              "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '92'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '87'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumAffected': '6',\n",
              "             'OtherEventStatsNumAtRisk': '104'},\n",
              "            {'OtherEventStatsGroupId': 'EG003',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '98'}]}},\n",
              "         {'OtherEventTerm': 'Dyskinesia',\n",
              "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '92'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '87'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumAffected': '4',\n",
              "             'OtherEventStatsNumAtRisk': '104'},\n",
              "            {'OtherEventStatsGroupId': 'EG003',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '98'}]}},\n",
              "         {'OtherEventTerm': 'Anxiety',\n",
              "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '0',\n",
              "             'OtherEventStatsNumAtRisk': '92'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '87'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '104'},\n",
              "            {'OtherEventStatsGroupId': 'EG003',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '98'}]}},\n",
              "         {'OtherEventTerm': 'Depression',\n",
              "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '92'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '87'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '104'},\n",
              "            {'OtherEventStatsGroupId': 'EG003',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '98'}]}},\n",
              "         {'OtherEventTerm': 'Orthostatic Hypotension',\n",
              "          'OtherEventOrganSystem': 'Vascular disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA (12.0)',\n",
              "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '92'},\n",
              "            {'OtherEventStatsGroupId': 'EG001',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '87'},\n",
              "            {'OtherEventStatsGroupId': 'EG002',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '104'},\n",
              "            {'OtherEventStatsGroupId': 'EG003',\n",
              "             'OtherEventStatsNumAffected': '5',\n",
              "             'OtherEventStatsNumAtRisk': '98'}]}}]}},\n",
              "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
              "        'AgreementRestrictionType': 'OTHER',\n",
              "        'AgreementRestrictiveAgreement': 'Yes',\n",
              "        'AgreementOtherDetails': 'Publication of the results of the Study conducted at the Site shall not be made before the first multi-site publication by Sponsor.'},\n",
              "       'PointOfContact': {'PointOfContactTitle': 'Kaihong Jiang, Senior Director, Head of Biometrics',\n",
              "        'PointOfContactOrganization': 'Impax Laboratories, LLC',\n",
              "        'PointOfContactEMail': 'kaihong.jiang@amneal.com',\n",
              "        'PointOfContactPhone': '908-307-2234'}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}},\n",
              "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'C000009265',\n",
              "          'InterventionMeshTerm': 'Carbidopa, levodopa drug combination'},\n",
              "         {'InterventionMeshId': 'D000002230',\n",
              "          'InterventionMeshTerm': 'Carbidopa'},\n",
              "         {'InterventionMeshId': 'D000007980',\n",
              "          'InterventionMeshTerm': 'Levodopa'}]},\n",
              "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000276',\n",
              "          'InterventionAncestorTerm': 'Adjuvants, Immunologic'},\n",
              "         {'InterventionAncestorId': 'D000007155',\n",
              "          'InterventionAncestorTerm': 'Immunologic Factors'},\n",
              "         {'InterventionAncestorId': 'D000045505',\n",
              "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'},\n",
              "         {'InterventionAncestorId': 'D000000978',\n",
              "          'InterventionAncestorTerm': 'Antiparkinson Agents'},\n",
              "         {'InterventionAncestorId': 'D000018726',\n",
              "          'InterventionAncestorTerm': 'Anti-Dyskinesia Agents'},\n",
              "         {'InterventionAncestorId': 'D000018491',\n",
              "          'InterventionAncestorTerm': 'Dopamine Agonists'},\n",
              "         {'InterventionAncestorId': 'D000015259',\n",
              "          'InterventionAncestorTerm': 'Dopamine Agents'},\n",
              "         {'InterventionAncestorId': 'D000018377',\n",
              "          'InterventionAncestorTerm': 'Neurotransmitter Agents'},\n",
              "         {'InterventionAncestorId': 'D000045504',\n",
              "          'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'},\n",
              "         {'InterventionAncestorId': 'D000065105',\n",
              "          'InterventionAncestorTerm': 'Aromatic Amino Acid Decarboxylase Inhibitors'},\n",
              "         {'InterventionAncestorId': 'D000004791',\n",
              "          'InterventionAncestorTerm': 'Enzyme Inhibitors'}]},\n",
              "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M250568',\n",
              "          'InterventionBrowseLeafName': 'Carbidopa, levodopa drug combination',\n",
              "          'InterventionBrowseLeafAsFound': 'OMP-',\n",
              "          'InterventionBrowseLeafRelevance': 'high'},\n",
              "         {'InterventionBrowseLeafId': 'M10134',\n",
              "          'InterventionBrowseLeafName': 'Levodopa',\n",
              "          'InterventionBrowseLeafAsFound': 'OMP-',\n",
              "          'InterventionBrowseLeafRelevance': 'high'},\n",
              "         {'InterventionBrowseLeafId': 'M4641',\n",
              "          'InterventionBrowseLeafName': 'Carbidopa',\n",
              "          'InterventionBrowseLeafAsFound': 'OMP-',\n",
              "          'InterventionBrowseLeafRelevance': 'high'},\n",
              "         {'InterventionBrowseLeafId': 'M2780',\n",
              "          'InterventionBrowseLeafName': 'Adjuvants, Immunologic',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M9353',\n",
              "          'InterventionBrowseLeafName': 'Immunologic Factors',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M3447',\n",
              "          'InterventionBrowseLeafName': 'Antiparkinson Agents',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M6625',\n",
              "          'InterventionBrowseLeafName': 'Dopamine',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M19748',\n",
              "          'InterventionBrowseLeafName': 'Dopamine Agonists',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M17114',\n",
              "          'InterventionBrowseLeafName': 'Dopamine Agents',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M19657',\n",
              "          'InterventionBrowseLeafName': 'Neurotransmitter Agents',\n",
              "          'InterventionBrowseLeafRelevance': 'low'},\n",
              "         {'InterventionBrowseLeafId': 'M29614',\n",
              "          'InterventionBrowseLeafName': 'Aromatic Amino Acid Decarboxylase Inhibitors',\n",
              "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
              "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'AnDyAg',\n",
              "          'InterventionBrowseBranchName': 'Anti-Dyskinesia Agents'},\n",
              "         {'InterventionBrowseBranchAbbrev': 'All',\n",
              "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'},\n",
              "         {'InterventionBrowseBranchAbbrev': 'CaAg',\n",
              "          'InterventionBrowseBranchName': 'Cardiotonic Agents'}]}}}}},\n",
              "   {'Rank': 30,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02763683',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '201512032'},\n",
              "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01NS075321',\n",
              "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
              "          'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/R01NS075321'}]},\n",
              "       'Organization': {'OrgFullName': 'Washington University School of Medicine',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': 'Investigations of Dementia in Parkinson Disease',\n",
              "       'OfficialTitle': 'Investigations of Dementia in Parkinson Disease',\n",
              "       'Acronym': 'PIB'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'May 2021',\n",
              "       'OverallStatus': 'Recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'June 2016'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2030',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'March 2030',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'April 28, 2016',\n",
              "       'StudyFirstSubmitQCDate': 'May 3, 2016',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 5, 2016',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'May 12, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 13, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Washington University School of Medicine',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institutes of Health (NIH)',\n",
              "          'CollaboratorClass': 'NIH'},\n",
              "         {'CollaboratorName': 'National Institute of Neurological Disorders and Stroke (NINDS)',\n",
              "          'CollaboratorClass': 'NIH'},\n",
              "         {'CollaboratorName': 'National Institute on Aging (NIA)',\n",
              "          'CollaboratorClass': 'NIH'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': 'The purpose of this study is to use a brain imaging method called Pittsburgh B (PIB) Positron Emission Tomography (PET) and Vesicular Cholinergic Transport (VAT) PET to determine dementia subtypes in patients with Parkinson disease (PD). The ultimate goal of this project is to be able to identify individuals with PD who are at risk of developing dementia, and to distinguish the underlying cause of dementia.',\n",
              "       'DetailedDescription': 'The purpose of this study is to use a brain imaging method called PIB PET and VAT PET to determine dementia subtypes in patients with Parkinson disease (PD). The ultimate goal of this project is to be able to identify individuals with PD who are at risk of developing dementia, and to distinguish the underlying cause of dementia. The investigators will be including both PD and normal subjects in this study. This a long term study and we are considering including a total of 320 participants in this protocol.'},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinsons']},\n",
              "       'KeywordList': {'Keyword': ['Parkinsons Disease',\n",
              "         'PET Imaging',\n",
              "         'PIB',\n",
              "         'VAT',\n",
              "         'Dementia']}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'No',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
              "       'BioSpec': {'BioSpecRetention': 'Samples With DNA',\n",
              "        'BioSpecDescription': 'whole blood'},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '320',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Parkinsons Disease',\n",
              "          'ArmGroupDescription': 'Individuals with Parkinsons Disease',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Radiation: PiB and VAT']}},\n",
              "         {'ArmGroupLabel': 'Healthy Controls',\n",
              "          'ArmGroupDescription': 'Individuals without Parkinsons Disease',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Radiation: PiB and VAT']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Radiation',\n",
              "          'InterventionName': 'PiB and VAT',\n",
              "          'InterventionDescription': 'There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy Controls',\n",
              "            'Parkinsons Disease']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Investigations of Dementia in Parkinsons Disease',\n",
              "          'PrimaryOutcomeDescription': 'The investigators will perform memory/thinking testing, Lumbar puncture (LP), Magnetic Resonance Imaging (MRI) and (PET) scans to help to determine the cause(s) of memory and thinking in Parkinson Disease.\\n\\nThe memory and thinking testing by phone on average at 1.5 years through study completion and then in person on average at 3 years through study completion, this will help monitor if there is any decline in memory and thinking.\\n\\nThe Lumbar Puncture is done on willing participants on average at 3 years through study completion to assess for any abnormal proteins and correlate these with any changes in memory and thinking.\\n\\nThe MRI is done on average at 3 years through study completion for any abnormal signs or changes in regards to dementia at 3 years.\\n\\nThe (PiB) & (VAT) PET scans will be performed on average at 3 years through study completion, which will be analyzed to assess for changes in regards to abnormal proteins and signs of dementia.',\n",
              "          'PrimaryOutcomeTimeFrame': '2030'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPD patients must exhibit three of the following cardinal signs: rest tremor, rigidity, bradykinesia, or postural instability; or two of these features with one of the first three displaying asymmetry.\\n\\nExclusion Criteria:\\n\\nhistory of head trauma, major neurological or psychiatric diseases other than Parkinson disease and dementia, e.g. stroke, multiple sclerosis, depression or schizophrenia.\\nsevere systemic diseases.\\ninability to lie still for 90 minutes.\\nmetallic implants, pacemakers, or any other contraindication to MRI.\\nrefusal to consent to brain donation.',\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '50 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': 'Participants with and without Parkinson disease will be recruited from the Movement Disorders Center at Washington University, the St. Louis metro area, and throughout the midwest region.',\n",
              "       'SamplingMethod': 'Non-Probability Sample'},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Andrea Slavik, RN, BSN',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '3145807553',\n",
              "          'CentralContactEMail': 'andreaslavik@wustl.edu'},\n",
              "         {'CentralContactName': 'Enid McIntosh',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '314-362-6026',\n",
              "          'CentralContactEMail': 'enidmcintosh@wustl.edu'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Joel S Perlmutter, MD',\n",
              "          'OverallOfficialAffiliation': 'Washington University School of Medicine',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Washington University in St. Louis',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Saint Louis',\n",
              "          'LocationState': 'Missouri',\n",
              "          'LocationZip': '63110',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly McVey, BSN',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '314-362-0420',\n",
              "             'LocationContactEMail': 'mcveyk@wustl.edu'},\n",
              "            {'LocationContactName': 'Enid McIntosh',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '314-362-6026',\n",
              "             'LocationContactEMail': 'enidmcintosh@wustl.edu'}]}}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'Yes',\n",
              "       'IPDSharingDescription': 'de-identified data that has been published will be shared upon request.',\n",
              "       'IPDSharingInfoTypeList': {'IPDSharingInfoType': ['Informed Consent Form (ICF)']},\n",
              "       'IPDSharingTimeFrame': 'after publication of the results',\n",
              "       'IPDSharingAccessCriteria': 'request from a legitimate investigator with a proposal sent to and approved by Joel S Perlmutter at Washington University.'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'},\n",
              "         {'ConditionMeshId': 'D000003704', 'ConditionMeshTerm': 'Dementia'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'},\n",
              "         {'ConditionAncestorId': 'D000019965',\n",
              "          'ConditionAncestorTerm': 'Neurocognitive Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001523',\n",
              "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6056',\n",
              "          'ConditionBrowseLeafName': 'Dementia',\n",
              "          'ConditionBrowseLeafAsFound': 'Dementia',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20989',\n",
              "          'ConditionBrowseLeafName': 'Neurocognitive Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M13625',\n",
              "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3967',\n",
              "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
              "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 31,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05084209',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'K23NR019099-01A1',\n",
              "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
              "        'OrgStudyIdLink': 'https://reporter.nih.gov/quickSearch/K23NR019099-01A1'},\n",
              "       'Organization': {'OrgFullName': 'Purdue University',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Preparing Patient-Caregiver Dyads With Parkinson's Disease for Future Decision Making\",\n",
              "       'OfficialTitle': \"Preparing Patient-Caregiver Dyads With Parkinson's Disease for End-of-Life Decision Making\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'October 2021',\n",
              "       'OverallStatus': 'Not yet recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'December 2022',\n",
              "        'StartDateType': 'Anticipated'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2023',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'December 2023',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'September 25, 2021',\n",
              "       'StudyFirstSubmitQCDate': 'October 6, 2021',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 19, 2021',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'October 6, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 19, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Jiayun Xu',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Assistant Professor',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Purdue University'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Purdue University',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Persons with Parkinson's disease and family care partners are often unprepared to make difficult, future medical decisions. Earlier conversations about future medical decisions between persons with Parkinson's disease and family care partners are needed before communication and cognitive difficulties become severe. In this study, the investigators will pilot test a novel dyadic intervention to help persons with Parkinson's disease and family care partners make future medical decisions. The investigators hypothesize the intervention will be feasible and acceptable among persons with Parkinson's disease and family care partners.\",\n",
              "       'DetailedDescription': \"Investigators are looking for pairs of participants consisting of a person with a diagnosis of Parkinson's Disease, and a family care partner who is most likely to help make medical decisions in the future.\\n\\nFor this study, pairs will complete a survey to understand how engaged participants are in discussing future medical decisions, demographics, and the severity of Parkinson's disease. This survey will take about half an hour. Then, participants will work through a medical decision making support intervention together. Completing the intervention in-person, on the phone, or via video conferencing is acceptable. The resources will provide information on future medical decisions participants may need to make. The intervention is completely online and will take about 30 minutes to complete. Participants will have 2 weeks to complete the intervention.\\n\\nThe investigators will call participants a week after enrollment to ask about technical difficulties completing the intervention, provide assistance with intervention material navigation as needed, and answer questions about the intervention. Participants will receive another online survey 2 weeks after enrollment to understand engagement in discussing future medical decisions, and acceptability of the intervention. The 2 week survey will take about 15 minutes to complete.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': ['end of life',\n",
              "         'medical decision making',\n",
              "         'advanced illness',\n",
              "         'family']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'N/A',\n",
              "        'DesignInterventionModel': 'Single Group Assignment',\n",
              "        'DesignPrimaryPurpose': 'Supportive Care',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '72',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Parkinson's medical decision making support intervention group\",\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'All participants will complete an online medical decision making intervention, lasting about 30 minutes, and complete pre and post surveys.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Behavioral: Parkinson's medical decision making support\"]}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
              "          'InterventionName': \"Parkinson's medical decision making support\",\n",
              "          'InterventionDescription': \"Participants will be asked to view and work through medical decision making support resources. The resources will include information on medical decisions that may occur in Parkinson's disease, and general medical decisions that anyone may need to make (i.e. choosing a medical decision maker). The resources will also include suggestions on how to discuss these decisions.\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Parkinson's medical decision making support intervention group\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change from baseline Advance Care Planning Engagement Survey at 2 weeks',\n",
              "          'PrimaryOutcomeDescription': 'Assesses knowledge, contemplation, self-efficacy, and readiness on a 5-point Likert scale.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline, 2 weeks post intervention'},\n",
              "         {'PrimaryOutcomeMeasure': 'Intervention feasibility/acceptability',\n",
              "          'PrimaryOutcomeDescription': 'Ratings of ease of use, helpfulness, and likeliness of recommending the intervention to others on Likert-scales.',\n",
              "          'PrimaryOutcomeTimeFrame': '2 weeks post intervention'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Person with Parkinson's Disease Inclusion Criteria:\\n\\nSelf-report a clinical diagnosis of Parkinson Disease\\nDoes not have a diagnosis of dementia\\nSpeak and read English\\nHave access to a reliable phone or internet connection\\nHave access to an online connection through a smartphone, tablet, or computer device\\nBe comfortable navigating websites or have someone available to assist\\n\\nCare Partner Inclusion Criteria:\\n\\nSelf-identify as the family member who will likely make medical decisions for the person with Parkinson Disease in the future OR who is the legally appointed health care representative\\nSelf-report not having a diagnosis of dementia\\nSpeak and read English\\nHave access to a reliable phone or internet connection\\nHave access to an online connection through a smartphone, tablet, or computer device\\nBe comfortable navigating websites or have someone available to assist\\n\\nExclusion Criteria:\\n\\nCannot see well enough to see words on a newspaper even with corrective lenses\\nUsed the intervention resources before\\nScored below a 28 on the telephone interview for cognitive status tool\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Jiayun Xu',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '765-494-4017',\n",
              "          'CentralContactEMail': 'xu1115@purdue.edu'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jiayun Xu',\n",
              "          'OverallOfficialAffiliation': 'Purdue University',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Purdue University',\n",
              "          'LocationCity': 'West Lafayette',\n",
              "          'LocationState': 'Indiana',\n",
              "          'LocationZip': '47907-2069',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Xu',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '765-494-4017',\n",
              "             'LocationContactEMail': 'xu1115@purdue.edu'}]}}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M5997',\n",
              "          'ConditionBrowseLeafName': 'Death',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
              "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 32,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04876404',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'H19-03166'},\n",
              "       'Organization': {'OrgFullName': \"Pacific Parkinson's Research Centre\",\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Somatotopy in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Somatotopy and Striatal Plasticity in Parkinson's Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'May 2021',\n",
              "       'OverallStatus': 'Recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'January 25, 2021',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 1, 2022',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'May 1, 2022',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'May 3, 2021',\n",
              "       'StudyFirstSubmitQCDate': 'May 3, 2021',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 6, 2021',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'May 3, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 6, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'A. Jon Stoessl',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Professor & Head of Neurology',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': \"Pacific Parkinson's Research Centre\"},\n",
              "       'LeadSponsor': {'LeadSponsorName': \"Pacific Parkinson's Research Centre\",\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of British Columbia',\n",
              "          'CollaboratorClass': 'OTHER'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': 'This study aims to assess changes in connections within the brain in Parkinson\\'s disease (PD). We will invite up to 10 people with PD to participate in this study and complete several brain scans using PET (Positron Emission Tomography) and fMRI (functional Magnetic Resonance Imaging) on the Hybrid PET/MRI scanner. We will also invite 10 participants without PD to complete the same scans for comparison. \"Somatotopy\" refers to how areas of the brain are organized according to the body part they affect. The striatum is the brain region that coordinates complex thinking and movement. Plasticity refers to changes in connections within the brain, which can happen to make up for changes that are related to PD. In this study we will use PET and fMRI imaging together to investigate changes in the striatum in people affected by Parkinson\\'s disease. The hybrid PET/MR scanner allows us to perform simultaneous PET and MRI measurements to investigate this.',\n",
              "       'DetailedDescription': \"Purpose\\n\\nThe current investigation aims to study the altered striatal plasticity in early stage PD versus healthy controls to delineate the functional reorganization of dopaminergic projections in PD neurodegeneration. Analysis will be initially restricted to early PD, when compensatory mechanisms are likely compensating for deficits arising from dopamine deficiency. The use of hybrid PET-MRI imaging will allow for the simultaneous assessment of patterns of striatal activation and functional connectivity, as well as dopamine release induced by a variety of cognitive and motor tasks. In the future, depending upon the findings of this study, we will examine the effects of disease progression on segregation of striatal function. Altered plasticity is likely to contribute to clinical progression of disease and to disease and treatment related complications, thus this investigation may help advance the development of more effective PD treatment measures.\\n\\nThis investigation is intended as a pilot study. We currently do not have data on which to base a power analysis for sample size, however based on our previous experience using a double or triple bolus [11C] raclopride techniques, a sample size of 10 individuals per study group is adequate to detect between-group differences in dopamine release using a single bolus technique. Previous investigations we will be referencing in our study have similarly relied on small sample sizes to obtain their data.\\n\\nWe are specifically interested in tracking functional changes within the brain in early PD, as this is when compensatory mechanisms are still compensating for deficits arising from dopamine deficiency. Thus for the purposes of this investigation we would like to focus on early PD, with the potential to follow the PD cohort in a longitudinal fashion in future investigations, to assess progressive loss of segregation over time.\\n\\nHypotheses\\n\\nIn healthy subjects, there will be segregation of striatal activation as measured by cerebral blood flow determined by BOLD fMRI, as well as striatal dopamine release determined using simultaneous [11C]raclopride PET, according to body site (motor activation) and task type (motor vs. cognitive vs. reward)\\nIn patients with PD, this segregation will be lost in a progressive fashion, in which caudal and dorsal striatal activation and dopamine release are lost first, with these functions shifted to progressively more rostral and ventral regions of the striatum.\\n\\nResearch Design\\n\\nThis is a cross-sectional study on 20 subjects (10 healthy control, 10 PD), involving 2-3 visits per subject to the Pacific Parkinson's Research Centre in UBC, Vancouver, BC. Each study participant will undergo 4 separate scans, 2 scans per day.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'No',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '20',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Parkinson's Disease\",\n",
              "          'ArmGroupDescription': \"Individuals with early stage Parkinson's Disease (diagnosed within the last 5 years)\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: PET/MR Imaging']}},\n",
              "         {'ArmGroupLabel': 'Healthy Controls',\n",
              "          'ArmGroupDescription': 'Healthy control individuals with no neurological or mood disorders.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: PET/MR Imaging']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test',\n",
              "          'InterventionName': 'PET/MR Imaging',\n",
              "          'InterventionDescription': 'The hybrid PET/MR scanner can provide information on brain activity during various motor and cognitive tasks.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy Controls',\n",
              "            \"Parkinson's Disease\"]},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['Positron Emission Tomography and Magnetic Resonance Imaging']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Striatal Dopamine Release',\n",
              "          'PrimaryOutcomeDescription': '[11C]raclopride PET',\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline'},\n",
              "         {'PrimaryOutcomeMeasure': 'Striatal Activation',\n",
              "          'PrimaryOutcomeDescription': 'BOLD fMRI',\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Parkinson's Disease Individuals\\n\\nInclusion Criteria:\\n\\ni. Recently diagnosed with early stage Parkinson's Disease (within 5 years of diagnosis) ii. Between the ages of 50 to 85 iii. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study\\n\\nHealthy Control Individuals\\n\\nInclusion Criteria:\\n\\ni. Healthy male between the ages of 50 and 85 ii. Healthy female between the ages of 50 and 85 iii. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study\\n\\nExclusion Criteria (All Individuals):\\n\\ni. Current or past major psychiatric disorders (e.g. depression, anxiety disorders) or other major neurological disease ii. Current or past substance use problems iii. Serious head injury with loss of consciousness for  5 minutes iv. Fear of enclosed, confined spaces v. Pregnant or breastfeeding vi. Presence of active, recent, or repeated cancer vii. Unstable/undiagnosed medical conditions viii. Certain medications or conditions may impact the ability to participate and these will be discussed on a case by case basis with the study team.\\n\\nix. Weight of more 158 kg x. Inability to remain still during the scans. xi. People for whom MRI is contra-indicated:\\n\\nPeople with a non-MRI safe intrauterine device (IUD);\\nMachinist or Metalworkers;\\nCardiac pacemaker, wires or defibrillator;\\nPast injury where a piece of metal lodged in your eye or orbit;\\nFerromagnetic aneurysm clip;\\nArtificial heart valve;\\nBrain aneurysm clip;\\nElectrical stimulator for nerves or bones or brains;\\nEar or eye implant;\\nImplanted drug infusion pump;\\nCoil, catheter, or filter in any blood vessel;\\nOrthopaedic hardware (artificial joint, plate, screws);\\nOther metallic prostheses;\\nShrapnel, bullets, or other metal fragments;\\nSurgery (brain or otherwise), tattoos or injection into a join in the last 6 weeks\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '50 Years',\n",
              "       'MaximumAge': '85 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': \"People with Parkinson's Disease and those without.\",\n",
              "       'SamplingMethod': 'Non-Probability Sample'},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Alex Pavel',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '4162547734',\n",
              "          'CentralContactEMail': 'alexandra.pavel@alumni.ubc.ca'},\n",
              "         {'CentralContactName': 'Jess McKenzie',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '16048227764',\n",
              "          'CentralContactEMail': 'jess.mckenzie@ubc.ca'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jess McKenzie',\n",
              "          'OverallOfficialAffiliation': \"Pacific Parkinson's Research Centre\",\n",
              "          'OverallOfficialRole': 'Study Director'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Monica Yenko',\n",
              "          'LocationStatus': 'Recruiting',\n",
              "          'LocationCity': 'Vancouver',\n",
              "          'LocationState': 'British Columbia',\n",
              "          'LocationCountry': 'Canada',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Monica Yenko',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '16048271353',\n",
              "             'LocationContactEMail': 'monica.yenko@ubc.ca'},\n",
              "            {'LocationContactName': 'Jess McKenzie',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '+1-604-822-7764',\n",
              "             'LocationContactEMail': 'jess.mckenzie@ubc.ca'},\n",
              "            {'LocationContactName': 'A Jon Stoessl, MD',\n",
              "             'LocationContactRole': 'Principal Investigator'}]}}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 33,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03337464',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'H13-00084'},\n",
              "       'Organization': {'OrgFullName': \"Pacific Parkinson's Research Centre\",\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Single Exercise Bout in Parkinson's Disease (PD)\",\n",
              "       'OfficialTitle': \"The Effects of a Single Bout of Exercise in Parkinson's Disease.\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'March 2020',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'April 2, 2013',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2014',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'December 31, 2014',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'February 18, 2017',\n",
              "       'StudyFirstSubmitQCDate': 'November 6, 2017',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 9, 2017',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'March 2, 2020',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 4, 2020',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'A. Jon Stoessl',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Clinical Director of PET',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': \"Pacific Parkinson's Research Centre\"},\n",
              "       'LeadSponsor': {'LeadSponsorName': \"Pacific Parkinson's Research Centre\",\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': 'To assess 30 active people (15 with PD, 15 without) before and after 30 minutes of pedaling exercise using EEG-EMG, cognitive, mood and motor assessments.',\n",
              "       'DetailedDescription': \"Purpose: To assess 15 subjects with PD and 15 healthy controls, who exercise on a regular basis, before, during and after 30 minutes of pedaling exercise intervention. The investigators will assess subjects for alterations in motor cortex assessment, cognition and mood as measured by EMG/EEG, motor assessment and several batteries of questionnaires. Findings from this study will lay the foundation for long-term studies.\\n\\nHypotheses: The investigators anticipate to observe an altered involvement of motor cortex during steady pedaling in individuals suffering from PD. In healthy control subjects it is anticipated that changes in cognition will be observable.\\n\\nJustification: Hindered movement initiation and continuing locomotion is a common syndrome in PD with profound impact on the patient's mobility and quality of life. So far, the underlying pathophysiology is not completely understood. Since the observation that cortical activity contributes to the muscle activity during locomotion-like tasks underpins the importance of corticospinal function in humans, it is of importance to examine whether this cortical involvement is altered and displays abnormalities in patients with PD. Thus, the approach of corticomuscular coupling during a locomotion-like task would allow for better understanding of the pathophysiology of PD, a prerequisite to develop therapies. Findings of this study will lay the foundation for future long-term studies.\\n\\nAdditionally, by examining the oscillatory EEG patterns during the exercise intervention, the investigator will be able to read out the dose response curve in real time, which will provide information on the optimum intensity and duration of exercise. Findings will help to design future studies and to develop efficient exercise therapy interventions for people with PD.\\n\\nPeople living with PD often suffer from cognitive decline, depression, and fatigue. By assessing cognitive function before and after the exercise intervention, there will be laid a foundation for future studies investigating the effect of exercise on cognition. The collected pilot data will be relevant to learn more about the effects of exercise on mood and fatigue as well as concomitant obstacles and facilitators during exercise interventions in patients with PD.\\n\\nObjectives: The primary objective of this study is to investigate if activity that arises in the motor cortex and contributes to the muscle activity during moderate pedaling is altered in patients with PD compared to healthy gender- and age-matched controls. Thus, to better understand the role of the motor cortex and its contribution in simple automated repetitive tasks in patients with PD there will be analysis of the coherence of the coupling between EEG and EMG from active leg muscles during cycling on a stationary bicycle both in subjects with PD and age and gender matched healthy controls.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': ['exercise',\n",
              "         'EEG',\n",
              "         'EMG',\n",
              "         'Motor function',\n",
              "         'Mood',\n",
              "         'Cognition']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignInterventionModelDescription': '1 PD group and 1 one age matched non-PD subjects',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
              "         'DesignMaskingDescription': 'The assessor will be blinded to subject group and intervention.',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '23',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Parkinson's disease\",\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': \"Subjects with Parkinson's disease\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: cycling exercise']}},\n",
              "         {'ArmGroupLabel': 'Control',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': \"Subjects without Parkinson's disease\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: cycling exercise']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': 'cycling exercise',\n",
              "          'InterventionDescription': '5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control',\n",
              "            \"Parkinson's disease\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'EEG-EMG coherence',\n",
              "          'PrimaryOutcomeDescription': 'Coherence of the coupling between EEG and EMG from active leg muscles during cycling on a stationary bicycle both in subjects with PD and age and gender matched healthy controls.',\n",
              "          'PrimaryOutcomeTimeFrame': 'The change from immediately before, during, and immediatly after the single bout of exercise.'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Motor function',\n",
              "          'SecondaryOutcomeDescription': \"Examine motor function with the Movement disorders society unified Parkinson's disease rating scale motor section (MDS-UPDRS III)\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Immediately before and after the single bout of exercise.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Motor function',\n",
              "          'SecondaryOutcomeDescription': 'Examine motor function with the finger tapping',\n",
              "          'SecondaryOutcomeTimeFrame': 'Immediately before and after the single bout of exercise.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Motor function',\n",
              "          'SecondaryOutcomeDescription': 'Examine motor function with the Purdue pegboard',\n",
              "          'SecondaryOutcomeTimeFrame': 'Immediately before and after the single bout of exercise.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Motor function',\n",
              "          'SecondaryOutcomeDescription': 'Examine motor function with the Timed-up-and-go (TUG)',\n",
              "          'SecondaryOutcomeTimeFrame': 'Immediately before and after the single bout of exercise.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Cognitive function',\n",
              "          'SecondaryOutcomeDescription': 'Examine cognitive function with Montreal cognitive assessment (MoCA)',\n",
              "          'SecondaryOutcomeTimeFrame': 'Immediately before, after and at 3 hours following the single bout of exercise.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Cognitive function',\n",
              "          'SecondaryOutcomeDescription': 'Examine cognitive function with Verbal fluency',\n",
              "          'SecondaryOutcomeTimeFrame': 'Immediately before, after and at 3 hours following the single bout of exercise.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Cognitive function',\n",
              "          'SecondaryOutcomeDescription': 'Examine cognitive function with trail making test (A and B) and reaction time',\n",
              "          'SecondaryOutcomeTimeFrame': 'Immediately before, after and at 3 hours following the single bout of exercise.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Mood function',\n",
              "          'SecondaryOutcomeDescription': 'Examine mood with the Positive and Negative Affect Schedule.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Immediately before, after and at 3 hours following the single bout of exercise.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Mood function',\n",
              "          'SecondaryOutcomeDescription': 'Examine mood with the Starkein Apathy scale',\n",
              "          'SecondaryOutcomeTimeFrame': 'Immediately before, after and at 3 hours following the single bout of exercise.'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAdult between 40-80 years\\nHoehn and Yahr stage I-III\\nExercise on a regular basis (at least 100 minutes of aerobic exercise per week)\\nMontreal Cognitive Assessment score >/= 24\\nAble to communicate with study personnel\\nAble to be informed of the nature of the study and willing to give written consent form\\n\\nExclusion Criteria:\\n\\nHoehn and Yahr stages IV-V\\nSignificant cardiovascular disease\\nPrevious stroke\\nNot exercising on a regular basis\\nFunctional disabling dyskinesia\\nFunctional disabling dystonia\\nSmoker\\nSignificant neurological or psychiatric illness other than PD\\nDementia\\nSevere depression\\nSignificant musculoskeletal disorder (e.g. arthritis)\\nSignificant metabolic disorder (e.g. diabetes)\\nBrain surgery in the past\\nCurrently taking beta blocker medication',\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '40 Years',\n",
              "       'MaximumAge': '80 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Silke Cresswell, MD',\n",
              "          'OverallOfficialAffiliation': \"Pacific Parkinson's Research Centre\",\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': \"Pacific Parkinson's Research Centre\",\n",
              "          'LocationCity': 'Vancouver',\n",
              "          'LocationState': 'British Columbia',\n",
              "          'LocationZip': 'V6T 2B5',\n",
              "          'LocationCountry': 'Canada'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 34,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01747655',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'P13-893'},\n",
              "       'Organization': {'OrgFullName': 'AbbVie', 'OrgClass': 'INDUSTRY'},\n",
              "       'BriefTitle': \"A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study\",\n",
              "       'OfficialTitle': \"A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study - MONOTREAT\",\n",
              "       'Acronym': 'MONOTREAT'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'October 2016',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'February 2013'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2015',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'July 2015',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'December 10, 2012',\n",
              "       'StudyFirstSubmitQCDate': 'December 10, 2012',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 12, 2012',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'ResultsFirstSubmitDate': 'July 21, 2016',\n",
              "       'ResultsFirstSubmitQCDate': 'October 6, 2016',\n",
              "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'October 13, 2016',\n",
              "        'ResultsFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'October 6, 2016',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 13, 2016',\n",
              "        'LastUpdatePostDateType': 'Estimate'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'AbbVie (prior sponsor, Abbott)',\n",
              "        'LeadSponsorClass': 'INDUSTRY'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': 'Patients with advanced Parkinson\\'s Disease experience a range in the severity of their motor fluctuations. The rationale for this Post Marketing Observational Study is to demonstrate the benefits of Duodopa treatment on Parkinson\\'s Disease patients entering the advanced stage of the disease whose motor fluctuations have become troublesome and complicate management with oral therapy. The aim of this post-marketing observational study is to assess the effect of Duodopa treatment on activities of daily living in advanced Parkinson\\'s Disease participants characterised by either 2-4 hours of \"off\" time or 2 hours of non-troublesome or troublesome dyskinesia daily, supported by a Unified Parkinson\\'s Disease Rating Scale Total Score in the best \"on\" state of at least 40 points at baseline.',\n",
              "       'DetailedDescription': 'Data are recorded from visits most closely aligned with the planned periods of Visit 0 (V0): Baseline (After decision to use the temporary naso-duodenal tube (approximately 2-14 days) and after signature of the Patient Authorization/Informed Consent Form); Visit 1 (V1): At discharge from hospital; Visit 2 (V2): 3 months after discharge; Visit 3 (V3): 6 months after discharge; Visit 4 (V4): 12 months after discharge.\\n\\nAll participants have a temporary naso-duodenal tube used initially with the infusion pump to determine if the participant responds favorably to this method of treatment and to optimize the dose of Duodopa before permanent treatment is started.\\n\\nParticipants who choose a treatment other than Duodopa after the temporary naso-duodenal test phase are considered for the Standard of Care group. Participants who go on to select Apomorphine pump or Deep Brain Stimulation at any stage are not eligible to continue in this group or to continue in the observational period of study.\\n\\nParticipants who continue to with Duodopa treatment after the the temporary naso-duodenal test phase are the Duodopa group.'},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': ['Early Observational Advanced',\n",
              "         \"Parkinson's Disease\"]}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'DesignInfo': {'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '64',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Duodopa',\n",
              "          'ArmGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'},\n",
              "         {'ArmGroupLabel': 'Standard of Care',\n",
              "          'ArmGroupDescription': \"Participants that return to oral or transdermal anti-parkinson's disease medications\"}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 12 Months After Hospital Discharge\",\n",
              "          'PrimaryOutcomeDescription': 'The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson\\'s disease. The Part II score is the sum of the answers to 13 questions, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. UPDRS scores during \"On\" time (when PD symptoms are well controlled by the drug) are presented. Last observation carried forward (LOCF) was used for missing data.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline (Week 0) and 12 months after hospital discharge'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'SecondaryOutcomeDescription': 'The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson\\'s disease. The Part II score is the sum of the answers to 13 questions, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. UPDRS scores during \"On\" time (when PD symptoms are well controlled by the drug) are presented. n=the number of participants with data at baseline and given time point.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge'},\n",
              "         {'SecondaryOutcomeMeasure': 'Percentage of Participants Who Continued With Jejunal Extension Tube of the Percutaneous Endoscopic Gastrostomy (PEG-J) Treatment',\n",
              "          'SecondaryOutcomeDescription': 'The percentage of participants who continued with PEG-J treatment after treatment via temporary naso-jejunal tube.',\n",
              "          'SecondaryOutcomeTimeFrame': '14 days'},\n",
              "         {'SecondaryOutcomeMeasure': 'Primary Reasons for Discontinuing Duodopa Treatment or for Discontinuing the Study',\n",
              "          'SecondaryOutcomeDescription': 'The primary reasons for stopping treatment with Duodopa or for discontinuing the study.',\n",
              "          'SecondaryOutcomeTimeFrame': '12 months'},\n",
              "         {'SecondaryOutcomeMeasure': \"Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'SecondaryOutcomeDescription': 'The UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of \"off\" times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge'},\n",
              "         {'SecondaryOutcomeMeasure': \"Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'SecondaryOutcomeDescription': 'The UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of \"off\" times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge'},\n",
              "         {'SecondaryOutcomeMeasure': \"Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'SecondaryOutcomeDescription': 'The UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of \"off\" times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge'},\n",
              "         {'SecondaryOutcomeMeasure': \"Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'SecondaryOutcomeDescription': 'The UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of \"off\" times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge'},\n",
              "         {'SecondaryOutcomeMeasure': \"Unified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'SecondaryOutcomeDescription': 'The UPDRS III questionnaire consists of 14 questions on motor examinations rated from 0 (absent/normal) to 4 (extreme impairment). Questions 20-26 are multi-part questions in that they are evaluated separately for multiple body parts (for example, for the left and right hand). Counting each of these assessments leads to a total of 27 answers. The UPDRS III score ranges from 0 to 108 with higher values indicating greater impairment and was calculated as the sum of the 27 answers provided to the 14 questions. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge'},\n",
              "         {'SecondaryOutcomeMeasure': \"Non-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'SecondaryOutcomeDescription': 'Non-motor symptoms assessed over the previous month were scored with respect to severity (0 = none, 1 = mild, 2 = moderate, 3 = severe) and with respect to frequency (1 = rarely, 2 = often, 3 = frequent, 4 = very frequent). The total NMSS score ranges from 0 to 360 with higher values indicating greater impairment and was calculated as the sum of all individual score values. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge'},\n",
              "         {'SecondaryOutcomeMeasure': \"Parkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'SecondaryOutcomeDescription': 'Participants were asked to state how often they had encountered certain problems over the past four weeks using the following rating scale: Never (0), occasionally (1), sometimes (2), often (3), always or cannot do at all (4). The PDQ-8 summary index was derived as the sum of the single items divided by 32. Scores range from 0 to 100. A higher summary index score indicates a higher impairment of quality of life. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0), at discharge from hospital, and 3, 6, and 12 months after hospital discharge'},\n",
              "         {'SecondaryOutcomeMeasure': 'Healthcare Resource Utilization (HCRU) Number of Office Visits: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge',\n",
              "          'SecondaryOutcomeDescription': \"Participants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance [family/friend)], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at baseline and given time point.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge'},\n",
              "         {'SecondaryOutcomeMeasure': 'Healthcare Resource Utilization (HCRU) Number of Visits at Home: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge',\n",
              "          'SecondaryOutcomeDescription': \"Participants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance [family/friend)], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at baseline and given time point.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge'},\n",
              "         {'SecondaryOutcomeMeasure': 'Healthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital Discharge',\n",
              "          'SecondaryOutcomeDescription': \"Participants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance [family/friend)], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at given time point.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge'},\n",
              "         {'SecondaryOutcomeMeasure': 'Healthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital Discharge',\n",
              "          'SecondaryOutcomeDescription': \"Participants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance [family/friend)], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at given time point.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge'},\n",
              "         {'SecondaryOutcomeMeasure': 'Healthcare Resource Utilization (HCRU) Falls: Percentage of Participants With Falls at 3, 6, and 12 Months After Hospital Discharge',\n",
              "          'SecondaryOutcomeDescription': \"Participants were asked about their utilization of healthcare resources within the previous 3 months , including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance [family/friend)], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at baseline and given time point.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHas advanced levodopa-responsive Parkinson\\'s disease\\nThe decision to treat with Duodopa is made by the physician in accordance with the local label (Summary of Product Characteristics; product label) prior to any decision to approach the patient to participate in this study\\nParkinson\\'s Disease (PD) medicinal treatment is unchanged for at least four weeks prior to baseline\\nTakes oral medication four or more times daily\\nEither has 2-4 hours of \"off\" time or 2 hours of non-troublesome or troublesome dyskinesia daily supported by a Unified Parkinson\\'s Disease Rating Scale (UPDRS) Total Score in the best \"on\" state of at least 40 points at baseline; based on documented medical history\\n\\nExclusion Criteria:\\n\\nUse of Deep Brain Stimulation (DBS), Apomorphine pump or Duodopa treatment prior to baseline visit\\nSevere dementia based on a Mini-Mental State Examination (MMSE) of < 24',\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': 'Hospital clinic',\n",
              "       'SamplingMethod': 'Probability Sample'},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Koray Onuk, MD',\n",
              "          'OverallOfficialAffiliation': 'AbbVie',\n",
              "          'OverallOfficialRole': 'Study Director'}]}},\n",
              "      'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Related Info',\n",
              "          'SeeAlsoLinkURL': 'http://rxabbvie.com'}]}}},\n",
              "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
              "          'FlowGroupTitle': 'Duodopa',\n",
              "          'FlowGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'},\n",
              "         {'FlowGroupId': 'FG001',\n",
              "          'FlowGroupTitle': 'Standard of Care',\n",
              "          'FlowGroupDescription': \"Participants that return to oral or transdermal anti-Parkinson's Disease medications\"}]},\n",
              "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Temporary Naso-jejunal Tube Period',\n",
              "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementComment': 'Main Analysis Set (MAS): participants with baseline and 1 further visit and  1 Duodopa treatment',\n",
              "                'FlowAchievementNumSubjects': '64'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '0'}]}},\n",
              "            {'FlowMilestoneType': 'COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '64'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '0'}]}},\n",
              "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '0'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '0'}]}}]}},\n",
              "         {'FlowPeriodTitle': 'PEG-J Period (Duodopa Treatment)',\n",
              "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementComment': 'Dudopa MAS: Participants in the MAS that received Duodopa via PEG-J.',\n",
              "                'FlowAchievementNumSubjects': '58'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementComment': 'Participants in the MAS that returned to SoC (no PEG-J introduced; did not meet selection criteria)',\n",
              "                'FlowAchievementNumSubjects': '6'}]}},\n",
              "            {'FlowMilestoneType': 'COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '44'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '6'}]}},\n",
              "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '14'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '0'}]}}]},\n",
              "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Investigator Decision (Medical Event)',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '5'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'}]}},\n",
              "            {'FlowDropWithdrawType': 'Patient Decision',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '8'},\n",
              "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'}]}},\n",
              "            {'FlowDropWithdrawType': 'Lost to Follow-up',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '1'},\n",
              "               {'FlowReasonGroupId': 'FG001',\n",
              "                'FlowReasonNumSubjects': '0'}]}}]}},\n",
              "         {'FlowPeriodTitle': 'PEG-J Period (Continued Treatment)',\n",
              "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '41'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementComment': 'SoC MAS: 6 SoC participants plus 9 participants who received Duodopa via PEG-J then returned to SoC',\n",
              "                'FlowAchievementNumSubjects': '15'}]}},\n",
              "            {'FlowMilestoneType': 'COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '41'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '15'}]}},\n",
              "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '0'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '0'}]}}]}}]}},\n",
              "      'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'All subjects in the MAS',\n",
              "       'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
              "          'BaselineGroupTitle': 'Duodopa',\n",
              "          'BaselineGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'}]},\n",
              "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
              "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
              "             'BaselineDenomCountValue': '64'}]}}]},\n",
              "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous',\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'years',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '70.4',\n",
              "                   'BaselineMeasurementSpread': '7.8'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '25'}]}},\n",
              "               {'BaselineCategoryTitle': 'Male',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '39'}]}}]}}]}}]}},\n",
              "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': \"Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 12 Months After Hospital Discharge\",\n",
              "          'OutcomeMeasureDescription': 'The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson\\'s disease. The Part II score is the sum of the answers to 13 questions, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. UPDRS scores during \"On\" time (when PD symptoms are well controlled by the drug) are presented. Last observation carried forward (LOCF) was used for missing data.',\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Standard of Care',\n",
              "             'OutcomeGroupDescription': \"Participants that return to oral or transdermal anti-Parkinson's Disease medications\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '47'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '14'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-2.1',\n",
              "                   'OutcomeMeasurementSpread': '6.9'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '1.4',\n",
              "                   'OutcomeMeasurementSpread': '5.1'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'OutcomeMeasureDescription': 'The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson\\'s disease. The Part II score is the sum of the answers to 13 questions, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. UPDRS scores during \"On\" time (when PD symptoms are well controlled by the drug) are presented. n=the number of participants with data at baseline and given time point.',\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Standard of Care',\n",
              "             'OutcomeGroupDescription': \"Participants that return to oral or transdermal anti-Parkinson's Disease medications.\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '58'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '15'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Change from baseline to 3 months (n=47,7)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-4.4',\n",
              "                   'OutcomeMeasurementSpread': '5.6'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.9',\n",
              "                   'OutcomeMeasurementSpread': '6.0'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 6 months (n=44,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-3.4',\n",
              "                   'OutcomeMeasurementSpread': '4.9'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-1.5',\n",
              "                   'OutcomeMeasurementSpread': '2.3'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months (n=41,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-1.8',\n",
              "                   'OutcomeMeasurementSpread': '7.1'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.5',\n",
              "                   'OutcomeMeasurementSpread': '5.3'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Percentage of Participants Who Continued With Jejunal Extension Tube of the Percutaneous Endoscopic Gastrostomy (PEG-J) Treatment',\n",
              "          'OutcomeMeasureDescription': 'The percentage of participants who continued with PEG-J treatment after treatment via temporary naso-jejunal tube.',\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Number',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'percentage of participants',\n",
              "          'OutcomeMeasureTimeFrame': '14 days',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '64'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '90.6'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Primary Reasons for Discontinuing Duodopa Treatment or for Discontinuing the Study',\n",
              "          'OutcomeMeasureDescription': 'The primary reasons for stopping treatment with Duodopa or for discontinuing the study.',\n",
              "          'OutcomeMeasurePopulationDescription': 'Participants in the MAS who stopped treatment with Duodopa or discontinued from study.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Number',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'participants',\n",
              "          'OutcomeMeasureTimeFrame': '12 months',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '23'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Patient decision',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '9'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Investigator decision (due to medical event)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '8'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Investigator decision (other than medical event)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '2'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Does not feel has adequate support after discharge',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Does not wish to carry the pump / device system',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Does not wish to undergo the PEG-J procedure',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Lost to follow-up',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'OutcomeMeasureDescription': 'The UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of \"off\" times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Standard of Care',\n",
              "             'OutcomeGroupDescription': \"Participants that return to oral or transdermal anti-Parkinson's Disease medications\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '58'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '15'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Change from baseline to 3 months (n=47,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.5',\n",
              "                   'OutcomeMeasurementSpread': '1.1'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.5',\n",
              "                   'OutcomeMeasurementSpread': '0.8'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 6 months after (n=44,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.6',\n",
              "                   'OutcomeMeasurementSpread': '1.0'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.5',\n",
              "                   'OutcomeMeasurementSpread': '1.0'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months (n=41,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.4',\n",
              "                   'OutcomeMeasurementSpread': '1.2'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.2',\n",
              "                   'OutcomeMeasurementSpread': '1.2'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months LOCF (n=47,14)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.5',\n",
              "                   'OutcomeMeasurementSpread': '1.2'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.4',\n",
              "                   'OutcomeMeasurementSpread': '0.9'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'OutcomeMeasureDescription': 'The UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of \"off\" times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Standard of Care',\n",
              "             'OutcomeGroupDescription': \"Participants that return to oral or transdermal anti-Parkinson's Disease medications\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '58'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '15'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Change from baseline to 3 months (n=47,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.9',\n",
              "                   'OutcomeMeasurementSpread': '0.9'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.3',\n",
              "                   'OutcomeMeasurementSpread': '0.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 6 months (n=44,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.9',\n",
              "                   'OutcomeMeasurementSpread': '1.0'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.3',\n",
              "                   'OutcomeMeasurementSpread': '0.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months (n=41,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.5',\n",
              "                   'OutcomeMeasurementSpread': '1.1'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.5',\n",
              "                   'OutcomeMeasurementSpread': '1.4'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months LOCF (n=47,14)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.9',\n",
              "                   'OutcomeMeasurementSpread': '1.1'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.6',\n",
              "                   'OutcomeMeasurementSpread': '1.1'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'OutcomeMeasureDescription': 'The UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of \"off\" times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Standard of Care',\n",
              "             'OutcomeGroupDescription': \"Participants that return to oral or transdermal anti-Parkinson's Disease medications\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '58'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '15'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Change from baseline to 3 months (n=47,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.3',\n",
              "                   'OutcomeMeasurementSpread': '0.8'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.2',\n",
              "                   'OutcomeMeasurementSpread': '0.4'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 6 months (n=43,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.3',\n",
              "                   'OutcomeMeasurementSpread': '0.8'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.3',\n",
              "                   'OutcomeMeasurementSpread': '0.8'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months (n=41,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.3',\n",
              "                   'OutcomeMeasurementSpread': '0.7'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.3',\n",
              "                   'OutcomeMeasurementSpread': '0.8'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months LOCF (n=47,14)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.3',\n",
              "                   'OutcomeMeasurementSpread': '0.8'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.0',\n",
              "                   'OutcomeMeasurementSpread': '0.9'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'OutcomeMeasureDescription': 'The UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of \"off\" times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Standard of Care',\n",
              "             'OutcomeGroupDescription': \"Participants that return to oral or transdermal anti-Parkinson's Disease medications\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '58'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '15'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Change from baseline to 3 months (n=47,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.9',\n",
              "                   'OutcomeMeasurementSpread': '1.0'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.5',\n",
              "                   'OutcomeMeasurementSpread': '1.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 6 months (n=44,6',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.9',\n",
              "                   'OutcomeMeasurementSpread': '0.9'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.7',\n",
              "                   'OutcomeMeasurementSpread': '0.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months (n=41,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.8',\n",
              "                   'OutcomeMeasurementSpread': '0.8'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.3',\n",
              "                   'OutcomeMeasurementSpread': '1.0'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months LOCF (n=47,14)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-0.8',\n",
              "                   'OutcomeMeasurementSpread': '0.9'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-0.4',\n",
              "                   'OutcomeMeasurementSpread': '1.1'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Unified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'OutcomeMeasureDescription': 'The UPDRS III questionnaire consists of 14 questions on motor examinations rated from 0 (absent/normal) to 4 (extreme impairment). Questions 20-26 are multi-part questions in that they are evaluated separately for multiple body parts (for example, for the left and right hand). Counting each of these assessments leads to a total of 27 answers. The UPDRS III score ranges from 0 to 108 with higher values indicating greater impairment and was calculated as the sum of the 27 answers provided to the 14 questions. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Standard of Care',\n",
              "             'OutcomeGroupDescription': \"Participants that return to oral or transdermal anti-Parkinson's Disease medications\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '58'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '15'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Change from baseline to 3 months (n=51)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-12.9',\n",
              "                   'OutcomeMeasurementSpread': '16.2'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-6.3',\n",
              "                   'OutcomeMeasurementSpread': '11.9'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 6 months (n=49)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-8.9',\n",
              "                   'OutcomeMeasurementSpread': '12.3'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-17.0',\n",
              "                   'OutcomeMeasurementSpread': '22.6'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months (n=46)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-8.7',\n",
              "                   'OutcomeMeasurementSpread': '12.6'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '0.3',\n",
              "                   'OutcomeMeasurementSpread': '16.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months LOCF (n=61)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-8.9',\n",
              "                   'OutcomeMeasurementSpread': '12.6'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-8.7',\n",
              "                   'OutcomeMeasurementSpread': '21.2'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Non-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'OutcomeMeasureDescription': 'Non-motor symptoms assessed over the previous month were scored with respect to severity (0 = none, 1 = mild, 2 = moderate, 3 = severe) and with respect to frequency (1 = rarely, 2 = often, 3 = frequent, 4 = very frequent). The total NMSS score ranges from 0 to 360 with higher values indicating greater impairment and was calculated as the sum of all individual score values. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Standard of Care',\n",
              "             'OutcomeGroupDescription': \"Participants that return to oral or transdermal anti-Parkinson's Disease medications\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '58'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '15'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Change from baseline to 3 months (n=44,5)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-39.5',\n",
              "                   'OutcomeMeasurementSpread': '38.0'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-8.0',\n",
              "                   'OutcomeMeasurementSpread': '14.6'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 6 months (n=40,5)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-33.7',\n",
              "                   'OutcomeMeasurementSpread': '33.1'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-45.0',\n",
              "                   'OutcomeMeasurementSpread': '64.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months (n=38,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-33.9',\n",
              "                   'OutcomeMeasurementSpread': '40.6'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-10.3',\n",
              "                   'OutcomeMeasurementSpread': '15.2'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months LOCF (n=40,10)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-32.5',\n",
              "                   'OutcomeMeasurementSpread': '40.1'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-32.7',\n",
              "                   'OutcomeMeasurementSpread': '45.9'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': \"Parkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge\",\n",
              "          'OutcomeMeasureDescription': 'Participants were asked to state how often they had encountered certain problems over the past four weeks using the following rating scale: Never (0), occasionally (1), sometimes (2), often (3), always or cannot do at all (4). The PDQ-8 summary index was derived as the sum of the single items divided by 32. Scores range from 0 to 100. A higher summary index score indicates a higher impairment of quality of life. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.',\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0), at discharge from hospital, and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Standard of Care',\n",
              "             'OutcomeGroupDescription': \"Participants that return to oral or transdermal anti-Parkinson's Disease medications\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '58'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '15'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': '3 months after discharge (n=46,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-15.7',\n",
              "                   'OutcomeMeasurementSpread': '17.8'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-2.6',\n",
              "                   'OutcomeMeasurementSpread': '6.4'}]}}]}},\n",
              "            {'OutcomeClassTitle': '6 months after discharge (n=43,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-15.4',\n",
              "                   'OutcomeMeasurementSpread': '17.2'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-10.9',\n",
              "                   'OutcomeMeasurementSpread': '20.3'}]}}]}},\n",
              "            {'OutcomeClassTitle': '12 months after discharge (n=41,6)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-12.3',\n",
              "                   'OutcomeMeasurementSpread': '20.6'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-3.6',\n",
              "                   'OutcomeMeasurementSpread': '7.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': '12 months after discharge LOCF (n=42,10)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-12.1',\n",
              "                   'OutcomeMeasurementSpread': '20.4'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '-8.1',\n",
              "                   'OutcomeMeasurementSpread': '16.2'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Healthcare Resource Utilization (HCRU) Number of Office Visits: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge',\n",
              "          'OutcomeMeasureDescription': \"Participants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance [family/friend)], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at baseline and given time point.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'office visits',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '64'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline (n=64)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '8.7',\n",
              "                   'OutcomeMeasurementSpread': '9.8'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 3 months (n=53)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-3.0',\n",
              "                   'OutcomeMeasurementSpread': '8.0'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 6 months (n=49)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-2.7',\n",
              "                   'OutcomeMeasurementSpread': '9.8'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months (n=47)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-2.1',\n",
              "                   'OutcomeMeasurementSpread': '18.5'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Healthcare Resource Utilization (HCRU) Number of Visits at Home: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge',\n",
              "          'OutcomeMeasureDescription': \"Participants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance [family/friend)], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at baseline and given time point.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'visits at home',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '64'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline (n=64)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '11.2',\n",
              "                   'OutcomeMeasurementSpread': '31.4'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 3 months (n=53)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '0.8',\n",
              "                   'OutcomeMeasurementSpread': '25.8'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 6 months (n=49)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '-1.0',\n",
              "                   'OutcomeMeasurementSpread': '21.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Change from baseline to 12 months (n=47)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '4.0',\n",
              "                   'OutcomeMeasurementSpread': '31.5'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Healthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital Discharge',\n",
              "          'OutcomeMeasureDescription': \"Participants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance [family/friend)], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at given time point.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Number',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'percentage of participants',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '64'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Overnight hospital stay at Baseline (n=64)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '14.1'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Overnight hospital stay at 3 months (n=53)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '9.4'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Overnight hospital stay at 6 months (n=49)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '10.2'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Overnight hospital stay at 12 months (n=47)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '6.4'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Visit at emergency room at Baseline (n=64)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '10.9'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Visit at emergency room at 3 months (n=53)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '3.8'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Visit at emergency room at 6 months (n=49)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '14.3'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Visit at emergency room at 12 months (n=47)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '8.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Calls for immediate assistance at Baseline (n=64)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '25.0'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Calls for immediate assistance at 3 months (n=53)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '26.4'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Calls for immediate assistance at 6 months (n=49)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '6.1'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Calls for immediate assistance at 12 months (n=46)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '4.3'}]}}]}},\n",
              "            {'OutcomeClassTitle': '911/Emergency at Baseline (n=64)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '4.7'}]}}]}},\n",
              "            {'OutcomeClassTitle': '911/Emergency at 3 months (n=53)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1.9'}]}}]}},\n",
              "            {'OutcomeClassTitle': '911/Emergency at 6 months (n=49)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '4.1'}]}}]}},\n",
              "            {'OutcomeClassTitle': '911/Emergency at 12 months (n=46)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '4.3'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Healthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital Discharge',\n",
              "          'OutcomeMeasureDescription': \"Participants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance [family/friend)], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at given time point.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Number',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'percentage of participants',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '64'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Family/friend at Baseline (n=64)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '59.4'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Family/friend at 3 months (n=53)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '49.1'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Family/friend at 6 months (n=49)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '44.9'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Family/friend at 12 months (n=47)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '46.8'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Paid caregiver at Baseline (n=64)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '10.9'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Paid caregiver at 3 months (n=53)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '24.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Paid caregiver at 6 months (n=49)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '24.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'Paid caregiver at 12 months (n=47)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '25.5'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Healthcare Resource Utilization (HCRU) Falls: Percentage of Participants With Falls at 3, 6, and 12 Months After Hospital Discharge',\n",
              "          'OutcomeMeasureDescription': \"Participants were asked about their utilization of healthcare resources within the previous 3 months , including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance [family/friend)], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at baseline and given time point.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'MAS population',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Number',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'percentage of participants',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0) and 3, 6, and 12 months after hospital discharge',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Duodopa',\n",
              "             'OutcomeGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '64'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline (n=64)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '35.9'}]}}]}},\n",
              "            {'OutcomeClassTitle': '3 months (n=53)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '17.0'}]}}]}},\n",
              "            {'OutcomeClassTitle': '6 months (n=49)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '24.5'}]}}]}},\n",
              "            {'OutcomeClassTitle': '12 months (n=47)',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '14.9'}]}}]}}]}}]}},\n",
              "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
              "       'EventsTimeFrame': 'All adverse events were collected from Baseline (Week 0) to 12 months after discharge (up to 13 months).',\n",
              "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
              "          'EventGroupTitle': 'Duodopa',\n",
              "          'EventGroupDescription': 'Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy',\n",
              "          'EventGroupSeriousNumAffected': '14',\n",
              "          'EventGroupSeriousNumAtRisk': '64',\n",
              "          'EventGroupOtherNumAffected': '10',\n",
              "          'EventGroupOtherNumAtRisk': '64'}]},\n",
              "       'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'CARDIAC FAILURE',\n",
              "          'SeriousEventOrganSystem': 'Cardiac disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'DYSPHAGIA',\n",
              "          'SeriousEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'MELAENA',\n",
              "          'SeriousEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'GAIT DISTURBANCE',\n",
              "          'SeriousEventOrganSystem': 'General disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'GENERAL PHYSICAL HEALTH DETERIORATION',\n",
              "          'SeriousEventOrganSystem': 'General disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'PYREXIA',\n",
              "          'SeriousEventOrganSystem': 'General disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'SUDDEN DEATH',\n",
              "          'SeriousEventOrganSystem': 'General disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'CLOSTRIDIUM DIFFICILE INFECTION',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'LUNG INFECTION',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'PERITONITIS',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'PNEUMONIA',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'STOMA SITE INFECTION',\n",
              "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'OVERDOSE',\n",
              "          'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'SUBDURAL HAEMATOMA',\n",
              "          'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'FASCIITIS',\n",
              "          'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'PAIN IN EXTREMITY',\n",
              "          'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'BASILAR ARTERY THROMBOSIS',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'COGNITIVE DISORDER',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'DYSTONIA',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'HYPOGLYCAEMIC COMA',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'MOTOR DYSFUNCTION',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'SPASMODIC DYSPHONIA',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'TREMOR',\n",
              "          'SeriousEventOrganSystem': 'Nervous system disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'ABNORMAL DREAMS',\n",
              "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'DEPRESSION',\n",
              "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'DOPAMINE DYSREGULATION SYNDROME',\n",
              "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'PSYCHOTIC DISORDER',\n",
              "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '2',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'POLYURIA',\n",
              "          'SeriousEventOrganSystem': 'Renal and urinary disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'URINARY INCONTINENCE',\n",
              "          'SeriousEventOrganSystem': 'Renal and urinary disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'RESPIRATORY ARREST',\n",
              "          'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'RESPIRATORY FAILURE',\n",
              "          'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'HYPOTENSION',\n",
              "          'SeriousEventOrganSystem': 'Vascular disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}},\n",
              "         {'SeriousEventTerm': 'PALLOR',\n",
              "          'SeriousEventOrganSystem': 'Vascular disorders',\n",
              "          'SeriousEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
              "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
              "             'SeriousEventStatsNumAffected': '1',\n",
              "             'SeriousEventStatsNumAtRisk': '64'}]}}]},\n",
              "       'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'ABDOMINAL PAIN UPPER',\n",
              "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'VOMITING',\n",
              "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'CATHETER SITE HAEMATOMA',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'DEVICE DISLOCATION',\n",
              "          'OtherEventOrganSystem': 'General disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'CELLULITIS',\n",
              "          'OtherEventOrganSystem': 'Infections and infestations',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'STOMA SITE INFECTION',\n",
              "          'OtherEventOrganSystem': 'Infections and infestations',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'STOMA SITE DISCHARGE',\n",
              "          'OtherEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'STOMA SITE GRANULOMA',\n",
              "          'OtherEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '2',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'WEIGHT DECREASED',\n",
              "          'OtherEventOrganSystem': 'Investigations',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'DECREASED APPETITE',\n",
              "          'OtherEventOrganSystem': 'Metabolism and nutrition disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'MUSCULAR WEAKNESS',\n",
              "          'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'READING DISORDER',\n",
              "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'CHRONIC KIDNEY DISEASE',\n",
              "          'OtherEventOrganSystem': 'Renal and urinary disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'THERAPY CESSATION',\n",
              "          'OtherEventOrganSystem': 'Surgical and medical procedures',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '3',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}},\n",
              "         {'OtherEventTerm': 'ORTHOSTATIC HYPOTENSION',\n",
              "          'OtherEventOrganSystem': 'Vascular disorders',\n",
              "          'OtherEventSourceVocabulary': 'MedDRA 18.0',\n",
              "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
              "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
              "             'OtherEventStatsNumAffected': '1',\n",
              "             'OtherEventStatsNumAtRisk': '64'}]}}]}},\n",
              "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
              "        'AgreementRestrictionType': 'OTHER',\n",
              "        'AgreementRestrictiveAgreement': 'Yes',\n",
              "        'AgreementOtherDetails': 'AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.'},\n",
              "       'PointOfContact': {'PointOfContactTitle': 'Global Medical Information',\n",
              "        'PointOfContactOrganization': 'AbbVie',\n",
              "        'PointOfContactPhone': '1-800-633-9110'}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022',\n",
              "       'RemovedCountryList': {'RemovedCountry': ['Austria',\n",
              "         'Denmark',\n",
              "         'Germany',\n",
              "         'Greece',\n",
              "         'Ireland',\n",
              "         'Italy',\n",
              "         'Netherlands',\n",
              "         'Spain']}},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 35,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03848455',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '2018-SJNK-008-1'},\n",
              "       'Organization': {'OrgFullName': 'Zhujiang Hospital',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Multi-chip Meta-analysis of Parkinson's Disease for Clinical Validation of Small Samples of Key Genes in Disease\",\n",
              "       'OfficialTitle': \"Multi-chip Meta-analysis of Parkinson's Disease for Clinical Validation of Small Samples of Key Genes in Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'July 2020',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'February 25, 2019',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 20, 2019',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'October 20, 2019',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'February 19, 2019',\n",
              "       'StudyFirstSubmitQCDate': 'February 19, 2019',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 20, 2019',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'ResultsFirstSubmitDate': 'November 12, 2019',\n",
              "       'ResultsFirstSubmitQCDate': 'January 5, 2020',\n",
              "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'January 18, 2020',\n",
              "        'ResultsFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'July 15, 2020',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 3, 2020',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Gao Xiaoya',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Associate Chief Physician',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Zhujiang Hospital'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Zhujiang Hospital',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"The research team used meta-analytical statistical methods to integrate the results of different research groups on Parkinson's disease, using meta-analysis to find key genes related to the pathogenesis and development of Parkinson's disease, and to make small clinical results. The verification of the sample, the internal mechanism of the pathogenesis of Parkinson's disease and provide guidance and reference for subsequent experimental research.\",\n",
              "       'DetailedDescription': \"Parkinson's disease (PD) is a relatively common degenerative disease of the central nervous system. As society gradually becomes aging, the number of PD patients is increasing, but its exact pathogenesis is still not fully understood. May be related to genetic factors, environmental factors, immunological abnormalities, mitochondrial dysfunction and oxidative stress, ageing, apoptosis and other factors; the current genetic diagnosis is in the ascendant, making the understanding of the etiology and pathogenesis of Parkinson's disease more In-depth, provide more basis and means for the pathogenesis and development of Parkinson's disease, but due to the number of individual samples, operational norms and platform differences, different research groups have great differences in the results of gene chip research on Parkinson's mechanism, resulting in the reliability is poor; In order to improve the credibility of the pathogenesis of Parkinson's disease and the development of genetic diagnosis, the investigators use the statistical means of meta-analysis to integrate the results of the chip research on Parkinson's disease in different research groups and find synaptic correlation function may be closely related to the development of Parkinson's disease, PPP2CA, PPP3CB, SYNJ1, NSF, CYCS genes may be key genes in the pathogenesis of Parkinson's disease, and the expression of these genes is related to the pathogenesis and development of PD patients. the investigators will conduct a small sample validation in the clinic to explore the intrinsic mechanism of Parkinson's disease and follow-up experimental research provides guidance and reference.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's disease\",\n",
              "         'synaptic correlation function',\n",
              "         'key gene']}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'No',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
              "       'BioSpec': {'BioSpecRetention': 'Samples With DNA',\n",
              "        'BioSpecDescription': 'After admission, 2 tubes of venous blood (8ml) were extracted from PD group and control group respectively for genetic testing'},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '238',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Parkinson's disease group\",\n",
              "          'ArmGroupDescription': \"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;\\nNewly diagnosed primary PD patients, diagnosed within 3-6 months;\\ninformed consent to the study;\\nage > 18 older.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: genetic diagnosis']}},\n",
              "         {'ArmGroupLabel': 'Non-parkinson group',\n",
              "          'ArmGroupDescription': 'Non-parkinson group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: genetic diagnosis']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test',\n",
              "          'InterventionName': 'genetic diagnosis',\n",
              "          'InterventionDescription': 'The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Non-parkinson group',\n",
              "            \"Parkinson's disease group\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Parkinson's Key Gene\",\n",
              "          'PrimaryOutcomeDescription': 'The blood of patients were taken for genetic testing and relative expression levels of the genes(These genes expression relative to a house keeping gene:GAPDH) for PPP2CA, PPP3CB, SYNJ1, NSF were extracted.The method we used is RT-PCR.',\n",
              "          'PrimaryOutcomeTimeFrame': '3 days'},\n",
              "         {'PrimaryOutcomeMeasure': \"Unified Parkinson's Disease Rating Scale 3.0UPDRS 3.0\",\n",
              "          'PrimaryOutcomeDescription': \"The total score ranges from 0 to 199( minimum score is 0 and maximum scores is 199), in which a lower score denotes a better perception of the patient's.\\n\\nScoring the mental, behavioral and emotional, daily living activities, exercise tests, and drug treatment complications associated with UPDRS3.0 in patients with Parkinson's disease;each item 0-4 points, total score 199 points, 0-50 points: limb and body mild dysfunction, posture response normal;51-100 points: mild postural reaction disorder, self-care in daily life, loss of labor force;101-199: obvious postural reaction disorder, loss of daily life and labor force, may need help to get up and confined to wheelchair life;The more severe the symptoms of Parkinson's disease, the higher the score.\",\n",
              "          'PrimaryOutcomeTimeFrame': '2 days'},\n",
              "         {'PrimaryOutcomeMeasure': 'Non-motor Symptom Scale (NMSS)',\n",
              "          'PrimaryOutcomeDescription': \"Scoring based on the patient's own situation in the last month Severity: 1 = mild; 2 = moderate; 3 = severe Frequency: 1 = very little (less than once a week); 2 = often (1 time a week); 3 = frequent (a few times a week); 4 = very frequent (every day or persist)\",\n",
              "          'PrimaryOutcomeTimeFrame': '2 days'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nPD group\\n\\nPatients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria\\nNewly diagnosed primary PD patients, diagnosed within 3-6 months\\nInformed consent to the study\\nAge > 18 older\\n\\nNon-PD group:\\n\\nAge, gender-matched PD group\\nNon-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history\\nInformed consent to the study\\nAge > 18 older\\n\\nExclusion Criteria:\\n\\nSevere craniocerebral trauma patients\\nDisturbance of consciousness\\nSevere organic diseases, cerebral hemorrhage, cerebral thrombosis, severe coronary heart disease and lung disease, severe liver and kidney dysfunction, severe diabetes, severe hearing And visual impairment\\nHistory of severe brain tumors, encephalitis or brain surgery\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': \"From March 25, 2019 to April 25, 2019, patients with Parkinson's disease who were admitted to the Department of Neurology, Zhujiang Hospital, and healthy volunteers who recruited from population of community and students of the Southern Medical University.\",\n",
              "       'SamplingMethod': 'Non-Probability Sample'},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Xiaoya Gao, doctor',\n",
              "          'OverallOfficialAffiliation': 'Southern Medical University, China',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Zhujiang Hospiatal',\n",
              "          'LocationCity': 'Guangzhou',\n",
              "          'LocationState': 'Guangdong',\n",
              "          'LocationZip': '510000',\n",
              "          'LocationCountry': 'China'}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28970800',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Li X, Zhang Y, Wang Y, Xu J, Xin P, Meng Y, Wang Q, Kuang H. The Mechanisms of Traditional Chinese Medicine Underlying the Prevention and Treatment of Parkinson's Disease. Front Pharmacol. 2017 Sep 19;8:634. doi: 10.3389/fphar.2017.00634. eCollection 2017. Review.\"},\n",
              "         {'ReferencePMID': '28952032',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Lee Y, Kim MS, Lee J. Neuroprotective strategies to prevent and treat Parkinson's disease based on its pathophysiological mechanism. Arch Pharm Res. 2017 Oct;40(10):1117-1128. doi: 10.1007/s12272-017-0960-8. Epub 2017 Sep 26. Review.\"},\n",
              "         {'ReferencePMID': '28936761',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson's Disease: Recent Advancement. Neurosci Bull. 2017 Oct;33(5):585-597. doi: 10.1007/s12264-017-0183-5. Epub 2017 Sep 21. Review.\"},\n",
              "         {'ReferencePMID': '27600230',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Walsh CJ, Hu P, Batt J, Santos CC. Microarray Meta-Analysis and Cross-Platform Normalization: Integrative Genomics for Robust Biomarker Discovery. Microarrays (Basel). 2015 Aug 21;4(3):389-406. doi: 10.3390/microarrays4030389. Review.'},\n",
              "         {'ReferencePMID': '22262733',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Tseng GC, Ghosh D, Feingold E. Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res. 2012 May;40(9):3785-99. doi: 10.1093/nar/gkr1265. Epub 2012 Jan 19. Review.'},\n",
              "         {'ReferencePMID': '22863766',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Wang X, Kang DD, Shen K, Song C, Lu S, Chang LC, Liao SG, Huo Z, Tang S, Ding Y, Kaminski N, Sibille E, Lin Y, Li J, Tseng GC. An R package suite for microarray meta-analysis in quality control, differentially expressed gene analysis and pathway enrichment detection. Bioinformatics. 2012 Oct 1;28(19):2534-6. Epub 2012 Aug 3.'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
              "          'FlowGroupTitle': \"Parkinson's Disease Group\",\n",
              "          'FlowGroupDescription': \"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;\\nNewly diagnosed primary PD patients, diagnosed within 3-6 months;\\ninformed consent to the study;\\nage > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD ,PPS patients and healthy controls.\"},\n",
              "         {'FlowGroupId': 'FG001',\n",
              "          'FlowGroupTitle': 'Healthy Controls',\n",
              "          'FlowGroupDescription': 'healthy group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and PPS patients and healthy controls .'},\n",
              "         {'FlowGroupId': 'FG002',\n",
              "          'FlowGroupTitle': 'Parkinson-plus Syndrome Group',\n",
              "          'FlowGroupDescription': '1. patients with Parkinson-plus syndrome were diagnosed according to 2017 MDS progressive supranuclear paralysis and 2017 clinical diagnostic criteria for MDS progressive supra palsy (PSP patients) and Giman standard, the 2008 American board of neurology (AAN) MSA diagnostic consensus.2.informed consent to the study; 3.age > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and PPS patients and healthy controls .'}]},\n",
              "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
              "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '90'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '125'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '23'}]}},\n",
              "            {'FlowMilestoneType': 'COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '90'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '125'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '23'}]}},\n",
              "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '0'},\n",
              "               {'FlowAchievementGroupId': 'FG001',\n",
              "                'FlowAchievementNumSubjects': '0'},\n",
              "               {'FlowAchievementGroupId': 'FG002',\n",
              "                'FlowAchievementNumSubjects': '0'}]}}]}}]}},\n",
              "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
              "          'BaselineGroupTitle': \"Parkinson's Disease Group\",\n",
              "          'BaselineGroupDescription': \"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;\\nNewly diagnosed primary PD patients, diagnosed within 3-6 months;\\ninformed consent to the study;\\nage > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD ,PPS patients and healthy controls.\"},\n",
              "         {'BaselineGroupId': 'BG001',\n",
              "          'BaselineGroupTitle': 'Healthy Controls',\n",
              "          'BaselineGroupDescription': 'healthy group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and PPS patients and healthy controls .'},\n",
              "         {'BaselineGroupId': 'BG002',\n",
              "          'BaselineGroupTitle': 'Parkinson-plus Syndrome Group',\n",
              "          'BaselineGroupDescription': '1. patients with Parkinson-plus syndrome were diagnosed according to 2017 MDS progressive supranuclear paralysis and 2017 clinical diagnostic criteria for MDS progressive supra palsy (PSP patients) and Giman standard, the 2008 American board of neurology (AAN) MSA diagnostic consensus.2.informed consent to the study; 3.age > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and PPS patients and healthy controls .'},\n",
              "         {'BaselineGroupId': 'BG003',\n",
              "          'BaselineGroupTitle': 'Total',\n",
              "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
              "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
              "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
              "             'BaselineDenomCountValue': '90'},\n",
              "            {'BaselineDenomCountGroupId': 'BG001',\n",
              "             'BaselineDenomCountValue': '125'},\n",
              "            {'BaselineDenomCountGroupId': 'BG002',\n",
              "             'BaselineDenomCountValue': '23'},\n",
              "            {'BaselineDenomCountGroupId': 'BG003',\n",
              "             'BaselineDenomCountValue': '238'}]}}]},\n",
              "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '46'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '71'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '16'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '133'}]}},\n",
              "               {'BaselineCategoryTitle': '>=65 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '44'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '54'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '7'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '105'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Age, Continuous',\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'years',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '63.66',\n",
              "                   'BaselineMeasurementSpread': '11.94'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '63.42',\n",
              "                   'BaselineMeasurementSpread': '10.99'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '62.30',\n",
              "                   'BaselineMeasurementSpread': '8.13'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '63.40',\n",
              "                   'BaselineMeasurementSpread': '11.09'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '34'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '59'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '15'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '108'}]}},\n",
              "               {'BaselineCategoryTitle': 'Male',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '56'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '66'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '8'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '130'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'Not Hispanic or Latino',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '90'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '125'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '23'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '238'}]}},\n",
              "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Race (NIH/OMB)',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'Asian',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '90'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '125'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '23'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '238'}]}},\n",
              "               {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'Black or African American',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'White',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'More than one race',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '0'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'China',\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '90'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG001',\n",
              "                   'BaselineMeasurementValue': '125'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG002',\n",
              "                   'BaselineMeasurementValue': '23'},\n",
              "                  {'BaselineMeasurementGroupId': 'BG003',\n",
              "                   'BaselineMeasurementValue': '238'}]}}]}}]}}]}},\n",
              "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': \"Parkinson's Key Gene\",\n",
              "          'OutcomeMeasureDescription': 'The blood of patients were taken for genetic testing and relative expression levels of the genes(These genes expression relative to a house keeping gene:GAPDH) for PPP2CA, PPP3CB, SYNJ1, NSF were extracted.The method we used is RT-PCR.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Median',\n",
              "          'OutcomeMeasureDispersionType': 'Inter-Quartile Range',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'gene expression relative to GAPDH',\n",
              "          'OutcomeMeasureTimeFrame': '3 days',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': \"Parkinson's Disease Group\",\n",
              "             'OutcomeGroupDescription': \"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;\\nNewly diagnosed primary PD patients, diagnosed within 3-6 months;\\ninformed consent to the study;\\nage > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD ,PPS patients and healthy controls.\"},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Healthy Controls',\n",
              "             'OutcomeGroupDescription': 'healthy group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and PPS patients and healthy controls .'},\n",
              "            {'OutcomeGroupId': 'OG002',\n",
              "             'OutcomeGroupTitle': 'Parkinson-plus Syndrome Group',\n",
              "             'OutcomeGroupDescription': '1. patients with Parkinson-plus syndrome were diagnosed according to 2017 MDS progressive supranuclear paralysis and 2017 clinical diagnostic criteria for MDS progressive supra palsy (PSP patients) and Giman standard, the 2008 American board of neurology (AAN) MSA diagnostic consensus.2.informed consent to the study; 3.age > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and PPS patients and healthy controls .'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '90'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '125'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG002',\n",
              "                'OutcomeDenomCountValue': '23'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'PPP2CA',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1.502',\n",
              "                   'OutcomeMeasurementLowerLimit': '0.718',\n",
              "                   'OutcomeMeasurementUpperLimit': '3.110'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '3.653',\n",
              "                   'OutcomeMeasurementLowerLimit': '1.990',\n",
              "                   'OutcomeMeasurementUpperLimit': '5.856'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '0.916',\n",
              "                   'OutcomeMeasurementLowerLimit': '0.654',\n",
              "                   'OutcomeMeasurementUpperLimit': '1.452'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'PPP3CB',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1.669',\n",
              "                   'OutcomeMeasurementLowerLimit': '0.792',\n",
              "                   'OutcomeMeasurementUpperLimit': '2.947'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '2.237',\n",
              "                   'OutcomeMeasurementLowerLimit': '0.903',\n",
              "                   'OutcomeMeasurementUpperLimit': '4.416'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '2.320',\n",
              "                   'OutcomeMeasurementLowerLimit': '1.110',\n",
              "                   'OutcomeMeasurementUpperLimit': '3.269'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'SYNJ1',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '0.924',\n",
              "                   'OutcomeMeasurementLowerLimit': '0.537',\n",
              "                   'OutcomeMeasurementUpperLimit': '1.585'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '4.662',\n",
              "                   'OutcomeMeasurementLowerLimit': '2.278',\n",
              "                   'OutcomeMeasurementUpperLimit': '7.452'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '5.206',\n",
              "                   'OutcomeMeasurementLowerLimit': '2.541',\n",
              "                   'OutcomeMeasurementUpperLimit': '6.150'}]}}]}},\n",
              "            {'OutcomeClassTitle': 'NSF',\n",
              "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '1.002',\n",
              "                   'OutcomeMeasurementLowerLimit': '0.513',\n",
              "                   'OutcomeMeasurementUpperLimit': '2.150'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
              "                   'OutcomeMeasurementValue': '3.058',\n",
              "                   'OutcomeMeasurementLowerLimit': '1.665',\n",
              "                   'OutcomeMeasurementUpperLimit': '4.909'},\n",
              "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
              "                   'OutcomeMeasurementValue': '1.408',\n",
              "                   'OutcomeMeasurementLowerLimit': '0.864',\n",
              "                   'OutcomeMeasurementUpperLimit': '2.689'}]}}]}}]},\n",
              "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001',\n",
              "               'OG002']},\n",
              "             'OutcomeAnalysisGroupDescription': \"we use the method of RT-PCR to detect the relative expression level of PPP2CA gene in Parkinson's disease group(90 participants), healthy controls group(125 participants) and Parkinson-plus syndrome group(23 participants).This gene expression is relative to a house keeping gene GAPDH.The data were processed using 2-Ct. CT(test) = CT(target, test) - CT(ref, test), CT(calibrator) = CT(target, calibrator) - CT(ref, calibrator),CT = CT(test) - CT(calibrator).\",\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Other',\n",
              "             'OutcomeAnalysisPValue': '<0.001',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'Kruskal-Wallis'},\n",
              "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001',\n",
              "               'OG002']},\n",
              "             'OutcomeAnalysisGroupDescription': \"we use the method of RT-PCR to detect the relative expression level of SYNJ1 gene in Parkinson's disease group(90 participants), healthy controls group(125 participants) and Parkinson-plus syndrome group(23 participants).This gene expression is relative to a house keeping gene GAPDH.The data were processed using 2-Ct. CT(test) = CT(target, test) - CT(ref, test), CT(calibrator) = CT(target, calibrator) - CT(ref, calibrator),CT = CT(test) - CT(calibrator).\",\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Other',\n",
              "             'OutcomeAnalysisPValue': '<0.001',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'Kruskal-Wallis'},\n",
              "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001',\n",
              "               'OG002']},\n",
              "             'OutcomeAnalysisGroupDescription': \"we use the method of RT-PCR to detect the relative expression level of PPP3CB gene in Parkinson's disease group(90 participants), healthy controls group(125 participants) and Parkinson-plus syndrome group(23 participants).This gene expression is relative to a house keeping gene GAPDH.The data were processed using 2-Ct. CT(test) = CT(target, test) - CT(ref, test), CT(calibrator) = CT(target, calibrator) - CT(ref, calibrator),CT = CT(test) - CT(calibrator).\",\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Other',\n",
              "             'OutcomeAnalysisPValue': '0.149',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'Kruskal-Wallis'},\n",
              "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
              "               'OG001',\n",
              "               'OG002']},\n",
              "             'OutcomeAnalysisGroupDescription': \"we use the method of RT-PCR to detect the relative expression level of NSF gene in Parkinson's disease group(90 participants), healthy controls group(125 participants) and Parkinson-plus syndrome group(23 participants).This gene expression is relative to a house keeping gene GAPDH.The data were processed using 2-Ct. CT(test) = CT(target, test) - CT(ref, test), CT(calibrator) = CT(target, calibrator) - CT(ref, calibrator),CT = CT(test) - CT(calibrator).\",\n",
              "             'OutcomeAnalysisNonInferiorityType': 'Other',\n",
              "             'OutcomeAnalysisPValue': '<0.001',\n",
              "             'OutcomeAnalysisStatisticalMethod': 'Kruskal-Wallis'}]}},\n",
              "         {'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': \"Unified Parkinson's Disease Rating Scale 3.0UPDRS 3.0\",\n",
              "          'OutcomeMeasureDescription': \"The total score ranges from 0 to 199( minimum score is 0 and maximum scores is 199), in which a lower score denotes a better perception of the patient's.\\n\\nScoring the mental, behavioral and emotional, daily living activities, exercise tests, and drug treatment complications associated with UPDRS3.0 in patients with Parkinson's disease;each item 0-4 points, total score 199 points, 0-50 points: limb and body mild dysfunction, posture response normal;51-100 points: mild postural reaction disorder, self-care in daily life, loss of labor force;101-199: obvious postural reaction disorder, loss of daily life and labor force, may need help to get up and confined to wheelchair life;The more severe the symptoms of Parkinson's disease, the higher the score.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'The \"Unified Parkinson\\'s Disease Rating Scale 3.0\" is just suitable for PD patients,so there are no relative result for the group of healthy controls and Parkinson-plus syndrome group.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'score on a scale',\n",
              "          'OutcomeMeasureTimeFrame': '2 days',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': \"Parkinson's Disease Group\",\n",
              "             'OutcomeGroupDescription': \"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;\\nNewly diagnosed primary PD patients, diagnosed within 3-6 months;\\ninformed consent to the study;\\nage > 18 older.\\n\\ngenetic diagnosis: The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.\"},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Healthy Controls',\n",
              "             'OutcomeGroupDescription': 'healthy group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and PPS patients and healthy controls .'},\n",
              "            {'OutcomeGroupId': 'OG002',\n",
              "             'OutcomeGroupTitle': 'Parkinson-plus Syndrome Group',\n",
              "             'OutcomeGroupDescription': '1. patients with Parkinson-plus syndrome were diagnosed according to 2017 MDS progressive supranuclear paralysis and 2017 clinical diagnostic criteria for MDS progressive supra palsy (PSP patients) and Giman standard, the 2008 American board of neurology (AAN) MSA diagnostic consensus.2.informed consent to the study; 3.age > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and PPS patients and healthy controls .'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '90'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '0'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG002',\n",
              "                'OutcomeDenomCountValue': '0'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '61.352',\n",
              "                   'OutcomeMeasurementSpread': '29.611'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': 'Non-motor Symptom Scale (NMSS)',\n",
              "          'OutcomeMeasureDescription': \"Scoring based on the patient's own situation in the last month Severity: 1 = mild; 2 = moderate; 3 = severe Frequency: 1 = very little (less than once a week); 2 = often (1 time a week); 3 = frequent (a few times a week); 4 = very frequent (every day or persist)\",\n",
              "          'OutcomeMeasurePopulationDescription': 'Data were not collected.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureTimeFrame': '2 days',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': \"Parkinson's Disease Group\",\n",
              "             'OutcomeGroupDescription': \"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;\\nNewly diagnosed primary PD patients, diagnosed within 3-6 months;\\ninformed consent to the study;\\nage > 18 older.\\n\\ngenetic diagnosis: The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.\"},\n",
              "            {'OutcomeGroupId': 'OG001',\n",
              "             'OutcomeGroupTitle': 'Healthy Controls',\n",
              "             'OutcomeGroupDescription': 'healthy group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and PPS patients and healthy controls .'},\n",
              "            {'OutcomeGroupId': 'OG002',\n",
              "             'OutcomeGroupTitle': 'Parkinson-plus Syndrome Group',\n",
              "             'OutcomeGroupDescription': '1. patients with Parkinson-plus syndrome were diagnosed according to 2017 MDS progressive supranuclear paralysis and 2017 clinical diagnostic criteria for MDS progressive supra palsy (PSP patients) and Giman standard, the 2008 American board of neurology (AAN) MSA diagnostic consensus.2.informed consent to the study; 3.age > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and PPS patients and healthy controls .'}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '0'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG001',\n",
              "                'OutcomeDenomCountValue': '0'},\n",
              "               {'OutcomeDenomCountGroupId': 'OG002',\n",
              "                'OutcomeDenomCountValue': '0'}]}}]}}]}},\n",
              "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
              "       'EventsTimeFrame': '1 years',\n",
              "       'EventsDescription': 'There is no Serious Adverse Events occured',\n",
              "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
              "          'EventGroupTitle': \"Parkinson's Disease Group\",\n",
              "          'EventGroupDescription': \"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;\\nNewly diagnosed primary PD patients, diagnosed within 3-6 months;\\ninformed consent to the study;\\nage > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD ,PPS patients and healthy controls.\",\n",
              "          'EventGroupDeathsNumAffected': '0',\n",
              "          'EventGroupDeathsNumAtRisk': '90',\n",
              "          'EventGroupSeriousNumAffected': '0',\n",
              "          'EventGroupSeriousNumAtRisk': '90',\n",
              "          'EventGroupOtherNumAffected': '0',\n",
              "          'EventGroupOtherNumAtRisk': '90'},\n",
              "         {'EventGroupId': 'EG001',\n",
              "          'EventGroupTitle': 'Healthy Controls',\n",
              "          'EventGroupDescription': 'healthy group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and PPS patients and healthy controls .',\n",
              "          'EventGroupDeathsNumAffected': '0',\n",
              "          'EventGroupDeathsNumAtRisk': '125',\n",
              "          'EventGroupSeriousNumAffected': '0',\n",
              "          'EventGroupSeriousNumAtRisk': '125',\n",
              "          'EventGroupOtherNumAffected': '0',\n",
              "          'EventGroupOtherNumAtRisk': '125'},\n",
              "         {'EventGroupId': 'EG002',\n",
              "          'EventGroupTitle': 'Parkinson-plus Syndrome Group',\n",
              "          'EventGroupDescription': '1. patients with Parkinson-plus syndrome were diagnosed according to 2017 MDS progressive supranuclear paralysis and 2017 clinical diagnostic criteria for MDS progressive supra palsy (PSP patients) and Giman standard, the 2008 American board of neurology (AAN) MSA diagnostic consensus.2.informed consent to the study; 3.age > 18 older.\\n\\ngenetic diagnosis: The venous blood of the three groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and PPS patients and healthy controls .',\n",
              "          'EventGroupDeathsNumAffected': '0',\n",
              "          'EventGroupDeathsNumAtRisk': '23',\n",
              "          'EventGroupSeriousNumAffected': '0',\n",
              "          'EventGroupSeriousNumAtRisk': '23',\n",
              "          'EventGroupOtherNumAffected': '0',\n",
              "          'EventGroupOtherNumAtRisk': '23'}]}},\n",
              "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
              "        'AgreementRestrictiveAgreement': 'No'},\n",
              "       'PointOfContact': {'PointOfContactTitle': 'Xiaoya Gao',\n",
              "        'PointOfContactOrganization': 'Zhujiang Hospital of Southern Medical University',\n",
              "        'PointOfContactEMail': '4356975@qq.com',\n",
              "        'PointOfContactPhone': '18680282869'}}},\n",
              "     'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'Prot_SAP',\n",
              "          'LargeDocHasProtocol': 'Yes',\n",
              "          'LargeDocHasSAP': 'Yes',\n",
              "          'LargeDocHasICF': 'No',\n",
              "          'LargeDocLabel': 'Study Protocol and Statistical Analysis Plan',\n",
              "          'LargeDocDate': 'April 3, 2019',\n",
              "          'LargeDocUploadDate': '11/08/2019 04:09',\n",
              "          'LargeDocFilename': 'Prot_SAP_000.pdf'},\n",
              "         {'LargeDocTypeAbbrev': 'ICF',\n",
              "          'LargeDocHasProtocol': 'No',\n",
              "          'LargeDocHasSAP': 'No',\n",
              "          'LargeDocHasICF': 'Yes',\n",
              "          'LargeDocLabel': 'Informed Consent Form',\n",
              "          'LargeDocDate': 'April 3, 2019',\n",
              "          'LargeDocUploadDate': '11/08/2019 04:11',\n",
              "          'LargeDocFilename': 'ICF_001.pdf'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 36,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02265900',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'H14-02200'},\n",
              "       'Organization': {'OrgFullName': \"Pacific Parkinson's Research Centre\",\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Parkinson's Disease Exercise TMS PET Study\",\n",
              "       'OfficialTitle': \"Exercise and Parkinson's Disease: The Basis for Motor and Cognitive Benefits\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'March 2021',\n",
              "       'OverallStatus': 'Terminated',\n",
              "       'WhyStopped': 'Covid Restrictions have impacted longitudinal assessments for the effect of the intervention',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'November 2014'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 12, 2020',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'March 12, 2020',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'October 11, 2014',\n",
              "       'StudyFirstSubmitQCDate': 'October 11, 2014',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 16, 2014',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'March 15, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 17, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'A. Jon Stoessl',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Director of Clinical PET',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': \"Pacific Parkinson's Research Centre\"},\n",
              "       'LeadSponsor': {'LeadSponsorName': \"Pacific Parkinson's Research Centre\",\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"The therapeutic effects of exercise in Parkinson's disease (PD) are commonly reported, however the mechanisms are unknown. The purpose of this study is to investigate the potential mechanisms of exercise in the brain for the treatment of PD.\",\n",
              "       'DetailedDescription': 'Positron Emission Tomography will be used to measure dopamine neuron density, endogenous dopamine release and neuroimflammation. We will also use functional magnetic resonance imaging (fMRI) to measure brain activity. Assessments will be conducted before and after a 12-week exercise intervention and 3-year follow-up. Participants will be randomly allocated into either an aerobic or a stretching intervention. Clinical measures of motor function, cognition and mood will also be assessed.'},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': ['Positron Emission Tomography',\n",
              "         'Dopamine',\n",
              "         \"Parkinson's Disease\"]}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Quadruple',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
              "           'Care Provider',\n",
              "           'Investigator',\n",
              "           'Outcomes Assessor']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '26',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Exercise 1',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': 'One type of exercise',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Exercise']}},\n",
              "         {'ArmGroupLabel': 'Exercise 2',\n",
              "          'ArmGroupType': 'Placebo Comparator',\n",
              "          'ArmGroupDescription': 'A different type of exercise',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Exercise']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': 'Exercise',\n",
              "          'InterventionDescription': 'One type of exercise',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Exercise 1']}},\n",
              "         {'InterventionType': 'Other',\n",
              "          'InterventionName': 'Exercise',\n",
              "          'InterventionDescription': 'A different type of exercise',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Exercise 2']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Dopamine release measured by RAC PET',\n",
              "          'PrimaryOutcomeTimeFrame': '4 months'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria: Diagnosed with Parkinson's Disease, Exercise less than 3x per week.\\n\\nExclusion Criteria. Describe which potential participants will be excluded from participation, and list the criteria for their exclusion.\\n\\natypical Parkinson syndrome (progressive supranuclear palsy, multiple system atrophy, drug-induced etc.);\\nsignificant osteoporosis or arthritis;\\nother neurological disease/complications (e.g. myopathy, stroke, brain lesion, MS);\\nself-reports claustrophobia;\\nhistory of cancer within 5 years of study participation;\\nhigh dose of radiation from other procedures within the year;\\nnot able to tolerate being off PD medication for up to 24 hours;\\na female subject who is breast-feeding or pregnant.\\nSubjects who regularly use anti-inflammatories (only excluded for PBR scans).\\n\\nExclusion criteria for MRI scanning and magnetic stimulation from repetitive Transcranial Magnetic Stimulation (rTMS) scanning includes:\\n\\nartificial heart valve;\\nbrain aneurysm clip;\\nelectrical stimulator for nerves or bones;\\near or eye implant;\\nimplanted drug infusion pump;\\ncoil, catheter, or filter in any blood vessel;\\northopedic hardware (artificial joint, plate, screws);\\nother metallic prostheses;\\nshrapnel, bullets, or other metal fragments;\\nsurgery or tattoos (including tattooed eyeliner) in the last six weeks;\\nbrain surgery\\nhave a cardiac pacemaker, wires or defibrillator;\\nhave had an injury where a piece of metal lodged in the eye or orbit;\\nhave a ferromagnetic aneurysm clip; and\\nhave a history of seizures/epilepsy\\nhistory of severe or uncontrolled headaches/migraines\\ntaking medications that lower seizure threshold (e.g. amitryptiline, haloperidol)\\n\\nSubjects may be excluded following study enrollment if they meet any of the following exclusion criteria:\\n\\nsignificant cognitive impairment or depression;\\nsignificant or unstable cardiovascular or respiratory disease - all subjects will undergo a screening exercise bicycle stress test; or\\nfailure to comply with the exercise or stretching intervention program by not completing at least 30 of the 36 exercise classes.\\nSevere/multiple head trauma(s)\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '40 Years',\n",
              "       'MaximumAge': '80 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'A.J. Stoessl, MD',\n",
              "          'OverallOfficialAffiliation': \"Pacific Parkinson's Research Centre\",\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': \"Pacific Parkinson's Research Centre\",\n",
              "          'LocationCity': 'Vancouver',\n",
              "          'LocationState': 'British Columbia',\n",
              "          'LocationZip': 'V6T 2B5',\n",
              "          'LocationCountry': 'Canada'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}},\n",
              "      'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M6625',\n",
              "          'InterventionBrowseLeafName': 'Dopamine',\n",
              "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
              "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'CaAg',\n",
              "          'InterventionBrowseBranchName': 'Cardiotonic Agents'},\n",
              "         {'InterventionBrowseBranchAbbrev': 'All',\n",
              "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}},\n",
              "   {'Rank': 37,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01301651',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '200712039R'},\n",
              "       'Organization': {'OrgFullName': 'National Taiwan University Hospital',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Effects of Virtual Reality Training in Patients With Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Effects of Virtual Reality Augmented Balance Training for Postural Control in Patients With Parkinson's Disease\",\n",
              "       'Acronym': 'Parkinson'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'February 2011',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'November 2007'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2008',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'December 2008',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'February 18, 2011',\n",
              "       'StudyFirstSubmitQCDate': 'February 18, 2011',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 23, 2011',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'October 13, 2011',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 17, 2011',\n",
              "        'LastUpdatePostDateType': 'Estimate'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'National Taiwan University Hospital',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Science Council, Taiwan',\n",
              "          'CollaboratorClass': 'OTHER_GOV'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Background and Objective: Postural instability is common in patient with Parkinson's disease (PD). The purpose of this study was to investigate the effects of virtual reality (VR) balance training on sensory and cognitive domains of postural control.\\n\\nSetting: Balance Performance Laboratory. Participants: A total of 42 patients (Hoehn and Yahr stage II-III) were recruited and assigned into three groups randomly.\\n\\nIntervention: Participants in the virtual reality (VR) group and conventional balance training (CB) group received a 6 weeks balance training program. The control group (CG) did not receive any training.\\n\\nOutcome Measures: The sensory organization tests (SOT) of computerized dynamic posturography with single and dual tasks (i.e. with backward subtraction of number) were examined pre-, post-training and follow-up. The equilibrium score (ES) and sensory ratio were measured. The verbal reaction time (VRT) was recorded.\\n\\nResults: (1) Only VR significantly increased ES of SOT-6 (i.e., vestibular function at visual and somatosensory conflicting condition) post-training more than CG post-training in either single or dual task. (2) Only CB training significantly increased SOT-5 (i.e., vestibular function without visual conflict) and vestibular sensory ratio (i.e., SOT-5/SOT-1) more than CG post-training in either single or dual task. (3) (3) Neither VR nor CB training reduced VRT significantly under six sensory conditions at post-training and follow-up.\\n\\nConclusion: Both VR training and CB training can improve sensory organization for postural control by enhancing utilization of vestibular information, but VR could enhance vestibular function with conflicting proprioceptive and visual information under single and dual tasks in patients with mild to moderate PD.\",\n",
              "       'DetailedDescription': 'It is common that people who are diagnosed with idiopathic Parkinson disease (PD) experience postural instability during daily activities.Recently, postural instability is suggested as the underlying mechanism of falling in patients with PD. Therefore, how to improve postural stability by balance training is an important issue for these patients.\\n\\nBasal ganglia have been regarded to be predominantly involved in postural control. Several studies suggested that the dysfunction of basal ganglia in patients with PD might play a major role in postural instability. Furthermore, patients with PD might have impaired utilization of sensory information by the basal ganglia.Computerized dynamic posturography (CDP) has the Sensory Organization Test (SOT), which provides an objective assessment of the main sensory systems (i.e., vision, proprioception and vestibular system) involved in balance and stability. The role of sensory information under six conditions (i.e., eyes open, eyes closed, sway vision, eyes open sway support, eyes closed sway support, and sway vision sway support) has been studied in patients with PD by the SOT of computerized CDP. Their study indicated that patients with PD demonstrated a significant reduction in sensory integration of proprioception and vision, but no significant difference in vestibular function, as compared to age-matched controls. One study showed that patients with PD had visual dependence as an adaptive strategy partly compensating for the impaired proprioception. However, the other study suggested that the cerebellum might be important for sensory integration in patients with PD.'},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': ['Virtual Reality',\n",
              "         'Balance',\n",
              "         \"Parkinson's disease\",\n",
              "         'Dual Task']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Phase 1']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Factorial Assignment',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '42',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'virtual reality balance training',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'balance board training with virtual reality intervention',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: balance training']}},\n",
              "         {'ArmGroupLabel': 'conventional balance training',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'physical therapy conventional balance training',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: balance training']}},\n",
              "         {'ArmGroupLabel': 'control group',\n",
              "          'ArmGroupType': 'No Intervention',\n",
              "          'ArmGroupDescription': 'No physical therapy'}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
              "          'InterventionName': 'balance training',\n",
              "          'InterventionDescription': '30 minute each time, 2 times per week for 6 weeks.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['conventional balance training',\n",
              "            'virtual reality balance training']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['virtual reality']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The equilibrium score (ES) and sensory ratio were measured. The verbal reaction time (VRT) was recorded.',\n",
              "          'PrimaryOutcomeTimeFrame': '6 weeks'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\n(1) idiopathic Parkinson's disease, (2) intact cognition (Mini-Mental State Examination; MMSE>24), 22 (3) Hoehn and Yahr (H-Y) stage II-III diagnosed by neurologists, (4) not participated in any balance or gait training previously, (5) able to follow simple command and had no uncontrolled chronic condition.-\\n\\nExclusion Criteria:\\n\\n(1) history of other neurological, cardiovascular and orthopedic diseases affecting postural stability, (2) on-off motor fluctuation and dyskinesia above grade 3 by the Unified Parkinson' Disease Scale (UPDRS)\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '50 Years',\n",
              "       'MaximumAge': '80 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kwan-Hwa Lin, PhD',\n",
              "          'OverallOfficialAffiliation': 'School and Graduate Institute of Physical Therapy, National Taiwan University',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'National Taiwan University Hospital',\n",
              "          'LocationCity': 'Taipei',\n",
              "          'LocationCountry': 'Taiwan'}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '21474638',\n",
              "          'ReferenceType': 'derived',\n",
              "          'ReferenceCitation': 'Yen CY, Lin KH, Hu MH, Wu RM, Lu TW, Lin CH. Effects of virtual reality-augmented balance training on sensory organization and attentional demand for postural control in people with Parkinson disease: a randomized controlled trial. Phys Ther. 2011 Jun;91(6):862-74. doi: 10.2522/ptj.20100050. Epub 2011 Apr 7.'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 38,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04553185',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '2020 21/02'},\n",
              "       'Organization': {'OrgFullName': 'University of Exeter',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Aquaporin-4 Single Nucleotide Polymorphisms in Patients With Idiopathic and Familial Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Study on the Effects of Single Nucleotide Polymorphisms in Aquaporin-4 (AQP4) Gene on the Clinical Phenotype in Patients With Idiopathic and Familial Parkinson's Disease.\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'September 2021',\n",
              "       'OverallStatus': 'Active, not recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'November 28, 2018',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 1, 2024',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'September 1, 2024',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'August 26, 2020',\n",
              "       'StudyFirstSubmitQCDate': 'September 11, 2020',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 17, 2020',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'September 29, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 30, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'University of Exeter',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"The purpose of this study is to understand the relationship between problems in sleep, genetic variations in the Aquaporin-4 gene (AQP4), and the development of Parkinson's Disease.\",\n",
              "       'DetailedDescription': \"Parkinson's Disease (PD) is a progressive neurodegenerative disease characterized by the abnormal deposition in the brain of aggregates called Lewy Bodies, packed with a protein called -synuclein. The mechanisms why this protein accumulates in the brain of patients with PD, as well as its relationship with clinical symptoms, is unknown.\\n\\nRecently, an internal mechanism of drainage of waste proteins called glymphatic system has been identified and characterized. This system is silent during wakefulness and works during sleep. When it is active, a virtual space between the blood capillaries and cells of the brain called astrocytes opens and lets out waste products from the brain. This process is mediated by a protein of the astrocytes called Aquaporin-4 (AQP4). Preclinical studies have shown that the function of this system could be critical for the clearance of -amyloid, a protein linked with the development of Alzheimer's Disease. Studies in humans have shown that genetic variations some parts of the AQP4 gene, defined as single nucleotide polymorphisms, may increase the likelihood to develop an aggressive form of Alzheimer's Disease. However, no studies in humans have ever been performed in Parkinson's disease and -synuclein.\\n\\nIn this study, the investigators aim to elucidate whether genetic variations in the AQP4 gene contribute to variations in the clinical presentation and progression of sporadic and genetic forms of Parkinson's disease. To do so, the genetic profile of patients will be determined through a small venous blood sample collection. This will be coupled with clinical and sleep assessment.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's disease\",\n",
              "         'AQP4',\n",
              "         'Glymphatic System',\n",
              "         'Genetics']}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'No',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}},\n",
              "       'BioSpec': {'BioSpecRetention': 'Samples With DNA',\n",
              "        'BioSpecDescription': \"A venous sample will be collected from all participants. The venous sample will serve for genetic testing for Single Nucleotide Polymorphisms in the Aquaporin-4 gene and genetic testing for mutations in the following Parkinson's disease-related genes SNCA, LRRK2, VPS35, PARK2, PINK1, DJ-1, SYNJ1, DNAJ6, FBXO7, PLA2G6, LRP10, GBA and MAPT in a cohort of PD patients, as well as for the determination in the blood of the levels of the following substances: -synuclein (total and oligofragmented), S100, LRP1, and ABCB1.\"},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '800',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Parkinson's disease patients\",\n",
              "          'ArmGroupDescription': \"Patients with idiopathic or familial Parkinson's disease\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Study procedure']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': 'Study procedure',\n",
              "          'InterventionDescription': \"All participants will undergo a collection of demographic data, personal and family history for PD, a neurological examination and administration of clinical scales. All participants will undergo a collection of venous blood sample. At the end of the visit they will receive a wristwatch to monitor their sleep at home (Actigraph) and a sleep diary, together with a prepaid envelope to post the watch and the diary back to the investigators. They will also receive a link for a series of online tests for non-motor symptoms related to Parkinson's disease that they can complete remotely at home.\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Parkinson's disease patients\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Association between genetic variations in the AQP4 gene and worse motor symptoms in PD patients',\n",
              "          'PrimaryOutcomeDescription': \"The presence of genetic variations in the AQP4 gene, measured with single nucleotide polymorphisms will be correlated, in idiopathic and familial PD patients, with higher (worse) scores on the Movement Disorder Society - Unified Parkinson's disease Rating Scale (MDS-UPDRS).\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Up to 36 months'},\n",
              "         {'PrimaryOutcomeMeasure': 'Association between genetic variations in the AQP4 gene and worse motor symptoms in PD patients',\n",
              "          'PrimaryOutcomeDescription': 'The presence of genetic variations in the AQP4 gene, measured with single nucleotide polymorphisms will be correlated, in idiopathic and familial PD patients, with higher (worse) scores on the Hoehn & Yahr scales',\n",
              "          'PrimaryOutcomeTimeFrame': 'Up to 36 months'},\n",
              "         {'PrimaryOutcomeMeasure': 'Association between genetic variations in the AQP4 gene and worse cognitive symptoms in PD patients',\n",
              "          'PrimaryOutcomeDescription': 'The presence of genetic variations in the AQP4 gene, measured with single nucleotide polymorphisms will be correlated, in idiopathic and familial PD patients, with lower (worse) scores on Montreal Cognitive Assessment (MoCA) scale',\n",
              "          'PrimaryOutcomeTimeFrame': 'Up to 36 months'},\n",
              "         {'PrimaryOutcomeMeasure': 'Association between genetic variations in the AQP4 gene and worse cognitive symptoms in PD patients',\n",
              "          'PrimaryOutcomeDescription': 'The presence of genetic variations in the AQP4 gene, measured with single nucleotide polymorphisms will be correlated, in idiopathic and familial PD patients, with lower (worse) scores on the Cambridge Neuropsychological Test Automated Battery (CANTAB) assessment',\n",
              "          'PrimaryOutcomeTimeFrame': 'Up to 36 months'},\n",
              "         {'PrimaryOutcomeMeasure': 'Association between genetic variations in the AQP4 gene and worse sleep symptoms in PD patients',\n",
              "          'PrimaryOutcomeDescription': 'The presence of genetic variations in the AQP4 gene, measured with single nucleotide polymorphisms will be correlated, in idiopathic and familial PD patients, with worse sleep performances as assessed with sleep scales and Actigraph',\n",
              "          'PrimaryOutcomeTimeFrame': 'Up to 36 months'},\n",
              "         {'PrimaryOutcomeMeasure': 'Association between genetic variations in the AQP4 gene and worse non-motor symptoms in PD patients',\n",
              "          'PrimaryOutcomeDescription': 'The presence of genetic variations in the AQP4 gene, measured with single nucleotide polymorphisms will be correlated, in idiopathic and familial PD patients, with higher (worse) scores on scales for non-motor symptoms.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Up to 36 months'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Association between genetic variations in the AQP4 gene and altered levels of glymphatic system markers in PD patients',\n",
              "          'SecondaryOutcomeDescription': 'The presence of genetic variations in the AQP4 gene, measured with single nucleotide polymorphisms will be correlated, in idiopathic and familial PD patients, with increased levels of blood concentration of LRP-1, ABCB1 and AQP4',\n",
              "          'SecondaryOutcomeTimeFrame': 'Up to completion of study'},\n",
              "         {'SecondaryOutcomeMeasure': 'Association between genetic variations in the AQP4 gene and altered levels of astrocytic',\n",
              "          'SecondaryOutcomeDescription': 'The presence of genetic variations in the AQP4 gene, measured with single nucleotide polymorphisms will be correlated, in idiopathic and familial PD patients, with increased levels of blood concentration of S100',\n",
              "          'SecondaryOutcomeTimeFrame': 'Up to completion of study'},\n",
              "         {'SecondaryOutcomeMeasure': 'Association between genetic variations in the AQP4 gene and altered levels of protein aggregation markers in PD patients',\n",
              "          'SecondaryOutcomeDescription': 'The presence of genetic variations in the AQP4 gene, measured with single nucleotide polymorphisms will be correlated, in idiopathic and familial PD patients, with increased levels of blood concentration of -synuclein',\n",
              "          'SecondaryOutcomeTimeFrame': 'Up to completion of study'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n18-85 years of age\\nAble to give informed consent\\nAble to perform online neuropsychological examinations\\nDiagnosis of PD according to Brain Bank Criteria\\nNo presence or personal or family history of other neurological or psychiatric disorders\\n\\nExclusion Criteria:\\n\\nPresence of other neurological disorders and known intracranial co-morbidities such as stroke, haemorrhage, space-occupying lesions\\nInability to perform online neuropsychological assessment\\nInability to have access to informatics technology to perform the online assessment tests\\nInability to travel for the assessments\\nNative language different from English',\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'MaximumAge': '85 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': \"Patients with a diagnosis of Parkinson's disease according to Published Criteria.\",\n",
              "       'SamplingMethod': 'Non-Probability Sample'},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Marios Politis, MD MSc PhD',\n",
              "          'OverallOfficialAffiliation': 'University of Exeter',\n",
              "          'OverallOfficialRole': 'Study Chair'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'East Kent University Hospitals NHS Foundation Trust',\n",
              "          'LocationCity': 'Ashford',\n",
              "          'LocationCountry': 'United Kingdom'},\n",
              "         {'LocationFacility': 'University of Exeter',\n",
              "          'LocationCity': 'Exeter',\n",
              "          'LocationZip': 'SE16 7RJ',\n",
              "          'LocationCountry': 'United Kingdom'},\n",
              "         {'LocationFacility': 'Lewisham and Greenwich NHS Foundation Trust',\n",
              "          'LocationCity': 'London',\n",
              "          'LocationCountry': 'United Kingdom'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No',\n",
              "       'IPDSharingDescription': 'There is no plan to share IPD with other researchers.'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 39,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03384797',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'Pro00088250'},\n",
              "       'Organization': {'OrgFullName': 'Duke University', 'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Blood Biomarker in Early Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Blood Biomarker in Early Parkinson's Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'June 2019',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'January 22, 2018',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 7, 2019',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'January 7, 2019',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'December 20, 2017',\n",
              "       'StudyFirstSubmitQCDate': 'December 20, 2017',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 27, 2017',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'June 7, 2019',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 10, 2019',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Duke University',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Currently, there are no cures or disease modifying therapies for Parkinson's disease (PD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for PD. Several detection parameters will be assessed through enrollment of Parkinson's patients and age matched healthy volunteers over 50 years of age to learn more about the analytical process and biological variability.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': ['blood',\n",
              "         'biomarker',\n",
              "         \"Parkinson's disease\"]}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'No',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '65',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Healthy Volunteers'},\n",
              "         {'ArmGroupLabel': \"Parkinson's Disease\"}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Biological marker of Parkinson's disease\",\n",
              "          'PrimaryOutcomeDescription': \"Test for biological marker of Parkinson's disease, mtDNA damage\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Day 1'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion\\n\\nAge matched to PD patient Parkinson's Disease Patients:\\n\\n50 years and older\\nPD patient who is seen at the Duke Movement Disorders Center\\nEarly PD diagnosis (Hoehn and Yahr scale  3)\\nNon-smoking\\nNo cancer treatment in the last 5 years\\nAble to read and speak English\\n\\nHealthy Control Participants:\\n\\n50 years and older\\nNon-smoking\\nNo cancer treatment in the last 5 years\\nAble to read and speak English\\n\\nExclusion Criteria:\\n\\nParkinson's Disease Patients:\\n\\nKnown additional neurological disease\\nClinical trial intervention within the last 6 months\\n\\nHealthy Control Participants:\\n\\nNeurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)\\nClinical trial intervention within the last 6 months\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '50 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': \"Parkinson's patients will be recruited from the Duke Movement Disorders Clinic. Healthy adult volunteers will be recruited from the healthy volunteer registry at DEPRU or caregivers of patients seen at the Duke Movement Disorders Clinic.\",\n",
              "       'SamplingMethod': 'Non-Probability Sample'},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Laurie Sanders, PhD',\n",
              "          'OverallOfficialAffiliation': 'Duke University',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Duke University Medical Facility',\n",
              "          'LocationCity': 'Durham',\n",
              "          'LocationState': 'North Carolina',\n",
              "          'LocationZip': '27710',\n",
              "          'LocationCountry': 'United States'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 40,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01955616',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'RM-131-007'},\n",
              "       'Organization': {'OrgFullName': 'Motus Therapeutics, Inc.',\n",
              "        'OrgClass': 'INDUSTRY'},\n",
              "       'BriefTitle': \"A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation\",\n",
              "       'OfficialTitle': \"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients With Parkinson's Disease and Chronic Constipation Dissatisfied With Current Therapy\",\n",
              "       'Acronym': 'MOVE-PD'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'September 2016',\n",
              "       'OverallStatus': 'Terminated',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'September 2013'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2015',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'September 2015',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'September 25, 2013',\n",
              "       'StudyFirstSubmitQCDate': 'September 27, 2013',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 7, 2013',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'DispFirstSubmitDate': 'December 2, 2015',\n",
              "       'DispFirstSubmitQCDate': 'December 2, 2015',\n",
              "       'DispFirstPostDateStruct': {'DispFirstPostDate': 'January 1, 2016',\n",
              "        'DispFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'September 21, 2016',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 23, 2016',\n",
              "        'LastUpdatePostDateType': 'Estimate'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Motus Therapeutics, Inc.',\n",
              "        'LeadSponsorClass': 'INDUSTRY'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': \"Michael J. Fox Foundation for Parkinson's Research\",\n",
              "          'CollaboratorClass': 'OTHER'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"The purpose of this study, called MOVE-PD, is to investigate how individuals with Parkinson's disease (PD) and chronic constipation (CC) respond to RM-131 as compared to placebo. The study will look at how well RM-131 affects the frequency of spontaneous bowel movements over a 14-day period. The study will also evaluate the safety and tolerability of the study drug and evaluate whether the study drug relieves the uncomfortable GI symptoms related to chronic constipation in patients who are unsatisfied with other therapies they have tried for constipation.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's disease, chronic constipation\"]}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Phase 2']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Quadruple',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
              "           'Care Provider',\n",
              "           'Investigator',\n",
              "           'Outcomes Assessor']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '18',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'RM-131',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': 'RM-131 100 g by subcutaneous injection daily in the morning',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: RM-131']}},\n",
              "         {'ArmGroupLabel': 'Placebo',\n",
              "          'ArmGroupType': 'Placebo Comparator',\n",
              "          'ArmGroupDescription': 'by subcutaneous injection daily in the morning',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Placebo']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
              "          'InterventionName': 'RM-131',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['RM-131']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['Ghrelin receptor agonist',\n",
              "            'relamorelin']}},\n",
              "         {'InterventionType': 'Drug',\n",
              "          'InterventionName': 'Placebo',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Investigate the effects of treatment with RM-131 for 14 days on the frequency of spontaneous bowel movements (SBMs) when administered to patients with Parkinson's Disease (PD) and Chronic Constipation (CC)\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Screening through Day 28'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Evaluate the safety and tolerability of multiple doses of RM-131 when administered to patients with PD and CC',\n",
              "          'SecondaryOutcomeTimeFrame': 'Screening through Day 28'},\n",
              "         {'SecondaryOutcomeMeasure': 'Effect of RM-131 on stool frequency as measured by complete spontaneous bowel movements, stool consistency, straining, completeness of evacuation, abdominal pain, and global patient reported outcomes of severity of constipation and overall relief.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Screening through Day 28'},\n",
              "         {'SecondaryOutcomeMeasure': \"Assess symptoms of Parkinson's disease using the Unified Parkinson Disease Rating Scale (UPDRS)\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Screening through Day 28'}]},\n",
              "       'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Assess the effect of RM-131 on gastroparesis symptoms',\n",
              "          'OtherOutcomeTimeFrame': 'Screening through Day 28'},\n",
              "         {'OtherOutcomeMeasure': 'Time to first bowel movement (BM)',\n",
              "          'OtherOutcomeTimeFrame': 'Screening through Day 28'},\n",
              "         {'OtherOutcomeMeasure': 'Area under the concentration versus time curve of RM-131 will be measured',\n",
              "          'OtherOutcomeTimeFrame': 'Screening through Day 28'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAble to provide written informed consent and be willing and able to comply with study procedures.\\nDiagnosis of Parkinson's disease\\nDiagnosis of chronic constipation (CC), including experiencing constipation for ~12 or more weeks in the preceding 12 months.\\nRegular treatment for chronic constipation during the last 6 months, and dissatisfaction with current treatment for CC, after treatment with at least 2 regimens for constipation (see note at end of this section).\\nStable medication history defined as no changes in regimen for at least 2 weeks prior to the baseline period\\nBody mass index of 18-40 kg/m2\\nMini-mental status exam (at screening) 26\\nFemale patients must have negative serum or urine pregnancy tests and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. A vasectomized partner will be allowed as one in conjunction with another single-barrier method.\\nFemale patients unable to bear children must have this documented in the case report form(i.e., tubal ligation, hysterectomy, or post-menopausal [defined as a minimum of one year since the last menstrual period]). Post-menopausal status will be confirmed by follicle stimulating hormone (FSH) in women less than 60 years of age\\n\\nNote the following medications are allowed:\\n\\nSelective serotonin reuptake inhibitor (SSRI), SNRI, and tricyclic antidepressants are permissible at stable doses. All medications shall be reviewed and dis/approved by the investigator on a case-by-case basis.\\nBenzodiazepines are permissible at stable doses\\nStable doses of antacids, NSAIDS, Cox-2 inhibitors, calcium supplements, thyroid replacement, estrogen replacements, low-dose aspirin for cardioprotection, and birth control (but with adequate back up contraception as drug interactions with birth control have not been conducted) are permissible\\nDopamine agonists and amantadine allowed if on a stable dose\\nDeep brain stimulation is allowed.\\n\\nExclusion Criteria:\\n\\nUnable or unwilling to provide informed consent or to comply with study procedures\\nDiagnosis of secondary constipation beyond that of Parkinson's disease\\nStructural or metabolic diseases that affect the GI system\\n\\nUnable to withdraw the following medications 48 hours prior to the baseline period and throughout the study (except as protocol defined rescue medications; see below):\\n\\nMedications that alter GI transit including laxatives, prokinetics, erythromycin, narcotics, and anti-cholinergics (except as protocol defined rescue medications).\\nGABAergic agents\\nDrugs with a low therapeutic index, such as warfarin, digoxin, anti-seizure medications\\n\\nNOTE: Parkinson's disease therapies are allowed. Exceptions for Parkinson's disease medications include:\\n\\nCogentin (benztopine), Artane (trihexyphenidyl), and apomorphone are excluded\\nHistory of recent major surgery (within 60 days of screening)\\nAcute or chronic illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the patient or obscure interpretation of laboratory test results or interpretation of study data such as frequent angina, Class III or IV congestive heart failure, moderate impairment of renal or hepatic function, poorly controlled diabetes, etc.\\nHistory of symptomatic orthostatic hypotension or significant history of dizziness\\nHistory of hypersensitivity to mannitol which is an ingredient of both active and placebo study medications\\nAny clinically significant abnormalities on screening laboratories or physical examination as determined by the Investigator\\nAbnormal 12-lead electrocardiogram (ECG), including evidence of acute myocardial or subendocardial ischemia and clinically significant arrhythmias or conduction abnormalities (including prolonged QTc > 500 msec) or abnormal blood pressure at screening except minor deviations deemed to be of no clinical significance by the Investigator\\nAcute GI illness within 48 hours of the baseline period\\nHistory of major GI surgery, except that patients with uncomplicated appendectomy or cholecystectomy are allowed.\\nALT or AST > 1.5 X upper limit of normal (ULN) during screening\\nFemales who are pregnant or breastfeeding\\nHistory of excessive alcohol use or substance abuse\\nPatient or caregiver unable to administer daily SC injections\\nParticipation in an investigational clinical study within the 30 days prior to dosing in the present study\\nAny other reason, which in the opinion of the Investigator, would confound proper interpretation of the study\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'MaximumAge': '80 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Ronald Pfeiffer, MD',\n",
              "          'OverallOfficialAffiliation': \"Parkinson's Study Group\",\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'University of Southern California',\n",
              "          'LocationCity': 'Los Angeles',\n",
              "          'LocationState': 'California',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Colorado Neurological Institute',\n",
              "          'LocationCity': 'Englewood',\n",
              "          'LocationState': 'Colorado',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of Florida Ctr for Movement Disorders & Neurorestoration',\n",
              "          'LocationCity': 'Gainesville',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Emory University, Wesley Woods Health Center',\n",
              "          'LocationCity': 'Atlanta',\n",
              "          'LocationState': 'Georgia',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Georgia Regents University',\n",
              "          'LocationCity': 'Augusta',\n",
              "          'LocationState': 'Georgia',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of Iowa Hospitals, Movement Disorders Div, Dept of Neurology',\n",
              "          'LocationCity': 'Iowa City',\n",
              "          'LocationState': 'Iowa',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Michigan State University',\n",
              "          'LocationCity': 'East Lansing',\n",
              "          'LocationState': 'Michigan',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Henry Ford West Bloomfield Hospital',\n",
              "          'LocationCity': 'West Bloomfield',\n",
              "          'LocationState': 'Michigan',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'Atlantic Neuroscience',\n",
              "          'LocationCity': 'Summit',\n",
              "          'LocationState': 'New Jersey',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of Rochester',\n",
              "          'LocationCity': 'Rochester',\n",
              "          'LocationState': 'New York',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of Toledo Medical Center',\n",
              "          'LocationCity': 'Toledo',\n",
              "          'LocationState': 'Ohio',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': \"Movement Disorders Program & The Parkinson's Center of Oregon\",\n",
              "          'LocationCity': 'Portland',\n",
              "          'LocationState': 'Oregon',\n",
              "          'LocationCountry': 'United States'},\n",
              "         {'LocationFacility': 'University of Pennsylvania, Penn Neurological Institute',\n",
              "          'LocationCity': 'Philadelphia',\n",
              "          'LocationState': 'Pennsylvania',\n",
              "          'LocationCountry': 'United States'}]}}},\n",
              "     'ResultsSection': {'MoreInfoModule': {}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'},\n",
              "         {'ConditionMeshId': 'D000003248',\n",
              "          'ConditionMeshTerm': 'Constipation'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'},\n",
              "         {'ConditionAncestorId': 'D000012817',\n",
              "          'ConditionAncestorTerm': 'Signs and Symptoms, Digestive'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5624',\n",
              "          'ConditionBrowseLeafName': 'Constipation',\n",
              "          'ConditionBrowseLeafAsFound': 'Constipation',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M14774',\n",
              "          'ConditionBrowseLeafName': 'Signs and Symptoms, Digestive',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23',\n",
              "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 41,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02474329',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'NL53034.091.41'},\n",
              "       'Organization': {'OrgFullName': 'Radboud University Medical Center',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Real-PD: Development of Clinical Prognostic Models for Parkinson's Disease From Large-scale Wearable Sensor Deployment and Clinical Data - a Population Based Trial\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'October 2017',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'July 2015'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2016',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'November 2016',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'June 2, 2015',\n",
              "       'StudyFirstSubmitQCDate': 'June 12, 2015',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 17, 2015',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'ResultsFirstSubmitDate': 'January 7, 2021',\n",
              "       'ResultsFirstSubmitQCDate': 'October 28, 2021',\n",
              "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'December 6, 2021',\n",
              "        'ResultsFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'October 28, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 6, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Radboud University Medical Center',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': \"Michael J. Fox Foundation for Parkinson's Research\",\n",
              "          'CollaboratorClass': 'OTHER'},\n",
              "         {'CollaboratorName': 'Philips Electronics Nederland B.V. acting through Philips CTO organization',\n",
              "          'CollaboratorClass': 'INDUSTRY'},\n",
              "         {'CollaboratorName': 'Intel Corporation',\n",
              "          'CollaboratorClass': 'INDUSTRY'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Background: Long-term management of Parkinson's disease (PD) does not reach its full potential due to lack of knowledge about disease progression. The Real-PD study aim to evaluate the feasibility and compliance of usage of wearable sensors in PD patients in real life. Moreover, an explorative analysis concerning activity level, medication intake and mood will be done.\\n\\nMethods: Overall, 1000 PD patients and 250 physiotherapist will be enrolled in this observational study. Dutch PD patients will be recruited across the country and an assessment will be performed using a short version of the Parkinson's Progression Markers Initiative (PPMI) protocol. Moreover, participants will wear a set of medical devices (Pebble Smartwatch, fall detector) and they will use a smartphone with The Fox Insight App (Android app), 24/7, during 13 weeks. Primary measures of interest are: 1) physical activity, falls and tremor, measured by the axial accelerometers embedded in the Pebble watch and fall detector; and 2) medication intake and mood reports measured by patients' self-report in the Android app. To measure motor impact, an assessment will be performed by physiotherapists who are all certified to perform the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS).\\n\\nDiscussion: Management of PD patients is complex and appears to be a challenging task for health care professionals. The main reason is the lack of knowledge in the disease pattern. This issue could be solved by a long term follow-up of patients' during their everyday life, and wearable medical devices can act as a way to collect data about every day life activities. Therefore, the Real-PD study will be a first contribution in increasing the lack of knowledge in disease progression, developing a new medical decision system and improving PD patients' care.\",\n",
              "       'DetailedDescription': 'Rationale: Today\\'s management of patients with a chronic disorder like Parkinson\\'s disease (PD) is imperfect. The understanding of clinical profiles is based on observations in small, selective populations with brief follow-up. Moreover, treatment decisions are based on averaged population results that may not apply to a specific individual context. These drawbacks will be addressed with a \"big data\" approach. Ambulatory sensors will be used as an objective measure of patients\\' performance under everyday circumstances, for longer periods of time. The researchers aim to explore the potential of using longitudinal ambulatory data to enrich a standardized clinical dataset, which reflects current clinical practice for the assessment of disease status.\\n\\nObjective: The study will include a total of 250 physiotherapists and 1000 patients. The aims of this study are: (1) to perform \"big data\" analyses on the raw sensor data, in relation to concurrently acquired clinical data in these patients (limited version of the PPMI (Parkinson\\'s Progression Markers Initiative) protocol) to develop patient profiles; and (2) to correlate the ambulatory sensor data to simple self-assessments made during follow-up.\\n\\nStudy design: Observational descriptive study.\\n\\nStudy population: Dutch Parkinson patients, male or female, age 30 years or older, with PD diagnosis given by a physician, and own a suitable smartphone.\\n\\nlntervention: 250 ParkinsonNet physiotherapists and 1000 eligible patients will be included in this study. Patients and physiotherapists will be recruited in 5 consecutive cohorts based on geographic region. Patients will be asked to wear a smartwatch and a pendant movement sensor, both with triaxial accelerometers, during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling. During the 13 week follow-up, trained physiotherapists will perform a standardized clinical assessment, based on the PPMI protocol (www.ppmi-info.org) for every included patient. This assessment will last for 60 minutes. The smartphone is used to transmit data from the watch to a cloud-based data platform. lntel developed this dedicated data analysis platform for ambulatory data. lntel will receive coded data only.\\n\\nMain study parameters/endpoints: Study endpoints include parameters registered with the smartwatch, the pendant movement sensor, the self-monitoring app and collected with the PPMI assessment. The smartwatch data provides, after data processing, a measure for the level of physical activity during the day. Falls will be registered with the pendant movement sensor. Medication intake and mood are registered using the smartphone. Finally, PPMI assessment includes assessment of motor symptoms, cognition, depression, sleep and daily activity. Correlations will be determined between the above mentioned parameters.\\n\\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: First, participants are asked to wear the devices 24/7 and data will be recorded continuously, for a total duration of 13 weeks. Second, data will be transmitted to a data platform developed and managed by lntel, on behalf of the Michael J. Fox Foundation for Parkinson\\'s Research. To access these data, researchers can grant permission for research purposes, provided by Michael J. Fox Foundation. Patients will be asked for permission to share the raw coded data for dissemination to the research community, analysis and use in future publications. Participation in the study warrants that patients provide written permission for this.'},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's disease\",\n",
              "         'Ambulatory monitoring',\n",
              "         'Disease progression']}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'Yes',\n",
              "       'TargetDuration': '13 Weeks',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '304',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cohort 1',\n",
              "          'ArmGroupDescription': \"Dutch Parkinson's patients resident in the region of Noord-Holland whose fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Clinical assessment',\n",
              "            'Device: Fox Insight self-monitoring android app and falls detector']}},\n",
              "         {'ArmGroupLabel': 'Cohort 2',\n",
              "          'ArmGroupDescription': \"Dutch Parkinson's patients resident in the region of Zuid-Holland whose fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Clinical assessment',\n",
              "            'Device: Fox Insight self-monitoring android app and falls detector']}},\n",
              "         {'ArmGroupLabel': 'Cohort 3',\n",
              "          'ArmGroupDescription': \"Dutch Parkinson's patients resident in the region of Gelderland and Utrecht whose fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Clinical assessment',\n",
              "            'Device: Fox Insight self-monitoring android app and falls detector']}},\n",
              "         {'ArmGroupLabel': 'Cohort 4',\n",
              "          'ArmGroupDescription': \"Dutch Parkinson's patients resident in the region of Groningen, Friesland, Drenthe and Overijssel whose fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Clinical assessment',\n",
              "            'Device: Fox Insight self-monitoring android app and falls detector']}},\n",
              "         {'ArmGroupLabel': 'Cohort 5',\n",
              "          'ArmGroupDescription': \"Dutch Parkinson's patients resident in the region of Zeeland, Noord-Brabant and Limburg whose fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Clinical assessment',\n",
              "            'Device: Fox Insight self-monitoring android app and falls detector']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': 'Clinical assessment',\n",
              "          'InterventionDescription': 'During the 13 week follow-up, trained physiotherapists will perform a standardized clinical assessment, based on the PPMI protocol (www.ppmi-info.org) for every included patient. This assessment will last for 60 minutes, and it will be done once.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cohort 1',\n",
              "            'Cohort 2',\n",
              "            'Cohort 3',\n",
              "            'Cohort 4',\n",
              "            'Cohort 5']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': [\"PPMI (Parkinson's Progression Markers Initiative) protocol\"]}},\n",
              "         {'InterventionType': 'Device',\n",
              "          'InterventionName': 'Fox Insight self-monitoring android app and falls detector',\n",
              "          'InterventionDescription': 'Patients will be asked to wear a smartwatch and a pendant movement sensor, both with triaxial accelerometers, during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cohort 1',\n",
              "            'Cohort 2',\n",
              "            'Cohort 3',\n",
              "            'Cohort 4',\n",
              "            'Cohort 5']},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['Pebble smartphone',\n",
              "            'Philips falls detector']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Parkinson's Disease Symptoms\",\n",
              "          'PrimaryOutcomeDescription': \"The MDS-UPDRS is a revision of the Unified Parkinson's Disease Rating Scale (UPDRS). It was developed to evaluate various aspects of Parkinson's disease including non-motor and motor experiences of daily living, as well as motor complications. The MDS-UPDRS characterizes the extent and burden of disease across various populations. Here, we used data from one-point assessment (baseline). The total score used here was calculated by a sum of all scores from the 4 sub-scales (i.e. part I, up to part IV) composing the MDS-UPDRS. Total score ranges from 0 to 272. A higher score indicates higher disease severity and burden, being thus a worse outcome.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline'},\n",
              "         {'PrimaryOutcomeMeasure': 'Depression Scores as a Measure of Depression Rates',\n",
              "          'PrimaryOutcomeDescription': 'The scores obtained with the Geriatric Depression Scale were analysed in order to create a percentage of probably depressed participants. The total score goes from 0 to 15. A score higher than 6 indicates higher probability of suffer from a depression.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline'},\n",
              "         {'PrimaryOutcomeMeasure': 'Cognitive Impairment.',\n",
              "          'PrimaryOutcomeDescription': 'Total sum score obtained with the Montreal Cognitive Assessment. We analyzed the full score to investigate percentage of participants with a possible cognitive impairment. The Montreal Cognitive sum scores ranges from 0 to 30, in which a score lower or equal to 26 is considered as possible cognitive decline.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline'},\n",
              "         {'PrimaryOutcomeMeasure': 'Independency Level',\n",
              "          'PrimaryOutcomeDescription': 'The total sum score obtained with the Schwab and England activities of daily living scale were analyzed to describe the functional level of the sample. The total sum scores varies from 0 to 100, in which lower scores are associated with more dependency of others to perform daily life activities.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Number of Falls Per Patient Registered by the Falls Detector.',\n",
              "          'SecondaryOutcomeDescription': 'The fall event is recognized by the falls detector. Every time that the patient falls, the algorithm embedded at the falls detector recognize as a fall and record the fall event. At the end of the follow-up time, a sum of the falls event for each patient will be done.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Patients will be automatically assessed during the follow-up time (up to 13 weeks after the enrollment date), 24 hours a day, 7 days a week.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Number of Mood Reports for Each Patient Measured With a Four Point Scale',\n",
              "          'SecondaryOutcomeDescription': 'The number of mood reports will be collected through the smartphone application. A four point scale (very good, good, poor and fair) will be available, and by pressing the button which correspond to how the patient feels at that moment the report can be performed. At the end of the follow-up time a sum of all the reports will be done in order to measure the number of mood reports over the follow-up time.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Patients will be assessed during the follow-up time (up to 13 weeks after the enrollment date). It is expected that the assessment (self-report) will be performed as many times as the patient wants to report how they feel or at least once a day.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Number of Medication Intake Annotations Made by Each Participant Via the Self-report App.',\n",
              "          'SecondaryOutcomeDescription': 'The number of medication intake annotations made by the patients will be collected through the smartphone application. Every time that the patient take medication they must press the button reporting that they took the medication. At the end of the follow-up time a sum of all the reports will be done in order to measure the number of medication intake over the follow-up time.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline'},\n",
              "         {'SecondaryOutcomeMeasure': 'Time That Each Patient Was Active During the Day',\n",
              "          'SecondaryOutcomeDescription': 'The time that the patient was active during the day is calculated automatically through the app at the smartphone. The calculation is performed by using an algorithm, which analyze the patterns of walk. This algorithm is able to predict when the patient was active in a zone above his/her usual threshold (e.g. when the patient was performing one activity that makes him/her more active than during a quiet time). At the end of the follow-up time a sum of all active hours will be done in order to measure the amount of time that the patient was active over the follow-up time.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Patients will be automatically assessed continuously during the follow-up time (up to 13 weeks after the enrollment date), 24 hours a day, 7 days a week. The analyses was limited to walking activities.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Level of Activity for Each Patient During the Day',\n",
              "          'SecondaryOutcomeDescription': 'The level of activity for each patient is calculated automatically through the app at the smartphone. The calculation is performed by using the data collect with the accelerometers embedded in the smartwatch. An algorithm installed in the phone, which analyze the data collected with the smartwatch, can calculate the level of activity for each patient throughout the day.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Patients will be automatically assessed during the follow-up time (up to 13 weeks after the enrollment date), 24 hours a day, 7 days a week.'},\n",
              "         {'SecondaryOutcomeMeasure': 'Scores in Autonomic Dysfunctions Measure With the Autonomic Dysfunctions Scale',\n",
              "          'SecondaryOutcomeDescription': \"The scores for autonomic dysfunctions will be obtained with the Assessment of autonomic dysfunction in Parkinson's disease (SCOPA-AUT). The total sum scores ranges from 0 to 100, in which high scores are correlated with more burden of autonomic dysfunctions in Parkinson's patients.\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline'},\n",
              "         {'SecondaryOutcomeMeasure': 'Sleepiness Rates in the Epworth Sleepiness Scale as a Measure of Sleep Quantity.',\n",
              "          'SecondaryOutcomeDescription': \"The Epworth sleepiness scale was used to rate the level of sleepiness during the day. The scale's scores are related to the usual duration of sleep at night and increase with relative sleep deprivation. Here, we used data from one-point assessment (baseline). Then, we can suggest that if the sample has high scores they will have a low sleep quantity. Total sum score ranges from 0 (no sleepiness at all) to 24 (excessive sleepiness).\",\n",
              "          'SecondaryOutcomeTimeFrame': 'Baseline'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nCurrently own and use a smartphone device with access to the Internet\\n30 years of age or older;\\nDiagnosed with Parkinson's disease by a physician;\\nAble to walk without any assistance.\\n\\nExclusion Criteria:\\n\\nNone exclusion criteria will be used.\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '30 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': 'Dutch Parkinson patients.',\n",
              "       'SamplingMethod': 'Non-Probability Sample'},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Bastiaan R Bloem, Prof. Dr.',\n",
              "          'OverallOfficialAffiliation': 'Radboud University Medical Center',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Cohort 1',\n",
              "          'LocationCity': 'Multiple Locations',\n",
              "          'LocationState': 'Noord-Holland',\n",
              "          'LocationCountry': 'Netherlands'}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '16445257',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Prkk J, Ermes M, Korpip P, Mntyjrvi J, Peltola J, Korhonen I. Activity classification using realistic data from wearable sensors. IEEE Trans Inf Technol Biomed. 2006 Jan;10(1):119-28.'},\n",
              "         {'ReferencePMID': '24689772',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Hobert MA, Maetzler W, Aminian K, Chiari L. Technical and clinical view on ambulatory assessment in Parkinson's disease. Acta Neurol Scand. 2014 Sep;130(3):139-47. doi: 10.1111/ane.12248. Epub 2014 Apr 1. Review.\"},\n",
              "         {'ReferencePMID': '24030855',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Maetzler W, Domingos J, Srulijes K, Ferreira JJ, Bloem BR. Quantitative wearable sensors for objective assessment of Parkinson's disease. Mov Disord. 2013 Oct;28(12):1628-37. doi: 10.1002/mds.25628. Epub 2013 Sep 12. Review.\"},\n",
              "         {'ReferencePMID': '19846382',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Patel S, Lorincz K, Hughes R, Huggins N, Growdon J, Standaert D, Akay M, Dy J, Welsh M, Bonato P. Monitoring motor fluctuations in patients with Parkinson's disease using wearable sensors. IEEE Trans Inf Technol Biomed. 2009 Nov;13(6):864-73. doi: 10.1109/TITB.2009.2033471. Epub 2009 Oct 20.\"},\n",
              "         {'ReferencePMID': '22254617',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Patel S, Chen BR, Mancinelli C, Paganoni S, Shih L, Welsh M, Dy J, Bonato P. Longitudinal monitoring of patients with Parkinson's disease via wearable sensor technology in the home setting. Annu Int Conf IEEE Eng Med Biol Soc. 2011;2011:1552-5. doi: 10.1109/IEMBS.2011.6090452.\"},\n",
              "         {'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Tsanas A, Little MA, McSharry PE, Ramig L. Using the cellular mobile telephone network to remotely monitor parkinsons disease symptom severity. IEEE Transactions on Biomedical Engineering. 2012.'},\n",
              "         {'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Arora S, Venkataraman V, Donohue S, Biglan KM, Dorsey ER, Little MA, editors. High accuracy discrimination of Parkinson's disease participants from healthy controls using smartphones. Acoustics, Speech and Signal Processing (ICASSP), 2014 IEEE International Conference on; 2014: IEEE.\"},\n",
              "         {'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Pastorino M, Arredondo M, Cancela J, Guillen S, editors. Wearable sensor network for health monitoring: the case of Parkinson disease. Journal of Physics: Conference Series; 2013: IOP Publishing.'},\n",
              "         {'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Sharma V, Mankodiya K, De La Torre F, Zhang A, Ryan N, Ton TG, et al. SPARK: Personalized Parkinson Disease Interventions through Synergy between a Smartphone and a Smartwatch. Design, User Experience, and Usability User Experience Design for Everyday Life Applications and Services: Springer; 2014. p. 103-14.'},\n",
              "         {'ReferencePMID': '25393786',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Tzallas AT, Tsipouras MG, Rigas G, Tsalikakis DG, Karvounis EC, Chondrogiorgi M, Psomadellis F, Cancela J, Pastorino M, Waldmeyer MT, Konitsiotis S, Fotiadis DI. PERFORM: a system for monitoring, assessment and management of patients with Parkinson's disease. Sensors (Basel). 2014 Nov 11;14(11):21329-57. doi: 10.3390/s141121329.\"},\n",
              "         {'ReferencePMID': '25257518',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Lakshminarayana R, Wang D, Burn D, Chaudhuri KR, Cummins G, Galtrey C, Hellman B, Pal S, Stamford J, Steiger M, Williams A; SMART-PD Investigators. Smartphone- and internet-assisted self-management and adherence tools to manage Parkinson's disease (SMART-PD): study protocol for a randomised controlled trial (v7; 15 August 2014). Trials. 2014 Sep 25;15:374. doi: 10.1186/1745-6215-15-374.\"},\n",
              "         {'ReferencePMID': '25141850',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Gschwind YJ, Eichberg S, Marston HR, Ejupi A, Rosario Hd, Kroll M, Drobics M, Annegarn J, Wieching R, Lord SR, Aal K, Delbaere K. ICT-based system to predict and prevent falls (iStoppFalls): study protocol for an international multicenter randomized controlled trial. BMC Geriatr. 2014 Aug 20;14:91. doi: 10.1186/1471-2318-14-91.'},\n",
              "         {'ReferencePMID': '27565186',\n",
              "          'ReferenceType': 'derived',\n",
              "          'ReferenceCitation': \"Silva de Lima AL, Hahn T, de Vries NM, Cohen E, Bataille L, Little MA, Baldus H, Bloem BR, Faber MJ. Large-Scale Wearable Sensor Deployment in Parkinson's Patients: The Parkinson@Home Study Protocol. JMIR Res Protoc. 2016 Aug 26;5(3):e172. doi: 10.2196/resprot.5990.\"}]}}},\n",
              "     'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'After changing the inclusion process for one cohort only, a total of 347 eligible PD patients were invited to participate. Among those invited, 43 refused to participate. The main refusal reasons were \"Study protocol seems too burdensome\" (44%, n = 19), followed by \"Personal circumstances\" (33%, n = 14). A total of 304 patients (enrolment rate = 88%) were enrolled.',\n",
              "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
              "          'FlowGroupTitle': 'Cohort 1',\n",
              "          'FlowGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
              "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementComment': \"Participants (People with Parkinson's Disease) who signed a consent form.\",\n",
              "                'FlowAchievementNumSubjects': '304'}]}},\n",
              "            {'FlowMilestoneType': 'COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementComment': \"Participants (People with Parkinson's Disease) who contributed data for 13 weeks.\",\n",
              "                'FlowAchievementNumSubjects': '291'}]}},\n",
              "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
              "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
              "                'FlowAchievementNumSubjects': '13'}]}}]},\n",
              "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Withdraw or did not contribute data.',\n",
              "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
              "                'FlowReasonNumSubjects': '13'}]}}]}}]}},\n",
              "      'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'Inclusion was changed from 5 cohorts (total of 100 participants) to 1 cohort only.',\n",
              "       'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
              "          'BaselineGroupTitle': 'Cohort 1',\n",
              "          'BaselineGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
              "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
              "             'BaselineDenomCountValue': '291'}]}}]},\n",
              "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '291'}]}}]},\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '30'}]}},\n",
              "               {'BaselineCategoryTitle': '>=65 years',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '261'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '291'}]}}]},\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '123'}]}},\n",
              "               {'BaselineCategoryTitle': 'Male',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '168'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)',\n",
              "          'BaselineMeasureDescription': 'These data were not reported.',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '291'}]}}]},\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'Not Hispanic or Latino',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '0'}]}},\n",
              "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '291'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Disease severity',\n",
              "          'BaselineMeasureDescription': \"Participants were assessed using the Hoehn and Yarhn scale. The scale is a grading of the degree of severity of Parkinson's Disease. The scale goes from 0 to 5, in which a higher score indicates higher disease severity.\",\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '291'}]}}]},\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Stage 0 or 1',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '73'}]}},\n",
              "               {'BaselineCategoryTitle': 'Stage 2',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '127'}]}},\n",
              "               {'BaselineCategoryTitle': 'Stage 3',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '34'}]}},\n",
              "               {'BaselineCategoryTitle': 'Stage 4 or 5',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '6'}]}},\n",
              "               {'BaselineCategoryTitle': 'Missing',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '51'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Depression',\n",
              "          'BaselineMeasureDescription': 'Depression was assessed using the Geriatric Depression Scale. The total score goes from 0 to 15. A score higher than 6 indicates higher probability of suffer from a depression.',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '291'}]}}]},\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'No',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '238'}]}},\n",
              "               {'BaselineCategoryTitle': 'Yes',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '53'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Cognitive impairment',\n",
              "          'BaselineMeasureDescription': 'Cognitive Impairment was measured using the Montreal Cognitive Assessment (MoCA). The MoCA total scores goes from 0 to 30. A score lower than 26 indicates possible presence of Mild Cognitive Impairment.',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '291'}]}}]},\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'No',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '124'}]}},\n",
              "               {'BaselineCategoryTitle': 'Yes',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '167'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Independency level',\n",
              "          'BaselineMeasureDescription': 'Independency Level was assessed using the Modified Schwab and England Activities of Daily Living Scale. The scale goes from 0 to 100. The higher the score, the more independent is the person. We opted for clustering the data into 4 categories because this provided a better overview of participants completely independent, independent, somewhat independent and dependent.',\n",
              "          'BaselineMeasureParamType': 'Number',\n",
              "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Equal or small to 70',\n",
              "             'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '291'}]}}]},\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '36'}]}}]}},\n",
              "            {'BaselineClassTitle': '71-80',\n",
              "             'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '291'}]}}]},\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '51'}]}}]}},\n",
              "            {'BaselineClassTitle': '81-90',\n",
              "             'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '291'}]}}]},\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '110'}]}}]}},\n",
              "            {'BaselineClassTitle': 'Equal or higher to 91',\n",
              "             'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '291'}]}}]},\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '41'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'MDS-UPDRS',\n",
              "          'BaselineMeasureDescription': \"The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) was developed to evaluate various aspects of Parkinson's disease, including non-motor and motor experiences of daily living, as well as motor complications. The total score used here was calculated by a sum of all scores from the 4 sub-scales (i.e. part I up to part IV) composing the MDS-UPDRS. Total score ranges from 0 to 272. A higher score indicates higher disease severity and burden, being thus a worse outcome.\",\n",
              "          'BaselineMeasureParamType': 'Median',\n",
              "          'BaselineMeasureDispersionType': 'Full Range',\n",
              "          'BaselineMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '291'}]}}]},\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '52.5',\n",
              "                   'BaselineMeasurementLowerLimit': '35',\n",
              "                   'BaselineMeasurementUpperLimit': '69'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Age at disease onset.',\n",
              "          'BaselineMeasureDescription': 'These data were not reported.',\n",
              "          'BaselineMeasurePopulationDescription': 'Age at disease onset was first included as an outcome. During data-collection, we have chosen not to collect it because other measures (such as MDS-UPDRS) better reflects the impact, burden and severity of the disease.',\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'years',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '0'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Time since Diagnose',\n",
              "          'BaselineMeasureDescription': 'These data were not reported.',\n",
              "          'BaselineMeasurePopulationDescription': 'Time since diagnose was first included as an outcome. During data-collection, we have chosen not to collect it because other measures (such as MDS-UPDRS) better reflects the impact, burden and severity of the disease.',\n",
              "          'BaselineMeasureParamType': 'Mean',\n",
              "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
              "          'BaselineMeasureUnitOfMeasure': 'years',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '0'}]}}]}}]}},\n",
              "         {'BaselineMeasureTitle': 'Level of education',\n",
              "          'BaselineMeasureDescription': 'We asked participants to report their highest education finished. After, we categorized answers into: > Highschool - High; < Highschool AND > Middel education - middle; < middel educatoin - low',\n",
              "          'BaselineMeasureParamType': 'Count of Participants',\n",
              "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
              "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
              "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
              "                   'BaselineClassDenomCountValue': '291'}]}}]},\n",
              "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Low',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '51'}]}},\n",
              "               {'BaselineCategoryTitle': 'Middel',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '103'}]}},\n",
              "               {'BaselineCategoryTitle': 'High',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '101'}]}},\n",
              "               {'BaselineCategoryTitle': 'Missing',\n",
              "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
              "                   'BaselineMeasurementValue': '36'}]}}]}}]}}]}},\n",
              "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': \"Parkinson's Disease Symptoms\",\n",
              "          'OutcomeMeasureDescription': \"The MDS-UPDRS is a revision of the Unified Parkinson's Disease Rating Scale (UPDRS). It was developed to evaluate various aspects of Parkinson's disease including non-motor and motor experiences of daily living, as well as motor complications. The MDS-UPDRS characterizes the extent and burden of disease across various populations. Here, we used data from one-point assessment (baseline). The total score used here was calculated by a sum of all scores from the 4 sub-scales (i.e. part I, up to part IV) composing the MDS-UPDRS. Total score ranges from 0 to 272. A higher score indicates higher disease severity and burden, being thus a worse outcome.\",\n",
              "          'OutcomeMeasurePopulationDescription': 'We have analysed data from all participants who completed the study.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Median',\n",
              "          'OutcomeMeasureDispersionType': 'Full Range',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Cohort 1',\n",
              "             'OutcomeGroupDescription': \"Dutch Parkinson's patients resident in the region of Noord-Holland whose fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\\n\\nClinical assessment: During the 13 week follow-up, trained physiotherapists will perform a standardized clinical assessment, based on the PPMI protocol (www.ppmi-info.ors) for every included patient. This assessment will last for 60 minutes, and it will be done once.\\n\\nFox Insight self-monitoring android app and falls detector: Patients will be asked to wear a smartwatch and a pendant movement sensor, both with triaxial accelerometers, during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '291'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '52.5',\n",
              "                   'OutcomeMeasurementLowerLimit': '35',\n",
              "                   'OutcomeMeasurementUpperLimit': '69'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': 'Depression Scores as a Measure of Depression Rates',\n",
              "          'OutcomeMeasureDescription': 'The scores obtained with the Geriatric Depression Scale were analysed in order to create a percentage of probably depressed participants. The total score goes from 0 to 15. A score higher than 6 indicates higher probability of suffer from a depression.',\n",
              "          'OutcomeMeasurePopulationDescription': 'We have analyzed all participants who completed the study.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Count of Participants',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Participants',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Cohort 1',\n",
              "             'OutcomeGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '291'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': 'No',\n",
              "                'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '238'}]}},\n",
              "               {'OutcomeCategoryTitle': 'Yes',\n",
              "                'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '53'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': 'Cognitive Impairment.',\n",
              "          'OutcomeMeasureDescription': 'Total sum score obtained with the Montreal Cognitive Assessment. We analyzed the full score to investigate percentage of participants with a possible cognitive impairment. The Montreal Cognitive sum scores ranges from 0 to 30, in which a score lower or equal to 26 is considered as possible cognitive decline.',\n",
              "          'OutcomeMeasurePopulationDescription': 'We analyzed all participants who completed the study.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Count of Participants',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Participants',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Cohort 1',\n",
              "             'OutcomeGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '291'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': 'No cognitive decline',\n",
              "                'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '125'}]}},\n",
              "               {'OutcomeCategoryTitle': 'Possible cognitive decline',\n",
              "                'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '166'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Primary',\n",
              "          'OutcomeMeasureTitle': 'Independency Level',\n",
              "          'OutcomeMeasureDescription': 'The total sum score obtained with the Schwab and England activities of daily living scale were analyzed to describe the functional level of the sample. The total sum scores varies from 0 to 100, in which lower scores are associated with more dependency of others to perform daily life activities.',\n",
              "          'OutcomeMeasurePopulationDescription': 'We analyzed all participants who completed the study.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Count of Participants',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'Participants',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Cohort 1',\n",
              "             'OutcomeGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '291'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': 'Lower or equal to 70',\n",
              "                'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '36'}]}},\n",
              "               {'OutcomeCategoryTitle': 'Higher than 70 and lower than 81',\n",
              "                'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '51'}]}},\n",
              "               {'OutcomeCategoryTitle': 'Higher than 80 and lower than 91',\n",
              "                'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '109'}]}},\n",
              "               {'OutcomeCategoryTitle': 'higher than 90',\n",
              "                'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '41'}]}},\n",
              "               {'OutcomeCategoryTitle': 'Missing',\n",
              "                'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '54'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Number of Falls Per Patient Registered by the Falls Detector.',\n",
              "          'OutcomeMeasureDescription': 'The fall event is recognized by the falls detector. Every time that the patient falls, the algorithm embedded at the falls detector recognize as a fall and record the fall event. At the end of the follow-up time, a sum of the falls event for each patient will be done.',\n",
              "          'OutcomeMeasurePopulationDescription': \"We invited 43 study participants to wear the fall detector, of whom 13 consented to wear it. Unfortunately the quality of the collected data did not allow for automated falls detection. Therefore we couldn't determine this outcome measure.\",\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureTimeFrame': 'Patients will be automatically assessed during the follow-up time (up to 13 weeks after the enrollment date), 24 hours a day, 7 days a week.',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Cohort 1',\n",
              "             'OutcomeGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '0'}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Number of Mood Reports for Each Patient Measured With a Four Point Scale',\n",
              "          'OutcomeMeasureDescription': 'The number of mood reports will be collected through the smartphone application. A four point scale (very good, good, poor and fair) will be available, and by pressing the button which correspond to how the patient feels at that moment the report can be performed. At the end of the follow-up time a sum of all the reports will be done in order to measure the number of mood reports over the follow-up time.',\n",
              "          'OutcomeMeasurePopulationDescription': 'Though the smartphone application had to option to report \"mood\", participants hardly used this feature. Therefore there were no data collection that were suitable for analysis.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureTimeFrame': 'Patients will be assessed during the follow-up time (up to 13 weeks after the enrollment date). It is expected that the assessment (self-report) will be performed as many times as the patient wants to report how they feel or at least once a day.',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Cohort 1',\n",
              "             'OutcomeGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '0'}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Number of Medication Intake Annotations Made by Each Participant Via the Self-report App.',\n",
              "          'OutcomeMeasureDescription': 'The number of medication intake annotations made by the patients will be collected through the smartphone application. Every time that the patient take medication they must press the button reporting that they took the medication. At the end of the follow-up time a sum of all the reports will be done in order to measure the number of medication intake over the follow-up time.',\n",
              "          'OutcomeMeasurePopulationDescription': '96% (n = 280) of data-contributors reported their medication through the app.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'number of annotations',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Cohort 1',\n",
              "             'OutcomeGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '280'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '351',\n",
              "                   'OutcomeMeasurementSpread': '217'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Time That Each Patient Was Active During the Day',\n",
              "          'OutcomeMeasureDescription': 'The time that the patient was active during the day is calculated automatically through the app at the smartphone. The calculation is performed by using an algorithm, which analyze the patterns of walk. This algorithm is able to predict when the patient was active in a zone above his/her usual threshold (e.g. when the patient was performing one activity that makes him/her more active than during a quiet time). At the end of the follow-up time a sum of all active hours will be done in order to measure the amount of time that the patient was active over the follow-up time.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'minutes per day',\n",
              "          'OutcomeMeasureTimeFrame': 'Patients will be automatically assessed continuously during the follow-up time (up to 13 weeks after the enrollment date), 24 hours a day, 7 days a week. The analyses was limited to walking activities.',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Cohort 1',\n",
              "             'OutcomeGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '291'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '72',\n",
              "                   'OutcomeMeasurementSpread': '39'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Level of Activity for Each Patient During the Day',\n",
              "          'OutcomeMeasureDescription': 'The level of activity for each patient is calculated automatically through the app at the smartphone. The calculation is performed by using the data collect with the accelerometers embedded in the smartwatch. An algorithm installed in the phone, which analyze the data collected with the smartwatch, can calculate the level of activity for each patient throughout the day.',\n",
              "          'OutcomeMeasurePopulationDescription': 'The collected accelerometer data turned out to be unsuitable to calculate the level of activity during the day. Algorithms produced unreliable information on activity levels and therefore no data on this outcome measure were available.',\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureTimeFrame': 'Patients will be automatically assessed during the follow-up time (up to 13 weeks after the enrollment date), 24 hours a day, 7 days a week.',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Cohort 1',\n",
              "             'OutcomeGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '0'}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Scores in Autonomic Dysfunctions Measure With the Autonomic Dysfunctions Scale',\n",
              "          'OutcomeMeasureDescription': \"The scores for autonomic dysfunctions will be obtained with the Assessment of autonomic dysfunction in Parkinson's disease (SCOPA-AUT). The total sum scores ranges from 0 to 100, in which high scores are correlated with more burden of autonomic dysfunctions in Parkinson's patients.\",\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'score on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Cohort 1',\n",
              "             'OutcomeGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '245'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '17.2',\n",
              "                   'OutcomeMeasurementSpread': '7.9'}]}}]}}]}},\n",
              "         {'OutcomeMeasureType': 'Secondary',\n",
              "          'OutcomeMeasureTitle': 'Sleepiness Rates in the Epworth Sleepiness Scale as a Measure of Sleep Quantity.',\n",
              "          'OutcomeMeasureDescription': \"The Epworth sleepiness scale was used to rate the level of sleepiness during the day. The scale's scores are related to the usual duration of sleep at night and increase with relative sleep deprivation. Here, we used data from one-point assessment (baseline). Then, we can suggest that if the sample has high scores they will have a low sleep quantity. Total sum score ranges from 0 (no sleepiness at all) to 24 (excessive sleepiness).\",\n",
              "          'OutcomeMeasureReportingStatus': 'Posted',\n",
              "          'OutcomeMeasureParamType': 'Mean',\n",
              "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
              "          'OutcomeMeasureUnitOfMeasure': 'score on a scale',\n",
              "          'OutcomeMeasureTimeFrame': 'Baseline',\n",
              "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
              "             'OutcomeGroupTitle': 'Cohort 1',\n",
              "             'OutcomeGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\"}]},\n",
              "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
              "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
              "                'OutcomeDenomCountValue': '245'}]}}]},\n",
              "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
              "                   'OutcomeMeasurementValue': '6.0',\n",
              "                   'OutcomeMeasurementSpread': '4.7'}]}}]}}]}}]}},\n",
              "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
              "       'EventsTimeFrame': '13 weeks',\n",
              "       'EventsDescription': 'Serious Adverse Events: Include adverse events that result in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect.\\n\\nOther (Not Including Serious) Adverse Events: Adverse events that are not Serious Adverse Events.',\n",
              "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
              "          'EventGroupTitle': 'Cohort 1 (The Study Only Included 1 Cohort).',\n",
              "          'EventGroupDescription': \"Dutch Parkinson's patients who fulfill the eligibility criteria.\\n\\nInterventions/Exposures to be administered:\\n\\nPPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.\\nFox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.\",\n",
              "          'EventGroupSeriousNumAffected': '0',\n",
              "          'EventGroupSeriousNumAtRisk': '291',\n",
              "          'EventGroupOtherNumAffected': '0',\n",
              "          'EventGroupOtherNumAtRisk': '291'}]}},\n",
              "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'},\n",
              "       'PointOfContact': {'PointOfContactTitle': 'Marjan Meinders',\n",
              "        'PointOfContactOrganization': 'Radboudumc',\n",
              "        'PointOfContactEMail': 'Marjan.Meinders@radboudumc.nl',\n",
              "        'PointOfContactPhone': '+00000000'}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M19712',\n",
              "          'ConditionBrowseLeafName': 'Disease Progression',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
              "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 42,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03241966',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '1204E'},\n",
              "       'Organization': {'OrgFullName': 'Boston University Charles River Campus',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Perception, Cognition, and Gait in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Perception, Cognition, and Gait in Parkinson's Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'February 2021',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'April 1, 2017',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 15, 2019',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'January 15, 2019',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'August 4, 2017',\n",
              "       'StudyFirstSubmitQCDate': 'August 7, 2017',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 8, 2017',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'February 9, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 11, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Alice Cronin-Golomb',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Director of Vision and Cognition Laboratory',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Boston University Charles River Campus'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Boston University Charles River Campus',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"The investigators are examining how aspects of daily function are perceived in persons with PD and in those who interact with them on a regular basis. If eligible, participants will receive a set of online questionnaires by email. The questionnaires will take about 1 hour to complete, and can be done at the participant's convenience. The investigators are looking for volunteers who have a diagnosis of Parkinson's disease without dementia (age 40 or older and proficient English speakers). If a spouse, family member, significant other or other close associate is available (age 18 or older, proficient English speakers), the investigators will send them questionnaires as well. There is no monetary or other compensation for this study. For more information, please contact the Vision and Cognition Laboratory at vcognition@gmail.com or 617-358-1377.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': [\"Parkinson's Disease\",\n",
              "         'Online Study',\n",
              "         'Quality of Life',\n",
              "         'Activities of Daily Living',\n",
              "         'Perception',\n",
              "         'Cognition',\n",
              "         'Gait']}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'No',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '439',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"People with Parkinson's Disease\",\n",
              "          'ArmGroupDescription': \"Individuals diagnosed with idiopathic Parkinson's disease without dementia.\"},\n",
              "         {'ArmGroupLabel': 'Informant',\n",
              "          'ArmGroupDescription': \"Family member, spouse, significant other, caregiver, or other close associate of someone with Parkinson's disease.\"}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Parkinson's Disease Questionnaire (PDQ-39)\",\n",
              "          'PrimaryOutcomeDescription': \"Measures the health status of Parkinson's disease patients and the impact the disease has on their aspects of daily living. There are 39 items.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Within 24 hours of starting the study'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nDiagnosed with Parkinson's disease without dementia OR close associate of someone with Parkinson's disease\\n40 years or older\\nProficient English speaker\\nAccess to a computer\\n8+ years of education\\n\\nExclusion Criteria:\\n\\nCo-existing active neoplasm, serious cardiac disease, other serious chronic medical illness\\nPrior intracranial surgery\\nHistory of traumatic brain injury\\nPsychiatric or neurological diagnoses other than Parkinson's disease\\nHistory of alcoholism or other drug abuse\\nHistory of treatment with electroshock therapy\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '40 Years',\n",
              "       'MaximumAge': '100 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': 'Participants are accepted regardless of location, community, clinic, etc.',\n",
              "       'SamplingMethod': 'Non-Probability Sample'},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Alice Cronin-Golomb, Ph.D.',\n",
              "          'OverallOfficialAffiliation': 'Boston University',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Vision and Cognition Laboratory at Boston University',\n",
              "          'LocationCity': 'Boston',\n",
              "          'LocationState': 'Massachusetts',\n",
              "          'LocationZip': '02215',\n",
              "          'LocationCountry': 'United States'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'T6034',\n",
              "          'ConditionBrowseLeafName': 'Quality of Life',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
              "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
              "   {'Rank': 43,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03466723',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'DRPAR01'},\n",
              "       'Organization': {'OrgFullName': 'Neuromed IRCCS', 'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"miRNAs Profiling in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Novel and Minimal Invasive Biomarkers for Parkinson's Disease: Profiling of Serum Circulating miRNAs and Patho-physiological Implications\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'March 2018',\n",
              "       'OverallStatus': 'Unknown status',\n",
              "       'LastKnownStatus': 'Not yet recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'June 2018',\n",
              "        'StartDateType': 'Anticipated'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2019',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'May 2021',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'March 9, 2018',\n",
              "       'StudyFirstSubmitQCDate': 'March 9, 2018',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 15, 2018',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'March 16, 2018',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 19, 2018',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Daniela Ruggiero',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'Ph.D.',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Neuromed IRCCS'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Neuromed IRCCS',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"microRNAs (miRNAs) regulate fundamental cell processes. Dysregulation of miRNA expression and function is reported in various diseases including cancer, metabolic disorders as well as neurological disorders. Circulating miRNAs have been proposed to mirror physiological and pathological conditions suggesting their use as biomarkers for various diseases. The study will focus on a case-control study cohort (N=1000) of subjects recruited at the IRCCS Neuromed for which a deep clinical characterization and genome-wide sequencing data are available. This study will enable to identify novel circulating biomarkers for Parkinson's disease (PD). Further, the project will give new insights on the involvement of miRNAs in the etiology of PD and in the understanding of the genetics of the disease thus opening avenues for novel therapeutic strategies.\",\n",
              "       'DetailedDescription': \"Hypothesis and Significance:\\n\\nThe project intends to identify novel biomarkers for PD and clinical parameters related to the PD etiology. To do that circulating miRNA profiling through a next-generation sequencing will be performed using a single sample approach in the case-control study cohort and identified miRNAs will be validated by qRT-PCR and functional analyses. In addition, the project will contribute expanding the knowledge of the genetic architecture of PD taking advantage of genetic characterization of the study sample. miRNA genes and target genes will be used to prioritize genetic variants to be tested for association with PD to detect novel genes and functional variants that confer disease risk.\\n\\nSpecific Aim 1:\\n\\nProfile of circulating miRNAs in the serum of PD patients and controls by next-generation sequencing in individual samples. Correlation between identified miRNAs and PD-related parameters and validation in independent cohorts\\n\\nSpecific Aim 2:\\n\\nBioinformatics prediction of target genes and miRNA functional validation\\n\\nSpecific Aim 3:\\n\\nIdentification of genes/genetic variants in miRNA pathways predisposing to PD\\n\\nExpected outcomes:\\n\\nThe study will allow to discover novel circulating miRNAs as biomarkers for Parkinson's disease. As the deep phenotype characterization of the study sample, the project expects to find new associations of identified miRNAs with disease-related parameters and define the role of miRNAs in the physiological pathways in which those parameters are involved and in the etiology of PD. Also, the understanding of the genetics of the disease will open avenues for novel therapeutic strategies.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'Yes',\n",
              "       'TargetDuration': '5 Years',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
              "       'BioSpec': {'BioSpecRetention': 'Samples With DNA',\n",
              "        'BioSpecDescription': 'DNA, RNA, Serum'},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '1000',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Genetic',\n",
              "          'InterventionName': 'biomarker identification in Parkinson disease',\n",
              "          'InterventionDescription': 'circulating miRNAs profiling by NGS analysis functional miRNA characterization association of miRNA levels with genetic variants'}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Identification of novel circulating miRNAs as biomarkers for Parkinson's disease\",\n",
              "          'PrimaryOutcomeDescription': \"The study expects to discover novel circulating miRNAs as biomarkers for Parkinson's disease. As the deep phenotype characterization of the study sample, the project expects to identify new associations of identified miRNAs with disease-related parameters and define the role of miRNAs in the physiological pathways in which those parameters are involved and in the etiology of PD. Also, the understanding of the genetics of the disease will open avenues for novel therapeutic strategies\",\n",
              "          'PrimaryOutcomeTimeFrame': '3 years'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria for cases:\\n\\nPresence of at least two out the following cardinal signs: resting tremor, cogwheel rigidity, bradykinesia, asymmetrical onset of symptoms and symptomatic response to L-dopa (levodopa)\\n\\nExclusion Criteria for cases:\\n\\nPrevious thalamotomy on the implanted sided, significant brain atrophy or structural damage seen on CT or MRI, marked cognitive dysfunction, active psychiatric symptoms, or concurrent neurological or other uncontrolled medical disorders.\\n\\nExclusion Criteria for controls:\\n\\nPersonal or family history for neurodegenerative diseases',\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '30 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': 'Collection of 1000 case-control study samples with a large phenotype and genotype characterization. The study includes 500 PD patients and 500 age/gender-matched controls. All PD patients have been diagnosed at the IRCCS Neuromed and followed-up (at least for 5 years) for disease progression. Data collected from patients and unrelated controls include: socio-demographic status, life style, anamnesis and family history, exposure to toxic chemical and/or environmental agents. Patients have been studied with a protocol comprising neurological examination (Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test) and evaluation of no motor symptoms. Information about drugs therapy have been also collected.',\n",
              "       'SamplingMethod': 'Probability Sample'},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Daniela Ruggiero, Ph. D.',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '+39 081 6132358',\n",
              "          'CentralContactEMail': 'daniela.ruggiero@igb.cnr.it'},\n",
              "         {'CentralContactName': 'Mafalda G Reccia, Ph.D.',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '+39 0865 915249',\n",
              "          'CentralContactEMail': 'mafaldareccia@yahoo.it'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Daniela Ruggiero, Ph.D.',\n",
              "          'OverallOfficialAffiliation': 'Neuromed IRCCS',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Neuromed IRCCS',\n",
              "          'LocationCity': 'Pozzilli',\n",
              "          'LocationState': 'Molise',\n",
              "          'LocationZip': '86077',\n",
              "          'LocationCountry': 'Italy',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Daniela Ruggiero, Ph.D.',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'daniela.ruggiero@igb.cnr.it'},\n",
              "            {'LocationContactName': 'Mafalda G Reccia, Ph.D.',\n",
              "             'LocationContactRole': 'Sub-Investigator'}]}}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 44,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03105401',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '69HCL17_0137'},\n",
              "       'Organization': {'OrgFullName': 'Hospices Civils de Lyon',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease\",\n",
              "       'Acronym': 'HALLUPARK'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'January 2019',\n",
              "       'OverallStatus': 'Terminated',\n",
              "       'WhyStopped': 'recruitment difficulties',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'May 15, 2017',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 25, 2018',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'April 25, 2018',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'April 4, 2017',\n",
              "       'StudyFirstSubmitQCDate': 'April 4, 2017',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 10, 2017',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'January 15, 2019',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 17, 2019',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Hospices Civils de Lyon',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"This study aims to describe hallucinations prevalence in a sample of patients affected by Parkinson's disease and consulting in an outpatient facility.\\n\\nAn unique one hour interview will be offered to volunteers patients. Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.\\n\\nThe study hypothesis is that hallucinations prevalence in Parkinson's disease is underestimated and is higher than usually described in the scientific literature when all hallucinations modalities and minor hallucinatory phenomenons are searched for.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'No',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '32',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Patients affected by Parkinson's disease\",\n",
              "          'ArmGroupDescription': \"Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': [\"Other: Assessment of hallucinations in Parkinson's disease\"]}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': \"Assessment of hallucinations in Parkinson's disease\",\n",
              "          'InterventionDescription': 'Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Patients affected by Parkinson's disease\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Hallucinations Prevalence',\n",
              "          'PrimaryOutcomeDescription': 'Semi-structured questionnaire precisely describing hallucinations of all modalities and their characteristics, as well as minor hallucinations and delusions. Binary Yes/No possible answers.\\n\\nUnique 1 hour interview to assess semi-structured questionnaire for primary outcome measurement, and psychometric scales.',\n",
              "          'PrimaryOutcomeTimeFrame': '1 hour'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAge  18 years-old\\nAbsence of opposition from the patient himself/herself or his/her legal representant for his/her participation to the study\\nPatient without superior age limit with a diagnosis of Parkinson's disease made according to the UKPDSBB criteria (UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria)\\nOutpatient consulting in neurology at the Charpennes'hospital\\n\\nExclusion Criteria:\\n\\nOpposition to the study\\nDeafness or blindness which could compromise the interview\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': \"Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer\",\n",
              "       'SamplingMethod': 'Non-Probability Sample'},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jing XIE, MD',\n",
              "          'OverallOfficialAffiliation': 'Hpital des Charpennes. Centre de Recherche Clinique - vieillissement, cerveau, fragilit',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Hpital des Charpennes. Centre de Recherche Clinique - vieillissement, cerveau, fragilit',\n",
              "          'LocationCity': 'Villeurbanne',\n",
              "          'LocationZip': '69100',\n",
              "          'LocationCountry': 'France'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'},\n",
              "         {'ConditionMeshId': 'D000006212',\n",
              "          'ConditionMeshTerm': 'Hallucinations'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'},\n",
              "         {'ConditionAncestorId': 'D000010468',\n",
              "          'ConditionAncestorTerm': 'Perceptual Disorders'},\n",
              "         {'ConditionAncestorId': 'D000019954',\n",
              "          'ConditionAncestorTerm': 'Neurobehavioral Manifestations'},\n",
              "         {'ConditionAncestorId': 'D000009461',\n",
              "          'ConditionAncestorTerm': 'Neurologic Manifestations'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M8456',\n",
              "          'ConditionBrowseLeafName': 'Hallucinations',\n",
              "          'ConditionBrowseLeafAsFound': 'Hallucinations',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M12531',\n",
              "          'ConditionBrowseLeafName': 'Perceptual Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20979',\n",
              "          'ConditionBrowseLeafName': 'Neurobehavioral Manifestations',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11556',\n",
              "          'ConditionBrowseLeafName': 'Neurologic Manifestations',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
              "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
              "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 45,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04485468',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'RC31/20/0184'},\n",
              "       'Organization': {'OrgFullName': 'University Hospital, Toulouse',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': 'Integrated Parkinson Care Networks: Assessment of Economics and Socials Barriers',\n",
              "       'OfficialTitle': 'Integrated Parkinson Care Networks: Assessment of Economics and Socials Barriers to the Optimal Care Pathway for Parkinson Disease Patients',\n",
              "       'Acronym': 'ECOSO-ICAREPD'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'April 2021',\n",
              "       'OverallStatus': 'Not yet recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'May 9, 2021',\n",
              "        'StartDateType': 'Anticipated'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 9, 2021',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'November 9, 2021',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'July 21, 2020',\n",
              "       'StudyFirstSubmitQCDate': 'July 21, 2020',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 24, 2020',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'April 8, 2021',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 9, 2021',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'University Hospital, Toulouse',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"According to the latest public health report in France, Parkinson's disease (PD) affects around 160,000 patients.\\n\\nIt is therefore essential to estimate the overall consumption of medical and non-medical resources by patients with PD in order to characterize the share of medical and non-medical care reimbursed by health insurance, the share of medical and non-medical care not reimbursed. by health insurance, as well as the share of formal and informal care in order to identify potential economic barriers to an optimal care path for patients with PD. It is also necessary to have information on the socio-economic characteristics and the place of residence of the resident in order to estimate the impact of these determinants on an optimal course of care.\",\n",
              "       'DetailedDescription': \"According to the latest public health report in France, Parkinson's disease (PD) affects around 160,000 patients\\n\\nThe coordination of the care pathway for patients with Parkinson disease has been improved since the implementation on the national territory of 7 interregional coordination centers and 25 regional expert centers in 2012.\\n\\nHealth insurance reimburses 100% of direct medical and non-medical care as soon as patients are registered in Long-Term Condition n16. However, we currently have little information about care that is not recognized for financial coverage by health insurance.\\n\\nIt is therefore essential to estimate the overall consumption of medical and non-medical resources by patients with PD in order to characterize the share of medical and non-medical care reimbursed by health insurance, the share of medical and non-medical care not reimbursed. by health insurance, as well as the share of formal and informal care in order to identify potential economic barriers to an optimal care path for patients with PD. It is also necessary to have information on the socio-economic characteristics and the place of residence of the resident in order to estimate the impact of these determinants on an optimal course of care.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']},\n",
              "       'KeywordList': {'Keyword': ['Parkinson Disease,', 'Socio-economic']}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'No',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '100',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Parkinson's disease patients\",\n",
              "          'ArmGroupDescription': \"Parkinson's disease patients and over 18 years old\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Questionnaire']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
              "          'InterventionName': 'Questionnaire',\n",
              "          'InterventionDescription': 'The patient answers the questionnaire directly following his consultation or teleconsultation or may arrange a telephone appointment with the clinical research associate a little later.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Parkinson's disease patients\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Identify the economic barriers to an optimal care path',\n",
              "          'PrimaryOutcomeDescription': 'It is the collection of the number of resources consumed and the remainder to be borne by the patient as well as the number of hours of informal help that will be valued using the replacement cost approach.',\n",
              "          'PrimaryOutcomeTimeFrame': 'Day 0'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Identify and quantify the cost of the care pathway for patients with Parkinson's disease\",\n",
              "          'SecondaryOutcomeDescription': 'it is the quantification of the number of resources consumed and identification of the unit costs for each type of resources consumed.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Day 0'},\n",
              "         {'SecondaryOutcomeMeasure': 'identify socio-economic determinants',\n",
              "          'SecondaryOutcomeDescription': 'identify the socio-economic and territorial determinants that could have an impact on an optimal care path.',\n",
              "          'SecondaryOutcomeTimeFrame': 'Day 0'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nPatients with Parkinson's disease of any stage of severity\\nPatients over 18 years of age\\nPatients living at home\\nPatient consultant at the expert center Parkinson's at Toulouse University Hospital\\n\\nExclusion Criteria:\\n\\nPregnant and lactating woman\\nPatient under guardianship, curatorship or safeguard of justice\\nPerson who does not understand French to be able to answer the questionnaire\\nPatient who participated or participated in the iCare PD project\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': \"Parkinson's disease patients and over 18 years old\",\n",
              "       'SamplingMethod': 'Non-Probability Sample'},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Delphine Vernet',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '5 61 77 72 16',\n",
              "          'CentralContactPhoneExt': '33',\n",
              "          'CentralContactEMail': 'vernet.d@chu-toulouse.fr'}]},\n",
              "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Olivier Rascol',\n",
              "          'OverallOfficialAffiliation': 'University Hospital, Toulouse',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'CHU de Toulouse',\n",
              "          'LocationCity': 'Toulouse',\n",
              "          'LocationZip': '31059',\n",
              "          'LocationCountry': 'France',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Delphine Vernet',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '5 61 77 72 16',\n",
              "             'LocationContactPhoneExt': '33',\n",
              "             'LocationContactEMail': 'vernet.d@chu-toulouse.fr'}]}}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 46,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04797611',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'SNS-PD-002'},\n",
              "       'Organization': {'OrgFullName': 'Scion NeuroStim',\n",
              "        'OrgClass': 'INDUSTRY'},\n",
              "       'BriefTitle': \"STEM-Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Non-Invasive Brainstem Modulation for the Treatment of Non-Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial (RCT)\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'April 2022',\n",
              "       'OverallStatus': 'Not yet recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'May 2022',\n",
              "        'StartDateType': 'Anticipated'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2023',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'May 2023',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'March 10, 2021',\n",
              "       'StudyFirstSubmitQCDate': 'March 10, 2021',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 15, 2021',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'April 11, 2022',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 12, 2022',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Scion NeuroStim',\n",
              "        'LeadSponsorClass': 'INDUSTRY'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'Yes',\n",
              "       'IsUnapprovedDevice': 'Yes',\n",
              "       'IsUSExport': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.\",\n",
              "       'DetailedDescription': \"Up to 218 participants will enter the double-blinded, controlled, randomized clinical trial (RCT) and will self-administer treatments twice daily in the home setting over a period of 12 weeks following a 4 week baseline period. The RCT will have 6 study visits: 3 visits at the study center and 3 visits completed in the participant's home by video call.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease',\n",
              "         \"Parkinson's Disease and Parkinsonism\"]},\n",
              "       'KeywordList': {'Keyword': ['Randomized Controlled Trial (RCT)',\n",
              "         'Medical Devices',\n",
              "         'Non-Motor Symptoms (NMS)',\n",
              "         'Non-Invasive Brain Stimulation']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'Triple',\n",
              "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
              "           'Care Provider',\n",
              "           'Investigator']}}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '218',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Investigational Treatment 1',\n",
              "          'ArmGroupType': 'Other',\n",
              "          'ArmGroupDescription': 'Investigational treatment mode (stimulation pattern) 1',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Non-invasive brainstem stimulation']}},\n",
              "         {'ArmGroupLabel': 'Investigational Treatment 2',\n",
              "          'ArmGroupType': 'Other',\n",
              "          'ArmGroupDescription': 'Investigational treatment mode (stimulation pattern) 2',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Non-invasive brainstem stimulation']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
              "          'InterventionName': 'Non-invasive brainstem stimulation',\n",
              "          'InterventionDescription': \"Study participants will self-administer ~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device. The device has been deemed to be a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Investigational Treatment 1',\n",
              "            'Investigational Treatment 2']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change from baseline in The International Parkinson and Movement Disorder Society - Non-Motor Rating Scale (MDS-NMS) Total Score',\n",
              "          'PrimaryOutcomeDescription': \"The MDS-NMS is a 52-item rater-administered scale used to assess a wide range of non-motor symptoms in Parkinson's disease. Scores range between 0-832, with the higher score indicating greater non-motor symptom burden. (day 113 score - average of baseline scores from days 1 and 29)\",\n",
              "          'PrimaryOutcomeTimeFrame': '3 months'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Change from baseline in The International Parkinson and Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II\",\n",
              "          'SecondaryOutcomeDescription': 'The MDS-UPDRS Part II is a 13-item patient-reported assessment of activities of motor aspects of experiences of daily living. Scores range between 0-52, with the higher score indicating greater impairment to activities of daily living. (day 113 score - average of baseline scores from days 1 and 29)',\n",
              "          'SecondaryOutcomeTimeFrame': '3 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change from baseline in the Clinical Global Impression-Improvement (CGI-I)',\n",
              "          'SecondaryOutcomeDescription': \"The CGI-I is a clinician assessment the extent of clinically meaningful change that has occurred in the patient's illness at day 113 relative to a baseline state (assessed at day 29). Changes in all aspects of Parkinson's disease (e.g., motor symptoms, non-motor symptoms and complications of anti-Parkinsonian medications) are considered.\",\n",
              "          'SecondaryOutcomeTimeFrame': '3 months'},\n",
              "         {'SecondaryOutcomeMeasure': 'Change from baseline in the MDS-UPDRS Part III',\n",
              "          'SecondaryOutcomeDescription': 'The MDS-UPDRS Part III is a 33-item assessment of motor function evaluated by a trained blinded rater. Scores range between 0-132 with higher scores indicating more sever motor symptoms. (day 113 score - average of baseline scores from days 1 and 29)',\n",
              "          'SecondaryOutcomeTimeFrame': '3 months'},\n",
              "         {'SecondaryOutcomeMeasure': \"Change from baseline in the Parkinson's Disease Quality of Life Questionnaire Summary Index (PDQ-39 SI)\",\n",
              "          'SecondaryOutcomeDescription': 'The PDQ-39 SI is a 39-item patient-reported quality of life measure that assesses how often people living with PD are affected across 8 dimensions of daily living. Scores range from 0-100, with the higher scores indicating worse perception of quality of life. (day 113 score - average of baseline scores from days 1 and 29)',\n",
              "          'SecondaryOutcomeTimeFrame': '3 months'}]},\n",
              "       'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Change from baseline in the Mini-Balance Evaluation Systems Test',\n",
              "          'OtherOutcomeDescription': \"a measure of dynamic balance, functional mobility, and gait. This measure will be evaluated as a safety outcome to assess whether device therapy negatively impacts balance or gait for participants with Parkinson's disease (day 113 score - baseline day 29 score).\",\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in the Montreal Cognitive Assessment',\n",
              "          'OtherOutcomeDescription': 'a screening instrument used to facilitate the assessment of cognitive impairment.',\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in the Oral Symbol Digit Modality Test',\n",
              "          'OtherOutcomeDescription': 'a brief and commonly used test to evaluate processing speed.',\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': \"Change from baseline in the Parkinson's Disease Sleep Scale\",\n",
              "          'OtherOutcomeDescription': \"an assessment to quantify nocturnal sleep issues in Parkinson's disease.\",\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in Epworth Sleepiness Scale',\n",
              "          'OtherOutcomeDescription': 'a brief measure that is commonly used to assess daytime sleepiness.',\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in the Parkinson Anxiety Scale',\n",
              "          'OtherOutcomeDescription': \"a brief questionnaire to detect anxiety severity in Parkinson's disease.\",\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue Scale',\n",
              "          'OtherOutcomeDescription': \"a measure of an individual's level of fatigue during their usual daily activities over the past week.\",\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in the Geriatric Depression Scale-15',\n",
              "          'OtherOutcomeDescription': 'a short questionnaire for assessing depression in older adults.',\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in the MDS-NMS Non-Motor Fluctuations',\n",
              "          'OtherOutcomeDescription': \"a rater completed assessment evaluating fluctuations of non-motor symptoms in Parkinson's disease.\",\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': \"Change from baseline in the Unified Parkinson's Disease Rating Scale Part IV\",\n",
              "          'OtherOutcomeDescription': 'an assessment of complications of anti-Parkinsonian therapies.',\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in a Non-Motor Symptom focused Clinical Global Impression-Improvement',\n",
              "          'OtherOutcomeDescription': \"clinician assessment the extent of clinically meaningful change that has occurred as it relates to the patient's non-motor symptoms.\",\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in the Zarit Burden Interview',\n",
              "          'OtherOutcomeDescription': 'measure of caregiving burden completed by caregivers.',\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': \"Change from baseline in the Patient Reported Outcome - Parkinson's Disease\",\n",
              "          'OtherOutcomeDescription': \"a self-rating tool to assess symptom severity in Parkinson's disease.\",\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in The Modified Schwab and England Activities of Daily Living Scale',\n",
              "          'OtherOutcomeDescription': \"a clinical outcome assessment of an individual's ability to function independently in activities of daily living.\",\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in EncephaLogTM 3 meter Timed Up and Go Test',\n",
              "          'OtherOutcomeDescription': 'smart phone application assessment that provides indication of risk of falls in adults.',\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in EncephaLogTM finger tapping test',\n",
              "          'OtherOutcomeDescription': 'smart phone application providing a quantitative measure of bradykinesia.',\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in EncephaLogTM 10 meter Timed Up and Go Test',\n",
              "          'OtherOutcomeDescription': 'smart phone application that measures gait and that provides indication of risk of falls in adults.',\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': \"Change from baseline in Unified Parkinson's disease Rating Scale Part I (UPDRS I)\",\n",
              "          'OtherOutcomeDescription': \"a measure of mentation, behavior, and mood in Parkinson's disease.\",\n",
              "          'OtherOutcomeTimeFrame': '3 months'},\n",
              "         {'OtherOutcomeMeasure': 'Change from baseline in Hoehn & Yahr (H&Y)',\n",
              "          'OtherOutcomeDescription': \"staging tool describing the level of disability in Parkinson's disease.\",\n",
              "          'OtherOutcomeTimeFrame': '3 months'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAdult participants (aged 18 - 85 years inclusive)\\nDiagnosed with Parkinson's disease according to the UK Brain Bank Criteria\\nDemonstrates a positive response to oral anti-Parkinsonian medications (i.e. dopamine replacement therapies) and treated with these medications for minimum of three years prior to the screening visit\\nReport limitation to activities of daily living (e.g., writing, walking, bathing, dressing, eating, toileting, etc.)\\nAble and willing to consent to participate in the study.\\nWilling and able to comply with study requirements.\\nAnticipate being able to remain on a stable regimen of medications used for the management of PD motor and non-motor symptoms and not to introduce new medications used to treat symptoms associated with PD during the trial.\\nFully vaccinated from COVID-19 (at least 2 weeks from their final dose) with one of the current World Health Organization evaluated vaccines, prior to Screen.\\nHave at minimum a moderate burden of non-motor symptoms associated with Parkinson's disease\\nHave a study partner (defined as someone who sees the participant for more than one hour a day, 3 times per week) that is willing to consent and participate in the trial.\\nHave capabilities to use and access smartphones and or tablets for the collection of some study data.\\nMust be willing to answer questions related to sexual interest, arousal, and performance in an interview with study staff.\\n\\nExclusion Criteria:\\n\\nParticipant anticipates being unable to attend all visits and complete all study activities.\\n\\nWomen of child-bearing potential who are pregnant or plan to become pregnant during the course of the study trial. Women of child-bearing potential (i.e., are not yet 3 years removed from their first menopausal symptom), who are not abstinent or exclusively in same sex relationships must:\\n\\nTest negative for pregnancy as indicated by a negative urine pregnancy test\\nAgree to use an approved contraception method for the entirety of the trial\\nHave a history or prior diagnosis of dementia or evidence of dementia at study screen.\\nHave experienced a myocardial infarction, angina, or stroke within the past 12 months.\\nAre receiving deep brain stimulation therapy.\\nAre treated with a pump for continuous delivery of dopamine replacement medication.\\nUse apomorphine rescue.\\nHave received MRI guided high intensity focused ultrasound within the past 12 months.\\nExperience frequent falls.\\nWork night shifts\\nUse a hearing aid that is implanted or that cannot be easily removed and replaced.\\nHave a cochlear implant.\\nHave chronic (>3 months) tinnitus.\\nHave previously been diagnosed with traumatic brain injury with ongoing sequalae.\\nHave been diagnosed with a co-morbid neurological disorder that may present with symptoms overlapping with PD (e.g., stroke, brain tumor, epilepsy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, atypical Parkinsonism or aneurysm)\\nHave unresolved complications from a previous surgical procedure at the baseline visits, such as swelling or persistent pain, that requires medical intervention.\\nHave active ear infections, or other significant ear problems.\\nHave a recent history of frequent ear infections ( 1 per year over the past two years)\\nAre currently enrolled or have participated in another interventional clinical trial within the last 30 days.\\nHave had eye surgery within the previous three months or ear surgery within the previous six months.\\nHave planned surgery scheduled to occur during the study that requires sedation and/or would typically be followed with a prescription for pain management.\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'MaximumAge': '85 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Kara Richardson',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '(984) 884-1020',\n",
              "          'CentralContactEMail': 'krichardson@scionneurostim.com'},\n",
              "         {'CentralContactName': 'Jemica Warren',\n",
              "          'CentralContactRole': 'Contact',\n",
              "          'CentralContactPhone': '(984) 884-5230',\n",
              "          'CentralContactEMail': 'jwarren@scionneurostim.com'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': \"Parkinson's Disease and Movement Disorders Center of Boca Raton\",\n",
              "          'LocationCity': 'Boca Raton',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '33486',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'info@ParkinsonsCenter.org'}]}},\n",
              "         {'LocationFacility': 'Headlands Research Orlando',\n",
              "          'LocationCity': 'Orlando',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '32819',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Christopher Galloway, MD',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '407-705-3471',\n",
              "             'LocationContactEMail': 'Christopher.Galloway@HeadlandsResearch.com'}]}},\n",
              "         {'LocationFacility': \"USF Parkinson's Disease and Movement Disorders Center\",\n",
              "          'LocationCity': 'Tampa',\n",
              "          'LocationState': 'Florida',\n",
              "          'LocationZip': '33613',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Erica Botting',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '813-974-8026',\n",
              "             'LocationContactEMail': 'ericabotting@usf.edu'}]}},\n",
              "         {'LocationFacility': \"University of Kansas Medical Center - Parkinson's Disease Center\",\n",
              "          'LocationCity': 'Kansas City',\n",
              "          'LocationState': 'Kansas',\n",
              "          'LocationZip': '66160',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Sarina Fay',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '913-588-6924',\n",
              "             'LocationContactEMail': 'sfay2@kumc.edu'}]}},\n",
              "         {'LocationFacility': 'Quest Research',\n",
              "          'LocationCity': 'Farmington Hills',\n",
              "          'LocationState': 'Michigan',\n",
              "          'LocationZip': '48334',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Renee Najor',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'renee@questri.com'}]}},\n",
              "         {'LocationFacility': 'University of New Mexico',\n",
              "          'LocationCity': 'Albuquerque',\n",
              "          'LocationState': 'New Mexico',\n",
              "          'LocationZip': '87131',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'University of New Mexico Neurology Research',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '505-272-3199'}]}},\n",
              "         {'LocationFacility': 'Raleigh Neurology Associates, P.A.',\n",
              "          'LocationCity': 'Raleigh',\n",
              "          'LocationState': 'North Carolina',\n",
              "          'LocationZip': '27607',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Taylor Cestari',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'tcestari@raleighneurology.com'}]}},\n",
              "         {'LocationFacility': 'Medical University of South Carolina',\n",
              "          'LocationCity': 'Charleston',\n",
              "          'LocationState': 'South Carolina',\n",
              "          'LocationZip': '29425',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lisa Heidelberg',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '843-876-0829',\n",
              "             'LocationContactEMail': 'heidelbe@musc.edu'}]}},\n",
              "         {'LocationFacility': 'Riverside Neurology Specialists',\n",
              "          'LocationCity': 'Newport News',\n",
              "          'LocationState': 'Virginia',\n",
              "          'LocationZip': '23601',\n",
              "          'LocationCountry': 'United States',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kerianne Allen',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactEMail': 'Kerianne.Allen@rivhs.com'}]}},\n",
              "         {'LocationFacility': \"Booth Gardner Parkinson's Care Center\",\n",
              "          'LocationCity': 'Kirkland',\n",
              "          'LocationState': 'Washington',\n",
              "          'LocationZip': '98034',\n",
              "          'LocationCountry': 'United States'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'},\n",
              "         {'ConditionMeshId': 'D000020734',\n",
              "          'ConditionMeshTerm': 'Parkinsonian Disorders'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafAsFound': 'Parkinsonism',\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M11554',\n",
              "          'ConditionBrowseLeafName': 'Neuroleptic Malignant Syndrome',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'T4101',\n",
              "          'ConditionBrowseLeafName': 'Neuroleptic Malignant Syndrome',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC25',\n",
              "          'ConditionBrowseBranchName': 'Substance Related Disorders'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'Rare',\n",
              "          'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}},\n",
              "   {'Rank': 47,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04933513',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '2020PI179'},\n",
              "       'Organization': {'OrgFullName': 'Central Hospital, Nancy, France',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Development and Validation of a Scale Measuring Preoperative Expectations in Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Development and Validation of a French Scale Measuring Preoperative Expectations of Parkinson's Disease Patients Candidate to Deep Brain Stimulation : the DBS-PS (Deep Brain Stimulation Perception Scale)\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'March 2022',\n",
              "       'OverallStatus': 'Not yet recruiting',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'March 30, 2022',\n",
              "        'StartDateType': 'Anticipated'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 30, 2022',\n",
              "        'PrimaryCompletionDateType': 'Anticipated'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'August 30, 2022',\n",
              "        'CompletionDateType': 'Anticipated'},\n",
              "       'StudyFirstSubmitDate': 'June 8, 2021',\n",
              "       'StudyFirstSubmitQCDate': 'June 18, 2021',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 21, 2021',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'March 10, 2022',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 25, 2022',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Mme Mylne MEYER',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'psychologist, PhD',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Central Hospital, Nancy, France'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Central Hospital, Nancy, France',\n",
              "        'LeadSponsorClass': 'OTHER'},\n",
              "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University Hospital, Bordeaux',\n",
              "          'CollaboratorClass': 'OTHER'},\n",
              "         {'CollaboratorName': 'Poitiers University Hospital',\n",
              "          'CollaboratorClass': 'OTHER'},\n",
              "         {'CollaboratorName': 'Assistance Publique - Hpitaux de Paris',\n",
              "          'CollaboratorClass': 'OTHER'},\n",
              "         {'CollaboratorName': 'University Hospital, Lille',\n",
              "          'CollaboratorClass': 'OTHER'}]}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Subthalamic nucleus deep brain stimulation (STN-DBS) has become a choice treatment for fluctuating Parkinson's disease (PD) patients, inducing remarkable improvement in motor symptoms. However, as PD is a complex neuropsychiatric disease, it has been hypothesized that in some patients, non-motor features, i.e. dysfunctional expectations for the result of neurosurgery, could interfere with postoperative result of DBS, even in case of motor improvement. Recent literature highlights the necessity to take these preoperative expectations into account, but to our knowledge, no specific scale investigating these cognitions in this PD-specific condition is available. So, the investigators developped the DBS-PS, a self-scale constructed to measure preoperative expectations for DBS, with 11 questions and visuo-analogical responses (1 to 10), theorically divided in three domains investigating the expectations concerning symptoms of PD, postoperative social-life and leisures, and postoperative familial and marital sphere. The investigators would like to validate this new-developped scale in the preoperative subthalamic nucleus deep brain stimulation population through patients recruited in the Predistim study, whereas the investigators did not recruite sufficiently patients through the PsyParkinson study, the one in which the DBS-PS scale was developed. The DBS-PS constitutes an interesting basis for the consideration of these cognitive and affective factors in preoperative PD patients.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': ['deep brain stimulation',\n",
              "         'preoperative expectations',\n",
              "         'DBS-PS',\n",
              "         'validation',\n",
              "         \"Parkinson's disease\"]}},\n",
              "      'DesignModule': {'StudyType': 'Observational',\n",
              "       'PatientRegistry': 'No',\n",
              "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
              "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Retrospective']}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '22',\n",
              "        'EnrollmentType': 'Anticipated'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"preoperative Parkinson' disease\",\n",
              "          'ArmGroupDescription': \"pre DBS parkinson's disease patients responding to the DBS-PS scale preoperatively\",\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: pre DBS patients responding to the DBS-PS scale']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
              "          'InterventionName': 'pre DBS patients responding to the DBS-PS scale',\n",
              "          'InterventionDescription': \"we propose to parkinson's disease patients selected for subthalamic deep brain stimulation to complete the DBS-PS scale preoperatively\",\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"preoperative Parkinson' disease\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Validation of the Deep-brain stimulation - perception scale (DBS-PS scale)',\n",
              "          'PrimaryOutcomeDescription': \"Deep Brain Stimulation-Perception Scale completed by Parkinson's disease patients enrolled in the Predistim study; minimum scale score 0 - maximum scale score 50, for each sub-scores (3 dimensions) ; a higher score corresponding to higher expectations in the dimension, and a lower score coresponding to lower expectations in the dimension\",\n",
              "          'PrimaryOutcomeTimeFrame': 'during the inclusion/baseline period of Predistim study'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nParkinson's disease patients included in the Predistim study and having completed the DBS-PS scale during the preoperative phase\\n\\nExclusion Criteria:\\n\\nParkinson's disease patients not included in the Predistim study or not having completed the DBS-PS scale during the preoperative phase\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
              "       'StudyPopulation': \"- Parkinson's disease patients selected for STN DBS and participating to the Predistim study\",\n",
              "       'SamplingMethod': 'Non-Probability Sample'},\n",
              "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'CHU de Nancy',\n",
              "          'LocationCity': 'Nancy',\n",
              "          'LocationZip': '54000',\n",
              "          'LocationCountry': 'France',\n",
              "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Mylene MEYER, PhD',\n",
              "             'LocationContactRole': 'Contact',\n",
              "             'LocationContactPhone': '0383859661',\n",
              "             'LocationContactEMail': 'my.meyer@chru-nancy.fr'}]}}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 48,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01428648',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '133272'},\n",
              "       'Organization': {'OrgFullName': 'University of Arkansas',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Impact of Dance Therapy on Parkinson's Disease\",\n",
              "       'OfficialTitle': \"Impact of Dance Therapy on Parkinson's Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'March 2015',\n",
              "       'OverallStatus': 'Withdrawn',\n",
              "       'WhyStopped': 'Recruitment slow',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'August 2012'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2013',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'March 2013',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'September 2, 2011',\n",
              "       'StudyFirstSubmitQCDate': 'September 2, 2011',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 5, 2011',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'March 3, 2015',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 4, 2015',\n",
              "        'LastUpdatePostDateType': 'Estimate'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'University of Arkansas',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"Parkinson's disease (PD) affects ability of individuals to perform unconscious learned motor tasks, affects quality of life and has been associated with depression. The purpose of this study is to investigate the effect of dance therapy on motor performance, quality of life and depression in PD patients, by comparing certain symptoms between a group of subjects with PD who undergo ballroom dancing classes and a control group of subjects with PD. The investigators will assess mental status, severity of PD, quality of life and depression using rating scales. Subjects will be randomized to intervention and control group. Intervention group will participate in dance therapy for 12 weeks and will be examined at 12 and 20 weeks. Control group will be examined at same time intervals. Classes will follow a curriculum designed by Arthur Murray Dance Studio Staff. The investigators do not anticipate significant risk for participants.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': ['Parkinson', 'ballroom dancing']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
              "        'DesignInterventionModel': 'Parallel Assignment',\n",
              "        'DesignPrimaryPurpose': 'Supportive Care',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '0', 'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'intervention',\n",
              "          'ArmGroupType': 'Active Comparator',\n",
              "          'ArmGroupDescription': 'group of patients receiving ballroom dancing classes',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Ballroom Dancing Classes']}},\n",
              "         {'ArmGroupLabel': 'control',\n",
              "          'ArmGroupType': 'No Intervention',\n",
              "          'ArmGroupDescription': 'group of patients who will not receive dancing classes.'}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
              "          'InterventionName': 'Ballroom Dancing Classes',\n",
              "          'InterventionDescription': 'bi-weekly, 12-Week ballroom dance classes',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['intervention']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Effect of ballroom dancing classes on motor function in patients with Parkinson's disease.\",\n",
              "          'PrimaryOutcomeDescription': \"The improvement in participant's motor function will be measured by the UPRS III score. The aim is to detect an 18-20% difference in UPDRS III scores among the two groups.\",\n",
              "          'PrimaryOutcomeTimeFrame': '3 and 5 months'}]},\n",
              "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Effect of ballroom dancing classes on depression in patients with Parkinson's disease.\",\n",
              "          'SecondaryOutcomeDescription': \"The improvement in participant's depression will be measured by the Hamilton Depression Scale.\",\n",
              "          'SecondaryOutcomeTimeFrame': '3 and 5 months'},\n",
              "         {'SecondaryOutcomeMeasure': \"Effect of ballroom dancing classes on quality of life of patients with Parkinson's disease.\",\n",
              "          'SecondaryOutcomeDescription': \"The improvement in participant's quality of life will be measured by the Parkinson's Disease-39 questionnaire PDQ-39 scale.\",\n",
              "          'SecondaryOutcomeTimeFrame': '3 and 5 months'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\n18 years and older, both males and females, all races and all ethnicities\\nIdiopathic Parkinson's disease diagnosed using United Kingdom Parkinson's Disease Society brain bank diagnostic criteria\\nMild to moderate disease severity (Stage 2 to 3 on the Modified Hoehn and Yahr scale)\\nStable medication regimen for a minimum of 1 month before testing\\nAbility to ambulate independently without using a walking aid\\nAbility to give informed consent\\n\\nExclusion Criteria:\\n\\nPrior enrollment in a dancing class during the last 6 months\\nPresence of another neurological or medical disorder likely to affect gait or causing frequent falls (rheumatologic/orthopedic disease, stroke, myelopathy, severe neuropathy)\\nSignificant cognitive decline (MMSE  24)\\nVisual deficit\\nHearing deficit that impairs music perception\\nPsychotic symptoms\\nSymptomatic heart disease\\nDepression associated with suicidal ideation\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Nancy Maalouf, MD',\n",
              "          'OverallOfficialAffiliation': 'University of Arkansas',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'University of Arkansas for Medical Sciences',\n",
              "          'LocationCity': 'Little Rock',\n",
              "          'LocationState': 'Arkansas',\n",
              "          'LocationZip': '72205',\n",
              "          'LocationCountry': 'United States'}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '9923759',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999 Jan;56(1):33-9. Review.'},\n",
              "         {'ReferencePMID': '19711119',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Park A, Stacy M. Non-motor symptoms in Parkinson's disease. J Neurol. 2009 Aug;256 Suppl 3:293-8. doi: 10.1007/s00415-009-5240-1. Review.\"},\n",
              "         {'ReferencePMID': '21461962',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Ransmayr G. Physical, occupational, speech and swallowing therapies and physical exercise in Parkinson's disease. J Neural Transm (Vienna). 2011 May;118(5):773-81. doi: 10.1007/s00702-011-0622-9. Epub 2011 Apr 3. Review.\"},\n",
              "         {'ReferencePMID': '8264910',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Ellgring H, Seiler S, Perleth B, Frings W, Gasser T, Oertel W. Psychosocial aspects of Parkinson's disease. Neurology. 1993 Dec;43(12 Suppl 6):S41-4.\"},\n",
              "         {'ReferencePMID': '19691125',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Barichella M, Cereda E, Pezzoli G. Major nutritional issues in the management of Parkinson's disease. Mov Disord. 2009 Oct 15;24(13):1881-92. doi: 10.1002/mds.22705. Review.\"},\n",
              "         {'ReferencePMID': '21426462',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Joanna Briggs Institute. The Joanna Briggs Institute Best Practice Information Sheet: music as an intervention in hospitals. Nurs Health Sci. 2011 Mar;13(1):99-102. doi: 10.1111/j.1442-2018.2011.00583.x. Review.'},\n",
              "         {'ReferencePMID': '8544252',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Marwick C. Leaving concert hall for clinic, therapists now test music's 'charms'. JAMA. 1996 Jan 24-31;275(4):267-8.\"},\n",
              "         {'ReferencePMID': '21154376',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Bradt J, Dileo C, Grocke D. Music interventions for mechanically ventilated patients. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006902. doi: 10.1002/14651858.CD006902.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;12:CD006902.'},\n",
              "         {'ReferencePMID': '18395022',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Nilsson U. The anxiety- and pain-reducing effects of music interventions: a systematic review. AORN J. 2008 Apr;87(4):780-807. doi: 10.1016/j.aorn.2007.09.013. Review.'},\n",
              "         {'ReferencePMID': '8902026',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': 'Glover H, Kalinowski J, Rastatter M, Stuart A. Effect of instruction to sing on stuttering frequency at normal and fast rates. Percept Mot Skills. 1996 Oct;83(2):511-22.'}]}}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 49,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03578653',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': '17-7398H'},\n",
              "       'Organization': {'OrgFullName': 'Colorado State University',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': 'Merging Yoga and Occupational Therapy for Parkinson Disease: Phase 2',\n",
              "       'OfficialTitle': 'Merging Yoga and Occupational Therapy for Parkinson Disease: Phase 2',\n",
              "       'Acronym': 'MY-OT for PD'},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'February 2019',\n",
              "       'OverallStatus': 'Completed',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'June 1, 2018',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2018',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'March 31, 2019',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'June 13, 2018',\n",
              "       'StudyFirstSubmitQCDate': 'July 3, 2018',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 6, 2018',\n",
              "        'StudyFirstPostDateType': 'Actual'},\n",
              "       'LastUpdateSubmitDate': 'July 24, 2019',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 25, 2019',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Colorado State University',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No',\n",
              "       'IsFDARegulatedDrug': 'No',\n",
              "       'IsFDARegulatedDevice': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"The full program is focused on identifying and reducing risk factors surrounding falls. Based on previous research, we believe that occupational therapy group classes and adaptive yoga are an ideal pairing to reduce fall risk. The occupational therapy sessions will consist of lecture, group discussion, and activities designed to target biological, behavioral, environmental, and socioeconomic factors that contribute to fall risk specifically for people with Parkinson's disease.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': ['Parkinson Disease']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'N/A',\n",
              "        'DesignInterventionModel': 'Single Group Assignment',\n",
              "        'DesignPrimaryPurpose': 'Prevention',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '18',\n",
              "        'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Merging Yoga and Occupational Therapy for Parkinson disease',\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'The group participates in three assessment periods: August, October, and December. Then in October-December the group will receive group occupational therapy and recommended community adaptive yoga programming 2x/week for 8 weeks.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Merging Yoga and Occupational Therapy for Parkinson disease']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
              "          'InterventionName': 'Merging Yoga and Occupational Therapy for Parkinson disease',\n",
              "          'InterventionDescription': 'The group occupational therapy portion focuses on lecture, group discussion, and activities to reduce fall risk. The yoga program is part of an ongoing community yoga program specifically designed for people with Parkinson disease.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Merging Yoga and Occupational Therapy for Parkinson disease']}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Fall Risk Factor Management',\n",
              "          'PrimaryOutcomeDescription': 'Self-report 5 scales measuring the ability to manage fall risk factors',\n",
              "          'PrimaryOutcomeTimeFrame': 'Baseline, Pre-assessment (8-weeks after baseline), and post-assessment (8-weeks after pre-assessment)'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nIndividuals with a diagnosis of Parkinson's disease OR their care partners\\nIndividuals who read and understand English\\nIndividuals who can stand with or without an assistive device\\nPeople who are willing to commit to yoga practice 2x/week for 8 weeks and pay $5/class through Raintree Athletic Club (Scholarships are available if needed!)\\nPeople who are willing to commit to group occupational therapy 2x/week for 8 weeks free of charge\\nscore of at least 4/6 on the short mini mental status exam\\n\\nExclusion Criteria:\\n\\nless than 18 years of age\",\n",
              "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '18 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Laura Grimm, MS',\n",
              "          'OverallOfficialAffiliation': 'Colorado State University',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Colorado State University',\n",
              "          'LocationCity': 'Fort Collins',\n",
              "          'LocationState': 'Colorado',\n",
              "          'LocationZip': '80521',\n",
              "          'LocationCountry': 'United States'}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}},\n",
              "   {'Rank': 50,\n",
              "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00976430',\n",
              "       'OrgStudyIdInfo': {'OrgStudyId': 'JHC525'},\n",
              "       'Organization': {'OrgFullName': 'Jaslok Hospital and Research Centre',\n",
              "        'OrgClass': 'OTHER'},\n",
              "       'BriefTitle': \"Autologous Mesenchymal Stem Cell Transplant for Parkinson's Disease\",\n",
              "       'OfficialTitle': \"To Study the Safety and Efficacy of Bone Marrow Derived Mesenchymal Stem Cells Transplant in Parkinson's Disease\"},\n",
              "      'StatusModule': {'StatusVerifiedDate': 'August 2018',\n",
              "       'OverallStatus': 'Terminated',\n",
              "       'WhyStopped': 'Adequate no. of patients could not be recruited in the set time frame.',\n",
              "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
              "       'StartDateStruct': {'StartDate': 'July 2009',\n",
              "        'StartDateType': 'Actual'},\n",
              "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 30, 2011',\n",
              "        'PrimaryCompletionDateType': 'Actual'},\n",
              "       'CompletionDateStruct': {'CompletionDate': 'April 30, 2012',\n",
              "        'CompletionDateType': 'Actual'},\n",
              "       'StudyFirstSubmitDate': 'September 11, 2009',\n",
              "       'StudyFirstSubmitQCDate': 'September 11, 2009',\n",
              "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 14, 2009',\n",
              "        'StudyFirstPostDateType': 'Estimate'},\n",
              "       'LastUpdateSubmitDate': 'August 12, 2018',\n",
              "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 14, 2018',\n",
              "        'LastUpdatePostDateType': 'Actual'}},\n",
              "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
              "        'ResponsiblePartyInvestigatorFullName': 'Dr Paresh Doshi',\n",
              "        'ResponsiblePartyInvestigatorTitle': 'In-charge Stereotactic and Functional neurosurgery',\n",
              "        'ResponsiblePartyInvestigatorAffiliation': 'Jaslok Hospital and Research Centre'},\n",
              "       'LeadSponsor': {'LeadSponsorName': 'Jaslok Hospital and Research Centre',\n",
              "        'LeadSponsorClass': 'OTHER'}},\n",
              "      'OversightModule': {'OversightHasDMC': 'No'},\n",
              "      'DescriptionModule': {'BriefSummary': \"This study is intended to look at the safety and efficacy of the use of autologous bone marrow derived stem cell transplant in patients with advanced Parkinson's disease.\",\n",
              "       'DetailedDescription': \"Parkinson's disease, a neurodegenerative disorder, still at its best can only be controlled by medical or surgical treatment. For more than two decades various groups have tried using modified cell transplants for curing this disease. Earlier results with use of fetal mesencephalic cell transplant were encouraging, but this had to be discontinued due to severe side effects.\\n\\nCurrent interest, in the use of Mesenchymal stem cells as a pluripotent cell for developing neural cells has been the background for this study. Reliance Life sciences had found encouraging results with the use of human MSCs in Rat model of PD. Based on this and other data, Jaslok Hospital and Research Centre has initiated a pilot study to investigate the efficacy of Autologous MSCs in treating advanced PD. This cells will be harvested from bone marrow, processed at RLS laboratory and transplanted by stereotactic techniques into the striatum of the patient.\"},\n",
              "      'ConditionsModule': {'ConditionList': {'Condition': [\"Parkinson's Disease\"]},\n",
              "       'KeywordList': {'Keyword': ['Autologous Stem Cells.']}},\n",
              "      'DesignModule': {'StudyType': 'Interventional',\n",
              "       'PhaseList': {'Phase': ['Not Applicable']},\n",
              "       'DesignInfo': {'DesignAllocation': 'N/A',\n",
              "        'DesignInterventionModel': 'Single Group Assignment',\n",
              "        'DesignPrimaryPurpose': 'Treatment',\n",
              "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
              "       'EnrollmentInfo': {'EnrollmentCount': '5', 'EnrollmentType': 'Actual'}},\n",
              "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Therapy for Parkinson's disease\",\n",
              "          'ArmGroupType': 'Experimental',\n",
              "          'ArmGroupDescription': 'Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells.',\n",
              "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Autologous Bone marrow derived stem cells transplant']}}]},\n",
              "       'InterventionList': {'Intervention': [{'InterventionType': 'Procedure',\n",
              "          'InterventionName': 'Autologous Bone marrow derived stem cells transplant',\n",
              "          'InterventionDescription': 'Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.',\n",
              "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Therapy for Parkinson's disease\"]},\n",
              "          'InterventionOtherNameList': {'InterventionOtherName': ['stem cells',\n",
              "            \"cell therapy for Parkinson's disease\"]}}]}},\n",
              "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Improvement in clinical condition of the patient assessed using UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) and Time Tests.\",\n",
              "          'PrimaryOutcomeTimeFrame': 'Up to 18 months from the day of stem cell transplant.'}]}},\n",
              "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria\\n\\nMale or female between 35-70 years of age.\\nPatient with current diagnosis of PD with motor complications (as confirmed by neurologist) as per the standard criteria and guidelines.\\nPatients with at least 5 years since the disease.\\nResponsiveness to Levodopa or dopa agonist. This is defined as improvement between Off and On UPDRS by at least 33% of the Motor UPDRS.\\nPD of Stage 2.5, 3 & 4 of HOEHN & YAHR staging.\\nStable Parkinsonian medications for the 60 days prior to the surgical therapy.\\nMRI not showing gross atrophy or any other pathology of brain.\\nPatients with score less than 19 for the Montgomery-Asberg Rating Scale (MADRS) for Depression.\\nNO Significant cognitive impairment.MMSE > 24.\\nThe participant is able to comply with and understand the required visit schedule and all required tests and procedures.\\nThe participant (and/or LAR) must sign an informed consent.\\n\\nExclusion Criteria:\\n\\nHistory of intracranial surgeries or implantation of a device for Parkinson's disease two years prior to treatment.\\nHistory of psychiatric disorders like schizophrenia or psychotic disorders.\\nHistory of other malignancy, with the exception of treated cutaneous squamous cell or basal cell carcinoma, within 5 years.\\nContraindication for MRI\\nGeneral medical contraindications for surgery like coagulopathy\\nSubjects with abnormal hematology and chemistry values, unless the out of range values are clinically significant with respect to general surgery.\\nSevere skin infection or osteomyelitis at the site of bone marrow aspiration potentially limiting the procedure.\\nPositive test results for HIV.\\nHistory of drug or alcohol abuse\\nPregnant or nursing women\",\n",
              "       'HealthyVolunteers': 'No',\n",
              "       'Gender': 'All',\n",
              "       'MinimumAge': '35 Years',\n",
              "       'MaximumAge': '70 Years',\n",
              "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
              "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Paresh k Doshi, MCh',\n",
              "          'OverallOfficialAffiliation': 'Incharge Stereotactic and functional Neurosurgery,Jaslok Hospital and Research Centre.',\n",
              "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
              "       'LocationList': {'Location': [{'LocationFacility': 'Jaslok Hospital And Research Centre',\n",
              "          'LocationCity': 'Mumbai',\n",
              "          'LocationState': 'Maharashtra',\n",
              "          'LocationZip': '400026',\n",
              "          'LocationCountry': 'India'}]}},\n",
              "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '19467573',\n",
              "          'ReferenceType': 'background',\n",
              "          'ReferenceCitation': \"Arias-Carrin O, Yuan TF. Autologous neural stem cell transplantation: a new treatment option for Parkinson's disease? Med Hypotheses. 2009 Nov;73(5):757-9. doi: 10.1016/j.mehy.2009.04.029. Epub 2009 May 24.\"}]}},\n",
              "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
              "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 28, 2022'},\n",
              "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010300',\n",
              "          'ConditionMeshTerm': 'Parkinson Disease'}]},\n",
              "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020734',\n",
              "          'ConditionAncestorTerm': 'Parkinsonian Disorders'},\n",
              "         {'ConditionAncestorId': 'D000001480',\n",
              "          'ConditionAncestorTerm': 'Basal Ganglia Diseases'},\n",
              "         {'ConditionAncestorId': 'D000001927',\n",
              "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
              "         {'ConditionAncestorId': 'D000002493',\n",
              "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009422',\n",
              "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
              "         {'ConditionAncestorId': 'D000009069',\n",
              "          'ConditionAncestorTerm': 'Movement Disorders'},\n",
              "         {'ConditionAncestorId': 'D000080874',\n",
              "          'ConditionAncestorTerm': 'Synucleinopathies'},\n",
              "         {'ConditionAncestorId': 'D000019636',\n",
              "          'ConditionAncestorTerm': 'Neurodegenerative Diseases'}]},\n",
              "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12365',\n",
              "          'ConditionBrowseLeafName': 'Parkinson Disease',\n",
              "          'ConditionBrowseLeafAsFound': \"Parkinson's Disease\",\n",
              "          'ConditionBrowseLeafRelevance': 'high'},\n",
              "         {'ConditionBrowseLeafId': 'M21647',\n",
              "          'ConditionBrowseLeafName': 'Parkinsonian Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M24756',\n",
              "          'ConditionBrowseLeafName': 'Ganglion Cysts',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M15510',\n",
              "          'ConditionBrowseLeafName': 'Synovial Cyst',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M3926',\n",
              "          'ConditionBrowseLeafName': 'Basal Ganglia Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4356',\n",
              "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M4894',\n",
              "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M11181',\n",
              "          'ConditionBrowseLeafName': 'Movement Disorders',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M2217',\n",
              "          'ConditionBrowseLeafName': 'Synucleinopathies',\n",
              "          'ConditionBrowseLeafRelevance': 'low'},\n",
              "         {'ConditionBrowseLeafId': 'M20711',\n",
              "          'ConditionBrowseLeafName': 'Neurodegenerative Diseases',\n",
              "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
              "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
              "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'All',\n",
              "          'ConditionBrowseBranchName': 'All Conditions'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
              "          'ConditionBrowseBranchName': 'Neoplasms'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
              "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
              "         {'ConditionBrowseBranchAbbrev': 'BC18',\n",
              "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}},\n",
              "      'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M6625',\n",
              "          'InterventionBrowseLeafName': 'Dopamine',\n",
              "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
              "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'CaAg',\n",
              "          'InterventionBrowseBranchName': 'Cardiotonic Agents'},\n",
              "         {'InterventionBrowseBranchAbbrev': 'All',\n",
              "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}]}}"
            ]
          },
          "execution_count": 33,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "dYsPomag4Vzm",
        "outputId": "e5468a7b-b50d-4b27-f898-46e1c87ee989"
      },
      "outputs": [],
      "source": [
        "api_pull_2 = ct.get_study_fields(\n",
        "    search_expr=\"Parkinson\",\n",
        "    fields=[\"NCTId\",\"IsFDARegulatedDrug\",\"IsFDARegulatedDevice\", \"IsUnapprovedDevice\", \"PrimaryOutcomeMeasure\", \"PrimaryOutcomeDescription\",\"PrimaryOutcomeTimeFrame\", \"SecondaryOutcomeMeasure\",\"SecondaryOutcomeDescription\", \"SecondaryOutcomeTimeFrame\",\"OtherOutcomeMeasure\"\n",
        ",\"OtherOutcomeDescription\",\"OtherOutcomeTimeFrame\",\"EligibilityCriteria\",\"StudyPopulation\",\"HealthyVolunteers\", \"ReferencePMID\", \"LocationCity\", \"LocationState\" , \"LocationFacility\"\n",
        "\n",
        "],\n",
        "    max_studies=999,\n",
        "    fmt=\"csv\",\n",
        ")\n",
        "\n",
        "# ClinicalTrials limits API queries to 1000 records\n",
        "# Count of studies may be useful to build loops when you want to retrieve more than 1000 records\n",
        "\n",
        "ct.get_study_count(search_expr=\"Parkinson\")\n",
        "\n",
        "# Read the csv data in Pandas\n",
        "import pandas as pd\n",
        "\n",
        "df2 = pd.DataFrame.from_records(api_pull_2[1:], columns=api_pull_2[0])"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "DQ1K9Cgd4xOC"
      },
      "source": [
        "##cleaning"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {},
      "outputs": [],
      "source": [
        "print(type(df1))"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "EF7TnjRu4X9G"
      },
      "outputs": [],
      "source": [
        "result = pd.merge(df1, df2,  on='NCTId', how='outer')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "phxa_Vqn5E5S"
      },
      "outputs": [],
      "source": [
        "print(result)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "Dgre9uB-INsI"
      },
      "outputs": [],
      "source": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "tYTMexoGHvxN"
      },
      "outputs": [],
      "source": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "LAqtYjoTICny",
        "outputId": "2f809d6a-4257-4ef1-b5f8-e601695a8d57"
      },
      "outputs": [],
      "source": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "CJgWIlIm47Cc",
        "outputId": "2ca52a69-39fc-4489-9cef-d3cff0685215"
      },
      "outputs": [],
      "source": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "TR2Eqnj5DCBZ"
      },
      "source": [
        "#Next let's drop the first row (SNo)\n",
        "\n",
        "## not need to drop SNO - will drop later - just moved the mask df to a new name"
      ]
    }
  ],
  "metadata": {
    "colab": {
      "collapsed_sections": [],
      "name": "HW2.ipynb",
      "provenance": []
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.10.4"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}
